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Primary cilia are highly conserved eukaryotic organelles that serve as a ‘’cellular antenna’’ for 
signaling functions. Dysfunctions or defects in primary cilia are associated with numerous human 
diseases. Typically, the mother centriole, transforms into a structure called basal body, which then 
templates the formation of the primary cilium. Abnormal cilia are implicated in cancer progressions 
such as in breast, pancreatic, brain, and prostate cancers. Glioblastoma multiforme (GBM) is one of 
the most frequent lethal primary brain tumors.  
 
GBM is characterized by extreme heterogeneity, rapid growth, and efficient invasion of neoplastic 
cells, called Glioblastoma Stem-like Cells (GSCs). GSCs represent a subpopulation of the cells that 
are resistant to treatment and are suspected to be driving forces for the disease recurrence. Until 
now, there is no effective treatment for GBM. The average median survival time of the patients from 
the initial diagnosis is 12-15 months. GBM cells appear to lose cilia, which can contribute to the 
malignant phenotype. However, the mechanism of suppressed ciliogenesis is not fully characterized 
yet. Thus, the aims of this thesis were (i) to understand the possible mechanisms that can suppress 
the ciliogenesis in GSCs, (ii) to investigate the pathways that could restore the ciliogenesis and, (iii) 
characterize GSCs after cilium induction. 
 
Primary cilium assembly and disassembly are a dynamic process, which is coupled with the cell 
cycle. At the onset of cilium disassembly, the Centrosomal-P4.1-associated protein (CPAP) provides 
a scaffold for the cilium-disassembly complex (CDC) proteins, including NDE1, OFD1, NEK2, and 
CPAP. These proteins are recruited to the ciliary base to ensure timely cilium disassembly and 
promote cell cycle progression. Hence, using multidisciplinary approaches, the current doctoral 
thesis investigated primary cilia dynamics in multiple patient-derived GSCs. The experiments 
revealed that elevated levels and recruitment of CDC components lead to suppressing of the 
ciliogenesis and an increase in the cell cycle progression.  
 
Moreover, depletion of different CDC proteins induced ciliogenesis in GSCs in which PDGFR-α level 
is elevated. Among the CDC proteins, NEK2 depletion induced the maximum frequencies of ciliation 
in GSCs. Furthermore, inducible overexpression of the catalytically inactive NEK2 in GSCs was 
sufficient to induce cilia irreversibly. Importantly, both functional, including transcriptomic analyzes, 
showed that cilium induction switched GSCs from self-renewal to differentiation state. Taken 
together, the current work provides evidence for a novel mechanism to induce ciliogenesis in patient-
derived GSCs and suggests that the cilium induction can potentially serve as a new strategy to 





Primäre Zilien sind hochkonservierte eukaryote Organellen, die als „zelluläre Antennen“ für die 
Signalfunktionen dienen. Fehlfunktionen oder Defekte in primären Zilien sind mit verschiedenen 
humanen Erkrankungen assoziiert. Die Formation des primären Ziliums erfolgt typischerweise durch 
die “Mutter-Zentriole”, die den Basalkörper des Ziliums formt. Abnormale Zilien spielen eine Rolle in 
der Progression bei z.B. Brust-, Pankreas-, Hirn-, und Prostata-Krebs. Das Glioblastom (GBM) ist 
einer der am häufigsten vorkommenden letalen primären Gehirntumore. Das GBM ist äußerst 
heterogen und durch ein rapides Wachstum und eine effiziente Invasion der neoplastischen Zellen, 
den sogenannten Glioblastom-Stammzell-ähnlichen Zellen (in engl. GSCs = Glioblastoma Stem-like 
Cells), gekennzeichnet. Die GSCs repräsentieren eine Untergruppe derjenigen Zellen, die 
behandlungsresistent sind und für die treibende Kraft beim Relaps dieser Erkrankung gehalten 
werden.  
Bis heute gibt es keine wirksame Therapie für das GBM. Die durchschnittliche Überlebenszeit der 
Patienten von der anfänglichen Diagnose beträgt zwischen 12 und 15 Monaten. GBM-Zellen 
scheinen das primäre Zilium zu verlieren, und dieser Verlust kann zu malignen Phänotypen 
beitragen. Der Mechanismus dieser supprimierten Ziliogenese ist jedoch noch nicht vollständig 
beschrieben. Aus diesem Grund war das Ziel dieser Arbeit (i) den möglichen Mechanismus zu 
verstehen, der die Ziliogenese unterdrückt, (ii) zu untersuchen, wie man die Ziliogenese wieder 
induzieren kann, und (iii) die GSCs nach dieser Induktion zu charakterisieren. Der Aufbau und 
Abbau des primären Ziliums ist ein dynamischer Prozess, der mit dem Zellzyklus gekoppelt ist. Zu 
Beginn des Zilium-Abbaus bildet das Centrosomal-P4.1-associated Protein (CPAP) ein Gerüst für 
die Proteine des Zilium-Abbau-Komplexes (Cilium-Disassembly-Complex, CDC), wie zum Beispiel 
Nde1, OFD1, NEK2 und CPAP. Diese Proteine werden dann an die Basis des Ziliums rekrutiert, um 
dessen Abbau sicherzustellen und das Voranschreiten des Zellzyklus zu fördern. Anhand 
multidisziplinärer Ansätze habe ich die Dynamik des primären Ziliums in mehreren von Patienten 
abstammenden GSCs untersucht. Mit meinen Experimenten konnte ich zeigen, dass erhöhte Level 
der CDC und dessen Rekrutierung zu einer Unterdrückung der Ziliogenese und zu einer Zunahme 
der Zellzyklus-Progression führten. Dagegen konnte die Abnahme der verschiedenen CDC-Proteine 
die Ziliogenese in den GSCs induzieren, in welchen das PDGFR-α Level erhöht war. Unter den 
CDC-Proteinen wurde die höchste Anzahl an ziliierten GSCs induziert, wenn NEK2 unterdrückt 
wurde. Des Weiteren reichte die induzierbare Überexpression des katalytisch inaktiven NEK2-
Proteins in GSCs aus, um die Zilien irreversibel zu induzieren. Sowohl funktionelle als auch 
transkriptionelle Analysen zeigten, dass durch die Induktion der Zilien die GSCs aus dem 
Selbsterneuerungs-Modus in den Differenzierungs-Modus umschalten. Schließlich demonstrierte 
ich anhand eines auf in vitro humanen Hirn-Organoiden basierenden GSCs-Invasions-Assays, dass 




Zusammenfassend liefert diese Arbeit wichtige Erkenntnisse auf einen neuen Mechanismus zur 
Induktion der Zilien in Patienten-abstammenden GSCs und gibt Hinweise, wie die Induktion des 





1.1 Cilium is a conserved eukaryotic cellular structure  
Eukaryotic cells display a complex and extensive intracellular compartmentalization based on 
numerous organelles. In contrast to prokaryotes, approximately half of the volume of eukaryotic 
cytoplasm consists of a variety of membrane-enclosed organelles, such as the nucleus, endoplasmic 
reticulum, Golgi apparatus, mitochondria, endosomes, lysosomes, and cilium. Extensive studies 
have identified the biogenesis mechanisms, functions, and dysfunctions of most of these organelles. 
However, the cellular structure and function of cilium is less explored, although it is an evolutionary 
conserved eukaryotic organelle, ranging from green algae to higher metazoans, including human 
cells (Alberts et al., 2002, Carvalho-Santos et al., 2011). Centrosomes are the major microtubule-
organizing centers of animal cells essential for accurate cell division. At their core, a centrosome 
consists of a pair of centrioles surrounded by a protein network of peri-centriolar material (PCM). 
Within a centrosome, the mature centriole functions as a basal body to template a cilium, a 
microtubule-based structure that protrudes from the surface of virtually all eukaryotic interphase 
cells, playing key roles in signaling pathways, cellular differentiation, and organism development 
(Avidor-Reiss and Gopalakrishnan, 2012, Nigg and Raff, 2009). 
Historically, cilia have been classified as either motile or immotile (primary cilia). The primary cilium 
is formed on the apical surface of most of the polarized vertebrate cells. The primary cilium is 
immotile, and it can sense physical and biochemical signals. On the other hand, the motile cilia are 
present on trachea and oviduct epithelial cell surfaces and collectively beat in wave-like patterns to 
promote fluid movement (Ishikawa and Marshall, 2011).  
Differences in structure, motility, and morphology define the different cilia types, namely the primary 
and motile cilia. The differences are especially evident for motile cilia that occur as bundles on 
epithelial cells versus the single motile sperm flagellum, or specialized sensory cilia like the 
photoreceptors and the prototypical primary cilium (Figure 1.1). Motile cilia (or flagella on unicellular 
organisms) are present on specialized cells such as sperm cells to control cell movement. However, 






Figure 1.1. Ciliary structure. 
A. Electron microscopy (EM) image of a primary cilium in retinal-pigmented epithelial (RPE) cells. Ciliary 
structure elements are labeled with arrows. BB (basal body); CP (ciliary pocket); Ax (axoneme).  
B. Immunofluorescence image of primary cilia in inner medullary collecting duct (IMCD3) cells. Primary 
cilia are shown in green, cell junctions are shown in red. 
C and D. Scanning electron microgram (SEM) of mouse nodal motile cilia. 
E. The core structure of a primary cilium is composed of microtubule bundles (ciliary axoneme) extending 
from the basal body, a microtubule-based structure derived from the mother centriole. The ciliary 
membrane is continuous with the plasma membrane.  
F and G. Cross-section diagrams of a primary cilium (with a 9+0 axoneme), and a motile cilium (with 9+2 
axoneme).  
Images in A-D, and F-G are adopted from Ishikawa and Marshall review (Ishikawa and Marshall, 2011). 








1.2 Historical aspects of the primary cilium  
In 1898, Zimmerman first visualized the primary cilium as a hair-like structure organelle in rabbit 
kidney tubule epithelial cells. However, the term “primary cilium” was first used in 1968 by Sorokin, 
who studied the ciliogenesis in human pulmonary development (Sorokin, 1968a, Satir et al., 2010). 
The primary cilium (hereafter referred to as cilium) had not been considered as important but rather 
rudimentary until studies discovered that it serves as a sensory antenna and play a crucial role in 
various signaling pathways (Hirokawa et al., 2006, Fliegauf et al., 2007, Satir and Christensen, 2007, 
Gerdes et al., 2009). Since then, the physiological relevance of the cilium has been recognized in a 
variety of human cells such as stem cells, epithelial, endothelial, kidney tubule, bile duct, 
photoreceptor, and pancreatic cells (Fliegauf et al., 2007). Importantly, defects in the cilium formation 
or function can cause a wide range of human disorders collectively termed ciliopathies (Badano et 
al., 2006, Waters and Beales, 2011, Seeger-Nukpezah et al., 2013). In this regard, the cilium has 
been particularly gaining attention and attracting many questions and thoughts about its role in 
human health and diseases, especially in cancer. However, the role of cilium in cancer development 
and progression is still not fully elucidated. 
 
1.3 Ciliogenesis 
The mother and the daughter centrioles are therefore important structures that govern future cilium 
formation. The centrioles and their surrounding proteins, called the pericentriolar material (PCM) are 
called centrosomes, which are basically tiny, non-membranous organelles involved in cell division. 
Ciliogenesis describes the assembly of the cilium when the cell is exiting the cell cycle. During 
ciliogenesis, the older mother centriole docks at the plasma membrane and functions as a basal 
body to initiate the cilium formation. The basal body nucleates the microtubule doublets to form the 
ciliary axoneme (Sorokin, 1968b, Vertii et al., 2016). The axoneme is the main skeleton of the cilium 
and emanates from the apical side of the basal body. The axoneme consists of nine doublet 
peripheral microtubules, either with or without a pair of singlet microtubules (Figure 1.2F and G) 
(Satir and Christensen, 2007). The 9+0 microtubule configuration in the non-motile primary cilium 
lacks dynein motors required for a ciliary movement. In contrast, motile cilia contain an additional 
pair of microtubules in the center (9+2), which provide cilia with motility (Figure 1F and G). Complex 
molecules of inner, outer dynein arms, radial spokes, and nexin links enable ciliary movement and 
beating (Satir et al., 2007, Satir et al., 2010, Lindemann and Lesich, 2010).  
The ciliary membrane closely sheaths the ciliary axoneme, which continues with the plasma 
membrane (Figure 1.1E) (Satir and Christensen, 2007, Sanchez and Dynlacht, 2016). Presumably, 
the ciliary membrane shares the same biochemical origins with the plasma membrane (Nachury et 
al., 2010, Garcia et al., 2018). However, it has been demonstrated that the ciliary membrane 
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constitutes at least 600 different proteins. But, until now, there is no evidence to prove that protein 
synthesis occurs within the cilium (Pazour et al., 2005, Ishikawa et al., 2012). 
The basal body's distal end functions as a permeability barrier between cilium and cytoplasm, called 
as 'ciliary gate', consisting of two subregions that include transition fibers and the transition zone 
(Figure 1.1E) (Garcia-Gonzalo and Reiter, 2012). Transition fibers, also named distal appendages, 
anchor the mature mother centriole to the plasma membrane through the recruitment of Centrosomal 
protein 164 kDa (CEP164) and Outer dense fiber protein 2 (ODF2) (Pitaval et al., 2010). 
Furthermore, the transition fibers can also mediate the assembling of intraflagellar transport 
complexes and are believed to form a ‘ciliary pore complex’ that may provide size-dependent ciliary 
protein trafficking. The transition zone controls the intracellular trafficking of biomolecules along the 
ciliary axoneme (Figure 1.1E). The ciliary pocket is another compartment of a membrane domain at 
the cilium base acting as a platform for ciliary endocytic activity, vesicular trafficking, and links the 
cilium to the actin cytoskeleton. Y-shaped linkers at the transition zone, called the ciliary necklace, 
also act as a permeability barrier, separate the cilium and cytoplasm components. 
 
Despite similar structure and morphology throughout the human body, the prototypic cilium shows 
tissue-specific functions. Mutations causing defects in ciliary structure or function result in the tissue-
specific phenotypes: they typically do not affect all ciliated cells. The specificity seems to be 
dependent on the mutation, cilia, and cell type. For example, loss of transition zone proteins (Tctn1, 
Tctn2, Tmem67 or Cc2d2a) in the worms, mice, or human cells have been shown to affect cilia and 
ciliary signaling in different tissues to a different extent (Wiegering et al., 2018, Garcia-Gonzalo et 
al., 2011, Williams et al., 2011). Likewise, depletion of a newly identified Microtubule organization 
protein AKNA (AKNA) did not affect cilia in neural stem cells, but rather ependymal cells of the brain, 
harboring motile cilia in the adult neural stem cell niche (Camargo Ortega et al., 2019). 
1.3.1 Stages of cilium biogenesis  
The process of cilium formation in vertebrate cells occurs through distinct routes, either extracellular 
or intracellular route, depending on whether the ciliogenesis starts at the cell surface or within the 
cytoplasm. The intracellular route of cilium formation occurs through a series of orchestrated events 
beginning with the mother centriole's maturation into a basal body and docking of the basal body at 
the plasma membrane (Westlake et al., 2011). In vitro experiments with mouse 3T3 fibroblast and 
retinal-pigmented epithelial (RPE) cells have contributed to the elucidation of ciliogenesis's critical 
aspects. In those models, the intracellular route's initial steps start with the formation of small 
cytoplasmic vesicles (pre-ciliary vesicles) that originate from the Golgi and the recycling endosome, 
accumulating in the proximity of mother centriole and distal appendages (Figure 1.2 B, C, and D). 
The vesicle that docks at the mother centriole initiates the mother centriole transition to the basal 
body. Then, the basal body docks with the distal appendages' help at the plasma membrane and 
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initiates an axoneme formation (Figure 1.2 E and F) (Kobayashi et al., 2014, Lu et al., 2015, Schmidt 
et al., 2012, Sorokin, 1968b). 
Figure 1.2. Biogenesis of the cilium. 
Multiple stages of ciliogenesis. A. The transition of mother centriole to the basal body. B. Golgi-derived 
ciliary vesicle localizes to the mother centriole (basal body) and invaginates the nascent axoneme. C. 
The appearance of transition structures (Y-shaped linkers). D. Distal appendages help the basal body to 
dock to the plasma membrane. E. IFT-dependent axoneme elongation. F. Ciliary vesicles fuse with the 
new membrane to form a sheath that surrounds the elongating axonemal. Adopted from Sorokin (Sorokin, 
1968b). 
 
The extracellular route differs from the intracellular one in a way that centrioles do not capture 
vesicles in the cytoplasm. Initially, mother centriole migrates to the cell surface and docks at the 
plasma membrane with the help of distal appendage proteins, microtubules, and the actin 
cytoskeletons (Pitaval et al., 2017, Pitaval et al., 2010, Avidor-Reiss and Gopalakrishnan, 2013, 
Kobayashi and Dynlacht, 2011). After the docking event, the microtubule-based axoneme extends 
from the cell surface and forms the transition zone together with the trafficking machinery. However, 
it remains unclear how cells decide for either the intracellular or extracellular route, and whether this 
determines the ciliary function. Fibroblasts, RPE cells, and neural precursor cells template the cilium 
formation through Golgi-derived ciliary vesicle (intracellular route) (Baudoin et al., 2012). Polarized 
epithelial cells, on the other hand, form cilia through the direct fusion of the basal body to the plasma 
membrane (extracellular route) (Sung and Leroux, 2013, Sorokin, 1968b, Molla-Herman et al., 
2010). The process of ciliogenesis may play a role in the cilium position, which can influence the 
functionality of the mature cilium. Importantly, in vertebrates, ciliogenesis is tightly coupled with cell 
division as centrioles are released from the plasma membrane to function as the spindle apparatus 
during mitosis. How cilia assembly and disassembly are coupled to the cell cycle, and the molecular 
players regulating cilia assembly and disassembly dynamics remain poorly understood. 
 
1.4 Cilium assembly 
During the cell cycle, newly formed centrioles are assembled from the existing mother and older 
(grandmother) centriole during the S-phase. Newly formed daughter centrioles are distinguished by 




Centrobin, and Neutralized-like protein 4 (NEURL4) (Li et al., 2012, Mahjoub et al., 2010, Zou et al., 
2005). In the following cell cycle, the newly formed centrioles in each of the two daughter cells mature 
and will become mother centrioles, through the loss of daughter centriole proteins (CEP120, 
Centrobin, and NEURL4) at the G1-S phase and followed by the gaining of distal appendages and 
subdistal appendages in the late G2 phase. The distal and subdistal appendage proteins (CEP83, 
CEP89, SCLT, CEP164, and FBF1) are recruited to the distal end of the mother centriole (basal 
body) to promote the initial step of cilium assembly (Figure 1.2) (Sanchez and Dynlacht, 2016). The 
distal appendages are crucial for the initiation of the ciliogenesis, starting with vesicle docking and 
for the recruitment of intraflagellar transport (IFT) machinery during the axoneme formation. 
Subdistal appendages, on the other hand, determine cilium positioning by anchoring centrioles to 
the cytoplasmic microtubule network (Figure 1.2) (Sanchez and Dynlacht, 2016, Yang et al., 2018).  
1.4.1 Initiation of cilium assembly 
In the initial step of ciliogenesis, the periciliary vesicle is transported to the mother centriole (basal 
body), together with microtubules in kinesin and dynein-dependent manner (Figure 1.2). The Kinesin 
family member C1 (KIFC1) is recruited to Golgi to transport periciliary vesicle to the mother centriole. 
It was shown that the depletion of KIFC1 in RPE cells interrupts the trafficking of the ciliary 
membrane proteins to centrioles. As a result, they accumulate at the Golgi, suggesting that KIFC1 
mediates the transport of vesicles from the Golgi to the mother centrioles to promote ciliogenesis 
(Lee et al., 2018). Another study demonstrated that the periciliary vesicle transport to the distal 
appendages is also mediated via the motor protein Myosin-Va (MYO5A) (Wu et al., 2018). The 
depletion of the MYO5A in RPE and 3T3 cells disrupts the centrosomal actin network, which leads 
to the blockade of periciliary vesicles docking.  
 
Furthermore, growing evidence suggests that the centrosomes, besides functioning as microtubule 
organizers, also act as an actin-organizing center (Farina et al., 2016). Ciliary membrane-associated 
proteome demonstrated the presence of actin-binding proteins as dynamic components inside the 
cilium in mammalian cells (Kohli et al., 2017). The actin cytoskeleton remodeling factors LIM domain 
kinase 2 (LIMK2) and Dual specificity testis-specific protein kinase 1 (TESK1), both serine/threonine 
kinases are present in the vicinity of the centrioles and control ciliogenesis via remodeling actin 
cytoskeleton (Kim et al., 2015a). Moreover, components of centriolar satellites, electron-dense 
cytoplasmic structures, in particular, C2 domain-containing protein 3 (C2CD3) and Oral-facial-digital 
syndrome 1 protein (OFD1), play an essential role in the periciliary vesicle trafficking, fusion, 
extension, and assembling distal appendages (Singla et al., 2010, Ye et al., 2014). Altogether the 
data suggests that the tightly regulated ciliogenesis is a very dynamic process. 
 
After ciliary vesicle formation, CEP164 recruits Tau tubulin kinase 2 (TTBK2) to the distal end of the 
basal body (mother centriole) to initiate cilium formation, triggering the removal of the centrosomal 
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protein CP110-CEP97 complex (Goetz et al., 2012, Cajanek and Nigg, 2014). A crucial mechanism 
that controls the basal body to cilium transition is supported by the reduced recruitment of 
Centrosomal protein of 110 kDa (CP110) and Centrosomal protein of 97 kDa (CEP97) at the distal 
end of the mother centriole, which promotes the cilium formation (Spektor et al., 2007). Indeed, the 
TTBK2 null mouse mutant lacks cilia and has defects in the sonic hedgehog (Hh) signaling. This 
phenotype could be due to the defects in the anchoring of the basal body and the recruitment of IFT 
machinery proteins essential for the trafficking, axoneme growth, and maintenance (Goetz et al., 
2012). Additionally, TTBK2 knockout cells retain CP110 at the basal body, proving that TTBK2 is a 
key player in removing CP110 from the mother centriole (basal body) and initiating the ciliogenesis. 
 
The centrosomal protein TALPID3 has been demonstrated to be essential for ciliary vesicle docking 
during ciliogenesis (Kobayashi et al., 2014). Recently, a study identified that TALPID3 interacts with 
the C2 domain-containing protein 3 (C2CD3) at the distal ends of the centrioles resulting in centriole 
maturation and distal appendages assembly (Wang et al., 2018). Subsequently, a recent report 
demonstrated that CEP120, besides its role in centriole elongation, regulates ciliogenesis. Depletion 
of CEP120 in RPE cells impaired recruitment of C2CD3 and TALPID3 to the distal end of the 
centriole, resulting in defective centriole elongation and cilium formation (Tsai et al., 2019). 
1.4.2 Maintenance of ciliary length  
During the axoneme growth, extensive amounts of tubulin dimers enter the cilium from the 
cytoplasm. The bidirectional cargo transport is provided via the IFT machinery that supports a 
mechanism for the cilium formation, maintenance, and function (Satir and Christensen, 2007, 
Ishikawa and Marshall, 2017). Directly after the IFT complex recruitment to the mother centriole, the 
transition zone, and the basal body begin to form. IFT proteins are divided into two large complexes, 
IFT-A (retrograde transport) and IFT-B (anterograde transport).  
The IFT-B is associated with kinesin II and mediates anterograde transport of molecules from base 
to the cilium tip, known as an anterograde transporter. The IFT-A is associated with dynein and 
mediates retrograde movement from the tip to the base of the cilium (Pedersen et al., 2008). Pazour 
and colleagues discovered that mutations in the IFT machinery, specifically the IFT88 knockout in 
Chlamydomonas, results in a loss of the flagella. Moreover, the same knockout studies in mice 
resulted in ciliary defects, which lead to polycystic kidney disease (Pazour et al., 2000). Defects in 
the IFT transport proteins or tubulin can perturb axoneme growth and cilium length. In agreement 
with this idea, studies in Chlamydomonas and mammalian cells revealed that increasing soluble 
tubulin affects cilium length, whereas stabilization of tubulin leads to shorter cilium (Sharma et al., 
2011, Wang et al., 2013b). Furthermore, the rate of IFT transport along with the axoneme has an 
impact on the cilium length. Therefore, increased and decreased anterograde transport rate is 
associated with longer or shorter cilium, respectively (Marshall and Rosenbaum, 2001, Marshall et 
al., 2005). Since the mother centriole (basal body) templates the cilium, it is possible that 
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centrosomal proteins can also interact with cytoplasmic tubulin and play a crucial role in regulating 
tubulin during the ciliary axoneme growth. Indeed, Centrosomal-P4.1-associated-protein (CPAP) 
binds tubulin via its PN2-3 domain, regulating ciliary length. Interestingly, mutations in PN2-3 CPAP 
(F375A) exhibit strongly reduced tubulin interaction, causing shorter cilia. Together this data 
suggests that CPAP defines ciliary microtubule length through binding and releasing the cytoplasmic 
tubulin to determine ciliary-microtubule lengths (Zheng et al., 2016, Sharma et al., 2016). 
 
The ciliary membrane also plays an essential role in the axoneme elongation during the cilium 
formation. Studies have demonstrated that overexpression of active small GTPases Rabin8 (Rab8a) 
in mammalian cells can affect ciliary membrane growth, resulting in the shorter cilia. The Rab8a 
forms a complex with the octameric protein complex BBSome and potentially cooperates with other 
unknown factors to organize ciliary membrane assembly (Nachury et al., 2007, Westlake et al., 
2011). Once the cilium is assembled and elongated, a selective mechanism that operates at the 
cilium base enables it to retain its composition. In particular, a soluble protein barrier, the transition 
zone functions to maintain the protein composition of the cilium (Jensen and Leroux, 2017, Nachury 
and Mick, 2019). Finally, it is noteworthy to emphasize that the cilium’s length is also under the 
control of cilium disassembly pathways, which prevent assembly pathways during the cell cycle re-
entry (see below). 
1.5 Cilium disassembly 
In contrast to cilium assembly, the mechanisms involved in cilium disassembly have not been well 
characterized. Thus, recent studies have begun to uncover the mechanisms linking cilium 
disassembly to cell cycle re-entry and identified proteins crucial for cilium disassembly. Experiments 
in mammalian cultured cells suggest that the cilium disassembles in two waves. The first wave 
occurs in the G1 phase of the cell cycle, shortly after the quiescent cells' mitogenic stimulation. In 
contrast, the second wave occurs before cells enter the mitosis (Figure 1.3) (Pugacheva et al., 2007, 
Tucker et al., 1979). In cycling cells, the cilium assembly occurs during the cell cycle exit (G1-G0) or 
quiescent state, whereas the cilium disassembly coincides with the cell cycle re-entry (G1-S to M) 
(Figure 1.3). Cilium disassembly and cell-cycle re-entry require the destabilization and 
depolymerization of axonemal microtubules (Figure1.3). Several studies have demonstrated 
numerous key regulator proteins that mediate cilium disassembly, a process that has an extensive 




Figure 1.3. Cilium dynamics in cell cycle. 
Cilium checkpoint. The mother centriole serves as a template for the cilium formation during the cell cycle 
exit in the G0 phase. Cilium disassembly starts at the S phase when centrioles duplicates. Cilium 
disassembles at the G2 phase when cells continue to mitotic progression. Modified from Gabriel et al., 
2016 (Gabriel et al., 2016) 
1.5.1 Aurora-A/HDAC6 dependent cilium disassembly 
The mitotic kinase Aurora-A plays a key role during both waves of cilium disassembly (Pugacheva 
et al., 2007). Aurora-A is a serine/threonine kinase essential for the cilium length and deciliation at 
the onset of cell cycle re-entry, as well as centrosome duplication, maturation, and spindle assembly 
(Pugacheva et al., 2007, Pan et al., 2004). The initial indication that Aurora-A controls the cilium's 
length was demonstrated in Chlamydomonas reinhardtii biflagellate alga (Pan et al., 2004). In 
cultured mammalian cells, upon cell cycle re-entry, Aurora-A is recruited to the basal body, which 
phosphorylates and activates Histone deacetylase 6 (HDAC6), which deacetylases and destabilizes 
tubulin polymer within the ciliary axoneme (Figure 1.4). Activation of Aurora-A is a complex process, 
stringently controlled by different signaling pathways, including calcium influx, which in turn induces 
binding of the calmodulin to the Aurora-A and its partner Enhancer of filamentation 1 (NEDD9). 
Another protein that regulates cilium disassembly via control of Aurora-A activation at the basal body 
is Trichoplein keratin filament-binding protein (Figure 1.4). In quiescent cells (G1-G0 phase), 
Trichoplein is absent from the basal body and localizes to the centrosome in proliferating RPE cells 
(Inoko et al., 2012). Additionally, the HDAC6 can promote cilium disassembly through another 
substrate, which is the Polo-like kinase1 (PLK1) (Wang et al., 2013a, Lee et al., 2012) (Figure 1.4). 
PLK1 is a G2-M phase kinase. It is recruited to the pericentriolar matrix before the cell cycle re-entry 
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and then activates the HDAC6 to promote its function for ciliary deacetylation resorption (Lee and 
Rhee, 2011) (Wang et al., 2013a) (Ramani et al., 2018).  
 
Protein pitchfork (PIFO) through binding to the beta-tubulin activates Aurora-A, promoting the cilium 
disassembly. Interestingly, Pifo heterozygous mutant mice display ciliopathy-related phenotypes, 
highlighting the consequences of perturbing cilium disassembly (Figure 1.3) (Kinzel et al., 2010). 
More recently, it has been recently shown that another Histone deacetylase 2 (HDAC2) plays an 
important role during the cilium disassembly (Kobayashi et al., 2017). Altogether the data illustrate 
that both HDAC6 and Aurora-A can regulate the cilium disassembly through different substrates and 
mechanisms. A delay or failure in cilium disassembly retains cells in the G0-G1 phase and transiently 
prevents the cell cycle progression (Pugacheva et al., 2007, Jackson, 2011, Kim et al., 2011). It has 
been demonstrated that cilium must be disassembled before the cell re-enter the cell cycle such that 
the mother centriole can be released from the plasma membrane to participate in organizing the 
mitotic spindle (Paridaen et al., 2013, Guemez-Gamboa et al., 2014).  
 
 
Figure 1.4. Cilium disassembly. 
Cell cycle re-entry requires the inhibition of axoneme growth and the recruitment of several regulatory 
proteins to trigger cilium disassembly. HEF1 is recruited and activates Aurora-A at the basal body, which 
then stimulates and activates HDAC6 (green H), and tubulin de-acetylation. This leads to axoneme 
disassembly. Pitchfork (Pifo) and Trichoplein are recruited to activate Aurora-A, and NdeI1 (same as 
NDE1) stabilizes Trichoplein at the basal body to inhibit ciliogenesis. (I-III). After mitogen stimulation, 
PLK1-mediated phosphorylation of kinesin KIF2A, which stimulates the depolymerization of axonemal 
microtubules. In the second wave of the cilium disassembly, NEK2 is expressed which then stimulates 
and activates another depolymerizing kinesin, KIF24. Activation of KIF24 prevents re-ciliation through the 
S-G2-M transition, ensuring that centrioles replicates in the S-phase and assemble a mitotic spindle in 




Additional centrosomal proteins are also engaged at the onset of cilium disassembly and cell cycle 
re-entry (S-phase) such as Nuclear distribution gene E homologue 1 (NDE1) and Dynein light chain 
Tctex-type1 (Tctex-1 or DYNLT1). NDE1 is a negative regulator of the ciliary length, and recruitment 
to the basal body initiates cilium disassembly (Kim et al., 2011). The depletion of Nde1 in mouse 
fibroblast NIH-3T3 cells resulted in the longer cilium formation and delay in the cell cycle progression 
(S-phase) via the CDK5 phosphorylation, which in turn ubiquitinylates F-box protein/WD repeat-
containing protein (Fbw7) as the E3 ligase that mediates the destruction of Nde1 (Alkuraya et al., 
2011).  
Furthermore, the Tctex-1 is phosphorylated and recruited to the ciliary transition zone before the S-
phase entry and promotes cilium disassembly and the cell cycle re-entry. The depletion of Tctex-1 
leads to persistent ciliation and retains cells in the G1-S phase. Exogenously expression of phosphor-
mimic Tctex-1 (T94E) mutant protein increases cilium disassembly and the S-phase entry. The 
potential mechanism of Tctex-1 to regulate cilium disassembly is mediated through actin dynamics 
(Li et al., 2011). These results support a model in which the cilium acts as a brake to prevent the 
cell-cycle progression. 
1.5.2 NEK2/KIF24 dependent cilium disassembly  
There are two kinesin 13 family members, Kinesin-like protein 2a (KIF2A) and Kinesin-like protein 
24 (KIF24). Both kinesins are implicated in cilium disassembly via destabilization or depolymerization 
of the axoneme microtubules for mitotic entry (Kim et al., 2015b, Kobayashi et al., 2011). KIF2A is 
recruited to the subdistal appendages of mother centrioles at the proximal ends of both centrioles 
and phosphorylates PLK1 during G2 - M phase. Recruitment of this kinesin promotes cell proliferation 
and microtubule-depolymerizing activity at the mother centrioles to disassemble cilium. The 
depletion of KIF2A in RPE cells showed an impaired cilium disassembly and cell cycle progression 
(Miyamoto et al., 2015). 
 
KIF24 was identified as a negative regulator of cilium assembly, which interacts with CP110 at the 
distal end of centrioles (Kobayashi et al., 2011). The depletion of this kinesin protein in RPE cells 
enhances cilia assembly, implicating the role of KIF24 during cilia disassembly (Kim et al., 2015b). 
In this study by Kim and colleagues revealed that KIF24 is a substrate for NEK2, co-expressed with 
the wild type form of NEK2 (NEK2-WT), but not with the catalytically inactive mutant NEK2-KD 
(amino acid site 37) (Figure 1.5). The phosphorylation sites in KIF24 are restricted to the carboxyl-
terminal kinesin domain (548-825), which is flanked by NEK2-binding surfaces (Figure1.5). 
 
NEK2 is a 445 amino acid (48kDA) protein comprising the N-terminal kinase domain and the C-
terminal non-catalytic regulatory domain (Figure 1.5). The kinase domain has all the motifs typical 
of serine/threonine protein kinases (Hanks and Hunter, 1995). The more C-terminal region contains 
the non-catalytic and coiled-coil regions. The central leucine zipper domain promotes 
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homodimerization, which leads to autophosphorylation (Fry et al., 1998). NEK2 is localized to the 
distal part of the mother centriole and functions in both cilium disassembly and centrosome 
duplication before mitosis, indicating the crucial role of NEK2 in cell cycle control (Spalluto et al., 
2012, Fry et al., 1995). Interestingly, similar to KIF24, the depletion of NEK2 also causes an 
increased ciliation in RPE cells (Spalluto et al., 2012). Overall, the cell cycle-specific phosphorylation 
of KIF24 by NEK2 is an essential step to provide a safeguard mechanism against an aberrant 
assembly of the cilium upon cell cycle re-entry. 
 
Figure 1.5. Schematic diagrams indicating KIF24 and NEK2 domains. 
Top: a schematic representation of the human KIF24 protein structure. Kinesin motif (black), NEK2 
binding sites (509-547, 924-999), NEK2 phosphorylation site (grey) are shown. 
Bottom: a schematic representation of the human NEK2 protein structure. The relative positions of the 
catalytic domain (Ser/Thr kinase, red), leucin zipper (yellow), coiled-coil (brown), K37R (NEK2-KD) 
indicates a mutant site, where the amino acid has been exchanged to prevent phosphorylation of KIF24. 





1.5.3 CPAP mediated cilium disassembly 
The centrosome plays a dual role, existing as a microtubule-nucleating center and as the basal body 
to template the cilium. CPAP, a conserved centrosomal protein, plays a role in centriole formation 
and provides a scaffold for protein complexes during centrosome assembly (Hayward et al., 2004, 
Gopalakrishnan et al., 2011, Lin et al., 2013, Zheng et al., 2016). CPAP contains both, a tubulin 
dimer-binding domain (PN2-3, 311–422 aa) and microtubule-binding domain (A5N, 423-607aa) (Hsu 
et al., 2008, Zheng et al., 2016, Cormier et al., 2009). The CC5 domain at the C-terminal CPAP 
provides a scaffold for CDC proteins to promote cilium disassembly (Gabriel et al., 2016). The C-
terminus of CPAP also includes a highly conserved region known as the G-box or TCP domain, 
providing crucial protein-protein interactions and might serve as a tethering site for centrosomal 
proteins (Zheng et al., 2014).  
 
 
Figure 1.6. Schematic diagram indicating CPAP different domains. 
PN2-3 (magenta) tubulin dimer-binding domain, MBD (blue) microtubule-binding domain, CC5 (green), 
and TCP (yellow) domain. The numbers indicate amino acid positions (Zheng et al., 2016). 
 
A recent study uncovered that CPAP is a negative regulator of ciliary length independent of its 
centrosome biogenesis role. During cilium disassembly, the CPAP's CC5 domain provides a scaffold 
for the cilium disassembly complex (CDC), which comprises NDE1, Aurora-A, and OFD1 that are 
recruited to the ciliary base for timely cilium disassembly. Mutated CPAP lacking the CC5 domain 
fails to localize at the ciliary base, resulting in inefficient CDC recruitment causing retarded cilium 
disassembly, and delayed cell cycle re-entry (Gabriel et al., 2016). Based on this, the cilium 
disassembly provides a conceptually novel ‘cilium checkpoint’ regulating the cell cycle progression. 
Consistently, cilium disassembly proteins are associated with pathological processes such as cancer 
(Chefetz et al., 2011, Kim et al., 2015b, Tang et al., 2013, Kobayashi et al., 2017). However, the 
exact role of the cilium disassembly molecules in this context still needs to be determined.  
 
1.6 The cilium functions as a signaling hub 
The sensory role of cilium depends on the spatiotemporal localization of the specific receptors and 
associated signaling modules in the ciliary membrane. More specifically, the cilium coordinates 
signal transduction pathways such as Hh signaling, Platelet-derived growth factor receptor alpha 
(PDGFR-α), Notch, and Wnt signaling pathways. Moreover, cilium provides photo-, mechano- and 
osmo-sensing functions that transduce information from the extracellular environment (Christensen 
et al., 2012, Bangs and Anderson, 2017).  
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1.6.1 Hedgehog signaling pathway 
The Hh signaling is a well-studied signaling pathway that acts through the cilium. In vertebrates, the 
cilium plays a major role in transducing the Hh signaling pathway that plays a vital role in embryonic 
development and stem cell maintenance (McMahon et al., 2003, Machold et al., 2003). 
Dysregulation of the pathway can cause various birth defects, including polydactyly, skeletal 
malformations, and human cancer (Goetz and Anderson, 2010). The first evidence linking cilium and 
Hh signaling stem from a phenotype-based genetic screen in the mouse that identified a set of 
proteins required to form the cilium (Huangfu et al., 2003). The relationship between ciliary function 
and mammalian Hh signaling has a complex and direct relevance for human diseases such as 
Kartagener syndrome, pulmonary dysfunction, polycystic kidney disease, retinal degeneration, 
infertility, hydrocephalus, holoprosencephaly, polydactyly and cancer (Bale, 2002). Most 
interestingly, the Hh signal transduction relies on the localization of Hh proteins to the cilium. In 
mammals, binding of Hh ligands Sonic (Shh), Indian (Ihh), and Desert (Dhh) to the patched-1 protein 
(PTCH1) receptors activate the Hh signaling pathway (Figure1.7) (Bangs and Anderson, 2017, 
Rohatgi et al., 2007). Upon Hh stimulation, the inhibitory effect of PTCH1 on GPCR-like protein 
Smoothened (SMO) is abolished, resulting in SMO translocation to the cilium. Accumulation of SMO 
allows for cilium-mediated signal transduction via the ciliary localized glioma transcription factors 
(GLI). Subsequently, GLI activates the expression of Hh target genes. Together these studies 
suggest that Hh signaling requires maintenance and function of cilia to sense Hh ligands and 
activates downstream signals, which are critical for development, carcinogenesis, and stem cell 
function (Figure1.6, panel “ON”) (Humke et al., 2010, Wen et al., 2010). Furthermore, both inactive 
GLI and suppressor of fused homolog (SUFU) localize to the ciliary tip.  
 
 
Figure 1.7. Hedgehog signaling at the primary cilium. 
A. In the unstimulated state, PTCH1 localizes to the ciliary membrane and represses SMO from 
translocating into the cilium. GLI transcription factors are sequestered and suppressed by SUFU at the 
tip of the primary cilium, generating GLI3 repressor (GLI3R), which moves to the nucleus and represses 
expression of Hh target genes. B. In the activated state of Hh signaling, upon binding of the Hh ligand to 
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PTCH1, the repression of SMO from Ptch1 is relieved, allowing SMO to translocate into the cilium where 
it can activate downstream signaling. This then allows SMO to disassociate the GLI/SUFU complex and 
the transport of the GLI2 activator to the nucleus to activate the expression of downstream target genes. 
Modified from (Gladiola Goranci-Buzhala, 2017). 
 
Interestingly, the IFT proteins Ift172/Wimple and Ift88/Polaris, and Kif3a mouse mutants displayed 
abnormal embryonic morphogenesis at neural tube levels, coinciding with reduced aberrant Hh 
signaling (Huangfu et al., 2003). In addition, a partial loss of function of Ift52, as well as mutated 
retrograde dynein IFT molecules revealed a similar aberrant phenotype during embryonic 
development in mice. It was also demonstrated that IFT function in mutant mice is essential to control 
both Gli2-R (repressor) and Gli2 (activator) transcriptional activities, which are essential for the Hh 
signaling cascade (Zhang et al., 2016, Liu et al., 2005). Altogether these elegant findings suggest 
that the primary cilium and IFT are required a proper Hh signaling pathway. However, whether IFT 
molecules directly participate in transporting Hh components still remains an open question. 
 
The ADP ribosylation factor-like GTPase 13B (Arl13B), mediates trafficking of Hh signaling 
components within the cilium. Mutation in mouse embryonic fibroblast Arl13Bhnn (hnn cell types within 
the neural tube) did not respond upon Hh ligand stimulation. It displayed an altered distribution of 
Hh signaling components, such as Gli2, Gli3, Sufu, and Smo. These components are localized along 
with the cilium in healthy cells. Thus, loss of Arl13b results in the ligand-independent SMO activation, 
suggesting that Arl13b acts downstream of the known tumor resistance mechanism. Mutations in 
the Hh signaling components (Ptch, Sufu, and Smo) are considered oncogenic drivers in basal cell 
carcinoma and medulloblastoma tumors (Taylor et al., 2002). Loss of Arl13b reduces Hh-dependent 
transcription and proliferation, and inhibits tumor formation in a mouse model of medulloblastoma 
(Bay et al., 2018). Further, in a subset of Hh signaling-dependent tumors, cilium regulates either 
tumor formation or suppression depending on the mutation of Hh signaling proteins (e.g., SmoM2 
and activated Gli2) (Wong et al., 2009). These results demonstrate that cilium plays a dual role in 
both activation and inactivation of the Hh signaling pathway, also functioning either as a mediator or 
suppressor of tumorigenesis depending on the genetic background. 
1.6.2 PDGFR-α signaling pathway 
Signaling via PDGFs and their receptors play an essential role in cell survival, growth control, 
proliferation, cell migration, embryonic development, and tissue homeostasis (Heldin and 
Westermark, 1999, Andrae et al., 2008). Lih et al discovered a functional link between PDGFR-α 
and cilium for the first time (Lih et al., 1996). Subsequent reports have demonstrated that the cilium 
partially coordinates PDGFR-α signaling in cultured mouse embryonic and NIH3T3 fibroblast cells 
(Schneider et al., 2005, Schneider et al., 2010). PDGFR-α forms homodimers and localizes to the 
cilium during the G0 phase (quiescence phase) (Fredriksson et al., 2004). Likewise, embryonic 
fibroblasts of orpk mutant mice (IFT88Tg737Rpw) failed to form a normal cilium and were not able to 
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upregulate PDGFR-α during cell cycle arrest upon serum-starvation, in contrast to wild type 
embryonic fibroblast. These data indicate that localization of PDGFR-α along the cilium is necessary 
for proper signal transduction (Schneider et al., 2005). In contrast to PDGFR-α, the PDGFR-
b signaling was not alerted in orpk mutant mice since the activation of PDGFR-b does not occur in 
the cilium. These findings support the conclusion that PDGFR-α signaling is coordinated through the 
cilium, which can control cell cycle and tissue homeostasis during the development of different cells 
and tissues (Christensen et al., 2012, Christensen et al., 2008).  
 
Pieces of evidence suggest that PDGFR-α signaling is associated with the cilium. The ligand 
PDGFR-AA activates PDGFR-α through phosphorylation (at the amino acid sites 720, 742, and 745) 
and localization at the cilium. Once PDGFR-α is activated, it induces the downstream signaling 
pathways such as Mek1/Erk1/2 and Akt pathways near the cilium base. Activated signaling 
subsequently phosphorylates Retinoblastoma protein (Rb) and Cyclin-dependent kinase 1 (CDC2 
of CDK1), which initiates cell cycle progression (Schneider et al., 2005). Deregulation of PDGFR-α 
signaling has been implicated in cancer development, and studies have indicated that 
gastrointestinal stromal tumors express elevated levels of PDGFR-α signaling (Andrae et al., 2008, 
Corless et al., 2011). Thus, it is conceivable that the cilium suppression could be beneficial for 
preventing cancer cell growth. Even though the role of PDGFR-α signaling/primary cilium in cancer 
progression remains still uncovered, to understand if the loss of primary cilium can lead either with 
signal activation or inhibition indicates that PDGFR-α demands primary cilium to function correctly. 
1.7 Primary cilia in the regulation of neural stem cell proliferation and brain 
development 
Neural progenitor cells (NPCs) are characterized by their ability of self-renewal and differentiation 
into neuronal cell types. A balance between self-renewal and differentiation is achieved through a 
controlled symmetric and asymmetric cell division to maintaining proper tissue homeostasis and the 
stem cell pool. During symmetric division, the cell divides two stem cells while in asymmetric division 
cell divides one stem cell and one differentiated cell. Defects during the asymmetric cell division may 
cause premature depletion of the stem cell pool and abnormal development (Shitamukai and 
Matsuzaki, 2012, Gomez-Lopez et al., 2014). During the quiescence state (G0 phase), NPCs 
assemble cilium responsible for sensing and transmitting signals into the cells. The symmetric 
division of NPCs during the development is regulated by the dynamic control of proteins that initiates 
cilium assembly and disassembly, together with downstream signaling cascades, responsible for cell 
lineage differentiation (Izawa et al., 2015, Goetz and Anderson, 2010). The precise timing of cilium 
disassembly ensures the length of G1-S transition and the self-renewal property of NPCs (Gabriel et 
al., 2016, Li et al., 2011, Kim et al., 2011). It has been demonstrated that Ift88 and Kif3a deficient 
mice exhibit suppressed ciliogenesis resulting in defective expansion of neural progenitor and 
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cerebellum development (Chizhikov et al., 2007, Spassky et al., 2008). Furthermore, conditional 
homozygous mouse mutants for ciliary genes (e.g., Ift88 or Stumpy) display cilia loss leading to 
aberrant Hh signaling and increased proliferation of progenitors (Breunig et al., 2008, Kumamoto et 
al., 2012). 
 
Recent studies have emerged, demonstrating an essential role of cilia in brain development (Gabriel 
et al., 2016, Lepanto et al., 2016). In brief, during the early stages of the neural epithelium 
development, NPCs rapidly self-renew and expand through symmetrical cell division. 
Neuroepithelium expansion is a rate-limiting step to generate a sufficient pool with enough NPCs, 
fundamental for brain development. Neuroepithelial polarity during the brain development process 
is tightly regulated between symmetric proliferation and asymmetric differentiation of NPCs (Gabriel 
et al., 2016). Thus, factors that can instruct NPCs to either self-renew or differentiate are tightly 
regulated. Lately, it has been identified that the CDC proteins are essential for timely cilium 
disassembly and stem cell pool maintenance. The impaired function of CDC proteins can affect the 
cilium disassembly and prevent NPCs from entering into mitosis. Prolonged G1-S transition leads to 
premature neural differentiation, depleting the NPC pools (Gabriel et al., 2016). These observations 
are consistent with previous work demonstrating that lengthening of the G1 phase by depletion of 
Cdk4/CyclinD1 in mouse cortical progenitors is sufficient to switch neural progenitors to the 
differentiation stage (neurogenesis) (Lange et al., 2009). Furthermore, another study has 
demonstrated that disruption of the cilium function via shRNA constructs targeting Kif3a in mice 
embryo, has resulted in a defective NPCs differentiation, additionally supporting a crucial role of 
cilium in the neurodevelopment (Chen et al., 2019). Together, these studies have identified the 
cilium's key roles in controlling NPCs' homeostasis during brain development. 
1.8 Primary cilia in human cancers 
Hallmarks of cancer include uncontrolled cell proliferation, disruption of the cell cycle, and altered 
signaling pathways that support tumorigenesis. How cilia control tumor initiation or progression, 
potentially through cell cycle regulation, is not fully understood yet. A growing body of evidence 
supports the notion that many cancer cells from different tissues with increased proliferation rates 
exhibit suppressed ciliogenesis (Fang and Zhang, 2016, Goranci-Buzhala et al., 2017, Plotnikova et 
al., 2008, Egeberg et al., 2012). However, it is not clear whether cilium loss is the cause or the 
consequence of cellular transformation. 
 
Intriguingly, the CDC's components are elevated in various cancer types and suggest that they could 
play a vital role in tumorigenesis (Egeberg et al., 2012, Dere et al., 2015, Fang and Zhang, 2016). 
There are numerous examples linking cilium loss to elevated expression levels of the CDC 
components. PLK1 is a mitotic kinase that regulates mitotic events by phosphorylating 
serine/threonine rich proteins of centrosomes, kinetochores, mitotic spindle, midbody, and cilium 
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disassembly (Kishi et al., 2009). PLK1 also plays a critical role in cilium disassembly. PLK1 forms a 
complex with Disheveled segment polarity protein 2 (Dvl2). It activates one of the non-canonical Wnt 
pathways, which also initiates cilium disassembly upon activation of Aurora-A through the Human 
Enhancer of Filamentation 1 (HEF1) (Lee et al., 2012). Plk1 is also reported to be a proto-oncogene. 
It is highly expressed in human colon and lung cancer cells suggesting that the elevated levels of 
Plk1 may accelerate cell cycle progression via maintaining cilium in a suppressed state (Raab et al., 
2018, Weichert et al., 2005). 
 
Aurora-A is a mitotic kinase that localizes to centrosomes and regulates entry to the S phase, which 
initiates the cilium disassembly process (see cilia disassembly section) (Gradilone et al., 2013, Xiang 
et al., 2017). Ovarian and clear cell renal carcinoma cells show increased expression levels of 
Aurora-A as well as a defect in cilium formation (Egeberg et al., 2012, Dere et al., 2015) (refer to 
Table 1). In line with these findings, other studies have demonstrated that inhibition of HDAC6 
restored ciliogenesis in chondrosarcoma and cholangiocarcinoma cancer cells and impaired 
capacity of cell proliferation and invasion (Xiang et al., 2017) (Table 1). 
 
NEK2 is a multifunctional protein kinase that regulates mitotic progression, centrosome duplication, 
separation, microtubule stabilization, kinetochore attachment, and the spindle assembly checkpoint 
(Jeong et al., 2007, Sonn et al., 2009, Boekhout and Wolthuis, 2015). 
Recently, NEK2 has been shown to play a role as a proto-oncogene affecting drug resistance, tumor 
progression, and metastasis (Cappello et al., 2014, Hayward et al., 2004, Zhou et al., 2013) 
Furthermore, it was demonstrated that mouse melanoma xenografts with shRNA-mediated depletion 
of Nek2 could overcome drug resistance (Zhou et al., 2013). NEK2 overexpression has also been 
identified in a wide range of human cancers, but it has not yet been determined whether NEK2 is 
part of a CDC component. However, NEK2 plays a prominent role in the final stage of the cilium 
disassembly through the phosphorylation of KIF24 (see cilia disassembly section 1.4), thus both 
proteins are attractive targets to restore ciliation as a mean to impair the cell cycle proliferation. This 
idea is supported by studies in which perturbing NEK2 impaired the proliferation of human breast 
cancer cells (Kim et al., 2015b). Altogether, these studies indicate a suppressive role of cilia in cell 
cycle progression, raising the possibility that cilia loss promotes unrestricted cell cycle progression 








Table 1. Cancer types and pathways that result in suppressed ciliogenesis. 
Cancer types 
(Exhibiting suppressed ciliogenesis) 
Potential mechanism for 
suppressed ciliogenesis  
Reference 
Pancreas 
Activation of KRAS 
pathway 
(Seeley et al., 
2009, Emoto et al., 
2014) 
Breast Unknown 
(Yuan et al., 2010, 
Nobutani et al., 
2014) 
Melanoma EZH2 overexpression (Zingg et al., 2018) 
Renal cell carcinoma 
Aurora-A, Nek8 
overexpression 
(Schraml et al., 
2009, Basten et al., 
2013, Ding et al., 
2015) 
Chondrosarcoma and Cholangiocarcinoma HDAC6 overexpression 
(Gradilone et al., 
2013, Razumilava 
et al., 2014, Xiang 
et al., 2017) 
Glioblastoma CCRK upregulation (Yang et al., 2013) 
Ovarian Aurora-A overexpression 
(Egeberg et al., 
2012, Dere et al., 
2015)  
Chondrosarcoma/Enchondromas Gli2 overexpression  (Ho et al., 2013) 
Rhabdomyosarcoma Unknown (Fu et al., 2014) 
 
1.9 Glioblastoma multiforme 
Glioblastoma multiforme (GBM) is the most aggressive type of adult brain tumor, and the World 
Health Organization (WHO) categorizes it as a grade IV stage tumor (Matsukado et al., 1961, Ostrom 
et al., 2014). The nature of the GBM is highly infiltrative and invasive. Patients have a poor prognosis 
and median survival of 12–15 months, with a maximum survival rate of less than 5% for five years. 
Upon initial diagnosis, GBM patients receive a harsh treatment that combines surgery, radiotherapy, 
and temozolomide (TMZ) prescription (Stupp et al., 2005, Johnson and O'Neill, 2012, Tanaka et al., 
2013). Classification of GBM obtained from genomic, and transcriptome analysis by The Cancer 
Genome Atlas Network (TCGA) is based on a genetic signature. According to this, there are four 
distinct GBM subclasses: classical, mesenchymal, proneural, and neural (Verhaak et al., 2010, Xie 
et al., 2015). 
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The classical subtype is characterized by an increased expression level of EGFR, deletion of PTEN, 
CDKN2A, TP53 loss, increased expression of neural stem cell markers, and constitutively activated 
Hh signaling. The loss of NF1 characterizes the mesenchymal subtype, mutations in PTEN, 
expression of mesenchymal markers such as CHI3L1 and MET, Mitogen-activated protein kinase 
(MAPK) activation and an elevated expression of genes involved in Tumor necrosis factor (TNF) and 
Nuclear factor-kappa B (NF-kB) pathways. The proneural subtype is classified based on 
amplification, mutation, and overexpression of genes such as PDGFR-α, IDH1, and TP53. This 
subtype is also characterized by the activation of the Phosphatidylinositol-3 kinase (PI3K) pathway. 
The final subtype is the neural subtype, and it has not been well characterized for a specific genetic 
profile. However, compared to other subtypes, the neural subtype expresses elevated levels of 
neural markers such as NEFL, GABRA1, SYT1, and SLC12A5 (Verhaak et al., 2010, Xie et al., 
2015). All of the subclasses of GBM are highly untreatable, and thus, considered as intractable 
cancer types. There are numerous reasons accounting for this, which include morphological, cellular, 
genetic, and intertumoral heterogeneity. The characterization of GBM subtypes could help in 
identifying the factors that underlie therapy resistance and tumor relapse. 
 
Regardless of the subtypes, all GBM types possess highly tumorigenic, self-renewing glioma stem 
cells (GSCs), contributing to tumor initiation, maintenance, resistance, and relapse (Lathia et al., 
2015, Rich and Eyler, 2008, Jacob et al., 2020). GSCs possess neural stem cell attributes exhibiting 
uncontrolled self-renewal properties, which might have been acquired or reactivated upon therapy 
resistance (Park et al., 2017, Rajakulendran et al., 2019). Nevertheless, it remains unclear if there 
is an alteration in cellular structures like centrosomes and cilium related to cell cycle control, self-
renewal, and differentiation. Intense effort is being made to understand the mechanism of GSCs 
proliferation, which can then be targeted to control GSCs proliferation as a potential therapeutic 
intervention. So far, only a few studies have emerged showing that the cilium is lost in cultured GBM 
cells, raising the question of whether loss of cilia is a cell culture artifact or a result of suppressed 
ciliogenesis is due to the uncontrolled cell cycle. 
1.9.1 Current evidence for role of primary cilia in glioblastoma 
Most of the altered signaling pathways in GBM are closely related to signals that are mediated 
through cilia especially the PDGFR-α, Hh, Wnt, TGF-ß and Notch pathways (Christensen et al., 
2012, Bangs and Anderson, 2017, Christensen et al., 2017, Ezratty et al., 2011, Wallingford and 
Mitchell, 2011). Therefore, it can be assumed that cilium is involved in the deregulation of cellular 
signaling in many GBM patients. Since the EGFR and PDGFR-α pathways are profoundly affected 
in GBMs, it is possible that the altered cilia-mediated signaling could deregulate cell cycle 




Moser and colleagues' initial works characterized the stages of primary cilium biogenesis in healthy 
astrocytes, astrocytoma, and GBM cells (Table 2), where they showed that the cilium structure is 
disrupted at the early stages of ciliogenesis. As a result, GBM cells were not able to form functional 
cilia. Moreover, the authors have identified the presence of GBM cells with the abnormal 
configuration of distal/subdistal appendages structure. By performing similar ultra-structural analysis 
in biopsy samples, the authors have characterized that GBM tissues also display structural defects 
in cilia (Moser et al., 2009b), (Moser et al., 2014). Taken together, these data indicate that GBM cells 
and tumor tissues have defects in ciliogenesis. Another study supported that cilia loss can determine 
cancer progression in eight cancer types, including GBM. Shpak and colleagues reported the 
downregulation of cilia-related genes, based on The Cancer Genome Atlas (TCGA) gene expression 
annotations (Shpak et al., 2014). 
 
Apart from correlative data, little evidence is provided whether GBM development is cilium-
dependent, and if reintroducing cilium can affect GBM proliferation. The depletion of the cell-cycle 
related kinase (CDK20/CCRK) can induce cilia in a small fraction of serum-starved U251MG cells 
(Table 1 and 2) (Yang et al., 2013). However, it is unclear whether the small fraction of ciliated cells 
was due to the depletion of the kinase or serum-starvation culture condition. Hence, addressing this 
question requires low-passage patient-derived GSCs and increase human cohorts. Since the 
mechanism of cilium loss was only shown in commercial cell lines, do not precisely reflect the 
characteristics of cells in GBM patients. Another study revealed that lysophosphatidic acid (LPA) 
could mediate signaling through cilia and impact the GBM cell proliferation (Loskutov and 
Pugacheva, 2019, Loskutov et al., 2018). LPA is a lipid-based mitogen highly expressed in the brain 
and increases proliferation and invasion of the GBM cells. A receptor of LPA (LPAR1) was found to 
accumulate at the cilium in human astrocytes. Loskutov and colleagues demonstrated that 
suppressed ciliogenesis increases cell proliferation of GBM and astrocytes through a LPA-
dependent mechanism involving primary cilium (Table 2). Targeting LPA-signaling using the inhibitor 
Ki16425 efficiently decreased the proliferation of astrocytes and GBM cells (Loskutov and 
Pugacheva, 2019, Loskutov et al., 2018). 
 
Table 2. Primary cilia in glioblastoma cells. 
Cell line used Source  
Culture 
condition  Cilia  Reference  
U87MG, T98G, U373MG, 
U138MG 
Commercial 
ATCC Serum  lost (Moser et al., 2009a) 
U251MG 
Commercial 
ATCC Serum  lost 
(Moser et al., 2009b) (Yang 
et al., 2013)  
Line 0, Line1, Line2, 
SN179(S2), SN186 (S3) 
patient 
derived cells  
Serum-free 
and growth 





Besides these initial studies in Table 2, only little is known regarding cilia's functional significance in 
GBM initiation and progression. One study demonstrated that smaller fraction (from 8 to 15%) of 
GBM cells are ciliated, and this fraction of cells express Zinc finger E-box binding homeobox 1(ZEB1) 
protein (Sarkisian et al., 2014). ZEB1 is a transcription factor for epithelial-mesenchymal-transition 
(EMT) in GBM. It is expressed in invasive GBM cells, particularly in patient cells with shorter survival 
and poor response to adjuvant chemotherapy TMZ treatment. Furthermore, EMT in GBM can lead 
to tumorigenesis, invasion, and chemoresistance demonstrated in GBM cells and xenograft mouse 
models (Siebzehnrubl et al., 2013). This study suggested that ZEB1 might be a good target in 
recurrent tumor cells since it is mainly expressed in the invasive GBM that also displays a poor 
response to treatment with TMZ. Similarly, the lack of cilia in both PCM1 and KIF3a depleted GBM 
cells, increases sensitivity to TMZ, suggesting that ciliary proteins which mediate ciliogenesis (PCM1 
and KIF3a) can modulate GBM resistance (Hoang-Minh et al., 2016a). Altogether, these data 
suggest that most GBM cells fail to assemble cilia, and only small subpopulations are ciliated cells 
in primary GBM tumor biopsies. 
Given that an increased cell cycle progression is one of the major features of GBM tumor invasion 
and propagation, the possibility of controlling cilia and, therefore, the cell cycle, would have great 
medical relevance. Hence, further studies, specifically in patient-derived primary cultures, could lead 
to a better understanding of the largely unexplored m cilia function mechanism, and could potentially 




2. Objectives and Aims 
The role of primary cilia in tumorigenesis has only begun to emerge, and due to its importance in 
cell cycle progression and proliferation, it has already received significant attention (Moser et al., 
2014, Goranci-Buzhala et al., 2017, Seeger-Nukpezah et al., 2013, Gradilone et al., 2017) Since 
cilia play decisive roles in regulating cell cycle progression and cellular signaling, suppressed 
ciliogenesis is anticipated to contribute to cancer initiation, invasion, and tumorigenesis (Michaud 
and Yoder, 2006, Gradilone et al., 2013, Plotnikova et al., 2008, Emoto et al., 2014). To  better 
understand the basics of cilia biology in GBM, I sought to achieve the following aspects in the 
doctoral thesis: 
 
1. Does suppressed ciliogenesis play a role in cell cycle progression of patient-derived GSCs? 
a) What is the prevalence of primary cilia in patient-derived GSCs and biopsies? 
b) Does suppressed ciliogenesis promotes cell cycle progression in GSCs? 
c) What is the molecular mechanism underlying the suppressed ciliogenesis in GSCs? 
 
2. What are the molecular mechanisms that regulate ciliogenesis and restrict cell cycle progression 
in GSCs? 
a) Which protein complexes are required to induce cilia in GSCs? 
b) Functional characterization of newly induced primary cilia in GSCs. 
c) To examine the cell fate decision of GSCs after cilium induction. 
 
3. Does induce ciliogenesis prevents GSCs invasion in a human brain organoid model? 
a) Develop a suitable assay to study GSCs invasion in the human brain organoids. 





3.1 Patient-derived GSCs exhibit suppressed ciliogenesis 
Since primary ciliogenesis is disrupted at an early stage in the majority of human GBM tumors (Moser 
et al., 2009), eight patient-derived GSCs (isolated cells) and nine different clinical tissues (fixed 
biopsy tumor section) were analyzed. Patient-derived GSCs were used from three subtypes based 
on their genetic background (Table 6) such as mesenchymal (U3024MG), classical (U3056MG), 
proneural (U3047MG, U3082MG, U3033MG, MGG87, MGG8, #275, #454). Most importantly, all of 
the samples represent the three subtypes of GBM characterized by specific genetic defects and 
altered signaling pathways (see introduction 1.8). Since the cellular origin of glioblastoma (GBM) 
might originate from neuroprogenitor cells (NPCs), NPCs-derived astrocytes, and oligodendrocyte 
precursor cells (Stiles and Rowitch, 2008, Yao et al., 2018). Therefore, patient-derived GSCs were 
compared to iPSCs-derived astrocytes and NPCs. Cilia were identified ciliary membrane marker 
ARL13B and centrosomal protein marker γ-Tubulin using immunofluorescence analyses. Our results 
demonstrate an overall suppressed ciliogenesis in patient-derived GSCs (Figure 3.1A, B). 
Additionally, the quantification of ciliated cells, comparing the astrocytes and NPCs, to GSCs exhibit 
a significant decrease in ciliation (Figure 3.1C). 
Similar to patient-derived GSCs, nine independent, GBM patient biopsies show an overall 
suppressed ciliogenesis. (Figure 3.1C-D). To visualize the tumor tissue cancer cells, Collapsin 
response mediator protein (CRMP5) is used along with the ciliary membrane marker (ARL13B). 
CRMP5 is expressed in cytoplasm and nucleus in GBM, predicting lower patient survival and tumor 
proliferation (Moutal et al., 2015). Tumor cells were scored based on CRMP5, and ciliogenesis was 




Figure 3.1. Patient-derived GSCs exhibit suppressed ciliogenesis. 
A. Compared to iPSCs-derived astrocytes and NPCs, U3047MG, a representative proneural subtype 
GSC line exhibits suppressed ciliogenesis. ARL13B (green) labels cilia and γ-Tubulin (magenta) labels 
centrosomes. Scale bar, 10µm (overview), 2µm (inset). At least 500 cells were analyzed for each cell line 
from (n=4) independent experiments. B. Irrespective of various genetic backgrounds, tested GSCs 
(proneural, classical or mesenchymal) exhibit suppressed ciliogenesis. ARL13B is used to label cilia 
(green), and γ-Tubulin is used to label the centrosomes (basal bodies, magenta). Scale bar, 20 µm. C. 
Cilia occurrence in clinical tissues. Grade IV glioblastoma tissues mostly lack cilia (red, arrows). 
CRMP5 marks cancer cells in clinical tissues (green). D. The bar diagram quantifies frequencies of 
ciliated cells. Note that compared to astrocytes and NPCs, GSCs display an overall decrease in 
ciliation. Likewise, in clinical tissues, at least 9 independent glioblastoma grade IV tissues show an 
overall reduction in ciliation. Tumor cells were scored based on CRMP5 immunolabeling. At least 
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500 cells were analyzed in each cell line from three (n=3) independent experiments. One-way 
ANOVA, followed by Dunnett’s multiple comparisons test ***P <0.0001. Error bars show +/- SEM. 
 
Afterward, we performed the ultrastructural analysis of centrioles at an early stage of ciliogenesis, 
when the centriole anchors at the membrane, and serves as a basal body. The electron microscope 
(EM) results showed that compared to NPCs, cilium formation is suppressed at the early stages of 
ciliogenesis, specifically in U3047MG (proneural) (Figure 3.2A). These results are in line with 
previously published data (Moser et al., 2014). Delayed cilia disassembly is associated with 
suppressing cell division via an extended G1-S transition. In contrast, accelerated cilia disassembly 
or loss of cilia promoted cell proliferation (Jackson, 2011, Kim et al., 2015b, Li et al., 2011). 
While ciliogenesis is suppressed in the various genetic backgrounds of GSCs, we anticipated that 
these GSCs could exhibit an increased cell proliferation. Therefore, astrocytes, NPCs, and GSCs 
were labeled with ethynyl-deoxyuridine (EdU). As expected, 24hrs after EdU pulse labeling, an 
increased cell number with incorporated EdU in NPCs compared to ciliated astrocytes were 
observed. Interestingly, the cell number of GSCs with incorporated EdU was also elevated and 
similar/comparable to NPCs (Figure 3.2B). Increased proliferation is coupled to the elevated rate of 
the cell cycle. Hence, to determine the cell cycle phase of GSCs, fluorescence ubiquitination cell-
cycle indicator (FUCCI) was used. This method employs fluorescent probes, which enables the 
visualization of cell cycle progression. Following analyzes of the FUCCI experiment revealed that 
unlike astrocytes but similar to fast proliferating NPCs, only a small fraction of GSCs reside at G1/G0, 
a cell cycle stage of cilium assembly in healthy cells (Figure 3.2C). These data indicate that 





Figure 3.2. Suppressed ciliogenesis promotes cell proliferation. 
A. Ultrastructural analysis of NPCs (top) compared to U3047MG cells (bottom). Note vesicle formation 
(yellow arrow). At least 15 independent centrioles were analyzed. Scale bar, 1µm (overview) and 100nm 
(inset). B. The bar diagram quantifies frequencies of EdU positive cells. Note that GSCs exhibit similar 
EdU profile of NPCs and exhibit an increased EdU incorporation compared to ciliated cycling astrocytes. 
At least 300 cells were analyzed in each cell line from (n=3) independent experiments. One-way ANOVA, 
followed by Dunnett’s multiple comparisons test, ***P<0.001. Error bars show +/- SEM. C. The bar 
diagram quantifies cell cycle analysis by Fluorescence Ubiquitin Cell Cycle Indicator (FUCCI) tracing. 
Note that a significant fraction of GSCs and NPCs are retained at G2-M (green). At least 100 cells were 
analyzed in each cell line from (n=4) independent experiments. Ordinary two-way ANOVA, followed by 




3.2 GSCs have an elevated level of CDC that contains NEK2 and KIF24 as crucial 
components 
Next, the aim was to investigate the molecular mechanism that suppressed ciliogenesis in GSCs. 
Because cilia formation is suppressed in GSCs at the early stages of ciliogenesis (Figure 3.1), we 
speculated that CDC protein levels are elevated in this critical period to suppress ciliogenesis. 
Assuming that suppressed ciliogenesis in GSCs allows them to proliferate continuously escaping 
from the quiescence state G0 (resting phase). This would aid in explaining the aggressive nature of 
GSCs.  
Studies have shown that NEK2, a S/G2 kinase, is elevated in cancer cells and plays a prominent role 
in cilia disassembly by activating its physiological substrate Kif24. This depolymerizing microtubule 
kinesin suppresses cilia formation (Kim et al., 2015b). To understand if NEK2 and KIF24 are part of 
the CDC complex co-immunoprecipitation was performed. Because CDC proteins are low abundant 
protein, the FLAG-tagged CPAP and FLAG-tagged NEK2 were used, which were stably expressed 
in HEK293 cells. By analyzing purified FLAG-tagged CPAP complexes, we identified that NEK2 co-
purifies with CDCs' known component. Reciprocally, CDC components of Aurora-A, HDAC6, NDE1, 
OFD1, and CPAP co-purify with FLAG-tagged NEK2, which also included its substrate KIF24. 
Centrosome associated Outer dense fiber protein-2 (OFD-2) does not co-purify with CPAP, 
indicating the specificity of CPAP interaction with CDC components (Figure 3.3A and B). Taken 
together, the co-immunoprecipitation performed in HEK293 confirms that NEK2 and KIF24 are 
components of the CDC.  
 
Figure 3.3. NEK2 and KIF24 co-purify with CDC proteins. 
A. Immunopurification of CPAP complex from HEK293 cell extracts expressing CPAP-flag. NEK2 co-
purifies with other components of CDC. Centrosome-associated Outer Dense Fiber protein-2 (OFD-2) 
does not co-purify with CPAP indicating the specificity of CPAP interaction with CDC components, 
including NEK2. IgG indicates negative control. B. Reciprocal immunopurification experiment. 
Immunopurification of NEK2 complex from HEK293 cell extracts expressing NEK2-flag. NEK2 co-purifies 




However, this is an overexpression model. Therefore, to gain more insights about the CDC protein 
levels in GSCs, we performed a semi-quantitative Western blot analysis in patient-derived GSCs 
(U3047MG, U3082MG, MGG87) compared to control astrocytes. The finding from the results 
indicates that amounts of CDC protein extract overall increase in GSCs compared to ciliated 
astrocytes (Figure 3.4A). Additionally, immunostaining using specific antibodies against CDC 
(NDE1, OFD1, Aurora-A, and CPAP) further revealed that compared to NPCs, GSCs that have 
suppressed ciliogenesis recruit an enhanced level of CDC proteins at the basal body (ciliary base) 
(Figure 3.4C). Moreover, compared to NPCs, U3047MG cells displayed a significant increase in the 
immunoreactivity of KIF24 both in the cytoplasm and basal bodies (Figure 3.4B). Altogether data 
suggest that elevated levels of CDC proteins might be involved in the molecular mechanism that 




Figure 3.4. GSCs have elevated levels of CDC components. 
A. Semi-quantitative Western blot exhibiting relative levels of tested CDC components between ciliated 
astrocytes and GSCs. An equivalent quantity of cell extracts was loaded. GSCs show an overall elevated 
level of CDC components. GAPDH was used as a loading control. B. The bar diagram quantifies the 
relative intensity of tested CDC components in ciliated astrocytes and GSCs. Western blots from three 
(n=3) independent experiments. Ordinary two-way ANOVA, followed by Sidak's multiple comparisons 
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test, ***P<0.001. Error bars show +/- SEM. C. Compared to NPCs, U3047MG exhibits an overall 
increased immunoreactivity to KIF24. Increased level of KIF24 is obviously visible in the cytoplasm and 
at ciliary bases. The bar diagram at right quantifies fluorescence intensity of KIF24. At least 200 cells 
were analyzed in each cell line from (n=4) independent experiments. Ordinary two-way ANOVA, followed 
multiple comparisons test, **P <0.001. Error bars show +/- SEM. D. Compared to NPCs, U3047MG cells 
recruit an enhanced level of CDC components to the ciliary base. Cilia are labeled either by ARL13B or 
acetylated α-tubulin (green). CDC components (red) were immunostained using antibodies specific to 
CPAP, Aurora-A, OFD1 and NDE1. Bar diagram at right quantifies fluorescence signal intensity. At least 
200 were analyzed in each cell line from (n=4) independent experiments. Ordinary two-way ANOVA 
followed by Tukey's multiple comparisons test. ***P <0.001, **P <0.001, P <0.01. Error bars show +/- 
SEM. Scale bar 2 µm. 
3.3 Depletion of CDC components induces cilia in GSCs 
To investigate the potential mechanism to induce cilia in GSCs, we asked if targeting overexpressed 
CDC proteins is sufficient to induce ciliogenesis in GSCs. Therefore, shRNA-mediated depletion of 
selected CDC components (NEK2, HDAC6, and NDE1) in U3047MG cells was performed. Using 
western blot analysis depletion of targeted NEK2, HDAC6, and NDE1 proteins were confirmed. 
Surprisingly, according to the immunostaining of ARL13B (ciliary membrane marker), the depletion 
of all CDC components induced cilia in U3047MG cultures. However, the quantification analysis 
shows the highest increase in ciliation after NEK2 depletion (Figure 3.5A-B). These data show that 
the depleting subset of CDC components in GSCs is sufficient to induce cilia. 
 
Based on the shRNA-mediated CDC depletion experiments, NEK2 was the most promising 
candidate to restore ciliogenesis in GSCs (Figure 3.5A and B). Therefore, we targeted NEK2 in 
GSCs with different genetic backgrounds (proneural, mesenchymal, and classical). Of note is that 
NEK2 is a multifunctional protein. Hence, we decided to target only the catalytic part of the protein, 
which is implicated explicitly in cilia disassembly. We took advantage of the previously used plasmid 
carrying catalytically inactive NEK2 (NEK2-KD, NEK2-kinase-dead, in which catalytically active 
lysine is replaced with catalytically inactive arginine, NEK2-K37R) (Fry et al., 1995). It has been 
shown that mutated NEK2-K37R (NEK2-KD) cannot phosphorylate its physiological substrate KIF24, 




Figure 3.5. Depletion of CDC components induce cilia in patient-derived GSC cell line. 
A. shRNA specifically targeting NEK2, HDAC6, and NDE1 depletes respective proteins and induces cilia 
in U3047MG cells. U3047MG is used as representative GSCs. ARL13B is applied to label cilia (green) 
and γ-Tubulin is used to label the centrosomes (basal bodies, magenta). Scale bar, 10 µm. Western blots 
below show shRNA-mediated depletion of specific CDC components. GAPDH is a loading control. 
B. Bar diagram quantifies frequencies of ciliated cells in cultures treated with shRNA specific to CDC 
components. At least 200 cells were analyzed from (n=3) experiments. Ordinary two-way ANOVA 
followed by Sidak's multiple comparisons test. ***P <0.0001. Error bars show +/- SEM. 3.4 
Overexpression of NEK2 kinase dead is sufficient restore cilia in GSCs. 
 
Therefore, instead of depleting endogenous NEK2, a lentil-based inducible system was used to 
overexpress the catalytic inactive NEK2-KD in GSCs. Following several cloning steps, we generated 
a panel of GSC lines stably expressing doxycycline (DOX) inducing GFP-tagged NEK2-WT and 
NEK2-KD. Using this system, we revealed that upon 24 hrs. DOX induction, NEK2-KD expression, 
could induce cilia in proneural subtype GSCs (U3047MG, U3082MG, and MGG87), however not in 




Figure 3.6. Overexpression of NEK2-KD induce cilia in proneural subtype of GSCs. 
A. Catalytically inactive NEK2 kinase (NEK2-KD) overexpression could induce cilia in proneural subtype 
GSCs. B. In contrast, catalytically inactive NEK2 kinase (NEK2-KD) overexpression cannot induce cilia 
in mesenchymal subtype GSCs (U3024MG). ARL13B labels cilia (yellow), NEK2-WT and KD both target 
basal bodies (green), and γ-Tubulin labels the centrosomes (basal bodies, magenta). Scale bar, 20 µm. 
 
Taken together, the data shed new light on the possible mechanism of cilia induction, suggesting 
that targeting CDC components can induce cilia in proneural subtype GSCs. To gain more insights 
into this mechanism, we studied the proneural GSCs in more detail. 
Since cilia induction in GSCs was possible by overexpressing NEK2-KD (induced by DOX for 24 
hrs), the percentage of ciliated cells was quantified, and then analyzed if this phenomenon is coupled 
to the cell cycle. First, all GSC lines stably expressing GFP-tagged NEK2-WT or NEK2-KD were 
treated with DOX for 24hrs and 72hrs and quantified the percentage of ciliated cells using ARL13B 
(ciliary membrane marker) (Figure. 3.7A-C). The frequencies of ciliated GSCs did not vary 
significantly after 72hrs of DOX induction. Quantification analyzes demonstrate that NEK2-KD 
overexpression could significantly restore ciliogenesis in proneural subtype GSCs (U3047MG, 
U304782, MGG87, and #275) (Figure 3.7C). Moreover, cell proliferation analysis of ciliated 
U3047MG cells revealed that they proliferated significantly slower than non-ciliated cells as 
determined by EdU incorporation and Ki67 staining (Figure 3.7E). Overall, the data show that 




Figure 3.7. Overexpression of NEK2-KD induces cilia and prevents cell proliferation. 
A. Experimental set up. Seeded GSCs were induced to express NEK2-WT and NEK2-KD (kinase dead, 
catalytically inactive), fixed and analyzed. B. Compared to U3047MG naïve or NEK2-WT expressing 
U3047MG, NEK2-KD expressing U3047MG displays cilia. NEK2 (green) labels centrosomes. ARL13B 
labels cilia (magenta). Scale bar, 20µm (overview), 5µm (Insert). n=4 independent experiments. C. Bar 
diagram quantifies frequencies of ciliated cells across different GSCs upon NEK2-KD expression. NEK2-
KD could induce ciliogenesis in selective GSCs lines and not in mesenchymal (U3024MG) or classical 
(U3056MG) subtypes. At least 300 cells were analyzed in each cell line from (n=5) independent 
experiments. P values were obtained using ordinary two-way ANOVA, followed by Tukey’s multiple 
comparisons test. ***P <0.0001. Error bars show +/- SEM. D. Cilium induction impairs proliferation rate 
of GSCs. Bar diagram quantifies cell proliferation profile of non-ciliated (naïve U3047MG, NEK2-WT 
expressing U3047MG) and ciliated GSCs (NEK2-KD expressing U3047MG) revealed by 48h EdU pulse 
chasing Ki67 immunoreactivity. At least 400 cells were analyzed in each cell line from (n=4) independent 




Data demonstrate that ciliated U3047MG cells are majorly retained at G1/G0 (Figure 3.2C) prompted 
us to speculate that NEK2-KD-induced cilia are persistent, and thus cells presumably did not proceed 
to G2-M transition. Thus cells presumably did not proceed to G2-M transition (cell cycle re-entry). To 
test this hypothesis, DOX was withdrawn after day 3 of incubation, and GSCs were further cultured 
for a prolonged period of up to 10 days without DOX. Although NEK2 expression is unnoticeable at 
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day 10, the abundance of ciliated GSCs in Nek2-KD expressing cultures remain unchanged (Figure 
3.8B immunofluorescence staining left panel). Concurrently, after DOX withdrawal, the cell 
proliferation did not continue in these GSCs (Figure 3.8B bar diagram). These findings indicate that 
NEK2-KD-induced cilia are persistent and suggest that these GSCs do not re-enter the cell cycle. 
Overall, data show that catalytically inactive NEK2 is sufficient to induce ciliation persistently in 
proneural GSCs subtype. 
 
 
Figure 3.8. Ciliogenesis is irreversibly induced in GSCs after NEK2-KD overexpression. 
Experimental scheme of doxycycline induction and wash out experiment. NEK2-KD expressing GSCs 
still harbor primary cilia at day 10 even after removing doxycycline (Scale bar 10 µm). Bar diagram at 
right quantifies the fraction of ciliated cells and absolute cell numbers at various time points of doxycycline 
wash out. At least 1000 cells were analyzed in each cell line from (n=4) independent experiments. 
Ordinary two-way ANOVA, followed by Tukey’s multiple comparisons test. ***P <0.001. Error bars show 
+/- SEM. 
 
3.4 Ciliogenesis is associated with reduced recruitment of CDC  
To understand plausible mechanisms of cilium induction, we analyzed the levels of CDC proteins 
before (U3047 naïve and NEK2-WT) and after cilium induction (U3047MG NEK2-KD). Since CDC 
proteins are downregulated in quiescence state (G1-G0) of the cell cycle, we analyzed protein levels 
before and after ciliation in GSCs. Western blot analysis of U3047MG cell extracts revealed an 
overall reduction in CDC protein levels after cilia induction (U3047MG NEK2-KD) (Figure 3.9A). 
Reasoning that this could be due to overall reduction in proliferation and retention of cells at G1-G0, 
prompting us to estimate the amount of individual CDC components recruitment to the basal bodies. 
Immunostaining using specific antibodies against CDC components (Aurora-A, CPAP, NDE1, and 
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OFD1) revealed that the recruitment of CDC components is drastically reduced in GSCs after cilium 
induction (U3047MG NEK2-KD) compared to healthy NPCs (Figure 3.9B). 
Kif24 is a depolymerizing microtubule kinesin that localizes between the distal end of the basal body 
and the minus end of the ciliary microtubule (Kim et al., 2015b). Upon activation by Nek2, Kif24 
readily stimulates ciliary microtubule depolymerization, possibly acting as a minus-end microtubule-
depolymerizing factor. This orchestrated interplay of Nek2-Kif24 interaction ensures the suppressed 
ciliogenesis (Kim et al., 2015b). Therefore, we turned our investigation into the localization dynamics 
of Kif24 before and after cilium induction. To our surprise, we detected a mislocalization pattern of 
Kif24 in almost all of the ciliated U3047MG cells expressing Nek2-KD. Specifically, Kif24 was 
restricted to basal bodies and often absent at the minus end of ciliary microtubules (Figure 3.9C-D). 
Altogether, these results revealed that overexpression of the inactive catalytic domain of NEK2 
(NEK2-KD) is sufficient to induce cilia in GSCs and to reduce CDC recruitment at the basal bodies. 
Surprisingly, upon cilium induction, the NEK2-KD is not able to localize its substrate KIF24 at the 
active site of the minus end ciliary microtubule. The data underlines an important role of the NEK2-





Figure 3.9. Overexpression of NEK2-KD impairs CDC recruitment to the newly induced cilia in 
GSCs. 
A. Semi-quantitative Western blot exhibiting relative levels of CDC components before and after cilium 
induction in U3047MG cells. Cilium induction (NEK2-KD expressing U3047MG) is associated with a 
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reduction in overall CDC component levels. NEK2 antibody recognizes both endogenous and exogenous 
proteins. GAPDH was used as a loading control. The bar diagram at right quantifies the relative intensity 
of CDC components before and after cilium induction. Western blots from three (n=3) independent 
experiments. Ordinary two-way ANOVA, followed by Tukey's multiple comparisons test, ***P<0.001. Error 
bars show +/- SEM. B. Compared to non-ciliated U3047MG naïve, NEK2-KD expressing ciliated 
U3047MG cells recruit a reduced level of CDC components. Cilia are labeled either by ARL13B or 
acetylated α-tubulin (yellow). CDC components (magenta) were immunostained using antibodies specific 
to Aurora-A, CPAP, NDE1, and OFD1. NEK2-KD labels centrosomes at the base of cilia (green). Graphs 
at right display the distribution of fluorescence intensity of CDC components recruited to ciliary base 
before (red, naïve) and after (blue, NEK2-KD) cilium induction. At least 300 cells were analyzed in each 
cell line from (n=4) independent experiments. Scale bar 2 µm. C. KIF24 (yellow) localizes at distal 
centriole or minus end ciliary microtubule GT335 (magenta) in healthy NPCs. In contrast, KIF24 is 
restricted only to basal bodies in most of the NEK2-KD expressing ciliated U3047MG cells. Schematic at 
right depicts the KIF24 localization pattern before and after cilium induction. Imaging of KIF24 in 
U3047MG naïve cells is not shown as they have suppressed ciliogenesis. At least 200 cells were 
analyzed in each cell line from (n=4) independent experiments (Bar diagram below). Unpaired t-test. 
***P<0.001. Error bars show +/- SEM. Scale bar 2 µm. 
D. The bar diagram quantifies fractions of NPCs and ciliated U3047MG cells displaying normal 
localization pattern of KIF24 at the minus end ciliary microtubule. At least 300 cells were analyzed in each 
cell line from (n=4) independent experiments. Unpaired t-test, ***P <0.001. Error bars show +/- SEM. 
3.5 Perturbing CDC recruitment can induce functional cilia in GSCs  
To analyze if the induced ciliogenesis in GSC is structurally normal, we performed EM analysis of 
unciliated (U3047MG naïve) and ciliated (U3047MG NEK2-KD) cells. Ultrastructural analysis 
showed an elevated level of CDC components in unciliated (U3047MG naïve), is somewhat 
corroborated by the frequent presence of electron-dense satellite-like particles concentrated at the 
vicinities of basal bodies which we infrequently observed in ciliated cells (U3047MG NEK2-KD) 
(Figure. 3.10A). The ultrastructure analysis revealed that newly induced cilia by NEK2-KD are 
structurally normal and comparable to healthy NPCs (Figure 3.2Ai). 
The results arise the question if the newly induced cilia in GSCs, despite the typical structure, also 
have normal function. During cilia formation, axoneme elongation requires the amount of tubulin to 
enter cilium. This process is supported via the IFT cargo transport mechanism, which is used for cilia 
formation, maintenance, and function (Harris et al., 2018). Therefore, to functionally analyze newly 
induced cilia in GSCs, we analyzed immunofluorescence staining of the ciliary marker IFT88 and 
acetylated tubulin (Act Tub). Data reveals that ciliated GSCs (U3047MG NEK2-KD) were positive 
for both ciliary markers similar to healthy ciliated NPCs (Figure 3.10B). Overall the data suggest 





Figure 3.10. Induced cilia in GSCs are structurally and functionally normal. 
A. Ultra-structural analysis of non-ciliated naïve U3047MG (top) compared to ciliated U3047MG cells 
(bottom). Numerous electron-dense satellite-like particles are prevalent (red arrow) in naïve U3047MG 
that are infrequently seen after cilium induction. The bar diagram at right quantifies it. At least 20 
centrioles were analyzed. Scale bar 1 µm (low magnification) and 100nm (high magnification). Unpaired 
t-test. ***P<0.001. Error bars show +/- SEM. B. Just like healthy NPCs (left), newly induced cilia of 
U3047MG cells (right) display IFT88 particles (magenta). Cilia are labeled by acetylated α-tubulin 
(yellow). Naïve U3047MG cells do not display cilia nor IFT88 (middle). Both overview and magnified 
single cells are shown. Scale bar 10 µm. At least 500 cells were analyzed from (n=3) independent 
experiments. 
 
However, the sole presence of ciliary markers does not reflect the functionality of newly induced 
cilia. Therefore, we also analyzed newly induced cilia to transduce Hh signaling because Hh 
signaling transduction acts through cilium (Bangs and Anderson, 2017). The overexpression of the 
catalytically inactive domain of NEK2 (U3047MG NEK2-KD) was induced with DOX for 48h, and the 
additionally stimulated with smoothened agonist (SAG) that activates SMO protein. SMO is an 
integral part of the Hh signaling pathway, which translocates from the plasma membrane to the cilium 
after activating the signaling (Bangs and Anderson, 2017). Upon SAG stimulation, the activated SMO 
relocated from basal body to the entire length of the cilium in healthy NPCs and newly induced cilium 
(U3047NEK2-KD) but not for unciliated cells (U3047MG naive) (Figure 3.11). These results 
collectively reveal that perturbing CDC recruitment is sufficient to induce structurally and functionally 




Figure 3.11. Induced cilia in GSCs can transduce Hh signaling upon SAG activation. 
Experimental set up of Shh signaling activation with SAG. In healthy NPCs, SMO (magenta) is restricted 
to basal bodies. Upon SAG addition, SMO translocates to primary cilium (top panel). Similar to healthy 
NPCs, U3047MG cells induced with cilia display SMO translocation to newly induced cilia (magenta, 
bottom panel). Cilia are labeled with ARL13B (green). Naïve U3047MG cells do not show cilia, and thus 
SMO is restricted to basal bodies (middle panel). Scale bar 5 µm. Bar diagram at right quantifies fractions 
of cells whose cilia respond to SAG activation. At least 200 cells were analyzed from (n=3) independent 
experiments. Ordinary two-way ANOVA followed by Sidak's multiple comparisons test ***P <0.0001. Error 
bars show +/- SEM. 
3.6 Inducing ciliogenesis triggers GSCs differentiation 
As cilia formation is coupled to the cell cycle in GSCs next, we asked the fate of the cells after 
ciliation. It has been shown that retarded cilium disassembly and extended G1-S transition due to an 
inefficient CDC recruitment are sufficient to switch healthy NPCs from self-renewal to differentiation 
state (Gabriel et al., 2016). Therefore, we analyzed if proneural subtype GSCs induced with cilia 
(U3047MG NEK2-KD) could undergo differentiation. Using immunofluorescence staining, we 
analyzed neural stem cell markers such as NESTIN, PAX6 and SOX2 and differentiation markers 
such as TUJ1 (neuron marker) and GFAP, S100β (astrocyte marker) in GSCs before(U3047MG 
naïve and NEK2-WT) and after cilium induction(U3047MG NEK2-KD). Surprisingly, and in contrast 
to unciliated cells (U3047MG naïve, and NEK2-WT), the ciliated GSCs (U3047MG and U3082MG) 
expressing NEK2-KD exhibited significantly increased proportion of GFAP, S100β and TUJ1 positive 
cells, which are the identity markers of astrocytes and neurons (Figure. 3.12A-B). Importantly, the 
ciliated cells exhibited strongly reduced levels of specific neural and cancer stem cell markers such 
as NESTIN, PAX6, and SOX2, compared to the unciliated cells. However, none of these markers 
were detected in mesenchymal (U3024MG) and classical (U3056MG) subtype GSCs. Moreover, the 
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DOX-induced overexpression of NEK2-KD did not restore ciliogenesis in mesenchymal GSCs 
(U3024MG), suggesting that the differentiation process might be a cilia-dependent (Figure 3.6B). 
 
Figure 3.12. Cilia induction trigger GSCs differentiation. 
A. Naïve or NEK2-WT expressing GSCs display neural stem cell marker Nestin (magenta), PAX6 
(magenta), and SOX2 (yellow) but not differentiation markers of GFAP (yellow), S100β (green), and TUJ-
1 (green) (left and middle panel). In contrast, upon cilium induction, GSCs are differentiated as specified 
by markers of GFAP, S100β, and TUJ1. Note that there is a drastic reduction in neural stem cell markers 
in NEK2-KD expressing cultures. Scale bar, 10 µm. B. Bar diagram at right quantifies fractions of GSCs 
(in percentages) positive for stemness (Nestin, SOX2, and PAX6) and differentiation (GFAP and TUJ1) 
markers. At least 200 cells were analyzed in each cell lines from (n=3) independent experiments. Ordinary 
two-way ANOVA followed by Tukey's multiple comparisons test ***P <0.0001, **P <0.001. Error bars 
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show +/- SEM. C. Western blot compares relative levels of stemness (CD133 and SOX2) and 
differentiation marker (GFAP) before and after cilium induction. GAPDH was used as a loading control. 
Bar diagram at right quantifies relative intensities of respective markers before and after cilium induction. 
Western blots from three (n=3) independent experiments. Ordinary two-way ANOVA followed by Tukey's 
multiple comparisons test, ***P<0.0001. Error bars show +/- SEM. 
 
Additionally, we confirmed the results from the immunofluorescence and Western blot analysis of 
selected markers in GSC before and after cilia induction. The data show that upon DOX induction of 
NEK2-KD, the U3047MG NEK2-KD exhibits a significant reduction of the surface stem cell marker 
CD133 and nuclear stem cell marker SOX2. Most importantly, the cell displayed and an increased 
level of GFAP (astrocyte marker) (Figure 3.12C). Collectively, data demonstrate that cilium controls 
the molecular switch between self-renew and differentiation state in GSCs. 
3.7 GSCs differentiation is a cilium-dependent process 
To further demonstrate that Nek2-KD induced GSCs differentiation is a cilium dependent process, 
we ablated cilia by depleting IFT88. Overexpression of IFT88 prevents G1-S transition, whereas 
depletion of IFT88 causes cilium loss and promotes cell cycle progression (Robert et al., 2007, 
Loskutov et al., 2018). Thus, we used siRNA to deplete IFT88 and as a control scramble siRNA, 
which did not affect the IFT88 expression (control siRNA). First, we transfected U3047MG naïve and 
U3047MG NEK2-KD cells with the siRNA or control siRNA. 48hrs later, DOX was added to 
overexpress the NEK2-KD. Following an additional 48hrs (in total 96hrs), we analyzed IFT88 ciliary 
marker and co-stained with a marker for basal bodies and connecting cilia GT335 (Giessl et al., 
2004) using immunofluorescence analysis. As expected, reduced levels of IFT88 and no 
colocalization of IFT88 with GT335 at the primary cilia were explicitly observed in siRNA-treated, but 





Figure 3.13. Depletion of IFT88 prevents cilium assembly in GSC cell line. 
Experimental plan. NEK2-KD expression does not induce cilia in GSCs depleted of IFT88. Note NEK2-
KD could induce cilia only in control siRNA-treated naïve GSCs cultures in which IFT88 immunoreactivity 
(yellow) is intact (left panel, both overview and magnified insets are shown). Cilia are labeled with 
glutamylated tubulin (magenta). In contrast, NEK2-KD does not induce cilia in IFT88 depleted cultures 
(right panel, both overview and magnified insets are shown). Note that IFT88 expression is lost. Scale 
bar 2 µm. Bar diagram at right quantifies frequencies of ciliated cells under various conditions tested. At 
least 300 cells were analyzed from (n=3) experiments. Ordinary one-way ANOVA followed by Tukey’s 
multiple comparisons test. ***P <0.001. Error bars show +/- SEM. 
 
We then tested whether NEK2-KD could still induce differentiation of U3047MG cultures unable to 
assemble cilia due to IFT88 siRNA treatment. Consequently, immunofluorescence analyzes of 
neural stem cell marker NESTIN and differentiation markers TUJ (neuron) and GFAP (astrocyte) 
were performed in GSCs after IFT88 depletion and NEK2-KD overexpression. Interestingly, NEK2-
KD expression induced differentiation of GSCs into -GFAP and -TUJ1-positive cells in control siRNA-
treated cultures but not in IFT88 siRNA-treated cultures (Figure 3.14 and the table summarize the 





Figure 3.14. NEK2-KD induced GSCs differentiation is cilium-dependent process.  
NEK2-KD expression triggers differentiation (GFAP and TUJ1-positive cells) only in control siRNA treated 
cells where NEK2-KD could induce cilia (refer to the previous experiment). Thus, NEK2-KD-mediated 
GSCs differentiation is cilium dependent. Note IFT88 depletion or control siRNA alone does not trigger 
GSCs differentiation (second and first panel from left). Except NEK2-KD expressing control siRNA-
treated cultures, the rest of the cultures exhibit neural stem cell marker Nestin. Scale bar 10 µm. At least 
100 cells were analyzed from (n=3) experiments. Ordinary two-way ANOVA followed by Tukey’s multiple 
comparisons test. ***P <0.0001. Error bars show +/- SEM. The table below summarizes the experimental 
results. 
3.8 PDGFR-α signaling is regulated through primary cilia  
To dissect the mechanistic link between cilium induction and GSCs differentiation, the status of 
PDGFR-α signaling in U3047MG cells was analyzed. Proneural subtypes of GBMs have a strong 
correlation between PDGFR-α overexpression, amplification, and mutation (Verhaak et al., 2010). 
Furthermore, an increased level of PDGFR-α signaling positively correlates to the self-renewal 
property of GSCs, accelerated tumor onset, and increased tumor invasion (Clarke and Dirks, 2003). 
It has also been reported that cilia regulate PDGFR-α signaling in healthy cells (Schneider et al., 
2005). Initially, the total protein levels were determined using western blot between different GSCs 
subtype. The data confirmed that PDGFR-α is overexpressed in proneural compare to mesenchymal 
and classical GSCs (Figure 3.15A). Furthermore, to demonstrate that NEK2-KD-mediated cilium 
induction was prominent only in proneural subtype GSCs that overexpressed PDGFR-α, levels of 
proteins associated with PDGFR-α signaling pathway in ciliated and unciliated cells were analyzed. 
Western blot analysis revealed that in contrast to unciliated U3047MG (naïve and NEK-WT) cells, 
the ciliated cells (U3047MG NEK2-KD) display a drastically reduced level of PDGFR-α, which in turn 
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correlated to reduced levels of its downstream PDGFR-α signaling (e.g., AKT and c-MYC) (Figure 
3.15B). This finding suggests that the newly induced cilia in U3047MG NEK2-KD cells can play a 
role in sequestering excessive PDGFR-α signaling. 
Since the protein levels of PDGFR-α after cilium induction were drastically reduced, the localization 
of PDGFR-α after the cilium induction was examined. The immunofluorescent analysis was 
performed using PDGFR-α antibody and ARL13B (ciliary marker) in GSCs before (U3047MG naïve) 
and after cilium induction (U3047MG NEK2-KD). A confocal microscopy and super-resolution 
microscopy stimulated emission depletion (STED) revealed the localization of PDGFR-α, mainly in 
the newly induced cilium (Figure 3.15 C-D). Importantly, naïve U3047MG cells that have suppressed 
ciliogenesis exhibited unspecific localization of PDGFR-α within the space of the nearly entire cell 
space suggesting that cilium induction switches PDGFR-α to be relocated to a newly induced cilium 
(Figure 3.15 C).  
 
Based on these findings, we reasoned that the upregulated PDGFR-α in GSCs is constitutively active 
in a ligand-independent manner, enabling them to continuously self-renew. To test this aspect, the 
dynamic localization of PDGFR-α at various time points upon its activation by its ligand PDGF-AA 
was imaged (Figure 3.16). In control experiments that used healthy NPCs, we detected PDGFR-α 
signal in cilia 20 min after the ligand addition (Figure 3.16A). In contrast, unciliated U3047MG cells 
always displayed excessive PDGFR-α localization in a ligand-independent manner (Figure 3.16B). 
Strikingly, after cilium induction, U3047MG NEK2-KD cells displayed PDGFR-α dynamics similar to 
healthy NPCs, in which PDGFR-α is directed to a newly induced cilium (Figure 3.16C). In summary, 
these results elucidate the dominant effect of cilium induction in triggering differentiation of GSCs 




Figure 3.15. Cilium induction relocates PDGFR-α to newly induced cilia. 
A. Proneural subtype GSCs (U3047MG, U3082MG, and MGG87) express higher levels of total PDGFR-
α than ciliated astrocytes (i) or mesenchymal (U3024MG) and classical subtype (U3056MG) GSCs (ii). 
Equivalent quantities of cell extracts were loaded. B. Western blot compares relative levels total PDGFR-
α and its downstream signaling effectors in GSCs before and after cilium induction. Note PDGFR-α level 
is drastically reduced after cilium induction (NEK2-KD expressing GSCs). Similarly, active AKT and c-
MYC levels are also reduced. GAPDH was used as a loading control. Bar diagram at right quantifies 
relative levels of PDGFR-α and its downstream signaling effectors before and after cilium induction. 
Western blots from three (n=3) independent experiments. Ordinary two-way ANOVA, followed by Sidak's 
multiple comparisons test, ***P<0.001. Error bars show +/- SEM. C-D. Newly induced cilium sequesters 
PDGFR-α. Non-ciliated naïve U3047MG displays an all over distribution of PDGFR-α (yellow, left panel). 
Upon cilium induction, excessive PDGFR-α is directed to the newly induced cilium. Scale bar 5 µm. In 
panel (F), N-Cadherin marks plasma membrane (green) and PDGFR-α is in magenta. Scale bar 10 µm. 
Bar diagram at right quantifies frequencies of cells (in percentage) exhibiting PDGFR-α in the newly 
induced cilium. At least 200 cells were analyzed from (n=4) independent experiments. Unpaired t-test, 




Figure 3.16. PDGFR-α in proneural GSCs is constitutively active. 
A. Experimental plan. Top panel. In healthy NPCs, PDGFR-α is activated within 20 mins of PDGF-AA 
addition. Note that activated receptor localizes at the primary cilium. ARL13B labels cilia (cyan) and 
PDGFR-α is stained using specific antibodies (magenta). The cartoon is given to simplify the visualization 
of PDGFR-α dynamics. Scale bar 2 µm. At least 200 cells were analyzed from (n=3) experiments. B. 
Middle panel. Naïve or NEK2-WT (Green) expressing U3047MG cells exhibit strong PDGFR-α 
immunoreactivity (magenta) regardless of PDGF-AA addition, indicating that PDGFR-α in these cell types 
is constitutively active in a ligand-independent manner. NEK2-WT (green) labels centrosomes. The 
cartoon shows PDGFR-α distribution. Scale bar 2 µm. At least 100 cells were analyzed from (n=3) 
experiments. C. Bottom panel. NEK2-KD (green) expressing ciliated U3047MG cells behaves just like 
healthy NPCs and exhibits similar PDGFR-α dynamics upon ligand addition. A visibly apparent level of 
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PDGFR-α is directed to newly induced cilium at 60 mins of PDGF-AA addition. ARL13B labels cilia (cyan) 
and PDGFR-α is stained using specific antibodies (magenta). NEK2-WT (green) labels basal bodies. 
Cartoon simplifies the visualization of PDGFR-α dynamics. Scale bar 2 µm. At least 200 cells were 
analyzed from (n=3) experiments. 
 
3.9 Global transcriptome analysis reveals differentiation toward neuronal lineage 
To uncover the global impact of cilia induction in GSCs, the transcriptome of U3047MG cells before 
and after cilium induction was analyzed. More than 3000 differentially regulated genes were 
identified, among which 1651 were up and 1751 downregulated (Figure. 3.17A). Next, the 
differentially expressed genes were functionally annotated based on biological significance. Most of 
the differentially expressed genes were associated with biological processes involved in cell division, 
cell cycle, spindle organization, and brain development (Figure 3.17B-C). The upregulated included 
genes involved in ciliogenesis (e.g., ARL13B, IFT88, IFT22, IFT57), and neural differentiation (e.g., 
TUBB3, GFAP) (neuron). In contrast, the genes upregulated in the U3047MG NEK2-KD cells 
included genes involved in cilia disassembly (KIF24, OFD1, NDE1, CENPJ; STIL, CCP110) and cell 
cycle renewal (e.g., MKI67, OLIG2, SOX10, PROM1) (Figure 3.17 D-E). The results further confirm 
that ciliated (U3047MG NEK2-KD) cells have a strong association with the pathways essential for 
neural differentiation. Overall, the results strongly suggest that NEK2-KD expressing in U3047MG 





Figure 3.17. NEK2-KD induces GSC expression profiles indicative of cilium-dependent cell 
differentiation. 
A. Scatter plot of changing gene expression levels (FPKM; >0.6 log2-fold change, FDR<0.01) in 
U3047MG naïve compared to ciliated GSCs U3047MG NEK2-KD cells. B. The top most enriched GO 
terms associated with the 1651 upregulated genes in NEK2-KD expressing U3047MG cells. Critical 
pathways related to cell cycle progression and differentiations are marked in red fonts. C. As in panel B, 
but for the 1751 downregulated genes in U3047MG NEK2-KD cells. Critical pathways related to cell cycle 
progression and differentiations are marked in red fonts. D. Log2-fold gene expression changes of genes 
associated with cilia, centrosome, and cell cycle regulation according to GSEA classification. E. As in 
panel D, but for genes associated with stem cell, self-renewal and cell differentiation. Selected genes 
related to stem cell and differentiation are marked in red fonts. Fold-change ±0.6 log2 adjusted P-value 




3.10 Infiltration assay in 3D brain organoids  
The current state-of-art to study GBM invasion behavior is based on injecting human GSCs into the 
mouse brain. However, this xenotransplantation approach does not fully recapitulate the GBM 
pathogenesis occurring in the human brain and limits the translation of basic GBM research to clinical 
application (Gopalakrishnan, 2019, Goranci-Buzhala et al., 2017, Linkous et al., 2019). The 
development of a suitable in vitro human model based on 3D brain organoids would provide a 
powerful model to study the invasive behavior of GSCs. Human brain organoids are powerful in vitro 
systems recapitulating many aspects of human brain development and functions, emerging as a 3D 
substrate to model GBM (Linkous et al., 2019, Ogawa et al., 2018), adapting our recently described 
protocol (Gabriel and Gopalakrishnan, 2017, Gabriel et al., 2016) and differentiated brain organoids 
from at least three independent hiPSCs lines (see methods section 5.6.3). Organoids exhibited 
typical cytoarchitectures such as ventricular zones and cortical plates, as shown before (Gabriel and 
Gopalakrishnan, 2017, Gabriel et al., 2016). Here, we demonstrated three different methods to assay 
GSCs invasion behavior in brain organoids; namely, i) Simultaneous co-culturing of GSCs during 
organoid differentiation ii) Supplementing GSCs as dispersed cells to organoids iii) Fusion of GSCs 
spheres to organoids. 
3.10.1 Assay 1: co-culture iPSCs and GSCs 
Taking advantage of having the GFP and RFP tagged iPSCs, we generated organoids that are more 
suitable to follow neurospheres formation and differentiation. First, we generated hybrid brain 
organoids by co-culturing 5000 GSCs with 35,000 iPSCs expressing a fluorescent reporter (Figure. 
3.18A). Co-cultured fluorescently tagged iPSCs were co-cultured together with primary U3047MG 
cells and with relapsed 275-BIS cells. Time-lapse imaging of these organoids at day-10, -20, and -
30 revealed that in contrast to primary GSCs (U3047MG), the relapsed GSCs (275-BIS) 
progressively increased to grow. However, in later time points (day-20 onwards) when the organoid 
size increased, and tissue got denser, imaging of the organoids became problematic (Figure. 3.18B, 
C). 
 
To overcome this limitation and to quantitatively visualize the invasiveness of GSCs growth in 
organoids, the samples were fixed with PFA at indicated time points, and the EtOH-ECI-based tissue 
clearing method was optimized. The method rapidly clarified the organoids within 10-20 min that 
could further be subjected to microscopy analysis. Importantly, these clarified organoids enabled 3D 
imaging without disruption of their cytoarchitectures (Figure. 3.19A, B). Quantification analysis 
demonstrates that the number of invasive protrusion and microtube length fail to grow in the later 
stages of development (Figure 3.19 C-E). The invasive protrusions and microtube networks are the 
known characteristics of invading GSCs into a host tissue (Osswald et al., 2015b). Strikingly, the 
invasive behavior of U3047MG with this protocol markedly differed from 275-BIS, which formed 
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distinct cell clusters exhibiting enhanced invasiveness, whereas, U3047MG grew as dispersed cells 
and stopped growing after day-10. Using this assay, we could study the early stage of the organoid 
development since, at later stage did not recapitulate GBM infiltration in the brain and the ability to 
form interconnected networks via tumor microtubes at day 30 (U3047MG and #275-BIS).  
 
Figure 3.18. Time-lapse confocal imaging of GSCs invasion in brain organoid using assay 1. 
A. Schematic of experimental set up displaying step-by-step process from culturing iPSCs/GSCs until 
the imaging of hybrid organoids. Our optimized clearing condition clarifies tissues within 10 min 
(organoids smaller than 500 μm) to 20 min (organoids bigger than 500 μm). B. Time-lapse imaging of an 
organoid (green) cultured with U3047MG-mCherry (pseudo color magenta) at day 10, 20 and 30. Note 
that U3047MG cells grow as dispersed and stop growing after day10. Scale bar 100 μm. Representative 
image. At least 5 organoids from 3 different batches were tested. See Table 1 summarizing cell lines and 
organoids. C. Time-lapse imaging of an organoid (green) cultured with 275-BIS-GFP (pseudo color 
magenta) at day-10, -20 and -30. Unlike primary U3047MG, relapse 275-BIS cells grow as clusters and 
continue to expand with the formation of invasive protrusions (arrows). Note that GSCs are not visible in 
fully-grown organoids at day-30. Scale bar 100 μm. At least 9 organoids were analyzed from 3 different 
batches. D. Rapid tissue clearing and 3D imaging of organoids (green) cultured with U3047MG-mCherry 
(red). GSCs grow with the formation of invasive protrusions (arrows) at day-10. Barely visible growth is 
observed at day-20 and -30. Scale bar 50 μm, insets 5 μm. At least 4 organoids were analyzed from 3 





Figure 3.19. Tissue cleared confocal imaging of GSCs invasion in brain organoid using assay 1. 
A. Rapid tissue clearing and 3D imaging of organoids (green) cultured with U3047MG-mCherry (pseudo 
color magenta). GSCs grow with the formation of invasive protrusions (arrows) at day-10. Barely visible 
growth is observed at day-20 and -30. Scale bar 50 μm, insets 5 μm. At least 4 organoids were analyzed 
from 3 different batches. B. Tissue clearing and 3D imaging of organoids (green) cultured with 275-BIS-
GFP (pseudo color magenta). GSCs progressively grow over time (from day-10 until day-30) with the 
formation of invasive protrusions and microtube networks (arrows). Scale bar 50 μm, insets 5 μm. At least 
6 organoids were analyzed from 2 different batches. C-E. Bar graphs quantify of parameters of 
invasiveness such as the number of invasive protrusions and microtube lengths in tested GSCs lines. At 
least 80 microtubes were measured for each condition. Note that relapse 275-BIS cells display an overall 
increase in invasiveness. P values were obtained ed using two-way ANOVA, followed by Tukey's multiple 
comparisons test. n=3 batches, N=20 organoids per GSCs line n.s, not significant. Error bars show +/- 
SEM. H. Tissue clearing enhances the imaging depth of organoids. Note that relapse 275-BIS cells 
display progressive growth over time. n=3 batches, N=20 organoids were analyzed. P values were 
obtained using two-way ANOVA, followed by Sidak's multiple comparisons test. **p <0.001, ***p <0.0001. 
Error bars show +/- SEM. (This work was performed in collaboration with Dr. Arul Mariappan) 
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3.10.2 Assay 2: supplying GSCs to organoids 
Since the first method could not recapitulate GBM infiltration at the later stages of brain organoid 
development, another invasion assay was developed aiming to study the attraction of GSCs toward 
organoids at the onset of the invasion. In this second assay condition, 5000 GSCs were applied at 
the vicinity of 10-day old organoids and imaged them at 1-day post-co-culture (dpc), 10 dpc, and 20 
dpc after supplementing GSCs (Figure 3.20A). Live and clarified tissue imaging revealed that within 
24 hrs, both of the tested GSCs lines were attracted toward the periphery of organoids as a crescent-
like structure that surrounded the organoid (Figure 3.20B-C). At later time points, invading GSCs 
establish protrusion-like processes by which they extend their invasive fronts in the form of 
microtubes. These microtube-like structures target inner regions of the organoids (Figure 3.21A, B).  
 
This assay could distinguish the invasive behaviors of primary GSCs U3047MG and relapsed GSCs 
275-BIS. The 275-BIS relapse line assembled into clusters of GSCs, which collectively invaded into 
organoids forming a tumor-like behavior. To analyze the infiltration of GSCs into brain organoid, the 
number of invasive protrusion and microtube length was quantified (Figure 3.21A-B). These clusters 
release single cells, which form characteristic invasive protrusions and microtube networks, which 
grew up 150 μm in length establishing networks within GSCs (Figure 3.21C-D). Importantly after the 
organoid clearing, the z-depth was increased and improved imaging of GSCs infiltration into brain 
organoid (Figure 3.21E). Collectively, establishing this assay offers an investigation of GBM biology 




Figure 3.20. Time-lapse confocal imaging of GSCs invasion in brain organoid using assay 2. 
A. Schematic of experimental set up displaying step-by-step process from culturing iPSCs until the 
imaging of organoids with invading GSCs. B. Time-lapse imaging of an organoid (green) supplemented 
with U3047MG-mCherry (pseudo color magenta). Note that primary U3047MG cells attracted toward 
organoids forming a crescent-like organization within 24 hrs. In later time points of day-10 and -20, GSCs 
progressively invaded into the organoid forming invasive protrusions and microtube networks (arrows). 
Scale bar 100 μm. Representative image. At least 10 organoids were analyzed from 3 different batches. 
C. Time-lapse imaging of an organoid (pseudo color green) cultured with relapse 275-BIS-GFP cells 
(pseudo color magenta). Unlike U3047MG, 275-BIS cells distinctly grew as clusters and continued to 
expand within the organoids forming a tumor-like entity. Scale bar 100 μm. Representative image. At 




Figure 3.21. Tissue cleared confocal imaging of GSCs invasion in brain organoid using assay 2. 
A. Tissue clearing enhances the visualization of U3047MG-mCherry (pseudo color magenta) growth in 
organoids (green). GSCs grew with the formation of invasive protrusions (arrows) within 24 hrs. Note a 
crescent-like organization at the periphery of organoids, which then spreads into organoids as invasive 
protrusions and microtube networks (arrows) at later time points. Scale bar 50 μm, insets 5 μm. 
Representative image. At least 5 organoids were analyzed from 3 different batches. B. Tissue clearing 
and subsequent imaging of relapse 275-BIS-GFP cells (pseudo color magenta) within the organoids-RFP 
(pseudo color green). Note that relapse 275-BIS cells assemble into large clusters and then invade into 
the organoids forming a tumor-like entity. These clusters release single cells, which form characteristic 
invasive protrusions and microtube networks (arrows). Scale bar 50 μm, insets 5 μm. Representative 
image. At least 6 organoids were analyzed from 3 different batches. C and D. Bar graphs quantify the 
parameters of invasiveness. Note that 275-BIS distinctly differs from U3047MG displaying enhanced 
invasiveness. At least 50 microtubes were measured for each condition. n=3 batches, N=22 organoids 
per GSCs line were analyzed. P values were obtained using two-way ANOVA, followed by Tukey's 
multiple comparisons test. n.s, not significant. *p <0.01, ***p <0.0001. Error bars show +/- SEM. H. Tissue 
clearing enhances the imaging depth of organoids as imaged by a confocal microscope. Note the volume 
occupied by 275-BIS progressively increases over time. Data represent mean +/- SEM. n=3 batches, 
N=22 organoids. P values were obtained using two-way ANOVA, followed by Sidak’s multiple 





Both of the above methods offer an investigation of GBM biology in a host tissue that is equivalent 
to the early stage of brain development. However, GBM is primarily a disease of the elderly 
population. Therefore, we studied whether GSCs show tropism for mature brain organoids. As a first 
step, we ensured that these organoids contain cell types that express mature neuronal markers such 
as pre-synaptic protein Synapsin1 and MAP2 in a region-specific manner Figure (3.22). 
 
Figure 3.22. iPSC-derived brain organoids express mature neural marker. 
Cryosection of 60-day-old organoids display mature markers such as Synapsin1 (magenta) and MAP2 
(magenta) at the cortical plate (CP), a region basal to the ventricular zone (VZ), which was demarcated 
by SOX2 (green). Representative image. At least 20 organoids were analyzed from 3 batches. Scale bar 




3.10.3 Assay3: fusion of GSCs spheres with mature organoids 
To allow the monitoring of the later stages of brain organoid development, we established the GSCs 
spheres assay. In assay 3, the GSCs cells are compactly packed (spheres) differently from assay 2, 
where the GSCs were dispersed as single cells. We combined 60-day-old organoids with GSCs 
spheres and incubated them for 24 hrs in low adherent “U” shaped wells. This process results in the 
formation of a fusion product that was named as GSCs-Organoids (GSCs spheres fused with 
organoids). GSCs-Organoids have been transferred into air diffusible plates that are amenable for 
applications such as time-lapse imaging and drug treatment (Figure 3.23A). Imaging of the samples 
revealed the onset of GSCs spheres integrating into organoids within 3 days (Figure 3.23B-E).  
 
Interestingly, individual GSCs started to invade into organoids after seven days in day-20 organoids, 
whereas older organoid day-60 required only three days to incorporate into the brain organoids. 
Quantification analysis for integrating GSCs into immature and mature organoids revealed that both, 
primary GSC and relapsed GSCs integrate faster into mature organoids. Moreover, the GSCs were 
compact in spheres, indicating a profound tropism of GSCs to mature brain organoids (Figure 3.23C-
H). In summary, all of the described assays unequivocally allow analyzing GSCs invasion and 
capable of distinguishing invasive patterns of primary and relapse GSCs. The described 3D invasive 
assays were able to show cell non-autonomous characteristics of GSCs such as interconnecting 
microtube networks and invasive processes. 3D organoids offer these unique opportunities for 






Figure 3.23. Tissue cleared confocal imaging of fussed GSCs spheres to brain organoids using 
assay 3. 
A. Schematic of experimental set up displaying step-by-step process from culturing iPSCs until the 
imaging of GSCs-Organoids. B. Imaging of U3047MG-mCherry spheres (pseudo color magenta) fusing 
with 20-day and confocal stacks of 60-day-old organoid (green) to form GSCs-Organoid. Note that GSCs 
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spheres take 7 days to integrate in day-20 organoid versus day-60 organoid GSCs completed by day-3. 
Scale bar 50 μm. Representative image. At least 4 organoids were analyzed. C. Tissue clearing and 3D 
imaging of 275-BIS GFP (pseudo color magenta) GSCs-Organoids at day 20 and day 60 organoids. Note 
that GSCs spheres take 6 days to integrate in day-20 organoid versus day-60 organoid GSCs completes 
by day-3. The inset image shows that GSCs-sphere starts to release GSCs (arrows), which migrates into 
organoids forming protrusions and microtubes. Scale bar 100 μm, inset, 5μm. Representative image. At 
least 4 organoids were analyzed. D. Box plot depicting the time duration for GSCs spheres integration 
into the organoids. Mature organoids (day-60) integrate GSCs spheres faster than younger organoids 
(day-20). Blue box, integration to younger organoids (day-20). Red box, integration into mature organoids 
(day-60). n=3 batches, n=12 organoids per GSCs line were analyzed. P values were obtained ed using 
the unpaired t-test. ***p <0.0001. Error bars show +/- SEM. E. Box plot depicting the time duration for 
GSCs-sphere integration into the organoids. Mature organoids (day-60) integrate GSCs spheres faster 
than younger organoids (day-20). Blue box, integration to younger organoids (day-20). Red box, 
integration into mature organoids (day-60). n=3 batches, N=12 organoids per GSCs line were analyzed. 
P values were obtained ed using the unpaired t-test. ***p <0.0001. Error bars show +/- SEM. F. Tissue 
clearing enhances the microscopy imaging as revealed by at least two-fold increase in-depth coverage. 
n=3 batches, N=22 organoids. P values were obtained using the unpaired t-test. **p <0.001. Error bars 
show +/- SEM. (This work was performed in collaboration with Dr. Arul Mariappan). 
 
3.11 Ciliated GSCs fail to invade into brain organoids 
To analyze the impact of cilium induction in the cell fate of GSCs invasion, we used our recently 
optimized brain organoid-based GSCs invasion assay 2 supplementing GSCs as dispersed cells to 
organoids recapitulate the in vivo behavior of GSCs. To analyze and measure invasion of GSCs, we 
tagged GSCs with mCherry reporter. Furthermore, we performed GSCs invasion assay by seeding 
1000 naïve and NEK2-KD expressing U3047MG cells at the vicinity of 10-day-old organoids. The 
organoids were generated from iPSCs expressing transgenic Tubulin-GFP reporter. After 24 hrs of 
seeding, we added DOX to induce NEK2-KD protein expression (Figure. 3.24A). Live imaging of 
the GSCs invasion into the brain organoid was followed at day-3. Time-lapse imaging of organoids 
at day-3 already revealed that U3047MG cells (pseudo color magenta) invaded into 3D organoids 
via establishing protrusion-like processes in the form of microtubes, known characteristics of 
invading GSCs into a host tissue (Figure. 3.24B) (Osswald et al., 2015b). In contrast, NEK2-KD 
expressing U3047MG cells failed to establish protrusion-like processes (Figure 3.24B).  
 
To enhance the image quality and quantitatively determine the 3D invasion behavior of GSCs at the 
later time point of day-20, we utilized our rapid organoid clearing method (see section method 
section 5.7.2 ). Whereas naïve U3047MG cells extensively diffused and recapitulated GBM 
infiltration in the brain, Nek2-KD expressing cells failed to grow in brain organoids (Figure 25A). As 
a result, in contrast to naïve, Nek2-KD expressing U3047MG cells exhibited as an impaired organoid 





Figure 3.24. Time-lapse confocal imaging shows that cilium induction prevents GSCs 
invasion into brain organoids. 
A. Experimental scheme showing the process of GSCs invasion assay. Co-culturing of labeled GSCs 
with 10-day-old brain organoids until imaging them. B. Imaging of live organoids (green) supplemented 
with U3047MG-mCherry (pseudo color magenta) 48-hrs after doxycycline induction. Note that U3047MG-
mCherry cells progressively invade into the organoid forming invasive protrusions and microtube 
networks within 48-hrs (arrows, top panel). In contrast, NEK2-KD expressing U3047MG cells fail to 
assemble invasive protrusions and microtubes and thus fail to invade into the 3D organoid space (bottom 






Figure 3.25. Tissue cleared confocal imaging shows that cilium induction prevents GSCs invasion 
into brain organoids. 
A. Tissue cleared 3D imaging of the whole organoid after 20 days of GSCs invasion. Tissue clearing 
enhances the visualization of U3047MG-mCherry (pseudo-colored as magenta) growth into the 
organoids (green). Invading GSCs form protrusions and microtube networks (top panel). In contrast, 
NEK2-KD expressing U3047MG cells poorly grow within organoids, as evidenced by poor growth and 
less intensity (bottom panel). B. Bar graphs quantifies the parameters of invasiveness before and after 
cilium induction. At least 50 microtubes were measured. Bar graphs left quantifies the paraments before 
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tissue clearing and at the right after tissue clearing. Unpaired t-test, ***P<0.0001, **P <0.001. Error bars 
show +/- SEM. 
 
3.12 Cilium induction triggers differentiation of GSCs within 3D organoids  
Cilia formation switch GSCs from self-renewal to differentiation state, to analyze if the differentiation 
is a cause for invasion, we used 3D brain organoid system. Immunostaining of thin-sectioned brain 
organoid GSCs was performed to analyze the cell fate of GSCs before and after cilium induction. 
The same was observed in 2D analyzes in NEK2-KD expressing cells, but not naïve U3047MG cells 
were strongly positive for GFAP (astrocyte marker) (Figure. 3.26A). 
 
 
Figure 3.26. Differentiated GSCs impairs invasion into brain organoids. 
A. Related to figure 3.15. Bright field images show that U3047MG-mCherry grows in 3D brain organoids. 
Upon NEK2-KD induction, U3047MG cells exhibit impaired growth. In these experiments, untagged 
iPSCs were used to generate brain organoids and imaged at day 20. Scale bar 200 µm. At least 20 
organoids were analyzed from 5 different batches. B. Immunostaining of thin-sectioned organoid slices 
exhibit diffused growth of U3047MG-mCherry (pseudo color magenta). Note, U3047MG-mCherry cells 
do not differentiate to GFAP positive cells at this condition. Scale bar 50 µm. U3047MG-mCherry 
(magenta) cells undergo differentiation to GFAP positive cells (yellow) upon NEK2-KD induction. Note 
U3047MG-mCherry (pseudo color magenta) cells at this condition did not proliferate. Instead, they 
undergo differentiation as judged by their colocalization with GFAP (yellow). Graph at right quantifies 
GFAP-negative and GFAP–positive cells. Scale bar 20 µm. At least 100 cells were analyzed from 5 
independent organoids. P values were obtained using the unpaired t-test. ***P <0.0001. Error bars show 
+/- SEM. 
 
Moreover, quantification analyzes showed significant percentages of GFAP positive cells co-localize 
with Cherry-tagged (magenta pseudo color) ciliated cells (U3047MG NEK2-KD) (Figure. 3.26B left 
bar diagram). These findings reveal that NEK2-KD expressing U3047MG cells underwent a 
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differentiation process identical to what was observed in our 2D experiments upon cilium induction. 
Together, our organoid-based invasion assay elucidates that NEK2-KD expression triggers the 
differentiation of GSCs within brain organoids impairing their invasion and migration. 
In summary, we identify that irrespective of various background mutations, a panel of tested patient-
derived GSCs exhibit suppressed ciliogenesis due to elevated CDC recruitment at the basal bodies. 
We then establish that suppressing CDC recruitment and altering their dynamic localization behavior 
at the basal body is sufficient to persistently induce cilium in a subset of GSCs that overexpress 
constitutively active receptor tyrosine kinase PDGFR-α. Upon cilium induction, PDGFR-α is 
sequestered to newly induced cilium from its original location with concomitant reduction of overall 
PDGFR-α levels. Inducing ciliogenesis triggers GSCs switching from self-renewal to differentiation 
state. Finally, GSCs induced with cilia failed to infiltrate into induced Pluripotent Stem Cells (iPSCs)-






4.1 Glioma stem cells have suppressed ciliogenesis  
Loss of primary cilia is commonly associated with multiple types of cancers, which have deregulated 
cell cycle progression, and altered cellular signaling, including glioblastoma tumors (Seeger-
Nukpezah et al., 2013, Goranci-Buzhala et al., 2017, Moser et al., 2014, Fabbri et al., 2019, Seeley 
and Nachury, 2009). Despite these observations, the molecular mechanisms by which ciliogenesis 
is suppressed in glioma stem cells (GSCs) are still not well understood.  
This thesis aimed to investigate the molecular mechanisms of cilia loss in patient-derived GSCs and 
identify molecular targets linked to primary cilia to control GCSs proliferation. Furthermore, the thesis 
also describes a novel method of analyzing GSCs invasion in human brain organoids. To determine 
at what degree ciliogenesis is suppressed in GBM, at least eight patient-derived GSCs (from tumors 
classified as proneural, mesenchymal, and classical) and nine different patient tissue biopsies were 
analyzed. Importantly, ciliogenesis was suppressed in both patient-derived GSCs and patient 
biopsies. These findings are in line with other studies, where suppressed ciliogenesis has been 
observed in a multitude of tumors, including breast cancer, prostate cancer, renal cell carcinoma, 
melanoma, and glioblastoma (Moser et al., 2009a, Moser et al., 2014, Seeger-Nukpezah et al., 2013, 
Yuan et al., 2010, Zingg et al., 2018).  
Especially in the renal cell carcinomas (RCC), it has been shown that several ciliary genes are 
deregulated. More than 80% of RCCs harbors a mutation in the von Hippel-Lindau (VHL) tumor 
suppressor gene (Basten et al., 2013). Von Hippel-Lindau syndrome is an inherited autosomal-
dominant disorder (VHL+/- heterozygotes). Patients with von Hippel-Lindau syndrome tend to 
develop multiple vascular tumors called hemangioblastomas, pheochromocytomas, and clear cell 
renal cell carcinomas (ccRCCs). Tumor development in patients with VHL syndrome is linked to 
inactivation or loss of remaining wild-type VHL allele in RCC (Lubensky et al., 1996, Mandriota et 
al., 2002). Protein VHL (pVHL) has been recognized as a multifunction protein mainly linked to tumor 
suppression (Frew and Krek, 2008). It has been shown that pVHL interacts and regulates 
microtubules dynamics, which is involved in the assembly and maintenance of primary cilia 
(Schermer et al., 2006, Thoma et al., 2010, Hergovich et al., 2003). The protein pVHL localizes to 
the cilia and controls ciliogenesis in kidney cells (Schermer et al., 2006). To control the ciliogenesis 
and signaling network, pVHL functions together with Glycogen synthase kinase-3 b (GSK3b) (Thoma 
et al., 2007), which is a protein kinase that regulates microtubule assembly, stability, and dynamics 
(Zhou and Snider, 2005). The depletion of pVHL fails to assemble cilia in kidney cells, whereas re-
expression of pVHL restores ciliation in VHL-negative RCCs (Schermer et al., 2006). This finding 
suggests that the expression of pVHL is crucial for cilia assembly. Altogether, the data obtained in 
these studies support the finding that the defects in primary cilia assembly promote cell proliferation 
and tumor growth in a broad range of cancers. 
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4.2 Elevated levels of CDC complex suppress ciliogenesis in GSCs  
Highly tumorigenic GSCs exhibit several similarities to NPCs: expression of neural stem cell 
markers, spheres assembly, and rapid self-renewal (Bhaduri et al., 2020, Rajakulendran et al., 
2019). Identifying the molecular and regulatory features of GSCs strikingly different from NPCs will 
open up new avenues and unique strategies to selectively impair GSC’s proliferation and invasion. 
Besides their similarities, NPCs and GSCs possibly differ in at least two aspects. First, cilium 
formation is suppressed at the early stages of ciliogenesis in patient-derived GSCs due to elevated 
levels of molecular players such as the CDC proteins that might trigger cilia disassembly. Second, 
GSCs are characterized by continuous self-renewal and suppressed capacity to neural 
differentiation (Park et al., 2017b, Rajakulendran et al., 2019). Delayed cilia disassembly triggers 
NPCs to exit the cell cycle (G1-G0), whereas accelerated cilia disassembly promotes NPCs 
proliferation (Li et al., 2011, Gabriel et al., 2016). Precise temporal cilia disassembly is essential for 
the switch between symmetric and asymmetric cell division essential for stem cell maintenance and 
tissue homeostasis (Calegari and Huttner, 2003, Lange et al., 2009, Li et al., 2011). This complex 
provide a novel cell cycle ‘cilium checkpoint’, that can control cell cycle progression in aberrant cells. 
It has been demonstrated that proteins that promote the cilium disassembly process are implicated 
in human diseases, particularly, cancer (Zhou et al., 2013, Xiang et al., 2017, Raab et al., 2018). 
These results led us to hypothesize that in hyper-proliferative patient-derived GSCs, the uncontrolled 
overexpression of CDC proteins could suppress cilium formation and facilitate chronic proliferation, 
a hallmark of GBM. 
In this thesis, we demonstrate for the first time that GSCs have elevated levels of CDC proteins, 
highlighting the importance of these proteins in cancer. More interestingly, loss of cilia due to 
elevated levels of CDC components is in line with several other studies, in which some of the CDC 
proteins have been implicated in accelerated cilium disassembly and cilium loss. For example, 
Aurora-A, which is essential to initiate cilium disassembly (Pugacheva et al., 2007), is overexpressed 
in epithelial ovarian cancer cells (Do et al., 2014). The overexpression and recruitment of Aurora-A 
at the basal body (mother centriole) indicate that Aurora-A increases the rate of cilium disassembly 
while inhibiting the process of cilium formation (Egeberg et al., 2012). Moreover, Histone 
deacetylase, HDAC2 was identified to be overexpressed in pancreatic ductal adenocarcinoma cells. 
The inactivation of HDAC2 decreased Aurora-A expression, resulting in a cilium assembly 
(Kobayashi et al., 2017).  
4.3 Targeting CDC complex is a potential mechanism to induce ciliogenesis in GSCs  
The molecular interplay between CDC components recruitment and cilium disassembly remains 
elusive to this day, with no apparent studies carried out to test whether cilium reintroduction could 
be anti-tumorigenic, triggering differentiation of GSCs and/or impairing their invasion. Here we show, 
that depleting selected CDC proteins using shRNA (HDAC6, NEK2, and NDE1) was sufficient to 
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induce cilia in GSCs. Among these CDC components, depletion of NEK2 induced cilia significantly 
compared to the depletion of HDAC6 and NDE1. Since NEK2 is a multifunctional protein, implicated 
not only in ciliary disassembly but also critically important for centriole duplication (Jeong et al., 2007, 
Sonn et al., 2009, Boekhout and Wolthuis, 2015), we decided to target NEK2 also via an inducible 
NEK2-KD system carrying catalytically inactive NEK2. NEK2-KD (catalytically inactive, ‘Kinase 
Dead’) cannot phosphorylate its substrate KIF24, promoting cilia assembly. It has been previously 
shown that NEK2 phosphorylates KIF24 and negatively regulates ciliogenesis (Kim et al., 2015b). 
Hence, with NEK2, the CDC might contain an enzyme that can be activated to depolymerize the 
microtubule cytoskeleton of cilia. Furthermore, our idea is supported by a co-immunoprecipitation 
analysis that reveled the tight interaction of other CDC proteins with NEK2 and KIF24, which can 
promote cilia disassembly and cell cycle re-entry. Moreover, here we identify that overexpression of 
NEK2-KD failed to localize KIF24 to its active site at the minus end of ciliary microtubules in patient-
derived GSCs. These findings prove a tight regulation of NEK2-KIF24 interaction as part of the CDC 
complex to promote cilium disassembly. 
Together these results demonstrate that CDC is a novel regulator of ciliogenesis in patient-derived 
GSCs. The depletion of a Cyclin-dependent kinase 20 (CDK20 or CCRK) has also been shown to 
induce cilia in a small fraction of serum-starved GBM U251MG cells (Yang et al., 2013). It is 
noteworthy that, unlike GSCs, the commercially available U251MG cells were cultured in the 
presence of serum (Yang et al., 2013). It also remains unclear in Yang and colleagues' study whether 
the small fraction of ciliated cells observed is due to the depletion of kinase or serum starvation. It 
remains to be tested if the kinase CDK20 interacts with the other proteins of the CDC complex. 
4.3.1 CDC proteins promote cell cycle progression in cancer cells  
The finding that CDC proteins are deregulated in GSCs and control the cell cycle progression agrees 
with other studies. Proteins related to the CDC complex are upregulated in various cancer cells, 
leading to defective cilium assembly and cell cycle progression (Kim et al., 2015b). NEK2 
overexpression has been reported to negatively regulate cilia formation, whereas depletion of kinase 
restores cilia and prevents cell proliferation in breast cancer cells (MCF10A, MCF10AT, 
MCF10DCIS.com, and MCF10CA1) (Kim et al., 2015b). Although MCF10A cells are non-malignant, 
they are immortal and hyperplastic and show increased levels of NEK2 (Neve et al., 2006, Yuan et 
al., 2010). Another CDC protein, HDAC6, is crucial for disassembling the ciliary axoneme. A recent 
study has shown that HDAC6 is upregulated in cholangiocarcinoma cancer and could be targeted 
using a pharmacological inhibitor (tubastatin-A), which induces cilia and prevents cell cycle 
proregression (Xiang et al., 2017).  
More interestingly, apart from CDC component proteins, it has been shown that cancerous inhibitor 
of protein phosphatase 2A (CIP2A) is involved in cilium disassembly. CIP2A interacts directly with 
the oncogenic transcription factor c-MYC and prevents c-MYC proteolytic degradation (Junttila et 
al., 2007). CIP2A localizes at centrosomes. Increased recruitment of this protein at the basal body 
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promotes cilium disassembly through Aurora-A kinase-dependent mechanisms, whereas depletion 
enhances ciliation and ciliary length in RPE cells. Interestingly CIP2a depletion induces metabolic 
reprogramming independent of the cilium (Jeong et al., 2018). Since CIP2A is a tumor suppressor 
protein, it would be interesting to study if this protein expression level is increased in GSCs, which 
have suppressed ciliogenesis. Furthermore, CIP2A would be a potential candidate to investigate its 
interactions with CDC components further. Taken together, results from this thesis and work from 
others suggest that several proteins that regulate cilium disassembly are also upregulated in several 
cancer cells, resulting in suppressed ciliogenesis.  
 
4.4 Newly induced cilia in GSCs are functional 
We have demonstrated that upon induction of ciliogenesis by genetic manipulation, GSCs behave 
like NPCs, undergoing a spontaneous differentiation, suggesting that newly induced cilia are 
structurally and functionally normal. The presented results show that the newly induced cilia in GSCs 
are positive for IFT88 along the axoneme and can transduce the Hh signaling by relocating SMO 
along the cilium similar to control healthy NPC cells (Briscoe and Therond, 2013, Hassounah et al., 
2012). Thus, we can conclude that GSCs are, in general, capable of forming a correct cilium, 
although ciliogenesis is not seen under malignant conditions. In astrocytes, the cilium is central hubs 
for Hh signaling, harboring Hh signaling key proteins, including SMO or PTCH1, and regulating cell 
survival under stress conditions (Yoshimura et al., 2011). Surprisingly, the cilium can mediate GBM 
proliferation through Hh signaling in GBM cells, but only in one of the three cell lines. This study 
suggests that GBM xenografts with GBM-S2 Kif3a disrupted cells increase GBM proliferation 
through Hh signaling compared to unmodified GBM-S2 cells in vitro and in vivo. This finding suggests 
that cilia could modulate GBM growth by Hh signaling, playing a dual role in GBM tumorigenesis 
(Hoang-Minh et al., 2016b). This finding might have more significant impact on the classical GBM 
subtype since the cell line used highly expressed several components of this pathway (Verhaak et 
al., 2010). 
4.4.1 Dual role of cilia in brain tumors 
Is the restoration of ciliogenesis a potential way to suppress tumorigenesis or tumor progression? Is 
it a general feature of cilia to block growth and proliferation? To elaborate cilia function and role in 
cancer, we will discuss the studies were it had been identified that cilia could have a dual role in cell 
cycle and tumorigenesis.  
Medulloblastoma is the most common malignant brain tumor in children, initiating from the cerebral 
neural precursor cells (Louis et al., 2007). It is known that aberrant Hh signaling is one of the 
signaling pathways that drive medulloblastoma formation (Han et al., 2009, Haycraft et al., 2005, Liu 
et al., 2005). Mutations of upstream or downstream components of the Hh pathway in a pioneered 
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work have shown that the primary cilium plays a dual role in medulloblastoma formation. Strikingly, 
tumorigenesis is inhibited in a medulloblastoma mouse model, which has a loss of the cilium and 
constitutive active Smo expression, an upstream activator of Hh signaling (Han et al., 2009). In 
contrast, cilium loss was required for medulloblastoma growth driven by a constitutively active Gli2, 
a downstream transcription factor of Hh signaling. Thus, primary cilia can play a dual role in 
medulloblastoma, promoting, and inhibiting tumorigenesis (Han et al., 2009). The above results 
suggest that the Gli2-driven medulloblastoma formation requires the loss of the cilium for 
medulloblastoma development, which is opposite for Smo-driven medulloblastoma. One possible 
explanation for the opposite roles could be that primary cilium is required not only for Smo function 
but also for Gli3 repressor formation (Haycraft et al., 2005, Liu et al., 2005). The ciliary cargo IFT 
proteins are required for both Gli activator and repressor functions, and Gli proteins are insensitive 
to Hh ligand in the absence of IFT proteins. The Gli3 repressor was reduced Gli2-driven 
medulloblastoma mouse model, suggesting Gli3 could have an inhibitory effect in medulloblastoma 
growth.  
Besides, the loss of primary cilium in a basal cell carcinoma mouse model driven by active Smo 
protects mice from tumorigenesis (Wong et al., 2009). In this context, disrupting Inturned (Intu), 
which is aberrantly elevated in the same mouse model, suppresses ciliogenesis and promotes basal 
cell carcinoma growth. Intu is crucial for IFT-a complex assembly during ciliogenesis (Yang et al., 
2017). Together these data suggest that in some cases, the presence of primary cilium in tumor cells 
can mediate Hh signaling and promote tumor formation. 
4.5 Cilium induction triggers GSCs to switch from a stemness to a differentiation 
state 
The recruitment of CDC components (CPAP, Aurora-A, Nde1, and OFD1) to the ciliary base is 
associated with temporal cilia disassembly at the onset of cell cycle re-entry (Kim et al., 2015b, Kim 
et al., 2011, Gabriel et al., 2016, Tang et al., 2013, Pugacheva et al., 2007). Therefore, we asked 
whether targeting CDC proteins in patient-derived GSC would be sufficient to restore ciliogenesis 
and switch the cell fate. Recently, others and our laboratory have identified that primary cilia act as 
a molecular switch whose spatiotemporal dynamics decisively regulate NPCs self-renewal versus 
differentiation (Jackson, 2011, Gabriel et al., 2016). These results provide a conceptually novel 
‘cilium checkpoint’ can be targeted to regulate stem cell fate. To address what happens to cell fate 
after cilium induction, differentiation markers (TUJ, GFAP, S100B) and stem cell proliferation 
markers (SOX2, PAX6, NESTIN) were analyzed by immunofluorescence and western blot analysis. 
Indeed, ciliated but not un-ciliated cells gained differentiation markers and lost neural and cancer 
stem cell markers.  
Furthermore, RNA sequencing analysis supported the data. The majority of downregulated genes 
were associated with biological processes involved in cell division, cell cycle, and spindle 
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organization. Altogether, the results showed that re-inducing ciliogenesis in a subset of patient-
derived GSCs triggered them to lose their stemness and switch to their differentiation programs. 
Data demonstrates that cancer stem cells, which have aberrantly expressed PDGFR- α are sensitive 
to cilium induction, resulting in cell cycle exit, cilium formation, and differentiation-like cells. How 
cilium is induced in the aberrantly expressing PDGFR-a, subtype, and how the correlation of cilium 
with PDGFR-a is will be discussed below. Indeed, RNA sequencing analysis shows that PDGFA 
and oligodendrocyte progenitor genes (OLIG2) were downregulated upon cilium induction. 
Furthermore, we found downregulation of transcription factor SOX9, which is also involved in brain 
development and lineage specification. Notably, SOX9 has been correlated with poor clinical 
outcome (Wen and Kesari, 2008). PDGFR-a overexpressing GSCs may harbor epigenetically 
regulated neurogenic and astrogenic features (Caren et al., 2015). Thus, restoring ciliogenesis could 
favor differentiation and loss of stemness. As an example, the transcription factor ASCL1 in 
proneural subtypes has been shown to unlock chromatin allowing new sites to activate differentiation 
programs (Caren et al., 2015). Although bulk RNA-sequencing approaches have been useful to 
support our functional analysis after cilium induction in GSCs, they provide limited insight into the 
actual heterogeneity of GBM tumors. GBM is a typical example of heterogeneous cancer; likewise, 
variation and molecular diversity are observed even within the same GBMs patient (Patel et al., 
2014, Stommel et al., 2007). Therefore, single cells RNA sequencing would provide a much clearer 
picture of the genes affected before and after cilium induction in GSCs and might reveal the unknown 
epigenetic factors that could prevent cilium induction and differentiation in non-responding subtypes. 
4.6 Cilium induction sequesters elevated level of PDGFR-α 
This thesis data supports the notion that the cilium can be functionally restored in a subset of GSCs 
categorized as proneural subtypes expressing an elevated level of PDGFR-a. Restoring of the cilium 
first sequesters excessive PDGFR-a into newly induced cilia and resets aberrant PDGFR-α 
signaling. Importantly, cilium induction was efficient only in the patient-derived GSCs, which harbor 
PDGFR-α overexpression, belonging to the proneural subtype (Verhaak et al., 2010). Alterations in 
PDGFR signaling components and genes involved in oligodendrocyte development (OLIG2, NKX2-
2, and PDGF) are observed to be hallmarks of the proneural signature in GBM, which accounts for 
approximately 30% of human gliomas (Brennan et al., 2009). Brain tumors derived from PDGFR-a 
displayed histologic features of oligodendroglioma. The gene products of both rearrangements 
showed constitutively elevated tyrosine kinase activity and transforming potential that can be 
reversed by PDGFR blockade (Ozawa et al., 2010). 
Furthermore, PDGFR-α is regulated by CblE3 ubiquitin ligase. Upon PDGFR-AA ligand stimulation, 
the Cbl complex interacts with IFT20 and ubiquitinates PDGFR-α, resulting in the internalization of 
PDGFR-α. If primary cilium is lost upon depletion of IFT20, the Cbl complex is ubiquitinated and 
degraded, allowing overactivation of PDGFR-α at the plasma membrane (Schmid et al., 2018). 
 
 82 
Notably, studies have shown that UBE3C, an E3 ubiquitin ligase, is highly expressed in glioma cells 
and tissues compared to adjacent healthy tissues. Clinically, the enhanced expression of UBE3C is 
correlated with poor patient survival and early disease recurrence (Low et al., 2012). This data 
suggests that the proneural GSCs that have suppressed ciliogenesis and overexpression of PDGFR-
α might have an impaired Cbl E3 ubiquitin ligase that can prevent cilium formation and promote cell 
cycle progression. Moreover, it has been shown that downregulation of ubiquitin ligase in GBM cells 
induces cell differentiation and apoptosis (Low et al., 2012). Besides, drastic reductions in total 
PDGFR-a levels after cilium induction is a surprising phenomenon, suggesting that cilia could harbor 
proteasomal subunit components. Interestingly, at least three components of the 19S proteasomal 
subunits have been identified in mouse embryonic fibroblast cilia (Gerhardt et al., 2016). It is thus 
tempting to investigate if primary cilia of NPCs and GSCs harbor proteasomal subunits that can 
recognize PDGFR-α and critically regulate its amount and downstream signaling. 
Additionally, activation of RTKs, such as EGFR, PDGFR-α, PDGFR-b  and FGFr1 by growth factors 
activates in vitro ubiquitin specific peptidase 8 (USP8) that deubiquitinates and stabilizes trichoplein 
and causes phosphorylation and activation of Aurora-A, resulting in the suppression of ciliogenesis 
(Kasahara et al., 2018). NDE1 also mediates the balance between ubiquitination and de-
ubiquitination of trichoplein, a modulator of dynein activity localized at mother centriole and 
promoting cilium disassembly. Overexpression of NDE1 indirectly inhibits the ubiquitination of 
trichoplein by CRL3 KCTD17 (an E3 ligase component protein for trichoplein) and suppresses 
ciliogenesis. The serum-starved cell culture cells degrade NDE1 via the ubiquitin-proteasome 
system following the removal of trichoplein at the mother centriole, which promotes ciliogenesis 
(Inaba et al., 2016). Taken together, these data indicate that RTKs, ubiquitination complexes, and 
proteins that promote cilium disassembly (NDE1 and trichoplein and Aurora-A) seem to play a critical 
role in regulating ciliogenesis. Overall, in proneural GSCs, if ubiquitination mechanisms are 
upregulated, it might contribute to the overexpression of CDC proteins at the ciliary base, which in 
turn causes suppressed ciliogenesis and overexpression of PDGFR-a. 
4.7 Human brain organoid as a tool to study GSCs invasion assay 
Cancer is not a cell-autonomous disease, thus requiring understanding cancer cells' biology and 
host cells, which are tightly connected, especially in GBM. GBM does not metastasize but infiltrates 
into brain epithelial tissue through diffused invasion and infiltration. Therefore, 2D cultures do not 
model the crucial cell-cell interactions process and tumor microenvironment. Mouse xenograft 
models address host-tumor cell interactions, but cannot recapitulate human brain development at 
the cellular and physiological level (Oberheim et al., 2009). The human brain's in vitro model is 
essential and provides useful insights into the many steps of GSCs invasion and progression. Recent 
advances in 3D cultures of human brain organoids allow us to study patient-specific GBMs ex vivo 
within a microenvironment similar to that in the human brain (Gabriel et al., 2016, Gabriel and 
 
 83 
Gopalakrishnan, 2017). Therefore, we took advantage of using fluorescently labeled hiPSC and 
patient-derived GSCs, and we developed three assays to model human GSCs growth, invasion, and 
proliferation. Applying this strategy, we could measure invasive protrusions and microtube networks, 
well-known characteristics of invading GSCs into a host tissue (Osswald et al., 2015b). 
i) Co-culturing of GSCs during organoid differentiation - the assay1, recapitulate GSCs behaviors to 
some extent in the early stage of development (day10 organoid) but failed to fully recapitulate it in 
the later stages (day20 and day30). Presumably, co-culturing GSCs with hiPSCs from the beginning 
of the organoid generation might change cell fate and does not further promote the growth of GSCs 
into brain organoid. Therefore the next assay aimed to study preference of GSCs for 10 day old 
organoids (supplementing GSCs as dispersed cells to organoids). 
ii) Supplementing GSCs as dispersed cells to organoids – assay 2. GSCs are supplemented in the 
vicinity of organoids to recapitulate invasive growth and spontaneous formation of microtube 
protrusions in the organoids' inner side. Reports have shown that targeting a membrane protrusion 
in glioma, termed as "tumor microtubes" (TM), would be a potential biomarker for glioma patients. 
Interestingly, depleting the gap junction proteins Cx43 and GAP-43 inhibit TM formation and function. 
Using the assay 2, GSCs formed long membrane protrusions and TM structures within brain 
organoids. It will also be interesting to analyze whether invaded GSCs in brain organoids express 
these markers (Osswald et al., 2015a). Furthermore, as this model is grown in vitro, this enables a 
more manageable analysis of different manipulations and drug treatments, and allows precise 
control of physiological and environmental conditions.  
iii)The fusion of GSCs spheres to organoids - assay 3. This data suggests that mature organoids 
can provide suitable microenvironmental determinants for GSCs growth. This aspect is consistent 
with the fact that neuronal activity generates mitogenic factors promoting glioma growth (Venkatesh 
et al., 2015, Venkatesh et al., 2017). Moreover, imaging GSC-organoids in 3D provided new 
opportunities to visualize structural morphology and host-tumor cell interaction in detail in the brain 
organoid environment. With the ECI-EtOH based clearing step, organoids can be rapidly tissue-
cleared and imaged with enhanced fluorescence intensity and increasing z-depth penetration, 
allowing identifying more invasive protrusions.  
Taken together, these three assay models provide the ability to successfully screen tumor cells in 
vitro for clinically active drugs and other interventions that have been extremely limited, particularly 
for GBM. 
To study how the cilium induction effect GSCs invasion, the second assay was used. Live imaging 
at early invasion and confocal microscopy at later invasion periods showed that NEK2-KD-
expressing-GSCs are not attracted to organoids than naïve GSCs. Interestingly, according to the 
expression of NEK2-KD, the subpopulation of cells that invade into the brain organoids are 
differentiated into astrocytes and cannot proliferate anymore. This data demonstrates that inducing 
ciliogenesis in subsets of patient-derived GSCs could trigger them to lose their stemness and switch 
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to their differentiation programs. As a result, GSCs with induced cilia failed to invade into 3D human 
brain organoids. 
4.8 Future perspectives 
 
Cilia loss has recently been recognized as a potentially important factor contributing to tumorigenesis 
and tumor growth (Zingg et al., 2018, Plotnikova et al., 2008, Seeger-Nukpezah et al., 2013). Even 
though the amount of molecular data is increasing, the underlying mechanisms for cilia loss 
remained poorly understood. In this dissertation, experiments substantiate that elevated  CDC levels 
are implicated in suppressed ciliogenesis, at least in GSCs. Whether this is true for all other human 
cancer types is unclear and warrants for future investigation. Re-introducing ciliogenesis in GSCs 
has never been attempted before. Surprisingly, downregulating CDC is sufficient to induce 
ciliogenesis in a subset of patient-derived GSCs. It is tempting to test if re-introducing ciliogenesis is 
possible in other cancer cell types with suppressed ciliogenesis. 
The observed elevated levels of CDC provide an opportunity to target the CDC components 
chemically. Ideally, it would be attractive to identify a chemical compound that can induce cilia in 
GSCs and trigger the cells to differentiate. The ideal lead compound will then serve as an alternative 
strategy to genetic manipulation (such as overexpressing NEK2-KD as performed in this work). 
Indeed, our laboratory has gained deep insights into CDCs' assembly mechanisms by purifying 
CPAP and its interacting components. Using high-throughput screening (HTS) will help to identify 
specific molecules that can induce ciliogenesis in GSCs using targets such as CPAP-CDC and 
NEK2-KIF24 interactions. 
The current work has laid a foundation for such a chemical biology program. In particular, one of the 
attractive targets is the NEK2-KIF24 interaction that has been described in this dissertation. We 
await future experiments to establish a quantifiable interaction between Nek2-KIF24 and eventually 
use them to screen for compounds that can prevent NEK2-KIF24 interaction in cells. 
Another intriguing aspect identified in this thesis is that cilium induction was possible only in the 
proneural subtype of GSCs that displayed an elevated level of PDGFR-α. This observation raises 
the question if cilium re-introduction depends on PDGFR-α status. It will be interesting to explore 
whether overexpressing PDGFR-α and Nek2-KD in other subtypes, can sensitize for cilium 
induction. This experiment may be particularly interesting in the mesenchymal subtype suggested 
evolving from proneural subtype (Ozawa et al., 2014). 
Finally, given a pivotal role of cilia triggering GSCs from stemness to differentiation state, it has a 
broader impact in 3D brain organoids, which has recently received considerable attention as a 
human in vitro system to evaluate GSCs invasion and glioma-neuron interaction (Ogawa et al., 
2018). It would be interesting to test if identified molecules, which prevent CPAP-CDC and NEK2-




5. Material and Methods 
5.1 Material  
Table 3. List of materials  
(D)-Sucrose Applichem, A4734 
2-Mercaptoethanol, > 99% Sigma-Aldrich, M6250 
2-Propanol, molecular biology grade Sigma-Aldrich, I9516 
Accutase  Life Technologies, A1110501 
Acetic Acid, Rotipuran 100% Roth, 3738.3 
Acrylamide/ Bis acrylamide 30% Sigma-Aldrich, A3574 
Agarose Applichem, A8963 
Albumin from bovine serum Sigma-Aldrich, A7906 
Ammonium persulfate Applichem, A3583 
Ampicillin sodium salt Applichem, A0839 
Antarctic Phosphatase NEB, M0289S 
Anti-Flag M2 Magnetic beads  Sigma-Aldrich, A2220 
B27 with Vitamin A Gibco, 3582801 
B27 without Vitamin A Gibco, 11500446 
bEGF Peprotech, AF-100-15 
bFGF Peprotech, 100-18B 
Bradford reagent Sigma-Aldrich, B6916 
BSA 10% Sigma-Aldrich, 
Chloroform Sigma-Aldrich,C2432 
Click-iTTM EdU Alexa FluorTM 594 Imaging kit Life Technologies, C10339 
Complete EDTA free protease inhibitor cocktail tablets Roche, 11844600 
D(+)-Glucose waterfree p. a. ACS Roth, X997.2 
Deoxynucleotide solution mix NEB, N0447S 
Di-methyl sulfoxide, molecular biology grade > 99.9% Sigma-Aldrich, D8418 
DMEM, high glucose, GlutaMAX™ supplement Gibco, 61965059 
DMEM/ F12, GlutaMAX™ supplement Gibco, 31331028 
DNA Gel Loading Dye (6X) 
Thermo Fischer Scientific, 
R0611 
Dorsomorphin Sigma, 5499 
Ethanol absolute, molecular biology grade Applichem, A3678 
Ethyl cinnamate Sigma, 112372-100G 
FBS Good PAN Biotech, #P30-19375 
Formaldehyde 37% p. A. Sigma-Aldrich, F8775 
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Gel Extraction Kit, peqGOLD VWR Peqlab, 732-2777 
GeneRuler 1kb DNA Ladder Fermentas, SM0311 
Glycerol, > 99% molecular biology grade Sigma-Aldrich, G5516 
Glycine, molecular biology grade Applichem, A1067 
Heparin Stem Cell, 07980 
HEPES Buffer 1M  Sigma-Aldrich, H0887 
Hydrochloric acid 32% Roth, X896.2 
Hygromycin B  InvivoGen, ant-hm-1 
Incidin Plus  Ecolab, 3011520 
Isopropanol  Carl Roth, 5752.3 
Kanamycin sulfate Applichem, A1493 
L-Glutamin Gibco, 25030081 
Laminin Sigma, L2020 
LB-Agar  Roth, X964.1 
LB-Medium (Luria/ Miller) Roth, X968.2 
Loading Dye Solution (6x) Thermo Scientific, R0611 
Magnesium chloride solution (1M) Applichem, A3888 
Matrigel Matrix   Corning, 356234 
MEM Non-Essential Amino Acids Solution Gibco, 11140050 
Methanol, Rotipuran >99.9% ACS Roth, 4627.5 
Mowiol 4-88 histology grade Applichem, A9011 
MycoAlert Mycoplasma Detection Kit  Lonza, LT07418 
N2 Supplement (100x) Gibco, 17502048 
Natriumhydrogencarbonate Merck, 1.063.290.500 
Neurobasal-A Medium Gibco, 10888022 
NeuroCult™ NS-A Basal Medium (Human) Stem Cell, 05750 
NNNN tetramethyl ethylenediamine TEMED 99% Sigma-Aldrich, T9281 
Non-fat dried milk powder Applichem, A80830 
Non-silencing siRNA Qiagen, 10272080 
On target plus human siRNA IFT88 Smartpool, D 
Opti-MEM  Invitrogen, 31985-047 
PageRuler Plus Prestained Ladder Fermentas, 26620 
Paraformaldehyde Roth, 0335 
PBS tablets Gibco, 18912-014 
PDGF-AA R&D system, AF-221-SP 
Pen/Strep Gibco, 15140122 
Penicillin, Streptomycin Gibco, 15140122 
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Phenylmethylsulfonyl Fluoride (PMSF) Sigma- Aldrich, P7626-25G 
Phusion® High-Fidelity DNA polymerase 
New England Biolabs (NEB), 
M0530 
Plasmid Miniprep Kit I, peqGOLD  VWR Peqlab, 732-2780 
Poly-L-lysine Culturex, 3438-100-01 
Poly-L-ornithine (PLO) Sigma, P3655 
Potassium acetate Merck, 4820.1000 
Potassium Chloride Roth, 6781 
Primocin InvivoGen, ant-pm-1 
RIPA lysis buffer system 
Santa Cruz Biotechnology,  
sc-24948 
SAG Tocris, 4366 
SB431542 Selleckchem, S1067 
SDS molecular biology grade Applichem, A2263 
Sodium acetate anhydrous p. A. Applichem, A1522 
Sodium azide Sigma-Aldrich, S8032 
Sodium carbonate Roth, 8563 
Sodium chloride Applichem, A1149 
Sodium dihydrogen phosphate dihydrate Applichem, A3902 
Sodium hydroxide 1M Applichem, A1432 
Sodium orthovanadate Applichem, A2196 
Sodium pyruvate Gibco, 11360-070 
Sodium sulfate anhydrous, molecular biology grade Applichem, A3487 
Supersignal West Femto Chemiluminescent substrate Thermo Scientific, #34095 
Supersignal West Pico Chemiluminescent substrate Thermo Scientific, #34080 
SYBR Safe  Invitrogen S33102 
T4 DNA ligase 
New England Biolabs  
(NEB), M0202 
Tissue-Tek O.C.T  Sakura, 4583 
TransIT-X2 Dynamic  Mirus, MR6003  
Tris Ultrapure Applichem, A1086 
Triton-X-100, molecular biology grade Applichem, A1388 
Trypsin-EDTA Solution  Sigma, T3924 
Tween20  Caesar & Lorentz, 3472 
Y-27632  Biozol, S1049 
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5.2 Instruments and Apparatus 
Biometra Thermal Cycler Biometra, TOne 
BIO-TEK plate reader Bio-Tek 
Docu pH-Meter Sartorius 
EPS 601 Power supply GE Healthcare, 18-1130-02 
Gel DocTM XR+ Gel Documentation system  Biorad, 1708195 
Mini-centrifuge MCF 2360 LMS 
Mini-PROTEAN Tetra Cell for Mini Precast Gels BioRad, 165-8004 
Multitube block heater VWR, 12621-104 
Nutating mixer VWR, 82007-202 
Optima L-80 XP ultracentrifuge Beckman Coulter Inc. 
Rotator Staurt, SB2 
SW 40 Ti Rotor, Swinging bucket, Titanium Beckman Coulter Inc. 
Vortex mixers Labtech, LVM-202 
VWR VistaVision Stereo microscope VWR, 82027-160 





5.3 Cell lines 
ATCC cell lines 
Table 4. ATCC cell lines 
Name  Organism Cell type 
HEK293 Homo sapiens,human Embryonic kidney 
hTERT RPE-1 Homo sapiens,human Human retinal pigmented 
epithelium  
 
Table 5. Human induced pluripotent stem cells 
Name  Organism Cell type 
NPC Homo sapiens,human hiPSC-differentiated neural progenitor cells  
Astrocyte Homo sapiens,human hiPSC-differentiated astrocyte 
hiPSC IMR-90 Homo sapiens,human Reprogramed skin cells 
hiPSC TUB A/B GFP Homo sapiens,human Reprogramed skin cells 
hIPSC TUBA/B RFP Homo sapiens,human Reprogramed skin cells 
 
Table 6. Patient-derived GSCs 
Name  Organism Cell type Subtypes 
U3047MG Homo sapiens, human GBM, brain Proneural 
U3033MG  Homo sapiens, human GBM, brain Proneural 
U3082MG Homo sapiens, human GBM, brain Proneural 
MGG87 Homo sapiens, human GBM, brain  Proneural 
MGG8 Homo sapiens, human GBM, brain Proneural 
#275 Homo sapiens, human GBM, brain Proneural  
U3056MG Homo sapiens, human GBM, brain Classical  





Table 7. Targeted GSC lines 
Original name 
(naïve) 
Targeting  Plasmid  Used Name  
U3047MG  NEK2-WT pLIX_403 NEK2-WT EGFP U3047MG NEK2-WT 
U3047MG  NEK2-KD pLIX_403 NEK2-KD EGFP U3047MG NEK2-KD 
U3082MG  NEK2-WT pLIX_403 NEK2-WT EGFP U3082MG NEK2-WT 
U3082MG NEK2-KD pLIX_403 NEK2-KD EGFP U3082MG NEK2-KD 
MGG87 NEK2-WT pLIX_403 NEK2-WT EGFP MGG87 NEK2-WT 
MGG87 NEK2-KD pLIX_403 NEK2-KD EGFP MGG87 NEK2-KD 
#275 NEK2-WT pLIX_403 NEK2-WT EGFP #275 NEK2-WT 
#275 NEK2-KD pLIX_403 NEK2-KD EGFP #275 NEK2-KD 
U3056MG NEK2-WT pLIX_403 NEK2-WT EGFP U3056MG NEK2-WT 
U3056MG NEK2-KD pLIX_403 NEK2-KD EGFP U3056MG NEK2-KD 
U3024MG NEK2-WT pLIX_403 NEK2-WT EGFP U3024MG NEK2-WT 
U3024MG NEK2-KD pLIX_403 NEK2-KD EGFP U3024MG NEK2-KD 
MGG87 NEK2-WT pLIX_403 NEK2-WT EGFP MGG87 NEK2-WT 
MGG87 NEK2-KD pLIX_403 NEK2-KD EGFP MGG87 NEK2-KD 
 
5.4 Antibodies  
Table 8. Primary antibodies 
Antibody/clone  dilution Company/ source 
Acetylated tubulin, mouse 1:500 (IF)  Sigma-Aldrich, T7451 
AKT, rabbit 1:10000 (WB) Cell signalling, 9272 
ARL13B, rabbit 1:200 (IF) Proteintech, 17711-1-AP 
Aurora-A, mouse 1:50 (IF), 1:1000 (WB) Cell Signaling, #12100 
c-MYC, rabbit 1:1000 (WB) Abcam, ab32072 
CD133, mouse 1:20 (IF), 1:100 (WB) DSHB, HB#7 
CD15, mouse 1:20 (IF), 1:100 (WB) DSHB, MC-480 
CD44, mouse 1:50 (IF) DSHB; H4C4 
CPAP, mouse 1:20 (IF) Hybridoma, C44 
GAPDH, mouse  1:10000 (WB) Proteintech, 60004-I-Ig 
GFAP, rabbit 1:200 (IF) Cell signaling, D1F4Q 
GT335 1:1000 (IF) Adipogen, AG-20B-0020-C100 
IFT88 1:500 (IF) Proteintech, 13967-1-AP 
Ki-67, mouse  1:50(IF)  DSHB, 3E6 
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KIF24, rabbit  1:200 (IF), 1:1000 (WB) Gift from Prof. Brian Dynlacht 
MAP2 1:200 (IF) Proteintech, 17490-1-AP 
N-cadherin, rabbit 1:500 (IF) Abcam, ab18203 
NDE1, rabbit 1:100(IF), 1:1000(WB9 Proteintech, 10233-1-AP 
NEK2, mouse 1:200 (IF), 1:1000 (WB) BD Bioscience, 610593 
NESTIN, mouse 1:100 (IF) Novus Biological, 4D11,  
ODF2, rabbit 1:1000 (WB) Proteintech,12058-1-AP 
OFD1, rabbit 1:100 (IF), 1:500 (WB) Gift from Prof. Jeremy Reiter 
PAX6, mouse 1: 50 (IF) DSHB, Iowa University 
PDGFR-a, mouse 1:100 (IF), 1:500 (WB) SantaCruz, sc-398206 
Phospho-AKT, rabbit 1:10000 (WB) Cell signalling,  
S100b 1:1000 (IF) Abcam, ab52642 
SOX2, rabbit   1:200 (IF) Millipore, AB5603 
Synapsin1 1:200 (IF) Cell Signalling, 5297S 
TUJ1, rabbit 1:500 (IF) Sigma, T2200 
a-FLAG, mouse 1:5000 (WB) Sigma-Aldrich, F1804 




Table 9. Secondary antibodies 
Antibody Dilution Company/ source 
Donkey anti-Rabbit IgG (H+L) Highly Cross-




Donkey anti-Rabbit IgG (H+L) Highly Cross-




Donkey anti-Rabbit IgG (H+L) Highly Cross-




Goat anti-Mouse IgG (H+L) Cross-Adsorbed 




Goat anti-Mouse IgG (H+L) Highly Cross-




Goat anti-Mouse IgG (H+L) Cross-Adsorbed 




Donkey anti-Rat IgG (H+L) Highly Cross-




Goat anti-Rat IgG (H+L) Cross-Adsorbed 








Thermo Fisher Scientific, 31430 














5.5 Solutions and mixtures 
Table 10. Buffers 
BRB80 (1X) 
80 mM K-Pipes (pH 6.8) 
1 mM MgCl2 
1 mM Na2EGTA 
Homogenization buffer 
BRB80(1x) 
100 mM NaCl 
14% Sucrose 
1 mM PMSF 
1 mM Sodium Orthovanadate1 Protease Inhibitor Cocktail tablet (per 30 mL)  
100 mM PMSF (stock solution)  
Dissolve in isopropanol, store at -20 °C in the dark. Must be heated to 37 °C to redissolve 
after storage  
10X DNA gel loading dye (CSH Protocols)  
3.9 ml glycerol 
500 μl 10% (w/v) SDS 
200 μl 0.5 M EDTA 
0.025 g bromophenol blue 
0.025 g xylene cyanol 
Bring to 10 ml total volume with H2O.  
PBS  
145 mM NaCl 







5.6 Molecular biology  
NEK2WT and NEK2KD (K32R) were subcloned from pLVX 3xflag plasmid into an inducible lentiviral 
vector pLIX_403 containing the hPGK promoter and in-frame with C-terminal GFP. The pLVX 3xflag 
NEK2-WT and pLVX 3xflagNEK2-KD were generously provided Daynlacht lab (Kim et al.,2015) 
5.6.1 Polymerase chain reaction (PCR) 
DNA fragments used for cloning were amplified from cDNA or plasmid using Phusion High -Fidelity 
DNA polymerase (NEB, M0530) as follows: 
 
Phusion PCR reaction mix: 
 
5x Phusion GC buffer                      10 µl  
10mM dNTPs                                  1µl 
10µM Forward primer                       2,5µl 
10µM Reverse primer                       2,5µl 
Template DNA                                50-250ng  
Phusion DNA Polymerase 0,5µl 
Nuclease -free H2O               up to 50µl 
 
Phusion PCR thermocycling conditions: 
 
STEP TEMPERATURE TIME  
1. Initial denaturation 98 ºC 5 mins 











30 s per kb 
3. Final extension 72 ºC 10 mins 





Table 11. List of oligonucleotide sequences used for cloning. 
Primers used for cloning 
NEK2 into pEGFP_N1 
 
Forward primer:  
CCGCTCGAGATGCCTTCCCGGGCTGAGG 
Reverse primer:  
ATAAGAATGCGGCCGCTAAACTATTTACTTGTACAGCTCGTCCA 
Primers used for cloning 
the NEK2 GFP into  
pENTR1a 
Forward primer:  
CGACGCGTCGATGCCTTCCCGGGCTGAG 
Reverse primer:  
ATAAGAATGCGGCCGCTAAACTATTTACTTGTACAGCTCGTCCA 
Primers used for cloning 
CPAP into pSin GFP 
 
Forward primer:  
CGGGATCCCGGGATGGTGAGCAAGGGCGAGGAGCTG 
Reverse primer:  
CGACGCGTCAGCTCCGTGTCCATTAGCACATTAC 
 
5.6.2 Gel electrophoresis  
The DNA fragments obtained by PCR were separated using 1% agarose gel 1xTAE buffer stained 
with SYBER Safe (Invitrogen). In brief, DNA product was mixed with 6X loading dye (Thermo Fischer 
Scientific), Gene ruler 1kb Plus was used as a reference ladder for DNA separation. Gel 
electrophoresis was carried out at the 120V for 45 min; bands were visualized using the Gel DocTM 
XR+ Gel Documentation system (Biorad). The separated DNA bands were cut from the agarose gel 
and further processed using the Gel Extraction Kit from Peqlab (peqGOLD) following manufacturers' 
instructions. 
5.6.3 Restriction digest 
New England Biolabs (NEB) restriction enzymes were used following the manufacturer’s instructions 
for the restriction digest of DNA at specific sites. 
5.6.4 Ligation 
T4 DNA Ligase (NEB, M0202) was used to perform ligation, following the manufacturer’s 




5.7 2D cell culture  
5.7.1 Culturing and maintenance of patient-derived GSCs 
Patient-derived GSCs (U3047MG, U3033MG, U3082MG, U3024MG, U3056MG #275) as previously 
described (Xie et al., 2015) (Marziali et al., 2017) were cultured in Neurocult NS-A basal medium 
(STEMCELL technologies, 05750), 10 % BSA (STEMCELL technologies), L-Glutamin (Gibco, 
25030081), Heparin (STEMCELL technologies), B27 without vitamin A (Gibco), N2 (Gibco, 
A1370701), 20ng/ml EGF (Peprotech), 20ng/ml bFGF (Peprotech). Cells were maintained at 37°C, 
and 5% CO2 on Poly-L Ornithine (Sigma) and Laminin (Sigma) coated plates. GSCs were cultured 
in stem cell medium as described above and analyzed for expression of stem cell markers such as 
SOX2, PAX6, and NESTIN for the absence of differentiation markers such as TUJ and GFAP. To 
study PDGFR-α signaling cells were stimulated with 20 ng/ml PDGF-AA ligand (R&D Systems) for 
10–60 min for Western blot and immunofluorescence analysis. To study Hh signaling the agonist 
SAG (Tocris) 100nM was used, cells were fixed after 24h and analyzed for the downstream signaling 
molecules. 
Prof. Dr. Karin Forsberg-Nilsson provided us most of the patient-derived GBM cells (U3024MG, 
U3056MG, U3047MG, U3082MG, U3033MG), acquired from the Human Glioblastoma Cell Culture 
resource (www.hgcc.se) at the Department of Immunology, Genetics, and Pathology, Uppsala 
University, Sweden. Dr. Hiroaki Wakimoto provided us with GSC cells MGG87, MGG8, from 
Massachusetts General Hospital. Prof. Dr. Roberto Pallini provided us GSC cells #450 and #275 
from Universita` Cattolica del Sacro Cuore, Rome, Italy. All patients provided written informed 
consent to the study according to research proposals approved by the Institutional Ethics Committee 
of Fondazione Policlinico Gemelli, ID 2253 of Universita` Cattolica del Sacro Cuore, Rome, Italy 
UCSC (Prot. 4720/17). 
5.7.2 Lentiviral production and transduction of target cells 
Constitutive overexpression of mCherry U3047MG lentiviral vectors was prepared using pSicoR-
Ef1a-mCh-Puro (Addgene, #31845), inducible pLix 603 NEK2-KD EGFP, pLix 603 NEK2-KD EGFP. 
The lentiviral shRNA constructs pLKO.1-puro of CDC components (NDE1, OFD1, HDAC, NEK2) 
were kindly gifted by Dr.Rajalingam. The cloned vectors were packed into lentivirus using second-
generation packaging plasmids (pPMD, Addgene, #12259 and pPAX, Addgene, #12260). Briefly, 
target vectors and packaging plasmids were transfected into HEK293TS cells using calcium chloride. 
After 16 h, the medium was changed, and the virus was collected after 8 h. The freshly collected 
virus was used to transduce target cells in a 1:1 ratio for 72–96 h. 
To generate GSCs lines stably expressing inducible NEK2-WT and NEK-KD, was used pLIX 603 
lenti inducible gateway cloning vector (Addgene, #31845). The target cells were transduced with 
lentivirus containing pLIX-NEK2-WT and pLIX-NEK2-KD and selected with Puromycin (InvivoGen). 
For the expression of transgene, all the stable cell lines generated under inducible promoter were 
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induced with 2-5 μg/ml of doxycycline (Sigma) for 24–96 h. Prof. Roberto Pallini kindly provided 
GSCs cell line #275 green fluorescent protein (GFP). 
5.7.3 Culturing and maintenance of human iPSC culture 
At least three different human iPSCs were used in this study, namely, mEGFP (AICS-0012), mRFP 
(AICS-0031) TUBA1B, and IMR90 (Wicell). Cells were plated on Matrigel (Corning) coated culture 
dishes for 1h at 37°C with 5% CO2 using mTeSR1 medium (STEMCELL technologies). Cultures 
were routinely tested for mycoplasma contamination using MycoAlert Kit (Lonza). Cells were 
dissociated into small aggregates with ReLeSR (STEMCELL technologies) every 5-7 days and split 
into 1:5 fresh Matrigel-coated dishes. 
5.7.4 Derivation of neural progenitor cells (NPCs) from iPSCs 
For the generation of NPCs, the protocol from STEMCELL technologies was used. In brief, 
mycoplasma free iPSCs were cultured and analyzed for appropriate stem cell morphology. Once 
freshly split iPSCs (48h) reached 80% confluence, cells were disassociated into single cells using 
Accutase (Sigma-Aldrich, A6964) for 5 min at 37°C. To start the neural differentiation, 45.000 iPSCs 
cells were seeded in Spheroid v-bottom 96-well microplates (Costar,) growing with neural induction 
medium (NIM, STEMCELL technologies, 05835) containing 10µM ROCK inhibitor Y-27632 (Biozol) 
for 24h. Medium for neurospheres was changed partly every day for 5 days. On day 5, 32 
neurospheres were plated in 35mm dish coated with Poly-L Ornithine (Sigma) and Laminin (Sigma) 
using NIM medium for another 7 days, the medium was replaced on alternate days. Neural rosettes 
were selected using Neural rosette selection reagent (STEMCELL technologies), and further plated 
into a coated plate (as above) using neural progenitor maintenance medium (STEMCELL 
technologies). After 5 days in neural maintenance medium, the cells were stained for neural stem 
cell markers such as NESTIN, SOX2, and PAX6. To prevent spontaneous differentiation, NPCs were 
maintained up to passage 6. 
5.7.5 Astrocyte generation from neural progenitor cells 
For the generation of astrocytes derived from NPCs, the modified protocol was used for NPC 
generation (Shi et al., 2012). In brief, mycoplasma free iPSCs were seeded in a Matrigel-coated 
dish. To start NPCs generation in 2D, iPSCs cells were grown till they reached 100% confluency. 
Optimized neural induction medium was used 1:1 mixture of DMEM/F12 and Neurobasal, 1:200 N2 
supplement (Gibco), 1:100 B27 supplement without vitamin A (Thermo Fisher Scientific), 50µl 2-
mercaptoethanol, 5µg/ml Insulin (Sigma), 1:100 L-Glutamin (Gibco), and 1:100 MEM-NEAA (Gibco), 
the medium supplemented with two SMAD pathway inhibitors 2,5 µM dorsomorphin (Sigma) and, 




The neural induction medium was changed every day, and cells were monitored for the 
morphological changes during the differentiation time between 8-10 days after plating. When the 
neuroepithelium sheet was properly formed, cells were split in aggregates of 300 to 500 cells using 
Dispase 1mg/ml for 30-45 min at 37°C.  
 
Aggregates were seeded into 6 cm coated PLO and Laminin plate with neural induction medium 
supplemented with 20ng/ml bFGF (Peprotech) and 10µM Rock inhibitor. FGF2 is used to promote 
the expansion of NSCs but does not block neural differentiation. The medium was changed the next 
day with a neural maintenance medium. Change medium next day with neural maintenance medium. 
The sizes of the passaged cell aggregates influence the cell fate of the primitive neuroepithelium. If 
the cell clumps are smaller in size, only fewer cortical stem and progenitor cells are generated. Low 
passage NPCs are used to start astrocyte differentiation. Ensure that NPCs are spit 24h before and 
confluency is 100% when we change medium to astrocyte differentiation: Neurobasal phenol-free 
(Gibco), IGF1 20ng/ml (Peprotech), Heregulin 10ng/ml (Peprotech) CNTF 10ng/ml, Glutamax 1x 
(Gibco), B27 without vitamin A 1x (Gibco), Primocin 100µg/ml (InvivoGen).  
 
The astrocyte differentiation medium was changed every day until we observed morphology change. 
After 15 days, cells were split and analyzed for NESTIN and CD44 intermediate astrocyte marker. 
Until 80 % of the cells expressed GFAP and S100β,98 the cells where maintain in the astrocyte 
differentiation medium. For the astrocyte maintenance, astrocyte growing medium was used up to 
passage 5 when astrocytes get terminated. Astrocyte growing medium: 1:1 mixture of 
DMEM/F12(Gibco) and Neurobasal (Gibco), EGF 5ng/ml (Peprotech), B27 without vitamin A 1x 
(Gibco), N2 (Gibco), Primocin 100µg/ml (InvivoGen). 
5.7.6 Small interfering (si)RNA transfection 
Synthetic siRNA oligonucleotides were obtained from SMARTPool Dharmacon. Cells U3047MG and 
U3047MG NEK2-KD (+DOX 48h) (1×106) were transfected with 40 nM siRNA targeting IFT88 or 
with a scrambled sequence (negative control siRNA) for 72 h using TransIT-X2 Dynamic (Mirus) 
according to manufactures instructions. The knockdown efficiency of IFT88 siRNA was assessed 
using western blot analysis and immunofluorescence staining for IFT88. Negative control siRNA 
(Qiagen) was used as a scramble siRNA. 
5.7.7 Immuno-staining and light microscopy analysis of 2D cells  
Fixation with Methanol: 
After removing the medium from the cells, cells were washed once washed in PBS, then cold 
Methanol (-20 °C) was added and incubated at -20 °C for 10 min. The methanol was then aspirated, 
and cold PBS was added to the fixed cells until further use.   
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Fixation with 4 % PFA: 
Briefly, the medium was aspirated from the cells, and the cells were washed with prewarmed PBS. 
Prewarmed, 4% PFA was used to fic the cells at 37°C for 10 min. The fixative was then removed, 
and the cells were once again washed with PBS and stored at 4°C until further use. 
Blocking: 
Blocking solution 0,5% Fish gelatin was added and incubated for one hour at RT. 
Primary antibodies: 
The primary antibody was prepared in the blocking solution. Cells were incubated for one hour at 
RT or overnight with the primary antibody. Cells were washed 3x with a blocking solution for 5 min 
at RT. 
Secondary antibody: 
The secondary antibody was prepared in the blocking solution. Cells were incubated for one hour at 
RT.  
Mounting: 
After the final wash with a blocking solution, the cells were washed once with water to remove any 
salt and proteins. The coverslips were then partially dried. For coverslips mounting, 8μl Mowiol® was 
applied onto the slide, followed by placement of the coverslip upside down on top of it. Stored at 4 
°C until imaging. Confocal images were collected using a Leica SP8 scanning confocal microscope. 
Fiji, Adobe Photoshop, and Illustrator were further used to process the images. 
5.8 3D cell culture  
5.8.1 Establishment of different assay conditions to model patient-derived GSCs in brain 
organoids  
5.8.1.1 Assay 1: Simultaneous co-culturing of GSCs with differentiating brain organoid 
differentiation  
Brain organoids were generated as previously demonstrated with slight modifications (Gabriel and 
Gopalakrishnan, 2017, Gabriel et al., 2017, Gabriel et al., 2016). In brief, mycoplasma free iPSCs 
were cultured and checked for appropriate stem cell morphology. Once iPSCs reached 80% 
confluency cells were disassociated into single cells using Accutase (Sigma-Aldrich) for 5 min at 
37°C. For this assay condition, we homogeneously mixed 35.000 iPSCs with 5000 GSCs in 
CellCarrier Spheroid ULA 96-well microplates (PerkinElmer) with the use of neural induction medium 
(NIM, STEMCELL technologies) containing 10µM ROCK inhibitor Y-27632 (Biozol) for 24h. 100µl of 
the mix was suspended into cell suspension was given into each well of ULA 96 well U-bottom and 
incubated at 37°C in 5% CO2. This process helps in the formation of neurospheres, and the medium 
is changed once every day for the next 5 days.  
 
Neurospheres were embedded in droplet of Matrigel (Corning, 356234) using an organoid-
embedding sheet (STEMCELL technologies, 08579). Droplets were solidified at 37°C and were 
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grown 4 days without agitation in neurosphere medium containing a 1:1 mixture of DMEM/F12 and 
Neurobasal, 1:200 N2 supplement (Thermo Fisher Scientific), 1:100 B27 supplement without vitamin 
A (Thermo Fisher Scientific), 50µl 2-mercaptoethanol, Insulin (Sigma), 1:100 L-Glutamin (Gibco), 
and 1:100 MEM-NEAA (Gibco). After 4 days, neurospheres were transferred to a spinner flask 
containing brain organoid medium which is essentially neurosphere medium supplemented with two 
SMAD pathway inhibitors 2,5 µM dorsomorphin (Sigma,) and 25 µm SB431542 (Selleckchem). We 
name these organoids as hybrid organoids, as described in the results. Hybrid organoids were taken 
at day 10 and cultured in air diffusing low adherent plates (Lumox, Sarstedt). This set up allows the 
growth of organoids for a prolonged period of time, allowing us to image the same organoids at day 
20 and 30. Imaging conditions are described at the respective section scheme (Figure 3.12A). 
Except for the selected organoids for time-lapse imaging, the remaining organoids were cultured in 
spinner flasks for up to day-30 for endpoint analysis. From this batch of spinner flask organoids, 
organoids were selected for tissue clearing and 3D imaging at day-10, day-20, and day-30. 
 
5.8.1.2 Assay 2: Supplementing GSCs as dispersed cells to organoids 
For this assay, brain organoids were generated as described above without co-culturing with GSCs. 
10-day old organoids were shifted to 35 mm air diffusing low adherent plate Lumox dish (Sarstedt), 
and 1000 GSCs were provided at the vicinity of the organoids as depicted in the experimental 
scheme (Figure. 3.13A). After 24h, organoids were subjected to live imaging to analyze. GSCs 
invasion in a time-lapse manner at day-1, day-10, and day-20. The organoids that were no needed 
for the time-lapse imaging were transferred into spinner flasks for endpoint analysis at day 30. 
Organoids were selected for tissue clearing and 3D imaging on day-1, day-10, and day- 20 after 
GSCs invasion. 
 
5.8.1.3 Assay3: Fusion of GSCs spheres to organoids  
Brain organoids used in this assay condition were generated as described above. Initiating fusion 
product  (GSCs-Organoids), first GSCs spheres were established by seeding 5000 GSCs in low 
adherent “U” shaped microwells (ULA 96 well plate). GSCs spheres were added to either 20-day or 
60-day organoids in low adherent “U” shaped microwells (Figure 3.14 A). The resulting fusion 
product (GSCs-Organoids) was used to mimic conditions similar to tumor microenvironment or drug 
treatments. To mimic tumor microenvironment, we provided 100 nM recombinant human 
Neuroglin3/NLGN3 (R&Dsystems, 9069-NL). For drug testing, GSCs-organoid were subjected to 
ADAM10 inhibitor GI254023X (Sigma, SML0789) at a final concertation 100 nM. 
5.8.2 Whole organoid tissue clearing 
Tissue clearing was essentially performed based on the previously described method adapting 
additional modifications and optimizations (Klingberg et al, 2017). In brief, organoids were fixed in 
4%PFA (Merck Millipore) for 30 min. Organoids were dehydrated sequentially in graded ethanol 
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(EtOH) series of 30% EtOH (vol/vol), 50% EtOH (vol/vol), 75% EtOH (vol/vol) and 100% EtOH 
(vol/vol) (each step for up to 5-10 min at 4°C in a gently shaking 2ml tube depending on the size of 
organoids) and subsequent tissue clearing was performed with Ethyl cinnamate (ECI; Sigma-Aldrich) 
for approximately 10-20 min at room temperature depending on the size of organoids. Clarified 
organoids were then placed into coverslip bottom μ-slides (Ibidi) and stored at 4°C until imaging. 
5.8.3 Immunofluorescence microscopy and time-lapse imaging of organoids 
For time-lapse imaging, organoids were grown in 35 mm air diffusing low adherent plate Lumox dish 
(Sarstedt), with low autofluorescence and high light transmission properties. Alternatively, we also 
used μ-Slide angiogenesis slides (Ibidi) for imaging live organoids. Images were acquired at different 
time points using Leica SP8 laser scanning confocal microscope equipped with 405, 488, 552 and 
638nm diode lasers, a hybrid GaAsP detector, two confocal PMT SP detector, a HC PL APO 
20x/0.75 CS2 plan apochromatic objective, and a HC PL APO 63x1.40 OIL CS2 plan apochromatic 
objective. Images were captured using the 20X air objective. The resulting 8-bit image files were 
imported into Fiji (ImageJ 1.52i) and maximum intensity projected. Finally, the TIFF files from Fiji 
were processed using Photoshop (Adobe CC 2018), and Adobe Illustrator (Adobe CC 2018).  
Tissue cleared organoids were imaged using Zeiss LSM 880 Airyscan confocal microscope 
equipped with laser lines 405, 488, 561, and 633 nm, a GaAsP detector, two PMT detectors Plan-
Neoflaur 10x/0.3, and Plan-Apochromat 20x/0.8 M27 objectives. The tissue organoids were placed 
in ECI in 35 mm air diffusing or μ-Slide angiogenesis slides while imaging. 3D image stacks were 
acquired for representative organoids. The interval between the stacks was kept 2-3 μm apart, 
depending on the size of the organoids. The captured image files were imported into Fiji. The files 
were further processed using Image J, Adobe photoshop CC 2018, and Adobe Illustrator CC 2018. 
The z-stack movies were prepared using Fiji. Image-based quantifications were performed manually 
using Fiji. 
Super-resolution microscopy was performed on a 3D dimensional structured illumination microscope 
ELYRA PS.1 equipped with an alpha Plan-Fluar 100x/1.45 M27 oil-immersion objective, 405, 488 
and 561nm laser lines, an EM-CCD camera with a maximum resolution of 1004x1004. SR-SIM 
images were processed using ZEN software (2.3, SP1, black, 64bit, release version 14.0.0.0; ZEISS, 
Oberkochen, Germany) for 3D reconstruction and deconvolution. 
5.8.4 Organoid Immunostaining 
Organoids were fixed with 4% paraformaldehyde (PFA, Merck Millipore) for 30 mins. Fixed organoids 
were then dehydrated in 30% sucrose overnight at 4 °C. Dehydrated organoids were added in the 
OCT compound and frozen for the sectioning at -20 °C. The sections were cut using a microtome. 
Cryosections were washed with PBS to remove excess OCT compound and blocked in 0,5% fish 
gelatin 0.1% Triton X-100 diluted in PBS for 1 h at room temperature. The sections were then 
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incubated overnight at 4 °C with primary antibodies diluted in blocking solution. The following primary 
antibodies were used for immunostaining: anti-MAP2 (rabbit, 1:200, Proteintech, 17490-1-AP), and 
anti-Synapsin1 (D12G5) (1:200, rabbit, Cell Signalling), and anti-GFAP (Cell signaling). 
Cryosections were incubated with secondary antibodies (goat-anti mouse Alexa 488 or 647; donkey 
anti-rabbit Alexa 488, 594 or 647) diluted in ablocking solution 1h at room temperature. 
5.9 Biochemistry 
5.9.1 Protein concentration 
Protein concentration was measured using Bradford assay. To generate a standard curve 
absorbance at 595 nm series dilution of BSA protein was prepared (BSA solutions of concentrations 
0, 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, and 2.00 mg/ mL). In the 96 well plates, 1 µL of protein sample 
was added to which 99 µL of Bradford reagent (Sigma-Aldrich) was added. The plate was shaken 
for 30 s, and incubated for 10 minutes at RT, after which the absorbance at 595 nm was measured 
using a BIO-TEK plate reader. Protein concentrations were calculated using the standard curve. 
5.9.2 Denaturing SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blot 
The electrophoretic gel separation of proteins was performed under denaturing conditions in the 
presence of SDS in a non-continuous gel system, which consisted of a 5 % stacking gel and 10 or 
12 % resolving gel. According to their molecular size, the proteins are separated based on their 
similar mass/charge ratios during electrophoresis. The separation is possible since the negatively 
charged detergent SDS is complex with the proteins, their charge superimposed, resulting in a 
uniform negative charge. The protein samples were prepared with the SDS sample buffer (4X) for 
10 min at 98 °C. As a reference, the pre-stained Gene Ruler from Thermofisher was used. 20 µg of 
protein per well was loaded on the well. The samples were allowed to run at 100 V for 10 min until it 
reached the resolving gel. Then the gel was run at 180 V until the ladder extended through the whole 
gel. 
The separated proteins were transferred from the gel to a nitrocellulose membrane applying the wet 
transfer method using 20 % methanol at 135 V for 1 hour 15 min. 
Once the transfer was complete, the membrane was soaked into 5 % milk in TRIS/HCl based buffer 
(TBS) for a minimum of 30 min at RT. The membrane was then washed six times with ddH20 followed 
by TBS with 0.1 % Tween 20 (TBST) and incubated with primary antibodies overnight at 4 °C. The 
next morning the membrane rewashed with ddH20 and TBST before incubating for one hour with the 
appropriate HRP-conjugated secondary antibody (1:5000 dilution). The membrane was developed 
using an ECL detection solution from Thermo scientific. To visualize the proteins, a conventional X-
Ray film developing technique was used. 
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5.9.3 FLAG-immunoprecipitation (FLAG-IP) 
Flag coted beads (Sigma Aldrich) were incubated with high-speed lysate (HSL) for 3h at 4°C. The 
lysates were prepared using HEK293T cells stable expressing pSIN CPAP-WT 3xflag and pLenti 
NEK2-WT 3xflag lysed with 1x BRB80 buffer (extract buffer) as described previously 
(Gopalakrishnan et al., 2011). After incubation, the beads were washed 3x times with extract buffer 
and washed 2x with high-salt buffer containing 500 mM salt, and final wash with buffer containing 
100 mM NaCl, the samples were eluted by boiling them in 2x Laemmli buffer at 98°C. The beads 
were analyzed by western blotting for the CPAP and NEK2-complexes. 
5.10 RNA sequencing and analysis 
U3047MG (before ciliation) cells and U3047-NEK2-KD (after ciliation) cells were collected and 
washed. Total RNA was isolated and DNase-treated using the DirectZol RNA kit (Zymo Research). 
Approximately 2 μg of total RNA was used to subselect poly(A)+ transcripts and generate strand-
specific cDNA libraries (TrueSeq kit; Illumina).  
Poly(A)-enriched RNA was prepared and sequenced on a HiSeq4000 platform (Illumina; strand-
specific) to >35x106 reads per sample. Reads were quality assessed and mapped to hg19 using 
STAR (Dobin et al., 2013), followed by quantification of unique exon counts using featureCounts 
(Liao et al., 2014). Counts were further normalized via the RUVs function of RUVseq (Risso et al., 
2014) to estimate factors of unwanted variation using those genes in the replicates for which the 
covariates of interest remain constant and correct for unwanted variation before differential gene 
expression was estimated using DESeq2 (Love et al., 2014). Genes with an FDR <0.01 and an 
absolute (log2) fold-change of >0.6 were deemed differentially-expressed and listed in the RNA 
sequencing table (Appendix). RNA sequencing analysis was performed and analyzed in Dr. Akis 
Papantoni's lab. 
5.11 Statistical analysis 
Data were analyzes statistically using GraphPad Prism 7 for Mac OS X (Version 7.0e, September 5, 
2018). Data are presented as mean ± SEM The following tests were used to obtain P values: two-
way ANOVA, followed by Sidak’s multiple comparisons test or Tukey’s multiple comparisons test or 
unpaired t-test or Dunnett’s multiple comparisons test. n.s, indicates no significance, *P <0.01, **P 
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Table 12. List of upregulated gene expression levels (FPKM; >0.6 log2-fold change, 
FDR<0.01) in U3047MG naïve), ciliated GSCs (U3047MG NEK2-KD) cells 
 
Sr.No Gene Gene names log2FoldChange  Pvalue 
1 ENSG00000089169 RPH3A 7,223861578 0 
2 ENSG00000133048 CHI3L1 6,339190967 9,67773E-93 
3 ENSG00000128564 VGF 5,525096015 0 
4 ENSG00000205929 C21orf62 5,194185801 1,5444E-258 
5 ENSG00000118785 SPP1 5,121100364 0 
6 ENSG00000117152 RGS4 4,821116799 3,1756E-274 
7 ENSG00000137033 IL33 4,778551429 4,88101E-64 
8 ENSG00000198535 C2CD4A 4,774229985 1,7816E-106 
9 ENSG00000135333 EPHA7 4,706968939 1,25233E-35 
10 ENSG00000171951 SCG2 4,697727707 0 
11 ENSG00000131435 PDLIM4 4,696743102 0 
12 ENSG00000166741 NNMT 4,545095093 4,53178E-53 
13 ENSG00000104415 WISP1 4,509770205 2,3418E-122 
14 ENSG00000082293 COL19A1 4,486141497 1,6506E-133 
15 ENSG00000196277 GRM7 4,479967931 4,59502E-51 
16 ENSG00000141338 ABCA8 4,364939485 1,6757E-115 
17 ENSG00000134668 SPOCD1 4,248727317 2,16105E-69 
18 ENSG00000151702 FLI1 4,227320144 4,11244E-28 
19 ENSG00000110628 SLC22A18 4,215143269 7,3218E-107 
20 ENSG00000185100 ADSSL1 4,184900639 2,20037E-25 
21 ENSG00000113389 NPR3 4,170508184 6,92015E-24 
22 ENSG00000090339 ICAM1 4,11441223 6,60666E-59 
23 ENSG00000117450 PRDX1 4,054866331 2,1284E-122 
24 ENSG00000157502 MUM1L1 4,030025214 4,21031E-44 
25 ENSG00000187134 AKR1C1 3,967356734 3,63692E-39 
26 ENSG00000149571 KIRREL3 3,928424643 5,47705E-49 
27 ENSG00000133110 POSTN 3,924937515 0 
28 ENSG00000100985 MMP9 3,903527142 7,99339E-20 
29 ENSG00000174343 CHRNA9 3,792780426 4,34077E-45 
30 ENSG00000145623 OSMR 3,782542214 3,0083E-259 
31 ENSG00000106366 SERPINE1 3,778584563 0 
32 ENSG00000145934 TENM2 3,697660309 0 
33 ENSG00000099256 PRTFDC1 3,684017036 2,60113E-55 
34 ENSG00000159674 SPON2 3,673398094 2,80409E-20 
35 ENSG00000111335 OAS2 3,660119344 7,27973E-46 
36 ENSG00000150540 HNMT 3,610830552 1,1213E-101 
37 ENSG00000127920 GNG11 3,603513422 1,0247E-160 
38 ENSG00000163694 RBM47 3,601137026 1,27391E-83 
39 ENSG00000197977 ELOVL2 3,585950569 7,1426E-272 
40 ENSG00000197261 C6orf141 3,546218125 1,41805E-19 
41 ENSG00000198838 RYR3 3,502919887 1,84243E-81 
42 ENSG00000145920 CPLX2 3,494393476 3,33653E-16 
43 ENSG00000185070 FLRT2 3,486672256 4,27659E-15 
44 ENSG00000221818 EBF2 3,435902278 1,71336E-50 
45 ENSG00000120093 HOXB3 3,431377679 2,0446E-204 
46 ENSG00000169436 COL22A1 3,421834523 3,5461E-238 
47 ENSG00000115956 PLEK 3,3282404 1,2895E-12 
48 ENSG00000108771 DHX58 3,326767579 2,65968E-14 
49 ENSG00000130513 GDF15 3,323073359 1,0623E-115 
50 ENSG00000001036 FUCA2 3,318160106 2,66476E-82 
51 ENSG00000144481 TRPM8 3,310572222 6,3578E-255 
52 ENSG00000108602 ALDH3A1 3,305347043 6,59887E-29 
53 ENSG00000134986 NREP 3,304125719 4,1515E-163 
54 ENSG00000138759 FRAS1 3,283955549 5,3887E-135 
55 ENSG00000128641 MYO1B 3,263969903 2,75977E-22 
56 ENSG00000136352 NKX2-1 3,233413766 8,35362E-13 
57 ENSG00000196872 KIAA1211L 3,219745442 1,633E-111 
58 ENSG00000014914 MTMR11 3,191785532 4,9463E-146 
59 ENSG00000105376 ICAM5 3,182369125 9,0675E-110 
60 ENSG00000138821 SLC39A8 3,16868888 5,92701E-66 
61 ENSG00000107562 CXCL12 3,15565312 5,57521E-56 
62 ENSG00000118898 PPL 3,099618255 5,59797E-63 
63 ENSG00000157542 KCNJ6 3,07317783 8,8223E-24 
64 ENSG00000167157 PRRX2 3,0548022 2,45341E-18 
65 ENSG00000175899 A2M 3,052371268 0 
66 ENSG00000154734 ADAMTS1 3,051828092 1,7946E-208 
67 ENSG00000163661 PTX3 3,0498456 4,6877E-186 
68 ENSG00000095303 PTGS1 3,026697624 4,756E-100 
 
 125 
69 ENSG00000135549 PKIB 3,012054632 3,3875E-260 
70 ENSG00000174791 RIN1 2,99922793 5,99016E-67 
71 ENSG00000113263 ITK 2,984377861 3,15066E-13 
72 ENSG00000149582 TMEM25 2,980403714 8,81278E-71 
73 ENSG00000124205 EDN3 2,978855229 3,63801E-09 
74 ENSG00000171658 NMRAL2P 2,97370674 1,64601E-10 
75 ENSG00000197921 HES5 2,963061095 2,23961E-24 
76 ENSG00000176697 BDNF 2,958458006 3,3059E-107 
77 ENSG00000180638 SLC47A2 2,951141178 3,05689E-22 
78 ENSG00000128165 ADM2 2,950014795 2,48628E-17 
79 ENSG00000204131 NHSL2 2,941277147 2,00109E-27 
80 ENSG00000196353 CPNE4 2,930843284 1,9898E-244 
81 ENSG00000108691 CCL2 2,928726749 5,36549E-13 
82 ENSG00000047648 ARHGAP6 2,903588008 1,5951E-166 
83 ENSG00000196878 LAMB3 2,900741475 2,64631E-68 
84 ENSG00000124145 SDC4 2,900077791 8,36492E-12 
85 ENSG00000256124 LINC01152 2,884868329 1,3833E-09 
86 ENSG00000064692 SNCAIP 2,884725022 8,44974E-42 
87 ENSG00000225217 HSPA7 2,874360754 5,25311E-22 
88 ENSG00000061337 LZTS1 2,87247717 0 
89 ENSG00000128285 MCHR1 2,87204445 1,32527E-56 
90 ENSG00000166482 MFAP4 2,858747309 3,45572E-74 
91 ENSG00000102024 PLS3 2,855342342 1,6081E-261 
92 ENSG00000211829 TRDC 2,843866122 3,78264E-10 
93 ENSG00000128849 CGNL1 2,83632936 1,83076E-97 
94 ENSG00000133083 DCLK1 2,830182604 4,17626E-77 
95 ENSG00000122861 PLAU 2,819575505 1,4303E-119 
96 ENSG00000139219 COL2A1 2,818155141 3,7493E-257 
97 ENSG00000141469 SLC14A1 2,81561976 3,88649E-39 
98 ENSG00000205090 TMEM240 2,815466558 1,52249E-11 
99 ENSG00000125931 CITED1 2,799709179 6,99787E-87 
100 ENSG00000113494 PRLR 2,788534459 7,64187E-11 
101 ENSG00000189184 PCDH18 2,786347851 5,10411E-44 
102 ENSG00000172020 GAP43 2,772473866 0 
103 ENSG00000174600 CMKLR1 2,758131131 8,16626E-30 
104 ENSG00000130429 ARPC1B 2,745934563 4,20651E-25 
105 ENSG00000089127 OAS1 2,740375413 2,067E-42 
106 ENSG00000056558 TRAF1 2,737347361 1,24275E-23 
107 ENSG00000138449 SLC40A1 2,736327389 1,41448E-54 
108 ENSG00000156265 MAP3K7CL 2,728226219 3,8955E-23 
109 ENSG00000129038 LOXL1 2,727903948 6,42557E-46 
110 ENSG00000175544 CABP4 2,72764762 1,10154E-08 
111 ENSG00000171189 GRIK1 2,725996361 1,85822E-96 
112 ENSG00000117650 NEK2 2,725159217 0 
113 ENSG00000127824 TUBA4A 2,720686367 1,6851E-116 
114 ENSG00000163191 S100A11 2,717204253 2,5602E-238 
115 ENSG00000063127 SLC6A16 2,716739173 6,92913E-21 
116 ENSG00000135744 AGT 2,712596076 2,7719E-208 
117 ENSG00000165905 LARGE2 2,712033136 1,4241E-08 
118 ENSG00000125851 PCSK2 2,711968198 6,79464E-12 
119 ENSG00000054356 PTPRN 2,706807965 1,66297E-73 
120 ENSG00000155760 FZD7 2,700584893 6,4574E-183 
121 ENSG00000110697 PITPNM1 2,696682041 2,21849E-19 
122 ENSG00000085871 MGST2 2,67692529 1,76517E-09 
123 ENSG00000182732 RGS6 2,67611169 9,5812E-104 
124 ENSG00000169116 PARM1 2,660961213 8,2045E-135 
125 ENSG00000265485 LINC01915 2,657997247 2,66301E-08 
126 ENSG00000011677 GABRA3 2,657862887 4,06767E-08 
127 ENSG00000196482 ESRRG 2,655662559 5,9347E-08 
128 ENSG00000102359 SRPX2 2,655114306 1,38499E-27 
129 ENSG00000181019 NQO1 2,617235178 1,0032E-243 
130 ENSG00000026559 KCNG1 2,61032574 2,25332E-20 
131 ENSG00000184574 LPAR5 2,596818284 2,39331E-09 
132 ENSG00000130775 THEMIS2 2,594899115 4,69952E-14 
133 ENSG00000168743 NPNT 2,59392634 2,3553E-17 
134 ENSG00000111087 GLI1 2,581733039 4,88935E-15 
135 ENSG00000244682 FCGR2C 2,580942516 9,81398E-15 
136 ENSG00000146674 IGFBP3 2,579656736 0 
137 ENSG00000213401 MAGEA12 2,555623736 1,32006E-06 
138 ENSG00000196139 AKR1C3 2,54964468 3,23108E-32 
139 ENSG00000229835 KHSRPP1 2,539513364 1,13556E-31 
140 ENSG00000198108 CHSY3 2,531834042 8,92562E-23 
141 ENSG00000172965 MIR4435-2HG 2,522790132 6,96488E-69 
142 ENSG00000158859 ADAMTS4 2,5140831 3,96972E-68 
143 ENSG00000120833 SOCS2 2,50777235 8,84414E-23 
144 ENSG00000170485 NPAS2 2,505815106 9,4841E-186 
145 ENSG00000075035 WSCD2 2,504603471 2,05004E-56 
146 ENSG00000140961 OSGIN1 2,503417179 6,92139E-73 
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147 ENSG00000127124 HIVEP3 2,500537977 3,04384E-72 
148 ENSG00000125869 LAMP5 2,496870117 1,0134E-124 
149 ENSG00000135457 TFCP2 2,477629929 1,69563E-25 
150 ENSG00000146648 EGFR 2,477075891 1,1354E-170 
151 ENSG00000128573 FOXP2 2,47523407 3,41086E-07 
152 ENSG00000188042 ARL4C 2,470667532 6,9564E-270 
153 ENSG00000257207 AC112229.3 2,467470418 6,31808E-08 
154 ENSG00000110492 MDK 2,46166455 1,19603E-36 
155 ENSG00000151388 ADAMTS12 2,457893709 2,80351E-78 
156 ENSG00000169499 PLEKHA2 2,446308978 1,7321E-118 
157 ENSG00000100097 LGALS1 2,441017358 0 
158 ENSG00000229298 TUBB8P1 2,440528359 3,14053E-12 
159 ENSG00000162374 ELAVL4 2,435182895 2,54685E-24 
160 ENSG00000142920 AZIN2 2,432704742 9,68336E-25 
161 ENSG00000179603 GRM8 2,431838306 6,90424E-10 
162 ENSG00000076344 RGS11 2,430412736 3,20123E-14 
163 ENSG00000008118 CAMK1G 2,429456283 3,35718E-09 
164 ENSG00000181649 PHLDA2 2,427687192 7,74967E-27 
165 ENSG00000133816 MICAL2 2,423930932 8,4885E-37 
166 ENSG00000074527 NTN4 2,422695517 3,52686E-08 
167 ENSG00000142627 EPHA2 2,411836358 1,62452E-67 
168 ENSG00000108846 ABCC3 2,38868819 1,05049E-24 
169 ENSG00000148344 PTGES 2,37905373 2,3257E-06 
170 ENSG00000143369 ECM1 2,377960149 2,97634E-37 
171 ENSG00000169220 RGS14 2,374527174 1,03603E-33 
172 ENSG00000060709 RIMBP2 2,369704175 2,39924E-20 
173 ENSG00000187867 PALM3 2,357447531 4,88808E-19 
174 ENSG00000246859 STARD4-AS1 2,353024638 5,2039E-17 
175 ENSG00000073150 PANX2 2,350697399 1,25938E-14 
176 ENSG00000147509 RGS20 2,349850149 6,54051E-25 
177 ENSG00000105639 JAK3 2,343814932 9,94586E-08 
178 ENSG00000100351 GRAP2 2,337453909 5,41042E-08 
179 ENSG00000141750 STAC2 2,331384607 9,73053E-24 
180 ENSG00000151023 ENKUR 2,329356333 2,35158E-19 
181 ENSG00000137752 CASP1 2,327205603 2,73818E-07 
182 ENSG00000184937 WT1 2,322076402 2,91155E-09 
183 ENSG00000110057 UNC93B1 2,318647109 8,44475E-41 
184 ENSG00000131378 RFTN1 2,318591236 3,47195E-65 
185 ENSG00000185885 IFITM1 2,31441695 1,35021E-12 
186 ENSG00000196542 SPTSSB 2,313539106 3,48557E-14 
187 ENSG00000163618 CADPS 2,308137433 2,06545E-10 
188 ENSG00000188523 CFAP77 2,299843404 5,96259E-09 
189 ENSG00000135363 LMO2 2,298225716 1,194E-129 
190 ENSG00000221866 PLXNA4 2,28153094 1,4782E-110 
191 ENSG00000158710 TAGLN2 2,280907136 4,9908E-159 
192 ENSG00000135077 HAVCR2 2,280101092 5,53831E-10 
193 ENSG00000196730 DAPK1 2,276348702 1,70904E-95 
194 ENSG00000160284 SPATC1L 2,275236621 1,48644E-36 
195 ENSG00000117114 ADGRL2 2,275060691 3,3421E-236 
196 ENSG00000161243 FBXO27 2,267811427 4,83232E-06 
197 ENSG00000120875 DUSP4 2,258775149 1,5381E-170 
198 ENSG00000147804 SLC39A4 2,254269459 7,43889E-18 
199 ENSG00000100336 APOL4 2,248529806 5,01494E-07 
200 ENSG00000130477 UNC13A 2,243440703 1,7155E-169 
201 ENSG00000160211 G6PD 2,235590068 1,6086E-246 
202 ENSG00000158246 FAM46B 2,22043465 9,34687E-27 
203 ENSG00000143333 RGS16 2,204605009 1,31743E-37 
204 ENSG00000137090 DMRT1 2,203813482 5,39616E-06 
205 ENSG00000162692 VCAM1 2,203538794 4,00647E-10 
206 ENSG00000081803 CADPS2 2,199346086 6,47097E-11 
207 ENSG00000130303 BST2 2,198406375 2,33417E-34 
208 ENSG00000204583 LRCOL1 2,195466105 2,97327E-09 
209 ENSG00000042286 AIFM2 2,188651641 6,28405E-21 
210 ENSG00000135324 MRAP2 2,183551404 1,48898E-46 
211 ENSG00000149295 DRD2 2,183075486 3,48239E-11 
212 ENSG00000197415 VEPH1 2,179210374 8,89709E-62 
213 ENSG00000117069 ST6GALNAC5 2,173198575 9,86473E-09 
214 ENSG00000167487 KLHL26 2,171591264 7,65426E-22 
215 ENSG00000059915 PSD 2,169829522 5,08749E-33 
216 ENSG00000175426 PCSK1 2,167230125 1,12458E-07 
217 ENSG00000154127 UBASH3B 2,162376461 8,9054E-202 
218 ENSG00000198865 CCDC152 2,16111847 3,14905E-18 
219 ENSG00000125531 FNDC11 2,160888912 2,24816E-05 
220 ENSG00000261801 LOXL1-AS1 2,159518797 1,31888E-05 
221 ENSG00000141524 TMC6 2,159083563 5,25305E-13 
222 ENSG00000182742 HOXB4 2,158318935 3,97087E-07 
223 ENSG00000146950 SHROOM2 2,145569156 1,9171E-171 
224 ENSG00000145703 IQGAP2 2,144702081 3,2946E-166 
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225 ENSG00000166750 SLFN5 2,143706974 1,92475E-51 
226 ENSG00000167011 NAT16 2,143312432 1,18983E-18 
227 ENSG00000249853 HS3ST5 2,142835853 8,74795E-07 
228 ENSG00000100433 KCNK10 2,142716528 1,74376E-21 
229 ENSG00000222041 CYTOR 2,14047033 3,07828E-28 
230 ENSG00000125398 SOX9 2,140236652 2,32E-290 
231 ENSG00000162595 DIRAS3 2,136520479 2,1599E-15 
232 ENSG00000223947 AC016738.1 2,134158527 2,7643E-09 
233 ENSG00000164251 F2RL1 2,129940751 4,51654E-22 
234 ENSG00000087116 ADAMTS2 2,129337023 7,05742E-08 
235 ENSG00000143786 CNIH3 2,127303387 1,6655E-112 
236 ENSG00000205683 DPF3 2,124466227 1,32188E-30 
237 ENSG00000132915 PDE6A 2,120179268 4,04357E-05 
238 ENSG00000117245 KIF17 2,120093006 1,45441E-07 
239 ENSG00000115461 IGFBP5 2,11809611 6,7762E-238 
240 ENSG00000184985 SORCS2 2,117957077 1,37477E-05 
241 ENSG00000164761 TNFRSF11B 2,116332079 2,51916E-16 
242 ENSG00000108448 TRIM16L 2,11370819 1,25363E-62 
243 ENSG00000266970 AC061992.1 2,109624879 6,11718E-06 
244 ENSG00000249992 TMEM158 2,109133412 4,2505E-204 
245 ENSG00000072210 ALDH3A2 2,101695763 3,1812E-267 
246 ENSG00000180801 ARSJ 2,098138562 1,62311E-75 
247 ENSG00000143473 KCNH1 2,082257273 9,38892E-12 
248 ENSG00000124839 RAB17 2,077238148 2,02607E-05 
249 ENSG00000099260 PALMD 2,068016514 1,54195E-08 
250 ENSG00000187260 WDR86 2,063651255 1,22849E-06 
251 ENSG00000185567 AHNAK2 2,055039681 2,79332E-41 
252 ENSG00000059804 SLC2A3 2,05430496 3,683E-138 
253 ENSG00000170290 SLN 2,04093409 6,13814E-05 
254 ENSG00000138823 MTTP 2,03012345 4,65882E-33 
255 ENSG00000176399 DMRTA1 2,028987244 1,25742E-18 
256 ENSG00000091986 CCDC80 2,027860847 2,3551E-214 
257 ENSG00000181291 TMEM132E 2,02758139 6,55861E-18 
258 ENSG00000155254 MARVELD1 2,023052101 1,51565E-29 
259 ENSG00000151136 BTBD11 2,022918666 2,91359E-09 
260 ENSG00000239552 HOXB-AS2 2,020764433 0,000102597 
261 ENSG00000261655 AC100803.2 2,018127011 0,000186187 
262 ENSG00000135074 ADAM19 2,010662068 5,395E-125 
263 ENSG00000133958 UNC79 2,002916193 5,78069E-24 
264 ENSG00000223414 LINC00473 2,001625175 8,2756E-05 
265 ENSG00000189171 S100A13 1,999428362 2,56782E-62 
266 ENSG00000184371 CSF1 1,994456852 4,69461E-92 
267 ENSG00000169245 CXCL10 1,994251332 0,000193765 
268 ENSG00000139410 SDSL 1,991679455 4,7165E-22 
269 ENSG00000147041 SYTL5 1,990267244 1,99955E-41 
270 ENSG00000174460 ZCCHC12 1,983962258 6,21322E-25 
271 ENSG00000226403 AL392089.1 1,981469679 8,97064E-16 
272 ENSG00000154736 ADAMTS5 1,968667397 9,65375E-05 
273 ENSG00000178033 FAM26E 1,96637833 7,75258E-06 
274 ENSG00000152137 HSPB8 1,963800459 4,09704E-10 
275 ENSG00000152954 NRSN1 1,962479697 1,61826E-11 
276 ENSG00000183323 CCDC125 1,962237035 3,69326E-06 
277 ENSG00000118257 NRP2 1,960429693 6,7865E-211 
278 ENSG00000234231 AC093616.1 1,955895995 7,06475E-10 
279 ENSG00000160712 IL6R 1,955873281 7,41449E-10 
280 ENSG00000162975 KCNF1 1,954920328 3,13489E-95 
281 ENSG00000137959 IFI44L 1,950705579 1,03516E-47 
282 ENSG00000197565 COL4A6 1,949729517 1,8059E-178 
283 ENSG00000178965 ERICH3 1,94902785 7,29516E-05 
284 ENSG00000197757 HOXC6 1,946325292 1,54218E-05 
285 ENSG00000019991 HGF 1,946115116 1,71232E-05 
286 ENSG00000142669 SH3BGRL3 1,945138395 5,8422E-89 
287 ENSG00000005884 ITGA3 1,944143187 1,9769E-149 
288 ENSG00000184524 CEND1 1,943029435 1,31037E-36 
289 ENSG00000110002 VWA5A 1,938486893 4,60091E-48 
290 ENSG00000156140 ADAMTS3 1,937598389 3,40213E-88 
291 ENSG00000165072 MAMDC2 1,929855722 1,81922E-06 
292 ENSG00000088882 CPXM1 1,92952266 3,9198E-134 
293 ENSG00000131477 RAMP2 1,928530045 1,54534E-12 
294 ENSG00000171227 TMEM37 1,926733201 5,94617E-06 
295 ENSG00000163803 PLB1 1,923988697 8,75746E-07 
296 ENSG00000172183 ISG20 1,923261917 7,41642E-08 
297 ENSG00000131080 EDA2R 1,923162326 2,1618E-08 
298 ENSG00000230314 ELOVL2-AS1 1,919618416 0,000315409 
299 ENSG00000135821 GLUL 1,911854852 6,1958E-305 
300 ENSG00000095752 IL11 1,906486624 4,25043E-06 
301 ENSG00000123496 IL13RA2 1,905993389 0,000186828 
302 ENSG00000188015 S100A3 1,905555795 5,67006E-05 
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303 ENSG00000162804 SNED1 1,903217928 4,02474E-21 
304 ENSG00000159409 CELF3 1,903012803 3,02765E-15 
305 ENSG00000188916 FAM196A 1,901670964 2,5376E-133 
306 ENSG00000165507 C10orf10 1,900616346 1,21667E-07 
307 ENSG00000185924 RTN4RL1 1,900421389 7,91975E-10 
308 ENSG00000175832 ETV4 1,899758182 1,26924E-89 
309 ENSG00000204706 MAMDC2-AS1 1,893305876 2,54937E-09 
310 ENSG00000112981 NME5 1,888368183 1,32734E-11 
311 ENSG00000134531 EMP1 1,888090022 6,5514E-252 
312 ENSG00000122176 FMOD 1,885936019 0,000108145 
313 ENSG00000168679 SLC16A4 1,883964304 5,587E-27 
314 ENSG00000100968 NFATC4 1,883807871 0,00040304 
315 ENSG00000173404 INSM1 1,883643435 8,70669E-27 
316 ENSG00000039139 DNAH5 1,881164617 0,000370263 
317 ENSG00000129667 RHBDF2 1,880647608 0,000112086 
318 ENSG00000188153 COL4A5 1,880394548 4,0779E-204 
319 ENSG00000181773 GPR3 1,874854819 2,16899E-15 
320 ENSG00000196187 TMEM63A 1,873443008 4,06889E-71 
321 ENSG00000233384 AC096537.1 1,872159388 3,39967E-06 
322 ENSG00000128342 LIF 1,871558954 4,53661E-05 
323 ENSG00000104894 CD37 1,861921752 5,80204E-18 
324 ENSG00000138166 DUSP5 1,857505426 2,41568E-19 
325 ENSG00000176907 C8orf4 1,847111337 6,91862E-10 
326 ENSG00000250722 SELENOP 1,838098393 0,000129718 
327 ENSG00000100292 HMOX1 1,83651427 7,84472E-64 
328 ENSG00000186451 SPATA12 1,834786394 0,000131673 
329 ENSG00000185022 MAFF 1,833733843 1,40807E-19 
330 ENSG00000171812 COL8A2 1,826327338 1,95027E-07 
331 ENSG00000135519 KCNH3 1,824618025 1,65992E-34 
332 ENSG00000120915 EPHX2 1,823660828 2,58271E-07 
333 ENSG00000114737 CISH 1,821827668 8,34877E-05 
334 ENSG00000149131 SERPING1 1,820383319 5,79782E-06 
335 ENSG00000170345 FOS 1,819528954 2,7877E-113 
336 ENSG00000126368 NR1D1 1,819204448 1,1014E-53 
337 ENSG00000174521 TTC9B 1,816979187 1,02391E-07 
338 ENSG00000100196 KDELR3 1,816734892 2,01467E-38 
339 ENSG00000181656 GPR88 1,816394827 9,00381E-05 
340 ENSG00000139132 FGD4 1,812322646 9,44302E-19 
341 ENSG00000153930 ANKFN1 1,811772595 1,62497E-07 
342 ENSG00000168528 SERINC2 1,810534377 5,03044E-69 
343 ENSG00000167767 KRT80 1,800283713 3,86133E-20 
344 ENSG00000174939 ASPHD1 1,79891926 1,49787E-22 
345 ENSG00000242732 RTL5 1,798879022 3,31041E-47 
346 ENSG00000064012 CASP8 1,797064753 1,52233E-19 
347 ENSG00000113361 CDH6 1,793854016 3,71511E-80 
348 ENSG00000163359 COL6A3 1,791021314 2,15608E-10 
349 ENSG00000116962 NID1 1,78695901 3,7193E-151 
350 ENSG00000235092 ID2-AS1 1,786885787 0,000141513 
351 ENSG00000168734 PKIG 1,786841357 1,4714E-111 
352 ENSG00000225649 AC064875.1 1,784786594 2,69114E-63 
353 ENSG00000042493 CAPG 1,784467914 9,5587E-06 
354 ENSG00000101955 SRPX 1,777730438 1,70093E-89 
355 ENSG00000260404 AC110079.1 1,776414959 6,20139E-07 
356 ENSG00000128536 CDHR3 1,776362021 4,9864E-05 
357 ENSG00000224854 CDKN2A-AS1 1,775583963 9,18774E-06 
358 ENSG00000188859 FAM78B 1,773211826 4,41086E-12 
359 ENSG00000196155 PLEKHG4 1,77208399 0,000844431 
360 ENSG00000111052 LIN7A 1,77131398 1,18207E-52 
361 ENSG00000067182 TNFRSF1A 1,770319291 6,3485E-123 
362 ENSG00000138798 EGF 1,770167041 1,22934E-17 
363 ENSG00000142494 SLC47A1 1,769655833 1,96971E-69 
364 ENSG00000108551 RASD1 1,768022988 0,000100629 
365 ENSG00000165434 PGM2L1 1,766051446 1,26934E-67 
366 ENSG00000112297 CRYBG1 1,763796653 0,000289023 
367 ENSG00000142089 IFITM3 1,762878001 5,8728E-11 
368 ENSG00000260027 HOXB7 1,759271714 0,000205877 
369 ENSG00000128016 ZFP36 1,752782553 4,72832E-46 
370 ENSG00000007866 TEAD3 1,752759669 3,55306E-23 
371 ENSG00000169418 NPR1 1,750229192 1,11926E-10 
372 ENSG00000203950 RTL8A 1,748949753 1,06189E-34 
373 ENSG00000074047 GLI2 1,748144277 6,07284E-22 
374 ENSG00000179094 PER1 1,747303797 9,00807E-32 
375 ENSG00000167107 ACSF2 1,745923189 1,16912E-23 
376 ENSG00000138771 SHROOM3 1,743019609 1,36776E-40 
377 ENSG00000026025 VIM 1,738954833 1,0143E-262 
378 ENSG00000139970 RTN1 1,738834472 2,8667E-112 
379 ENSG00000092054 MYH7 1,732572757 2,76339E-06 
380 ENSG00000111799 COL12A1 1,731175149 7,43731E-92 
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381 ENSG00000184557 SOCS3 1,730449761 2,15637E-51 
382 ENSG00000225783 MIAT 1,730401909 4,762E-157 
383 ENSG00000184584 TMEM173 1,727461751 4,65238E-20 
384 ENSG00000145390 USP53 1,72411106 1,85398E-29 
385 ENSG00000006327 TNFRSF12A 1,723958666 7,05148E-89 
386 ENSG00000107611 CUBN 1,716838313 2,63563E-10 
387 ENSG00000130600 H19 1,715716787 3,9198E-134 
388 ENSG00000184156 KCNQ3 1,714813208 0,000262917 
389 ENSG00000109861 CTSC 1,714739406 5,8906E-174 
390 ENSG00000090975 PITPNM2 1,714267979 7,55628E-36 
391 ENSG00000135480 KRT7 1,713543654 0,001628887 
392 ENSG00000145819 ARHGAP26 1,711799746 1,02592E-56 
393 ENSG00000166573 GALR1 1,711649886 0,000946633 
394 ENSG00000142102 PGGHG 1,711542609 3,32123E-34 
395 ENSG00000253676 TAGLN2P1 1,710105381 0,000682904 
396 ENSG00000182379 NXPH4 1,707852083 2,04201E-31 
397 ENSG00000175592 FOSL1 1,70023848 4,38639E-24 
398 ENSG00000019549 SNAI2 1,699447355 9,35082E-12 
399 ENSG00000138080 EMILIN1 1,699327095 1,77544E-08 
400 ENSG00000243364 EFNA4 1,694159964 2,68027E-09 
401 ENSG00000172159 FRMD3 1,690944539 6,67502E-21 
402 ENSG00000155511 GRIA1 1,689706236 1,6552E-154 
403 ENSG00000111344 RASAL1 1,685760657 0,001751376 
404 ENSG00000248905 FMN1 1,682910077 5,25865E-12 
405 ENSG00000168306 ACOX2 1,676836799 4,71177E-12 
406 ENSG00000160691 SHC1 1,674392397 6,08789E-85 
407 ENSG00000142549 IGLON5 1,670635009 2,75767E-16 
408 ENSG00000173805 HAP1 1,66831583 5,77997E-95 
409 ENSG00000202111 VTRNA1-2 1,664907385 0,000958311 
410 ENSG00000086967 MYBPC2 1,663286759 9,4093E-05 
411 ENSG00000205056 LINC02397 1,661546825 0,000443329 
412 ENSG00000179796 LRRC3B 1,66049044 0,001691551 
413 ENSG00000100342 APOL1 1,660359557 0,001326021 
414 ENSG00000018408 WWTR1 1,65946723 1,1764E-28 
415 ENSG00000229036 VDAC1P8 1,656721684 0,000778706 
416 ENSG00000132164 SLC6A11 1,649794459 0,002137859 
417 ENSG00000086717 PPEF1 1,647213058 0,000178509 
418 ENSG00000185518 SV2B 1,64666255 0,001387599 
419 ENSG00000174059 CD34 1,645553327 1,27142E-08 
420 ENSG00000167306 MYO5B 1,644785674 1,22712E-49 
421 ENSG00000184672 RALYL 1,641663503 0,001684393 
422 ENSG00000170439 METTL7B 1,6406892 2,5897E-110 
423 ENSG00000164403 SHROOM1 1,640645469 0,000376625 
424 ENSG00000144649 FAM198A 1,638230221 0,002759258 
425 ENSG00000203999 LINC01270 1,637404148 0,002965761 
426 ENSG00000132530 XAF1 1,636577506 0,002541417 
427 ENSG00000140873 ADAMTS18 1,633454955 0,000141105 
428 ENSG00000105355 PLIN3 1,631631756 4,18356E-91 
429 ENSG00000147889 CDKN2A 1,629828607 1,29384E-10 
430 ENSG00000177675 CD163L1 1,628770503 0,003087711 
431 ENSG00000197555 SIPA1L1 1,628125559 6,723E-110 
432 ENSG00000162976 PQLC3 1,627098143 3,79166E-32 
433 ENSG00000139278 GLIPR1 1,626732979 5,42176E-53 
434 ENSG00000180758 GPR157 1,625567603 0,000256034 
435 ENSG00000105642 KCNN1 1,62342242 0,002526026 
436 ENSG00000162981 FAM84A 1,623015732 3,59284E-28 
437 ENSG00000074370 ATP2A3 1,622696202 0,003668256 
438 ENSG00000166349 RAG1 1,6224717 1,79704E-05 
439 ENSG00000164946 FREM1 1,622289263 6,27713E-78 
440 ENSG00000110080 ST3GAL4 1,621434171 1,34847E-39 
441 ENSG00000238266 LINC00707 1,620735737 0,000797995 
442 ENSG00000131951 LRRC9 1,620564659 0,002096234 
443 ENSG00000197405 C5AR1 1,619724537 0,001473068 
444 ENSG00000149256 TENM4 1,615791837 4,44021E-45 
445 ENSG00000201185 RNA5SP202 1,613519412 0,003509824 
446 ENSG00000203780 FANK1 1,611199919 0,00044297 
447 ENSG00000138623 SEMA7A 1,61045608 2,7447E-28 
448 ENSG00000015592 STMN4 1,609454932 1,03839E-06 
449 ENSG00000081923 ATP8B1 1,608351104 2,07181E-06 
450 ENSG00000135697 BCO1 1,608179749 0,003864276 
451 ENSG00000136267 DGKB 1,60475564 7,84089E-09 
452 ENSG00000143669 LYST 1,603938324 1,55635E-57 
453 ENSG00000176956 LY6H 1,603334241 0,003472839 
454 ENSG00000162814 SPATA17 1,602453504 8,55689E-05 
455 ENSG00000197747 S100A10 1,601240535 5,1283E-105 
456 ENSG00000056998 GYG2 1,598150119 5,40097E-40 
457 ENSG00000138650 PCDH10 1,596386871 1,06151E-30 
458 ENSG00000189410 SH2D5 1,595166906 1,67785E-06 
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459 ENSG00000066248 NGEF 1,592482314 1,04353E-21 
460 ENSG00000163565 IFI16 1,588286143 9,95029E-87 
461 ENSG00000137691 C11orf70 1,587864359 3,85959E-10 
462 ENSG00000137872 SEMA6D 1,587640692 2,0955E-139 
463 ENSG00000067715 SYT1 1,586267734 5,00166E-11 
464 ENSG00000188643 S100A16 1,585292622 7,4778E-120 
465 ENSG00000095397 WHRN 1,584664359 1,08192E-42 
466 ENSG00000088340 FER1L4 1,583358546 0,003841234 
467 ENSG00000086544 ITPKC 1,582235459 9,632E-54 
468 ENSG00000137843 PAK6 1,581548489 0,0039284 
469 ENSG00000144191 CNGA3 1,58076713 9,87313E-08 
470 ENSG00000145248 SLC10A4 1,580232211 0,004829166 
471 ENSG00000158816 VWA5B1 1,580050213 0,00062381 
472 ENSG00000203799 CCDC162P 1,579619105 0,001023815 
473 ENSG00000166292 TMEM100 1,579556195 1,61826E-23 
474 ENSG00000254615 AC027031.2 1,579544331 7,9473E-44 
475 ENSG00000104267 CA2 1,574378558 5,76602E-29 
476 ENSG00000243964 RPL23AP65 1,574332257 2,89887E-06 
477 ENSG00000186960 LINC01551 1,567464039 0,001155312 
478 ENSG00000141013 GAS8 1,566868899 7,04167E-12 
479 ENSG00000177875 CCDC184 1,564123755 2,49482E-10 
480 ENSG00000111859 NEDD9 1,563717709 6,79173E-80 
481 ENSG00000197813 AC011450.1 1,563656871 1,84373E-05 
482 ENSG00000150873 C2orf50 1,563580488 0,000838014 
483 ENSG00000254560 BBOX1-AS1 1,561157716 0,003230342 
484 ENSG00000075275 CELSR1 1,560272781 3,87898E-70 
485 ENSG00000178773 CPNE7 1,559831723 0,005045592 
486 ENSG00000180720 CHRM4 1,557584091 4,82147E-05 
487 ENSG00000130540 SULT4A1 1,557481741 0,003552638 
488 ENSG00000139722 VPS37B 1,552462382 2,70551E-29 
489 ENSG00000171533 MAP6 1,54941873 7,97893E-46 
490 ENSG00000161638 ITGA5 1,546753269 7,39353E-41 
491 ENSG00000103740 ACSBG1 1,546524733 9,09727E-32 
492 ENSG00000136546 SCN7A 1,545494994 3,80381E-07 
493 ENSG00000154589 LY96 1,544685488 1,10817E-07 
494 ENSG00000162873 KLHDC8A 1,54425169 2,0256E-144 
495 ENSG00000131620 ANO1 1,540459591 0,004888982 
496 ENSG00000196968 FUT11 1,536245886 1,67382E-21 
497 ENSG00000171450 CDK5R2 1,534558835 0,000271981 
498 ENSG00000196502 SULT1A1 1,533086923 9,27486E-11 
499 ENSG00000141756 FKBP10 1,53093852 2,6276E-140 
500 ENSG00000101384 JAG1 1,530597565 8,9547E-125 
501 ENSG00000186732 MPPED1 1,529871101 0,005010252 
502 ENSG00000144857 BOC 1,529727961 4,7557E-101 
503 ENSG00000175868 CALCB 1,519556592 0,002359061 
504 ENSG00000196358 NTNG2 1,519180618 4,26221E-19 
505 ENSG00000181856 SLC2A4 1,519003195 2,09506E-06 
506 ENSG00000253368 TRNP1 1,518771623 8,44667E-24 
507 ENSG00000171811 CFAP46 1,516844769 0,000429094 
508 ENSG00000204052 LRRC73 1,516733905 9,54631E-05 
509 ENSG00000117525 F3 1,516312672 7,47404E-46 
510 ENSG00000168334 XIRP1 1,514769985 0,00280119 
511 ENSG00000075426 FOSL2 1,510708846 4,54659E-45 
512 ENSG00000186409 CCDC30 1,510681858 2,54611E-06 
513 ENSG00000145362 ANK2 1,509723114 1,93863E-92 
514 ENSG00000180875 GREM2 1,509615653 0,007479296 
515 ENSG00000013583 HEBP1 1,509576465 1,70437E-07 
516 ENSG00000144218 AFF3 1,508214842 2,06449E-08 
517 ENSG00000256576 LINC02361 1,500975264 0,000329835 
518 ENSG00000149257 SERPINH1 1,49889937 2,5954E-49 
519 ENSG00000100228 RAB36 1,498814345 1,09488E-27 
520 ENSG00000125089 SH3TC1 1,496437166 0,004465413 
521 ENSG00000106624 AEBP1 1,495058553 1,07128E-70 
522 ENSG00000244230 RN7SL151P 1,494134999 0,000992846 
523 ENSG00000261409 AL035425.3 1,493751851 0,00014375 
524 ENSG00000214402 LCNL1 1,491871613 0,001450824 
525 ENSG00000044524 EPHA3 1,491255777 1,013E-157 
526 ENSG00000146376 ARHGAP18 1,489040802 1,69618E-11 
527 ENSG00000164056 SPRY1 1,488793465 2,57712E-71 
528 ENSG00000108176 DNAJC12 1,48665556 3,76423E-05 
529 ENSG00000188766 SPRED3 1,485110508 3,00523E-09 
530 ENSG00000246985 SOCS2-AS1 1,485100224 0,006868457 
531 ENSG00000164749 HNF4G 1,484660395 2,05115E-07 
532 ENSG00000074181 NOTCH3 1,483787374 5,62644E-95 
533 ENSG00000158220 ESYT3 1,482992955 5,62533E-05 
534 ENSG00000152932 RAB3C 1,478305336 0,000166392 
535 ENSG00000157110 RBPMS 1,475923214 1,49034E-58 
536 ENSG00000147883 CDKN2B 1,474690024 1,23458E-83 
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537 ENSG00000074219 TEAD2 1,47442265 8,46946E-63 
538 ENSG00000185942 NKAIN3 1,473980533 0,002031041 
539 ENSG00000179761 PIPOX 1,469831225 1,70079E-16 
540 ENSG00000250993 AC020551.1 1,469757905 0,009460309 
541 ENSG00000127863 TNFRSF19 1,466312092 4,4545E-99 
542 ENSG00000272549 AL356123.2 1,465122249 0,000561725 
543 ENSG00000062716 VMP1 1,464193147 1,9411E-102 
544 ENSG00000179388 EGR3 1,46365661 3,31064E-20 
545 ENSG00000003249 DBNDD1 1,461711895 2,89912E-47 
546 ENSG00000089199 CHGB 1,458251965 3,23841E-08 
547 ENSG00000072694 FCGR2B 1,455621877 7,40117E-08 
548 ENSG00000101000 PROCR 1,453414779 0,002508371 
549 ENSG00000008056 SYN1 1,45320925 4,77159E-09 
550 ENSG00000144891 AGTR1 1,452643476 0,002690228 
551 ENSG00000144908 ALDH1L1 1,449486372 0,007920122 
552 ENSG00000113532 ST8SIA4 1,446231418 0,009178574 
553 ENSG00000185201 IFITM2 1,444980182 1,16097E-17 
554 ENSG00000130270 ATP8B3 1,438904345 0,003765156 
555 ENSG00000105672 ETV2 1,438193334 0,000676396 
556 ENSG00000162783 IER5 1,436875644 4,40915E-57 
557 ENSG00000189143 CLDN4 1,431990605 1,70929E-05 
558 ENSG00000173727 AP000769.1 1,430791782 0,011862275 
559 ENSG00000168765 GSTM4 1,430136499 2,85724E-14 
560 ENSG00000136379 ABHD17C 1,429955402 6,96915E-42 
561 ENSG00000120594 PLXDC2 1,429532307 5,23033E-27 
562 ENSG00000100092 SH3BP1 1,428660584 4,47699E-07 
563 ENSG00000134215 VAV3 1,428446393 2,95471E-31 
564 ENSG00000253549 CA3-AS1 1,428338832 0,00486848 
565 ENSG00000153237 CCDC148 1,426331378 0,000587656 
566 ENSG00000222009 BTBD19 1,42574637 4,31316E-12 
567 ENSG00000139679 LPAR6 1,425038241 9,28326E-10 
568 ENSG00000133124 IRS4 1,42342308 0,000450184 
569 ENSG00000237819 AC002454.1 1,421221838 4,00239E-08 
570 ENSG00000149292 TTC12 1,419822951 0,009659112 
571 ENSG00000089060 SLC8B1 1,418275809 1,04229E-15 
572 ENSG00000130702 LAMA5 1,416983488 1,23031E-84 
573 ENSG00000234409 CCDC188 1,411640707 1,33349E-12 
574 ENSG00000170909 OSCAR 1,408700754 0,004647071 
575 ENSG00000126790 L3HYPDH 1,407790031 2,44138E-31 
576 ENSG00000175505 CLCF1 1,40742855 0,003379289 
577 ENSG00000120738 EGR1 1,403330713 2,37231E-87 
578 ENSG00000116717 GADD45A 1,402911575 2,62355E-41 
579 ENSG00000124813 RUNX2 1,402070148 1,67059E-07 
580 ENSG00000141682 PMAIP1 1,398840875 4,15292E-30 
581 ENSG00000169855 ROBO1 1,397112023 3,6349E-124 
582 ENSG00000108511 HOXB6 1,395819598 3,83772E-11 
583 ENSG00000113448 PDE4D 1,394346878 6,22786E-12 
584 ENSG00000146555 SDK1 1,393193552 5,30756E-32 
585 ENSG00000116329 OPRD1 1,391933556 1,61043E-07 
586 ENSG00000157423 HYDIN 1,39146804 0,01462489 
587 ENSG00000142733 MAP3K6 1,39100476 1,20201E-33 
588 ENSG00000111885 MAN1A1 1,390814559 0,002888326 
589 ENSG00000153714 LURAP1L 1,388069596 0,001930512 
590 ENSG00000188674 C2orf80 1,386094868 2,54012E-23 
591 ENSG00000175471 MCTP1 1,385644439 1,7763E-23 
592 ENSG00000102900 NUP93 1,385303932 3,5208E-127 
593 ENSG00000254827 SLC22A18AS 1,38394074 0,01183388 
594 ENSG00000106484 MEST 1,381734031 1,94056E-91 
595 ENSG00000102265 TIMP1 1,380394276 1,7554E-102 
596 ENSG00000180447 GAS1 1,376383401 6,6379E-100 
597 ENSG00000186806 VSIG10L 1,37467177 1,17325E-15 
598 ENSG00000169744 LDB2 1,374615805 5,39347E-19 
599 ENSG00000164066 INTU 1,373363392 2,79162E-11 
600 ENSG00000130751 NPAS1 1,370991951 3,52191E-21 
601 ENSG00000176692 FOXC2 1,370371072 0,007855577 
602 ENSG00000181350 LRRC75A 1,370232613 1,27127E-15 
603 ENSG00000110446 SLC15A3 1,364809223 0,001329287 
604 ENSG00000123689 G0S2 1,358937424 0,015134996 
605 ENSG00000116117 PARD3B 1,357197193 3,78258E-26 
606 ENSG00000197291 RAMP2-AS1 1,357157956 0,000888093 
607 ENSG00000248161 AC098487.1 1,356943938 0,005239278 
608 ENSG00000129951 PLPPR3 1,356016468 0,001294431 
609 ENSG00000130055 GDPD2 1,354364387 3,67804E-14 
610 ENSG00000233396 LINC01719 1,353404881 0,002757155 
611 ENSG00000169213 RAB3B 1,35021232 1,79668E-41 
612 ENSG00000112139 MDGA1 1,349241692 2,03572E-20 
613 ENSG00000110675 ELMOD1 1,347000596 1,11155E-10 
614 ENSG00000148600 CDHR1 1,346962299 5,94106E-30 
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615 ENSG00000164330 EBF1 1,343930915 3,94338E-10 
616 ENSG00000172216 CEBPB 1,343087791 3,2236E-25 
617 ENSG00000185215 TNFAIP2 1,339742433 0,01184841 
618 ENSG00000255277 ABCC6P2 1,337762318 0,004243517 
619 ENSG00000002933 TMEM176A 1,336217776 0,012933365 
620 ENSG00000221890 NPTXR 1,332746336 2,0141E-62 
621 ENSG00000139209 SLC38A4 1,331654857 7,21822E-05 
622 ENSG00000266928 AC020905.1 1,331321525 0,015619296 
623 ENSG00000132357 CARD6 1,331276835 0,00460094 
624 ENSG00000170006 TMEM154 1,329346077 0,001202684 
625 ENSG00000118242 MREG 1,327887429 1,14478E-34 
626 ENSG00000172780 RAB43 1,32766673 0,010626758 
627 ENSG00000161381 PLXDC1 1,326239353 0,000143115 
628 ENSG00000259146 AC005476.2 1,325477275 0,008697164 
629 ENSG00000196754 S100A2 1,325098586 2,56602E-05 
630 ENSG00000234840 LINC01239 1,324563795 0,015748398 
631 ENSG00000127666 TICAM1 1,324477694 3,37615E-14 
632 ENSG00000122735 DNAI1 1,324067555 0,006515787 
633 ENSG00000148803 FUOM 1,324043279 0,004392907 
634 ENSG00000249751 ECSCR 1,319973921 0,021776079 
635 ENSG00000123609 NMI 1,317758585 2,62741E-08 
636 ENSG00000143819 EPHX1 1,315797245 2,98654E-73 
637 ENSG00000042832 TG 1,315409418 0,02185331 
638 ENSG00000168135 KCNJ4 1,312696694 0,000497594 
639 ENSG00000222000 AC092675.1 1,311431696 0,004529314 
640 ENSG00000257497 AC121761.1 1,311368392 0,016595978 
641 ENSG00000177606 JUN 1,310689051 1,4282E-111 
642 ENSG00000135439 AGAP2 1,309484528 6,61019E-29 
643 ENSG00000197646 PDCD1LG2 1,308910494 0,008990685 
644 ENSG00000152413 HOMER1 1,307468412 1,69767E-55 
645 ENSG00000087086 FTL 1,306064741 5,992E-105 
646 ENSG00000171223 JUNB 1,305951312 4,90331E-32 
647 ENSG00000231313 AC078875.1 1,305411816 1,28589E-16 
648 ENSG00000136158 SPRY2 1,305312408 5,32336E-74 
649 ENSG00000128606 LRRC17 1,301846863 9,62515E-15 
650 ENSG00000129159 KCNC1 1,30138047 2,07532E-27 
651 ENSG00000012124 CD22 1,300906782 0,023979788 
652 ENSG00000043462 LCP2 1,300491102 0,024239808 
653 ENSG00000166831 RBPMS2 1,300011249 1,48375E-07 
654 ENSG00000129422 MTUS1 1,299963073 5,73091E-37 
655 ENSG00000126106 TMEM53 1,29814761 2,70073E-15 
656 ENSG00000182871 COL18A1 1,297607886 4,66228E-49 
657 ENSG00000258711 AL358334.2 1,296649403 0,005993854 
658 ENSG00000103021 CCDC113 1,294518626 1,95959E-06 
659 ENSG00000167065 DUSP18 1,292633676 1,95967E-07 
660 ENSG00000214353 VAC14-AS1 1,290682112 0,000924244 
661 ENSG00000156515 HK1 1,29045174 1,02947E-61 
662 ENSG00000183971 NPW 1,286499506 0,008304326 
663 ENSG00000125355 TMEM255A 1,285137463 4,02618E-84 
664 ENSG00000166578 IQCD 1,28505286 0,00039034 
665 ENSG00000081853 PCDHGA2 1,283317957 0,000890633 
666 ENSG00000107282 APBA1 1,281355843 1,16503E-39 
667 ENSG00000184949 FAM227A 1,280396829 7,86529E-05 
668 ENSG00000110786 PTPN5 1,279667978 0,000774513 
669 ENSG00000221963 APOL6 1,27954049 2,61095E-23 
670 ENSG00000137573 SULF1 1,277509476 0,022070622 
671 ENSG00000091844 RGS17 1,275659826 4,03159E-42 
672 ENSG00000008196 TFAP2B 1,274434327 0,005746248 
673 ENSG00000134802 SLC43A3 1,273687245 6,60301E-06 
674 ENSG00000142408 CACNG8 1,272467022 1,13318E-27 
675 ENSG00000228031 AC078842.1 1,271883723 0,003785193 
676 ENSG00000215788 TNFRSF25 1,268796142 0,001548333 
677 ENSG00000196557 CACNA1H 1,267247445 1,21037E-10 
678 ENSG00000145349 CAMK2D 1,265198781 2,82683E-79 
679 ENSG00000082512 TRAF5 1,263618948 8,69368E-07 
680 ENSG00000007171 NOS2 1,262497367 0,014864935 
681 ENSG00000246334 PRR7-AS1 1,261343495 0,000192727 
682 ENSG00000118997 DNAH7 1,261132473 0,002297051 
683 ENSG00000187944 C2orf66 1,260645379 0,025402357 
684 ENSG00000138119 MYOF 1,259317607 1,45398E-34 
685 ENSG00000108797 CNTNAP1 1,258262192 1,50694E-63 
686 ENSG00000170801 HTRA3 1,258110823 0,027314 
687 ENSG00000132481 TRIM47 1,255225778 1,65245E-14 
688 ENSG00000175040 CHST2 1,255194869 2,10373E-37 
689 ENSG00000272341 AL137003.2 1,252719931 3,43889E-06 
690 ENSG00000113205 PCDHB3 1,252409957 1,1965E-06 
691 ENSG00000164038 SLC9B2 1,252051091 1,30232E-11 
692 ENSG00000132879 FBXO44 1,252010928 3,33384E-17 
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693 ENSG00000177432 NAP1L5 1,251416541 3,72523E-14 
694 ENSG00000043143 JADE2 1,249595307 1,1346E-24 
695 ENSG00000162426 SLC45A1 1,249508737 3,78416E-10 
696 ENSG00000171680 PLEKHG5 1,249058288 2,87664E-07 
697 ENSG00000163219 ARHGAP25 1,248767478 1,68741E-05 
698 ENSG00000225067 RPL23AP2 1,24738863 0,013061778 
699 ENSG00000179168 GGN 1,245983966 8,89136E-06 
700 ENSG00000116745 RPE65 1,243217155 1,77881E-36 
701 ENSG00000137727 ARHGAP20 1,242382603 2,11331E-43 
702 ENSG00000129474 AJUBA 1,241762209 2,16946E-18 
703 ENSG00000136840 ST6GALNAC4 1,241079227 3,19916E-22 
704 ENSG00000101222 SPEF1 1,239513346 0,018632157 
705 ENSG00000256234 AC022509.2 1,236467835 0,023668996 
706 ENSG00000137501 SYTL2 1,236380886 8,49261E-27 
707 ENSG00000085831 TTC39A 1,235478402 0,020139087 
708 ENSG00000170412 GPRC5C 1,235358183 0,020678692 
709 ENSG00000177283 FZD8 1,235007353 7,12751E-28 
710 ENSG00000139880 CDH24 1,231718104 1,93627E-31 
711 ENSG00000166448 TMEM130 1,231167611 9,89502E-06 
712 ENSG00000174804 FZD4 1,231162797 2,34575E-39 
713 ENSG00000198431 TXNRD1 1,229982037 2,92934E-87 
714 ENSG00000103888 CEMIP 1,226451047 2,1985E-29 
715 ENSG00000156113 KCNMA1 1,223523001 2,08339E-27 
716 ENSG00000119431 HDHD3 1,2221091 3,29853E-13 
717 ENSG00000135502 SLC26A10 1,219897866 0,005112921 
718 ENSG00000168062 BATF2 1,219719293 0,021419759 
719 ENSG00000104611 SH2D4A 1,217700616 9,27668E-06 
720 ENSG00000186854 TRABD2A 1,216799973 0,002655314 
721 ENSG00000080709 KCNN2 1,215866289 0,001027111 
722 ENSG00000169126 ARMC4 1,215036829 9,10317E-05 
723 ENSG00000258404 LINC02320 1,21354147 0,036659271 
724 ENSG00000011422 PLAUR 1,210256357 1,52799E-05 
725 ENSG00000223969 AC002456.1 1,209594134 0,00260881 
726 ENSG00000117425 PTCH2 1,206368262 7,32171E-06 
727 ENSG00000229644 NAMPTP1 1,203615078 8,14131E-10 
728 ENSG00000123810 B9D2 1,202296201 2,34805E-07 
729 ENSG00000187266 EPOR 1,200864662 1,14721E-09 
730 ENSG00000148935 GAS2 1,200582014 1,2114E-12 
731 ENSG00000198796 ALPK2 1,200001993 1,59277E-05 
732 ENSG00000205129 C4orf47 1,19952677 0,02697282 
733 ENSG00000034152 MAP2K3 1,199142699 2,46486E-24 
734 ENSG00000240498 CDKN2B-AS1 1,198265089 0,000103681 
735 ENSG00000146216 TTBK1 1,196726789 2,39846E-08 
736 ENSG00000143226 FCGR2A 1,196333405 1,07839E-13 
737 ENSG00000107554 DNMBP 1,196201286 3,12945E-35 
738 ENSG00000179071 CCDC89 1,191748874 0,021756187 
739 ENSG00000011105 TSPAN9 1,189928489 5,86047E-31 
740 ENSG00000129990 SYT5 1,188993106 0,008433475 
741 ENSG00000164220 F2RL2 1,188697603 0,03252831 
742 ENSG00000127418 FGFRL1 1,187963635 7,63811E-54 
743 ENSG00000150995 ITPR1 1,186313413 4,45167E-10 
744 ENSG00000135424 ITGA7 1,185505936 3,34395E-84 
745 ENSG00000228528 AC068057.1 1,184807615 0,01686229 
746 ENSG00000062524 LTK 1,184611908 0,039318932 
747 ENSG00000249061 AC109492.1 1,183124839 0,03124999 
748 ENSG00000168772 CXXC4 1,18285885 1,22882E-07 
749 ENSG00000113070 HBEGF 1,182676856 1,28652E-13 
750 ENSG00000188483 IER5L 1,182205584 8,71207E-36 
751 ENSG00000164023 SGMS2 1,181246651 0,000374884 
752 ENSG00000187678 SPRY4 1,180229838 4,63362E-86 
753 ENSG00000139318 DUSP6 1,178490892 1,29902E-64 
754 ENSG00000068831 RASGRP2 1,177994798 0,030768078 
755 ENSG00000148175 STOM 1,177628922 7,20859E-15 
756 ENSG00000186523 FAM86B1 1,177540387 0,016362477 
757 ENSG00000133687 TMTC1 1,177151765 1,05411E-34 
758 ENSG00000205517 RGL3 1,176001153 6,88313E-07 
759 ENSG00000251002 AC244502.1 1,174467732 0,02940066 
760 ENSG00000106546 AHR 1,174039536 0,045483664 
761 ENSG00000106038 EVX1 1,173049391 0,037092279 
762 ENSG00000160282 FTCD 1,173044241 0,040639211 
763 ENSG00000172346 CSDC2 1,172458488 0,028610909 
764 ENSG00000227533 SLC2A1-AS1 1,171951477 0,035444265 
765 ENSG00000105835 NAMPT 1,171885027 4,30747E-44 
766 ENSG00000145246 ATP10D 1,171729626 6,46173E-17 
767 ENSG00000126803 HSPA2 1,170051787 0,046524373 
768 ENSG00000185250 PPIL6 1,169545612 0,000120197 
769 ENSG00000185133 INPP5J 1,168185053 3,05998E-07 
770 ENSG00000115641 FHL2 1,165489431 1,5946E-09 
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771 ENSG00000111331 OAS3 1,164126869 1,0907E-55 
772 ENSG00000155495 MAGEC1 1,163472322 0,042611056 
773 ENSG00000121769 FABP3 1,15936355 1,13094E-09 
774 ENSG00000226608 FTLP3 1,157645496 8,41878E-11 
775 ENSG00000132470 ITGB4 1,157366865 2,15931E-06 
776 ENSG00000106025 TSPAN12 1,155427529 1,93201E-29 
777 ENSG00000258947 TUBB3 1,153750324 9,76244E-10 
778 ENSG00000104856 RELB 1,152941753 1,99738E-11 
779 ENSG00000102032 RENBP 1,15212822 1,42894E-05 
780 ENSG00000070808 CAMK2A 1,151944173 1,31211E-06 
781 ENSG00000143036 SLC44A3 1,150981128 0,014122767 
782 ENSG00000188051 TMEM221 1,15060009 0,000459638 
783 ENSG00000227502 LINC01268 1,150543407 9,41962E-16 
784 ENSG00000223652 AC106786.1 1,150416113 0,029740574 
785 ENSG00000185681 MORN5 1,149502022 0,039940661 
786 ENSG00000134871 COL4A2 1,149440988 2,77762E-18 
787 ENSG00000257594 GALNT4 1,149134767 0,03882595 
788 ENSG00000106565 TMEM176B 1,148901221 0,028493808 
789 ENSG00000233901 LINC01503 1,146669334 0,026677004 
790 ENSG00000103528 SYT17 1,146388035 2,85548E-43 
791 ENSG00000185245 GP1BA 1,145008799 0,007622852 
792 ENSG00000169764 UGP2 1,144776126 1,55957E-84 
793 ENSG00000174808 BTC 1,144773993 0,011904314 
794 ENSG00000124302 CHST8 1,144462793 9,25375E-08 
795 ENSG00000115107 STEAP3 1,144286816 2,594E-25 
796 ENSG00000183092 BEGAIN 1,143004757 1,70172E-23 
797 ENSG00000101098 RIMS4 1,141053279 7,65897E-50 
798 ENSG00000061455 PRDM6 1,140135747 0,00119557 
799 ENSG00000103876 FAH 1,139636445 2,73816E-09 
800 ENSG00000154153 RETREG1 1,137796183 1,40079E-25 
801 ENSG00000160111 CPAMD8 1,137671946 0,03233548 
802 ENSG00000157168 NRG1 1,137125597 2,5024E-14 
803 ENSG00000236714 LINC01844 1,136864019 0,017393868 
804 ENSG00000229743 LINC01159 1,134725884 0,009622265 
805 ENSG00000185274 WBSCR17 1,133505147 2,48606E-26 
806 ENSG00000164845 FAM86FP 1,129650455 0,022943083 
807 ENSG00000228412 AL022068.1 1,129395504 0,021652533 
808 ENSG00000066056 TIE1 1,128913964 0,046107548 
809 ENSG00000228065 LINC01515 1,128107299 0,002413385 
810 ENSG00000150967 ABCB9 1,127994647 5,20643E-13 
811 ENSG00000183828 NUDT14 1,127991649 2,26645E-09 
812 ENSG00000156453 PCDH1 1,125996293 6,63014E-41 
813 ENSG00000172985 SH3RF3 1,125974298 3,96496E-18 
814 ENSG00000165886 UBTD1 1,125342118 7,87584E-24 
815 ENSG00000117600 PLPPR4 1,123114718 0,00371653 
816 ENSG00000134107 BHLHE40 1,122010758 2,74824E-45 
817 ENSG00000175182 FAM131A 1,121794833 3,74725E-10 
818 ENSG00000196083 IL1RAP 1,121643562 2,05107E-49 
819 ENSG00000177181 RIMKLA 1,121632601 7,34048E-15 
820 ENSG00000139269 INHBE 1,121616035 0,000292237 
821 ENSG00000140104 C14orf79 1,120786747 1,80947E-15 
822 ENSG00000183831 ANKRD45 1,119287487 0,002903093 
823 ENSG00000139292 LGR5 1,115886589 1,17796E-38 
824 ENSG00000057657 PRDM1 1,112752351 0,014203629 
825 ENSG00000119681 LTBP2 1,112660478 7,37444E-07 
826 ENSG00000156345 CDK20 1,109989796 1,20625E-17 
827 ENSG00000250318 AC003072.1 1,109592625 0,017419203 
828 ENSG00000141505 ASGR1 1,10894071 0,00354953 
829 ENSG00000148832 PAOX 1,107615389 0,003871555 
830 ENSG00000123095 BHLHE41 1,107113383 2,60556E-12 
831 ENSG00000116285 ERRFI1 1,107022306 4,27054E-39 
832 ENSG00000242861 AL591895.1 1,106098251 0,021271642 
833 ENSG00000113594 LIFR 1,105805037 9,53744E-47 
834 ENSG00000123104 ITPR2 1,105316538 2,90829E-59 
835 ENSG00000104419 NDRG1 1,104782813 1,84478E-40 
836 ENSG00000255366 AC120036.5 1,103946151 0,025433525 
837 ENSG00000075539 FRYL 1,103938319 1,33411E-36 
838 ENSG00000184743 ATL3 1,103304825 2,13817E-16 
839 ENSG00000254489 AL136088.1 1,102911593 0,047736413 
840 ENSG00000171476 HOPX 1,101441332 2,04234E-15 
841 ENSG00000102271 KLHL4 1,100279609 1,30188E-20 
842 ENSG00000169019 COMMD8 1,099710133 5,36705E-08 
843 ENSG00000134874 DZIP1 1,099106515 2,86514E-27 
844 ENSG00000121900 TMEM54 1,098610396 1,31722E-14 
845 ENSG00000239697 TNFSF12 1,098589316 0,016772931 
846 ENSG00000270069 MIR222HG 1,09723375 3,82077E-05 
847 ENSG00000118432 CNR1 1,095314528 1,38038E-14 
848 ENSG00000105427 CNFN 1,095149091 0,034378007 
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849 ENSG00000168505 GBX2 1,092845344 9,20645E-05 
850 ENSG00000138400 MDH1B 1,092280021 0,00059814 
851 ENSG00000129003 VPS13C 1,09021024 7,55448E-58 
852 ENSG00000157193 LRP8 1,089245662 2,05897E-47 
853 ENSG00000105245 NUMBL 1,088282467 1,74062E-54 
854 ENSG00000151474 FRMD4A 1,087356198 1,04191E-08 
855 ENSG00000139263 LRIG3 1,087351095 1,78663E-12 
856 ENSG00000183114 FAM43B 1,08714601 8,18708E-05 
857 ENSG00000139178 C1RL 1,084990224 0,000100605 
858 ENSG00000234899 SOX9-AS1 1,084326411 3,0576E-06 
859 ENSG00000185634 SHC4 1,084070644 8,1421E-16 
860 ENSG00000161267 BDH1 1,083145138 0,004913108 
861 ENSG00000179292 TMEM151A 1,082637832 0,004355159 
862 ENSG00000100078 PLA2G3 1,080789435 5,54898E-20 
863 ENSG00000237797 AL161935.3 1,079119401 0,004373506 
864 ENSG00000224713 AC025165.1 1,078592476 0,046806463 
865 ENSG00000166171 DPCD 1,078477935 1,08087E-08 
866 ENSG00000155158 TTC39B 1,078272203 1,37367E-06 
867 ENSG00000232599 AL008707.1 1,077543718 0,00439801 
868 ENSG00000133937 GSC 1,077388574 3,61657E-07 
869 ENSG00000091136 LAMB1 1,076062974 5,24421E-64 
870 ENSG00000175264 CHST1 1,074421312 8,82248E-08 
871 ENSG00000131069 ACSS2 1,07320464 1,05064E-42 
872 ENSG00000179242 CDH4 1,072631992 1,06432E-06 
873 ENSG00000160867 FGFR4 1,072238013 3,41182E-05 
874 ENSG00000198003 CCDC151 1,071936387 0,001245925 
875 ENSG00000109171 SLAIN2 1,071764894 2,50104E-26 
876 ENSG00000118307 CASC1 1,071342569 0,035017873 
877 ENSG00000182718 ANXA2 1,069872313 7,45178E-12 
878 ENSG00000092850 TEKT2 1,068355964 0,0025474 
879 ENSG00000100036 SLC35E4 1,068195155 8,62282E-10 
880 ENSG00000227954 TARID 1,067877702 0,000144914 
881 ENSG00000129151 BBOX1 1,065938484 2,60556E-12 
882 ENSG00000123685 BATF3 1,063760792 1,19672E-07 
883 ENSG00000006071 ABCC8 1,062126996 4,45975E-13 
884 ENSG00000130164 LDLR 1,061127439 4,29267E-67 
885 ENSG00000148841 ITPRIP 1,05890121 7,92154E-14 
886 ENSG00000258754 LINC01579 1,058329128 0,013575469 
887 ENSG00000114654 EFCC1 1,058295886 0,037621767 
888 ENSG00000232699 BDH2P1 1,057840286 0,023172854 
889 ENSG00000002587 HS3ST1 1,057707203 2,54098E-14 
890 ENSG00000136160 EDNRB 1,056421983 3,50835E-40 
891 ENSG00000175104 TRAF6 1,055472779 1,06451E-22 
892 ENSG00000112319 EYA4 1,055301835 6,49599E-53 
893 ENSG00000075213 SEMA3A 1,053020735 8,2485E-41 
894 ENSG00000126217 MCF2L 1,052779099 2,51441E-32 
895 ENSG00000255823 MTRNR2L8 1,052490341 0,003544363 
896 ENSG00000112539 C6orf118 1,05241578 0,000790228 
897 ENSG00000080561 MID2 1,052064599 6,08077E-05 
898 ENSG00000131724 IL13RA1 1,051963976 4,63302E-42 
899 ENSG00000171940 ZNF217 1,05163115 3,25833E-31 
900 ENSG00000183036 PCP4 1,051069091 1,02551E-14 
901 ENSG00000148158 SNX30 1,048818166 3,99742E-26 
902 ENSG00000135272 MDFIC 1,048785784 0,008457234 
903 ENSG00000140464 PML 1,047840302 7,25193E-26 
904 ENSG00000145358 DDIT4L 1,046540362 0,015107409 
905 ENSG00000149927 DOC2A 1,046433239 0,001994923 
906 ENSG00000141519 CCDC40 1,045451931 2,39721E-06 
907 ENSG00000248712 CCDC153 1,04404137 0,021797452 
908 ENSG00000198400 NTRK1 1,0436732 0,035367061 
909 ENSG00000181619 GPR135 1,043484084 0,013878903 
910 ENSG00000135842 FAM129A 1,042721967 1,34543E-18 
911 ENSG00000124107 SLPI 1,040188826 0,044655118 
912 ENSG00000072274 TFRC 1,039925141 2,47158E-73 
913 ENSG00000102174 PHEX 1,039564251 0,001847424 
914 ENSG00000170775 GPR37 1,039270777 0,000241535 
915 ENSG00000271952 LINC01954 1,038554091 0,036618435 
916 ENSG00000185046 ANKS1B 1,037922103 6,27343E-19 
917 ENSG00000164692 COL1A2 1,037469004 0,044391329 
918 ENSG00000090013 BLVRB 1,037292135 4,43842E-20 
919 ENSG00000144583 MARCH4 1,036941336 0,000379667 
920 ENSG00000102349 KLF8 1,035798731 0,011624938 
921 ENSG00000177679 SRRM3 1,035741444 0,009097076 
922 ENSG00000261604 AC114947.2 1,035450906 3,66283E-06 
923 ENSG00000225518 LINC01703 1,032362797 0,048492412 
924 ENSG00000248593 DSTNP2 1,031361547 0,001614901 
925 ENSG00000080493 SLC4A4 1,025429578 1,15965E-57 
926 ENSG00000116729 WLS 1,024174694 4,28019E-68 
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927 ENSG00000186976 EFCAB6 1,023905454 0,002347215 
928 ENSG00000134070 IRAK2 1,023210756 8,53185E-08 
929 ENSG00000092421 SEMA6A 1,023204217 5,00443E-53 
930 ENSG00000071242 RPS6KA2 1,022727673 9,49932E-68 
931 ENSG00000106772 PRUNE2 1,021776839 1,17729E-64 
932 ENSG00000196843 ARID5A 1,020951479 7,47182E-25 
933 ENSG00000154265 ABCA5 1,020213727 0,000210054 
934 ENSG00000259523 AC022613.2 1,019529858 0,032046607 
935 ENSG00000135404 CD63 1,019346011 1,27261E-66 
936 ENSG00000105281 SLC1A5 1,018897984 1,86937E-29 
937 ENSG00000185507 IRF7 1,018540623 2,6068E-07 
938 ENSG00000138036 DYNC2LI1 1,018194245 5,21854E-16 
939 ENSG00000109180 OCIAD1 1,017224512 3,43476E-46 
940 ENSG00000010404 IDS 1,017058337 1,11303E-59 
941 ENSG00000237289 CKMT1B 1,016801196 0,009905172 
942 ENSG00000154678 PDE1C 1,016036569 0,000731531 
943 ENSG00000133019 CHRM3 1,015211186 9,47567E-26 
944 ENSG00000179361 ARID3B 1,013257923 0,001294642 
945 ENSG00000240204 SMKR1 1,01268258 0,04644253 
946 ENSG00000153976 HS3ST3A1 1,011898778 0,000671602 
947 ENSG00000196975 ANXA4 1,010551053 2,47564E-12 
948 ENSG00000148848 ADAM12 1,010218396 0,013332983 
949 ENSG00000243646 IL10RB 1,009945557 7,65885E-12 
950 ENSG00000130779 CLIP1 1,006819884 4,70089E-32 
951 ENSG00000165695 AK8 1,005935434 0,012280778 
952 ENSG00000124762 CDKN1A 1,005595955 3,60706E-36 
953 ENSG00000115657 ABCB6 1,005552626 1,80629E-05 
954 ENSG00000108379 WNT3 1,005341957 2,8452E-05 
955 ENSG00000108883 EFTUD2 1,004817395 6,01433E-77 
956 ENSG00000273079 GRIN2B 1,004755593 3,51841E-12 
957 ENSG00000105499 PLA2G4C 1,004491677 3,55296E-08 
958 ENSG00000213928 IRF9 1,003376561 0,010950268 
959 ENSG00000244026 FAM86DP 1,002647404 1,52612E-08 
960 ENSG00000175874 CREG2 1,001897293 0,025529851 
961 ENSG00000111817 DSE 1,000409346 5,00792E-09 
962 ENSG00000151025 GPR158 0,997383718 7,89338E-12 
963 ENSG00000126010 GRPR 0,996519858 0,037992264 
964 ENSG00000175197 DDIT3 0,995236404 6,34108E-11 
965 ENSG00000153832 FBXO36 0,994511125 3,67305E-06 
966 ENSG00000008283 CYB561 0,992379788 4,05079E-05 
967 ENSG00000235587 GAPDHP65 0,992063972 0,010419878 
968 ENSG00000247157 LINC01252 0,991961291 0,012941646 
969 ENSG00000101004 NINL 0,989393401 0,034072272 
970 ENSG00000096093 EFHC1 0,988909584 5,41094E-28 
971 ENSG00000251669 FAM86EP 0,988156422 0,01601319 
972 ENSG00000254429 AP001972.1 0,988024206 0,032191018 
973 ENSG00000172893 DHCR7 0,987675136 5,8892E-62 
974 ENSG00000144136 SLC20A1 0,987665734 2,67519E-46 
975 ENSG00000235363 SNRPGP10 0,987182945 0,004642612 
976 ENSG00000101255 TRIB3 0,986845308 5,48513E-20 
977 ENSG00000237172 B3GNT9 0,986728872 0,000201583 
978 ENSG00000143469 SYT14 0,982481366 2,39628E-05 
979 ENSG00000140939 NOL3 0,982377355 1,29838E-11 
980 ENSG00000106070 GRB10 0,9797426 1,44044E-38 
981 ENSG00000167601 AXL 0,976892544 1,98018E-32 
982 ENSG00000123364 HOXC13 0,976014008 0,007980046 
983 ENSG00000171160 MORN4 0,975849163 1,73321E-12 
984 ENSG00000262001 DLGAP1-AS2 0,975163987 0,000430848 
985 ENSG00000142694 EVA1B 0,97399156 0,000472377 
986 ENSG00000132688 NES 0,9736663 2,32477E-59 
987 ENSG00000186594 MIR22HG 0,973393944 7,75424E-05 
988 ENSG00000152315 KCNK13 0,973205706 0,004612926 
989 ENSG00000107798 LIPA 0,973013032 1,90225E-36 
990 ENSG00000131187 F12 0,972642088 2,39856E-07 
991 ENSG00000175866 BAIAP2 0,972299011 1,44791E-32 
992 ENSG00000139668 WDFY2 0,971928462 2,45874E-15 
993 ENSG00000137198 GMPR 0,970563126 7,4215E-12 
994 ENSG00000075043 KCNQ2 0,969408087 1,18078E-34 
995 ENSG00000026508 CD44 0,968755202 4,69463E-49 
996 ENSG00000178401 DNAJC22 0,968417287 1,48637E-06 
997 ENSG00000110660 SLC35F2 0,968390846 1,87338E-13 
998 ENSG00000178445 GLDC 0,967908974 1,51382E-40 
999 ENSG00000100592 DAAM1 0,967862835 1,13174E-13 
1000 ENSG00000243232 PCDHAC2 0,967609771 0,000123575 
1001 ENSG00000155962 CLIC2 0,966859223 0,004319645 
1002 ENSG00000111640 GAPDH 0,96393555 8,41408E-82 
1003 ENSG00000127125 PPCS 0,96369258 0,001709851 
1004 ENSG00000079974 RABL2B 0,963110618 8,17875E-15 
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1005 ENSG00000109944 C11orf63 0,963084352 0,000295772 
1006 ENSG00000102034 ELF4 0,961552045 5,98013E-05 
1007 ENSG00000174938 SEZ6L2 0,961395278 1,83343E-31 
1008 ENSG00000027001 MIPEP 0,960819181 2,22992E-08 
1009 ENSG00000160345 C9orf116 0,959670594 2,73358E-05 
1010 ENSG00000254389 RHPN1-AS1 0,959552677 0,019143237 
1011 ENSG00000130511 SSBP4 0,958671112 3,87557E-27 
1012 ENSG00000086062 B4GALT1 0,958029626 1,07164E-08 
1013 ENSG00000155367 PPM1J 0,957876695 0,002278197 
1014 ENSG00000104998 IL27RA 0,957693311 1,01652E-15 
1015 ENSG00000163485 ADORA1 0,957222321 1,1873E-09 
1016 ENSG00000136830 FAM129B 0,953691872 5,22429E-51 
1017 ENSG00000260528 FAM157C 0,952401327 0,044235055 
1018 ENSG00000069535 MAOB 0,950763369 0,021228325 
1019 ENSG00000135406 PRPH 0,950715765 4,44915E-06 
1020 ENSG00000168038 ULK4 0,94873688 3,96943E-05 
1021 ENSG00000105464 GRIN2D 0,948272261 1,03097E-07 
1022 ENSG00000230910 AL391807.1 0,946711357 3,39476E-07 
1023 ENSG00000204956 PCDHGA1 0,946286979 0,013150366 
1024 ENSG00000112936 C7 0,945334095 0,002779646 
1025 ENSG00000129167 TPH1 0,945160529 0,049010263 
1026 ENSG00000120278 PLEKHG1 0,944729243 1,21315E-19 
1027 ENSG00000183853 KIRREL 0,943870652 1,20968E-37 
1028 ENSG00000087266 SH3BP2 0,943055361 1,44193E-17 
1029 ENSG00000167617 CDC42EP5 0,941454303 0,000391705 
1030 ENSG00000134574 DDB2 0,939637073 7,9784E-07 
1031 ENSG00000196141 SPATS2L 0,939509193 3,40927E-41 
1032 ENSG00000124942 AHNAK 0,937943191 2,69848E-08 
1033 ENSG00000147588 PMP2 0,9363369 1,67339E-68 
1034 ENSG00000166886 NAB2 0,935784455 1,31682E-37 
1035 ENSG00000163331 DAPL1 0,935444845 0,039940661 
1036 ENSG00000228672 PROB1 0,935065178 1,15255E-05 
1037 ENSG00000198756 COLGALT2 0,934625552 1,90182E-46 
1038 ENSG00000160716 CHRNB2 0,934190846 0,003551788 
1039 ENSG00000165175 MID1IP1 0,934099738 2,78679E-28 
1040 ENSG00000160963 COL26A1 0,933719148 0,002294093 
1041 ENSG00000089159 PXN 0,932928592 2,38394E-36 
1042 ENSG00000160789 LMNA 0,932414545 1,4979E-45 
1043 ENSG00000091592 NLRP1 0,93241288 1,85331E-37 
1044 ENSG00000114744 COMMD2 0,931237318 3,20688E-44 
1045 ENSG00000054392 HHAT 0,930537578 1,42436E-05 
1046 ENSG00000105974 CAV1 0,929695183 2,05827E-08 
1047 ENSG00000167552 TUBA1A 0,927751449 2,08423E-68 
1048 ENSG00000171621 SPSB1 0,927706839 5,25936E-08 
1049 ENSG00000102445 RUBCNL 0,927684421 0,00767248 
1050 ENSG00000173110 HSPA6 0,927415486 0,011117726 
1051 ENSG00000028137 TNFRSF1B 0,926917123 2,64537E-05 
1052 ENSG00000197467 COL13A1 0,926180221 0,028265849 
1053 ENSG00000235703 LINC00894 0,925393771 3,36144E-05 
1054 ENSG00000146966 DENND2A 0,925333822 6,79724E-29 
1055 ENSG00000171798 KNDC1 0,923169895 0,01381885 
1056 ENSG00000100218 RSPH14 0,922994187 0,049333988 
1057 ENSG00000205593 DENND6B 0,920089372 1,40783E-10 
1058 ENSG00000130176 CNN1 0,920023587 0,005284729 
1059 ENSG00000226564 FTH1P20 0,919901013 1,76753E-06 
1060 ENSG00000152076 CCDC74B 0,918667035 3,33688E-06 
1061 ENSG00000131095 GFAP 0,918173648 4,22989E-47 
1062 ENSG00000107960 STN1 0,91708114 7,54005E-05 
1063 ENSG00000162645 GBP2 0,915941636 0,008124791 
1064 ENSG00000152582 SPEF2 0,9158292 0,01686229 
1065 ENSG00000071051 NCK2 0,915802219 2,22787E-34 
1066 ENSG00000116774 OLFML3 0,91573931 4,62982E-07 
1067 ENSG00000066382 MPPED2 0,915120668 1,43274E-10 
1068 ENSG00000075142 SRI 0,914638798 2,83308E-48 
1069 ENSG00000160813 PPP1R35 0,914535272 0,040212539 
1070 ENSG00000131981 LGALS3 0,914265148 0,000155548 
1071 ENSG00000151835 SACS 0,914200179 7,51479E-31 
1072 ENSG00000198879 SFMBT2 0,911360878 3,16208E-12 
1073 ENSG00000162745 OLFML2B 0,910675544 1,78303E-06 
1074 ENSG00000043355 ZIC2 0,910018078 7,7952E-08 
1075 ENSG00000260641 AC114811.2 0,909599086 0,027314 
1076 ENSG00000124788 ATXN1 0,909401825 2,34682E-27 
1077 ENSG00000092607 TBX15 0,909259484 0,000113871 
1078 ENSG00000145730 PAM 0,908445788 6,71884E-40 
1079 ENSG00000108861 DUSP3 0,907625905 3,55134E-28 
1080 ENSG00000248590 GLDCP1 0,907052653 0,007416197 
1081 ENSG00000272944 AC079834.2 0,90629508 0,048085674 
1082 ENSG00000123094 RASSF8 0,906251925 3,33551E-24 
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1083 ENSG00000174151 CYB561D1 0,906065716 5,41467E-11 
1084 ENSG00000139083 ETV6 0,905817511 1,00864E-14 
1085 ENSG00000180806 HOXC9 0,905386739 0,001443171 
1086 ENSG00000272502 AC104958.2 0,904852565 0,006474245 
1087 ENSG00000228232 GAPDHP1 0,904112023 3,41328E-08 
1088 ENSG00000159216 RUNX1 0,90338771 1,69981E-24 
1089 ENSG00000100994 PYGB 0,901414113 3,91191E-52 
1090 ENSG00000171444 MCC 0,900811698 1,81876E-15 
1091 ENSG00000198467 TPM2 0,899677353 3,25186E-09 
1092 ENSG00000103742 IGDCC4 0,899323593 1,75554E-09 
1093 ENSG00000149091 DGKZ 0,898827733 4,30131E-27 
1094 ENSG00000182103 FAM181B 0,897303864 2,08789E-32 
1095 ENSG00000106976 DNM1 0,896534072 4,34049E-31 
1096 ENSG00000152953 STK32B 0,89645714 1,34884E-25 
1097 ENSG00000186654 PRR5 0,894828133 0,044533965 
1098 ENSG00000126458 RRAS 0,892790884 6,76619E-11 
1099 ENSG00000023909 GCLM 0,891691309 5,05089E-11 
1100 ENSG00000111696 NT5DC3 0,891011107 7,74887E-16 
1101 ENSG00000109323 MANBA 0,890156016 1,26793E-12 
1102 ENSG00000171877 FRMD5 0,889389269 1,72333E-33 
1103 ENSG00000071575 TRIB2 0,888635795 1,14528E-59 
1104 ENSG00000040608 RTN4R 0,888523052 5,34196E-17 
1105 ENSG00000139044 B4GALNT3 0,888051692 3,66664E-17 
1106 ENSG00000240771 ARHGEF25 0,887609103 1,59413E-07 
1107 ENSG00000168778 TCTN2 0,886981236 2,87245E-09 
1108 ENSG00000122756 CNTFR 0,886677018 1,10175E-08 
1109 ENSG00000034510 TMSB10 0,88596284 3,30457E-61 
1110 ENSG00000107954 NEURL1 0,8845071 0,045987736 
1111 ENSG00000171992 SYNPO 0,882685881 0,022578569 
1112 ENSG00000149591 TAGLN 0,882375531 1,83919E-05 
1113 ENSG00000041982 TNC 0,882256544 1,18207E-52 
1114 ENSG00000163513 TGFBR2 0,881294209 2,39046E-16 
1115 ENSG00000103599 IQCH 0,880938849 0,00344217 
1116 ENSG00000169908 TM4SF1 0,880744473 8,02497E-38 
1117 ENSG00000169756 LIMS1 0,880460416 9,10801E-25 
1118 ENSG00000130940 CASZ1 0,880373876 0,007209251 
1119 ENSG00000135722 FBXL8 0,880287409 0,021475158 
1120 ENSG00000091409 ITGA6 0,878586118 2,59448E-31 
1121 ENSG00000221926 TRIM16 0,877327004 4,88504E-10 
1122 ENSG00000090020 SLC9A1 0,877071714 3,09055E-12 
1123 ENSG00000105287 PRKD2 0,876495129 1,7383E-14 
1124 ENSG00000145687 SSBP2 0,875926321 4,31305E-27 
1125 ENSG00000135437 RDH5 0,875368379 0,006675177 
1126 ENSG00000086205 FOLH1 0,873960305 2,89012E-13 
1127 ENSG00000157985 AGAP1 0,872981343 4,37329E-38 
1128 ENSG00000163545 NUAK2 0,870624668 7,30842E-05 
1129 ENSG00000121743 GJA3 0,870468945 0,013918194 
1130 ENSG00000198855 FICD 0,869319303 5,6619E-08 
1131 ENSG00000187534 PRR13P5 0,868006651 0,001247733 
1132 ENSG00000151322 NPAS3 0,867518106 1,10851E-26 
1133 ENSG00000269028 MTRNR2L12 0,865789735 0,002009361 
1134 ENSG00000185482 STAC3 0,865337183 0,007229228 
1135 ENSG00000116525 TRIM62 0,864815272 2,60694E-10 
1136 ENSG00000100151 PICK1 0,863071259 0,027329743 
1137 ENSG00000141569 TRIM65 0,860835802 2,32534E-15 
1138 ENSG00000234975 FTH1P2 0,857817673 4,31297E-13 
1139 ENSG00000009694 TENM1 0,856933584 4,49556E-22 
1140 ENSG00000115756 HPCAL1 0,856930075 2,33467E-14 
1141 ENSG00000172915 NBEA 0,856901368 7,0802E-18 
1142 ENSG00000178498 DTX3 0,856300717 2,35806E-14 
1143 ENSG00000143195 ILDR2 0,854720091 3,69383E-28 
1144 ENSG00000135048 TMEM2 0,853737357 2,3856E-22 
1145 ENSG00000159167 STC1 0,853452085 4,10734E-20 
1146 ENSG00000203727 SAMD5 0,852639093 3,97926E-05 
1147 ENSG00000187498 COL4A1 0,852425535 5,76304E-50 
1148 ENSG00000124772 CPNE5 0,852026349 1,88351E-19 
1149 ENSG00000126453 BCL2L12 0,850835513 2,08906E-09 
1150 ENSG00000250510 GPR162 0,850508315 3,20309E-22 
1151 ENSG00000131759 RARA 0,850163277 4,07636E-15 
1152 ENSG00000010626 LRRC23 0,849845951 1,39706E-07 
1153 ENSG00000196361 ELAVL3 0,848837134 3,47364E-20 
1154 ENSG00000151917 BEND6 0,848318774 0,000127986 
1155 ENSG00000068079 IFI35 0,84670478 1,73102E-07 
1156 ENSG00000184489 PTP4A3 0,846121264 1,11753E-12 
1157 ENSG00000006047 YBX2 0,845105612 0,012227486 
1158 ENSG00000179104 TMTC2 0,844666174 2,72257E-12 
1159 ENSG00000128284 APOL3 0,84459708 0,011589449 
1160 ENSG00000146242 TPBG 0,844278481 1,0675E-13 
 
 139 
1161 ENSG00000167565 SERTAD3 0,844036034 6,85558E-09 
1162 ENSG00000169242 EFNA1 0,843880459 3,20467E-17 
1163 ENSG00000177542 SLC25A22 0,843804957 1,26651E-13 
1164 ENSG00000131504 DIAPH1 0,843653657 2,64013E-42 
1165 ENSG00000142552 RCN3 0,843259734 0,025081555 
1166 ENSG00000205213 LGR4 0,842746211 2,25368E-27 
1167 ENSG00000139636 LMBR1L 0,842512549 5,90141E-14 
1168 ENSG00000125246 CLYBL 0,841851738 0,000253022 
1169 ENSG00000131019 ULBP3 0,841549613 0,007697725 
1170 ENSG00000117480 FAAH 0,840221075 0,018513933 
1171 ENSG00000104313 EYA1 0,838819653 3,51739E-16 
1172 ENSG00000123983 ACSL3 0,838138499 1,27959E-43 
1173 ENSG00000251661 AC136475.1 0,836921656 0,011775035 
1174 ENSG00000131848 ZSCAN5A 0,83621055 3,70406E-05 
1175 ENSG00000197208 SLC22A4 0,836133966 6,00316E-05 
1176 ENSG00000115520 COQ10B 0,834374911 6,2813E-11 
1177 ENSG00000177839 PCDHB9 0,834012328 4,43979E-07 
1178 ENSG00000164741 DLC1 0,833324522 1,09615E-13 
1179 ENSG00000107317 PTGDS 0,832931126 0,000434714 
1180 ENSG00000123700 KCNJ2 0,832799952 6,61425E-05 
1181 ENSG00000135047 CTSL 0,832737578 1,24116E-19 
1182 ENSG00000135472 FAIM2 0,832659206 2,32839E-14 
1183 ENSG00000075618 FSCN1 0,831684337 1,17756E-50 
1184 ENSG00000083067 TRPM3 0,831574182 6,19852E-28 
1185 ENSG00000068650 ATP11A 0,830476516 3,61489E-20 
1186 ENSG00000172062 SMN1 0,829543541 0,000275301 
1187 ENSG00000115556 PLCD4 0,8292012 2,55892E-09 
1188 ENSG00000170537 TMC7 0,827252716 5,73894E-06 
1189 ENSG00000181104 F2R 0,825524848 4,54163E-28 
1190 ENSG00000177469 CAVIN1 0,824880843 1,31465E-36 
1191 ENSG00000196569 LAMA2 0,824372318 0,009403267 
1192 ENSG00000149489 ROM1 0,823656441 2,50466E-05 
1193 ENSG00000198221 AFDN-AS1 0,82322223 0,024561192 
1194 ENSG00000105717 PBX4 0,819792195 0,002287475 
1195 ENSG00000197879 MYO1C 0,819269872 2,48734E-13 
1196 ENSG00000118292 C1orf54 0,819182799 8,7378E-06 
1197 ENSG00000135862 LAMC1 0,818342519 1,22152E-39 
1198 ENSG00000100429 HDAC10 0,818173219 0,017744043 
1199 ENSG00000116106 EPHA4 0,818086641 1,48978E-30 
1200 ENSG00000120306 CYSTM1 0,817389249 8,98795E-17 
1201 ENSG00000137494 ANKRD42 0,81695338 9,5587E-06 
1202 ENSG00000162992 NEUROD1 0,81680921 0,000680812 
1203 ENSG00000099625 CBARP 0,816627431 3,08024E-13 
1204 ENSG00000185015 CA13 0,813628849 0,009607591 
1205 ENSG00000177426 TGIF1 0,8119081 1,38053E-29 
1206 ENSG00000166275 BORCS7 0,811533198 1,71194E-06 
1207 ENSG00000229119 AC026403.1 0,810879227 6,19666E-05 
1208 ENSG00000260822 AC004656.1 0,81078121 3,57761E-10 
1209 ENSG00000178078 STAP2 0,810307842 0,008091903 
1210 ENSG00000219507 FTH1P8 0,809800188 1,21625E-11 
1211 ENSG00000124140 SLC12A5 0,809387452 0,005563903 
1212 ENSG00000115271 GCA 0,808574967 6,22973E-05 
1213 ENSG00000111145 ELK3 0,808552225 1,37359E-12 
1214 ENSG00000010295 IFFO1 0,808326943 8,5843E-18 
1215 ENSG00000153214 TMEM87B 0,808141444 1,8918E-07 
1216 ENSG00000111846 GCNT2 0,807980523 9,13973E-09 
1217 ENSG00000137266 SLC22A23 0,80724605 9,97199E-13 
1218 ENSG00000162545 CAMK2N1 0,807102407 8,18185E-16 
1219 ENSG00000159214 CCDC24 0,805957431 4,85853E-05 
1220 ENSG00000082438 COBLL1 0,804899027 1,51231E-06 
1221 ENSG00000144645 OSBPL10 0,804013637 2,94163E-11 
1222 ENSG00000136810 TXN 0,801962499 4,81023E-28 
1223 ENSG00000115310 RTN4 0,801936401 6,39604E-37 
1224 ENSG00000257698 AC084033.3 0,80183671 1,46315E-06 
1225 ENSG00000130653 PNPLA7 0,80166209 0,001451732 
1226 ENSG00000182463 TSHZ2 0,801237491 0,000680067 
1227 ENSG00000108018 SORCS1 0,801089792 1,06907E-10 
1228 ENSG00000177337 DLGAP1-AS1 0,800826094 0,001723913 
1229 ENSG00000103241 FOXF1 0,79739853 4,72961E-05 
1230 ENSG00000165959 CLMN 0,79664862 3,39026E-13 
1231 ENSG00000121966 CXCR4 0,795815239 0,013478287 
1232 ENSG00000130635 COL5A1 0,795775663 2,12564E-34 
1233 ENSG00000177098 SCN4B 0,7944504 3,37829E-06 
1234 ENSG00000173166 RAPH1 0,794060517 0,000443678 
1235 ENSG00000065308 TRAM2 0,794024251 1,31852E-28 
1236 ENSG00000100427 MLC1 0,793331311 4,45472E-48 
1237 ENSG00000100246 DNAL4 0,792992488 1,11476E-11 
1238 ENSG00000120885 CLU 0,792880887 1,49583E-46 
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1239 ENSG00000076067 RBMS2 0,791998457 1,01515E-08 
1240 ENSG00000163482 STK36 0,791975772 8,87908E-18 
1241 ENSG00000160145 KALRN 0,791465988 8,02418E-13 
1242 ENSG00000268364 SMC5-AS1 0,791423924 0,045907943 
1243 ENSG00000186007 LEMD1 0,790966557 0,015095951 
1244 ENSG00000178947 SMIM10L2A 0,790535235 0,002395618 
1245 ENSG00000204852 TCTN1 0,789947863 2,62506E-16 
1246 ENSG00000042317 SPATA7 0,788824939 1,23155E-06 
1247 ENSG00000137944 KYAT3 0,788605431 2,48222E-10 
1248 ENSG00000150773 PIH1D2 0,78843835 0,032697234 
1249 ENSG00000175938 ORAI3 0,78763167 0,018015579 
1250 ENSG00000269893 SNHG8 0,787341466 8,1991E-05 
1251 ENSG00000131398 KCNC3 0,787308433 0,000186939 
1252 ENSG00000052850 ALX4 0,787097688 0,007756447 
1253 ENSG00000204054 LINC00963 0,78663617 4,68339E-10 
1254 ENSG00000140525 FANCI 0,786612143 4,25279E-33 
1255 ENSG00000080298 RFX3 0,78634004 1,2017E-13 
1256 ENSG00000168610 STAT3 0,786234296 6,09306E-37 
1257 ENSG00000003989 SLC7A2 0,786123265 1,42266E-06 
1258 ENSG00000163040 CCDC74A 0,786121636 2,64979E-07 
1259 ENSG00000151746 BICD1 0,78572699 1,89306E-18 
1260 ENSG00000177697 CD151 0,785375017 1,49938E-36 
1261 ENSG00000119669 IRF2BPL 0,785353663 4,00054E-22 
1262 ENSG00000142173 COL6A2 0,785304729 1,78306E-29 
1263 ENSG00000135063 FAM189A2 0,784750803 0,003814921 
1264 ENSG00000066027 PPP2R5A 0,78418488 1,50571E-13 
1265 ENSG00000135144 DTX1 0,784002102 5,4039E-08 
1266 ENSG00000196914 ARHGEF12 0,783464775 3,74646E-28 
1267 ENSG00000051128 HOMER3 0,782390462 2,55667E-11 
1268 ENSG00000152767 FARP1 0,781256061 5,00094E-35 
1269 ENSG00000063660 GPC1 0,781227737 3,68108E-48 
1270 ENSG00000182957 SPATA13 0,780897367 1,01979E-14 
1271 ENSG00000255471 AP001528.2 0,780274689 0,040157525 
1272 ENSG00000188158 NHS 0,779618442 1,41324E-06 
1273 ENSG00000117298 ECE1 0,778730749 3,28826E-24 
1274 ENSG00000133678 TMEM254 0,777894939 4,08966E-10 
1275 ENSG00000122642 FKBP9 0,77712885 9,09105E-30 
1276 ENSG00000157796 WDR19 0,776923555 2,94989E-12 
1277 ENSG00000079156 OSBPL6 0,776631201 9,13833E-21 
1278 ENSG00000168785 TSPAN5 0,776525083 9,13239E-18 
1279 ENSG00000150938 CRIM1 0,776457708 5,10003E-23 
1280 ENSG00000196154 S100A4 0,775817996 0,001868798 
1281 ENSG00000122694 GLIPR2 0,775535607 3,43527E-19 
1282 ENSG00000249550 LINC01234 0,775372691 0,00187505 
1283 ENSG00000149115 TNKS1BP1 0,774531716 6,4595E-22 
1284 ENSG00000115425 PECR 0,773137442 4,24658E-06 
1285 ENSG00000115504 EHBP1 0,772756212 5,04453E-19 
1286 ENSG00000128833 MYO5C 0,772653344 2,31049E-09 
1287 ENSG00000237493 AC034102.1 0,771536075 0,00111908 
1288 ENSG00000106367 AP1S1 0,771511849 1,72651E-18 
1289 ENSG00000137936 BCAR3 0,771179454 0,000229297 
1290 ENSG00000095564 BTAF1 0,770653273 1,39179E-36 
1291 ENSG00000034677 RNF19A 0,770184871 4,80735E-28 
1292 ENSG00000144061 NPHP1 0,770156374 1,30141E-05 
1293 ENSG00000261559 FSCN1P1 0,768851245 0,001882627 
1294 ENSG00000072310 SREBF1 0,767766139 2,0099E-23 
1295 ENSG00000099330 OCEL1 0,766998541 4,40697E-06 
1296 ENSG00000153707 PTPRD 0,765608485 1,41834E-19 
1297 ENSG00000110619 CARS 0,765313868 1,73068E-20 
1298 ENSG00000197121 PGAP1 0,763677094 2,42989E-24 
1299 ENSG00000100889 PCK2 0,763377109 5,20119E-05 
1300 ENSG00000100564 PIGH 0,763285951 0,000145775 
1301 ENSG00000178662 CSRNP3 0,762714036 0,004234604 
1302 ENSG00000150893 FREM2 0,762559049 3,56774E-05 
1303 ENSG00000223745 CCDC18-AS1 0,761291745 5,54667E-07 
1304 ENSG00000187239 FNBP1 0,760743067 1,82933E-20 
1305 ENSG00000197324 LRP10 0,758294511 3,67056E-21 
1306 ENSG00000117016 RIMS3 0,757511126 3,32142E-08 
1307 ENSG00000197444 OGDHL 0,75615376 0,000397639 
1308 ENSG00000251562 MALAT1 0,756097743 5,1963E-34 
1309 ENSG00000149761 NUDT22 0,755766076 2,69483E-05 
1310 ENSG00000163251 FZD5 0,75447472 6,73338E-09 
1311 ENSG00000099204 ABLIM1 0,752333605 2,39917E-08 
1312 ENSG00000089123 TASP1 0,751927753 0,002657769 
1313 ENSG00000124216 SNAI1 0,751846588 0,001396858 
1314 ENSG00000167595 PROSER3 0,751817985 6,7729E-07 
1315 ENSG00000143891 GALM 0,751606816 0,006336398 
1316 ENSG00000197948 FCHSD1 0,751245364 0,00527693 
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1317 ENSG00000114251 WNT5A 0,751203888 2,2047E-05 
1318 ENSG00000166153 DEPDC4 0,751191939 0,04480256 
1319 ENSG00000188735 TMEM120B 0,750913584 3,41739E-07 
1320 ENSG00000162772 ATF3 0,750888756 5,4431E-06 
1321 ENSG00000007516 BAIAP3 0,750327157 4,73267E-05 
1322 ENSG00000116885 OSCP1 0,749866219 0,000148238 
1323 ENSG00000166924 NYAP1 0,749787898 0,005121417 
1324 ENSG00000171914 TLN2 0,749596456 1,27748E-13 
1325 ENSG00000113555 PCDH12 0,749111147 0,02070334 
1326 ENSG00000249087 ZNF436-AS1 0,748810439 2,31095E-05 
1327 ENSG00000112972 HMGCS1 0,748722729 7,01978E-44 
1328 ENSG00000172380 GNG12 0,74865427 3,14333E-37 
1329 ENSG00000100647 SUSD6 0,748637416 8,95337E-13 
1330 ENSG00000106100 NOD1 0,748509909 4,8002E-05 
1331 ENSG00000130813 C19orf66 0,747815807 8,35745E-08 
1332 ENSG00000173221 GLRX 0,746331461 0,00355123 
1333 ENSG00000198586 TLK1 0,746165862 3,00685E-17 
1334 ENSG00000152763 WDR78 0,746139999 0,017309416 
1335 ENSG00000008300 CELSR3 0,745793293 9,67184E-20 
1336 ENSG00000174915 PTDSS2 0,744054726 1,73875E-14 
1337 ENSG00000239713 APOBEC3G 0,74334043 4,50283E-05 
1338 ENSG00000103942 HOMER2 0,74286973 1,27475E-07 
1339 ENSG00000107731 UNC5B 0,742240867 0,000317972 
1340 ENSG00000135362 PRR5L 0,742085279 1,08838E-07 
1341 ENSG00000228878 SEPT7-AS1 0,741802496 0,001528123 
1342 ENSG00000257704 INAFM1 0,741085501 0,000112356 
1343 ENSG00000088826 SMOX 0,741034426 8,69149E-14 
1344 ENSG00000196739 COL27A1 0,74096062 9,02591E-15 
1345 ENSG00000142082 SIRT3 0,740504342 2,63211E-10 
1346 ENSG00000159388 BTG2 0,740429668 7,91075E-26 
1347 ENSG00000069020 MAST4 0,739840292 0,000491082 
1348 ENSG00000112769 LAMA4 0,739406318 3,35682E-40 
1349 ENSG00000185033 SEMA4B 0,739025518 3,25484E-17 
1350 ENSG00000197558 SSPO 0,737819293 0,037396452 
1351 ENSG00000163001 CFAP36 0,737571068 1,14268E-13 
1352 ENSG00000068323 TFE3 0,737363908 5,54015E-22 
1353 ENSG00000133195 SLC39A11 0,736806879 1,09567E-05 
1354 ENSG00000163931 TKT 0,736086133 4,48635E-44 
1355 ENSG00000261934 PCDHGA9 0,735113988 0,008223539 
1356 ENSG00000073670 ADAM11 0,734915843 6,75282E-06 
1357 ENSG00000136002 ARHGEF4 0,734374171 2,84754E-14 
1358 ENSG00000015475 BID 0,73427975 9,64257E-19 
1359 ENSG00000269069 AC007842.1 0,734223131 0,031480098 
1360 ENSG00000124785 NRN1 0,733654499 5,36014E-21 
1361 ENSG00000125844 RRBP1 0,73364273 2,32749E-25 
1362 ENSG00000184319 RPL23AP82 0,733091491 1,19012E-05 
1363 ENSG00000120332 TNN 0,731898479 0,036670684 
1364 ENSG00000133627 ACTR3B 0,731033742 8,34683E-06 
1365 ENSG00000139190 VAMP1 0,73007229 1,88829E-09 
1366 ENSG00000157103 SLC6A1 0,729313126 1,29436E-05 
1367 ENSG00000158715 SLC45A3 0,729010049 0,04153032 
1368 ENSG00000116514 RNF19B 0,728873369 2,54476E-07 
1369 ENSG00000087842 PIR 0,728848426 2,38832E-20 
1370 ENSG00000198961 PJA2 0,728427577 5,91541E-36 
1371 ENSG00000168067 MAP4K2 0,728286063 5,49115E-07 
1372 ENSG00000172890 NADSYN1 0,728136483 6,79309E-17 
1373 ENSG00000243199 AC115223.1 0,727351818 4,21628E-05 
1374 ENSG00000182132 KCNIP1 0,726830701 1,69779E-06 
1375 ENSG00000179295 PTPN11 0,726744953 1,19582E-33 
1376 ENSG00000155980 KIF5A 0,725592178 3,2466E-16 
1377 ENSG00000157514 TSC22D3 0,725137391 7,36187E-05 
1378 ENSG00000178234 GALNT11 0,725051828 9,78603E-13 
1379 ENSG00000185483 ROR1 0,725013347 0,028629787 
1380 ENSG00000179304 FAM156B 0,724353989 0,007718719 
1381 ENSG00000220848 RPS18P9 0,724010712 0,023303445 
1382 ENSG00000124313 IQSEC2 0,723699521 1,24078E-05 
1383 ENSG00000171159 C9orf16 0,722700482 1,52233E-19 
1384 ENSG00000177694 NAALADL2 0,721203314 0,009907698 
1385 ENSG00000109339 MAPK10 0,719870307 2,83026E-05 
1386 ENSG00000224183 SDHDP6 0,719830297 0,01686923 
1387 ENSG00000159842 ABR 0,718834983 3,95543E-21 
1388 ENSG00000133639 BTG1 0,718104833 7,1925E-26 
1389 ENSG00000069399 BCL3 0,717896891 0,000277985 
1390 ENSG00000125510 OPRL1 0,71745478 0,04207008 
1391 ENSG00000180739 S1PR5 0,717336395 0,002264493 
1392 ENSG00000164953 TMEM67 0,71690431 5,29405E-05 
1393 ENSG00000119408 NEK6 0,715493466 2,40206E-30 
1394 ENSG00000106992 AK1 0,715321344 0,011387651 
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1395 ENSG00000136425 CIB2 0,714136494 1,0143E-06 
1396 ENSG00000109736 MFSD10 0,712488967 3,26554E-11 
1397 ENSG00000162004 CCDC78 0,712327476 3,24285E-05 
1398 ENSG00000091129 NRCAM 0,711912951 6,78256E-22 
1399 ENSG00000221968 FADS3 0,711738144 1,01302E-13 
1400 ENSG00000177640 CASC2 0,711260875 0,047900661 
1401 ENSG00000145715 RASA1 0,709119932 8,45815E-16 
1402 ENSG00000107819 SFXN3 0,708829386 1,17862E-13 
1403 ENSG00000184056 VPS33B 0,708484639 4,62982E-07 
1404 ENSG00000218418 AL591135.1 0,707975401 0,018373116 
1405 ENSG00000139192 TAPBPL 0,7077751 0,000263398 
1406 ENSG00000006118 TMEM132A 0,707149474 2,11691E-29 
1407 ENSG00000102007 PLP2 0,706180081 7,0043E-07 
1408 ENSG00000139645 ANKRD52 0,705758573 2,66637E-22 
1409 ENSG00000169641 LUZP1 0,705380136 1,56027E-14 
1410 ENSG00000176155 CCDC57 0,704766885 3,34206E-11 
1411 ENSG00000230383 AC009245.1 0,702909074 0,002959458 
1412 ENSG00000082146 STRADB 0,702470609 9,01907E-15 
1413 ENSG00000146001 PCDHB18P 0,701905239 0,000730588 
1414 ENSG00000130304 SLC27A1 0,700909908 3,28995E-25 
1415 ENSG00000196182 STK40 0,7006976 1,4708E-18 
1416 ENSG00000197586 ENTPD6 0,700550419 2,01005E-16 
1417 ENSG00000148339 SLC25A25 0,700444512 1,6591E-17 
1418 ENSG00000254682 AP002387.1 0,700339471 9,10317E-05 
1419 ENSG00000181754 AMIGO1 0,699840117 0,000231946 
1420 ENSG00000185386 MAPK11 0,699736364 3,35326E-13 
1421 ENSG00000100344 PNPLA3 0,699656098 4,2367E-06 
1422 ENSG00000116157 GPX7 0,699333001 0,010492928 
1423 ENSG00000118707 TGIF2 0,698651248 0,000203728 
1424 ENSG00000171055 FEZ2 0,698519917 6,70136E-15 
1425 ENSG00000177614 PGBD5 0,697719364 7,09067E-07 
1426 ENSG00000084710 EFR3B 0,697510101 3,53672E-07 
1427 ENSG00000173846 PLK3 0,696762353 0,00037398 
1428 ENSG00000013364 MVP 0,696519008 3,4013E-08 
1429 ENSG00000143801 PSEN2 0,696142598 3,56343E-05 
1430 ENSG00000117280 RAB29 0,694704085 4,08261E-11 
1431 ENSG00000140022 STON2 0,694164709 4,62881E-05 
1432 ENSG00000125520 SLC2A4RG 0,694159774 1,2114E-12 
1433 ENSG00000198435 NRARP 0,693716561 0,002959458 
1434 ENSG00000167778 SPRYD3 0,69343939 1,20509E-10 
1435 ENSG00000205352 PRR13 0,692915643 3,64798E-09 
1436 ENSG00000162542 TMCO4 0,69285514 0,048614427 
1437 ENSG00000168389 MFSD2A 0,692736899 0,001186613 
1438 ENSG00000185008 ROBO2 0,692160744 7,71176E-23 
1439 ENSG00000143061 IGSF3 0,692085762 3,96617E-17 
1440 ENSG00000116406 EDEM3 0,692068845 3,00138E-17 
1441 ENSG00000186815 TPCN1 0,692039744 2,57807E-07 
1442 ENSG00000128294 TPST2 0,692034174 1,23662E-11 
1443 ENSG00000100612 DHRS7 0,690446346 1,47966E-11 
1444 ENSG00000130589 HELZ2 0,690116525 6,59622E-10 
1445 ENSG00000269958 AL049840.4 0,689922903 0,000797995 
1446 ENSG00000099999 RNF215 0,689395145 4,22477E-09 
1447 ENSG00000182095 TNRC18 0,689382167 3,93637E-23 
1448 ENSG00000060138 YBX3 0,688841211 9,2238E-24 
1449 ENSG00000058799 YIPF1 0,688748637 4,89951E-08 
1450 ENSG00000161714 PLCD3 0,688552296 4,472E-19 
1451 ENSG00000024422 EHD2 0,687926801 1,06011E-24 
1452 ENSG00000173295 FAM86B3P 0,687765734 0,024007574 
1453 ENSG00000072110 ACTN1 0,686920499 6,70241E-18 
1454 ENSG00000174943 KCTD13 0,686001748 2,75358E-06 
1455 ENSG00000140853 NLRC5 0,685560316 1,01298E-06 
1456 ENSG00000185043 CIB1 0,684733112 8,08578E-11 
1457 ENSG00000026652 AGPAT4 0,684096712 1,53087E-17 
1458 ENSG00000143590 EFNA3 0,68107109 0,015861904 
1459 ENSG00000114423 CBLB 0,680877908 3,03455E-13 
1460 ENSG00000128394 APOBEC3F 0,680579971 0,008577461 
1461 ENSG00000168890 TMEM150A 0,680447778 0,000298977 
1462 ENSG00000134253 TRIM45 0,679989445 5,36267E-09 
1463 ENSG00000162433 AK4 0,679289183 7,81672E-10 
1464 ENSG00000131711 MAP1B 0,67913779 1,99228E-28 
1465 ENSG00000171552 BCL2L1 0,677933834 4,33328E-16 
1466 ENSG00000105643 ARRDC2 0,677688761 0,00103502 
1467 ENSG00000178607 ERN1 0,677196791 0,000164173 
1468 ENSG00000256185 AC055720.2 0,676906231 0,036898581 
1469 ENSG00000099250 NRP1 0,676725282 3,68679E-05 
1470 ENSG00000197019 SERTAD1 0,676015931 6,84058E-06 
1471 ENSG00000164442 CITED2 0,67498157 1,27029E-09 
1472 ENSG00000128683 GAD1 0,674964111 9,80956E-19 
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1473 ENSG00000163879 DNALI1 0,673765431 1,27883E-11 
1474 ENSG00000197077 KIAA1671 0,673276084 4,47553E-07 
1475 ENSG00000130475 FCHO1 0,672107225 0,001376291 
1476 ENSG00000173706 HEG1 0,671717338 1,3366E-10 
1477 ENSG00000104936 DMPK 0,671401453 2,28637E-14 
1478 ENSG00000120658 ENOX1 0,671186679 0,00099389 
1479 ENSG00000151176 PLBD2 0,670616761 2,42372E-09 
1480 ENSG00000162923 WDR26 0,670311564 4,86546E-22 
1481 ENSG00000146006 LRRTM2 0,670251174 3,5928E-09 
1482 ENSG00000162576 MXRA8 0,669794534 0,045350249 
1483 ENSG00000173812 EIF1 0,669500361 3,81931E-32 
1484 ENSG00000123992 DNPEP 0,669481359 3,5157E-14 
1485 ENSG00000203943 SAMD13 0,668918459 0,049246501 
1486 ENSG00000187164 SHTN1 0,668768008 3,29548E-11 
1487 ENSG00000173153 ESRRA 0,668310007 8,35745E-08 
1488 ENSG00000170145 SIK2 0,668168872 1,86586E-14 
1489 ENSG00000184640 SEPT9 0,667416146 1,19616E-34 
1490 ENSG00000173227 SYT12 0,667093438 6,01718E-05 
1491 ENSG00000169519 METTL15 0,66634741 2,01656E-05 
1492 ENSG00000119922 IFIT2 0,666329052 1,14684E-06 
1493 ENSG00000142657 PGD 0,66599907 1,66563E-32 
1494 ENSG00000100095 SEZ6L 0,665249736 2,62169E-26 
1495 ENSG00000005238 FAM214B 0,664815978 1,10888E-06 
1496 ENSG00000132535 DLG4 0,663877703 9,1459E-12 
1497 ENSG00000099957 P2RX6 0,662612582 1,77822E-05 
1498 ENSG00000169871 TRIM56 0,662287829 1,69779E-06 
1499 ENSG00000136444 RSAD1 0,661565092 1,83088E-11 
1500 ENSG00000165323 FAT3 0,661225197 4,2872E-17 
1501 ENSG00000099326 MZF1 0,661152234 2,25933E-11 
1502 ENSG00000049759 NEDD4L 0,661095522 4,902E-12 
1503 ENSG00000168310 IRF2 0,661031995 1,07153E-08 
1504 ENSG00000185880 TRIM69 0,660324525 2,10624E-11 
1505 ENSG00000023171 GRAMD1B 0,658907022 1,62833E-05 
1506 ENSG00000184792 OSBP2 0,658490698 3,82639E-05 
1507 ENSG00000225177 AL590617.2 0,657255394 0,001122531 
1508 ENSG00000110013 SIAE 0,654608221 6,79473E-10 
1509 ENSG00000182405 PGBD4 0,65410755 0,005193943 
1510 ENSG00000008277 ADAM22 0,653832496 6,47327E-15 
1511 ENSG00000143545 RAB13 0,653148129 3,64329E-21 
1512 ENSG00000166411 IDH3A 0,652827769 1,68628E-07 
1513 ENSG00000152894 PTPRK 0,652022809 2,7045E-16 
1514 ENSG00000183579 ZNRF3 0,651104949 6,89616E-11 
1515 ENSG00000088836 SLC4A11 0,650972111 0,00103468 
1516 ENSG00000050130 JKAMP 0,650901381 5,80206E-10 
1517 ENSG00000184216 IRAK1 0,650292492 2,42558E-23 
1518 ENSG00000126705 AHDC1 0,649972975 1,6314E-11 
1519 ENSG00000170448 NFXL1 0,649930887 7,37147E-05 
1520 ENSG00000182168 UNC5C 0,649577713 7,20573E-11 
1521 ENSG00000176845 METRNL 0,649505647 3,02126E-06 
1522 ENSG00000164951 PDP1 0,649484534 1,87553E-08 
1523 ENSG00000128581 IFT22 0,648632563 1,33332E-08 
1524 ENSG00000005379 TSPOAP1 0,64852545 0,040336062 
1525 ENSG00000049130 KITLG 0,648513411 0,000101102 
1526 ENSG00000137486 ARRB1 0,648367576 0,001307352 
1527 ENSG00000165338 HECTD2 0,648345151 5,52254E-07 
1528 ENSG00000240036 AC104563.1 0,646791223 0,004791575 
1529 ENSG00000120068 HOXB8 0,646648538 0,004248784 
1530 ENSG00000143641 GALNT2 0,646534028 3,26445E-22 
1531 ENSG00000184465 WDR27 0,64621893 2,53829E-09 
1532 ENSG00000155542 SETD9 0,645025495 0,000124073 
1533 ENSG00000176826 FKBP9P1 0,644344635 0,01916257 
1534 ENSG00000160172 FAM86C2P 0,644284926 0,016023147 
1535 ENSG00000131370 SH3BP5 0,644072157 0,018866879 
1536 ENSG00000121039 RDH10 0,64404941 5,29751E-05 
1537 ENSG00000125746 EML2 0,643592506 1,36628E-05 
1538 ENSG00000074416 MGLL 0,64308183 1,04004E-19 
1539 ENSG00000035687 ADSS 0,642841889 4,51788E-10 
1540 ENSG00000204634 TBC1D8 0,642520074 4,39637E-06 
1541 ENSG00000159208 CIART 0,640146538 1,27149E-05 
1542 ENSG00000167037 SGSM1 0,640047585 0,001029086 
1543 ENSG00000167733 HSD11B1L 0,639281716 7,09598E-06 
1544 ENSG00000185621 LMLN 0,638767063 2,90371E-05 
1545 ENSG00000143995 MEIS1 0,638761087 2,32851E-07 
1546 ENSG00000004660 CAMKK1 0,638543912 0,028499031 
1547 ENSG00000133135 RNF128 0,638400512 8,35425E-09 
1548 ENSG00000152495 CAMK4 0,637912374 0,017513699 
1549 ENSG00000104687 GSR 0,637814176 5,58027E-14 
1550 ENSG00000160446 ZDHHC12 0,637696603 2,37068E-06 
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1551 ENSG00000168275 COA6 0,637669231 4,09782E-05 
1552 ENSG00000150977 RILPL2 0,637028536 0,000244679 
1553 ENSG00000179611 DGKZP1 0,636304712 0,000277616 
1554 ENSG00000133321 RARRES3 0,636171011 0,027299501 
1555 ENSG00000181004 BBS12 0,636108645 0,022516083 
1556 ENSG00000146776 ATXN7L1 0,63567838 0,007831875 
1557 ENSG00000102466 FGF14 0,635485304 0,002023282 
1558 ENSG00000255284 AP006621.3 0,635463104 0,016896682 
1559 ENSG00000006282 SPATA20 0,63432464 1,99669E-12 
1560 ENSG00000011028 MRC2 0,634043746 4,7165E-22 
1561 ENSG00000105855 ITGB8 0,633706702 4,69693E-19 
1562 ENSG00000124275 MTRR 0,633686923 1,42742E-11 
1563 ENSG00000003402 CFLAR 0,633251924 2,85486E-09 
1564 ENSG00000126777 KTN1 0,632802092 1,33468E-21 
1565 ENSG00000139146 FAM60A 0,632586491 2,51724E-09 
1566 ENSG00000084444 FAM234B 0,632324237 7,13533E-08 
1567 ENSG00000235750 KIAA0040 0,631946805 0,0004871 
1568 ENSG00000072195 SPEG 0,631738842 3,89047E-15 
1569 ENSG00000212694 LINC01089 0,631024268 0,003125776 
1570 ENSG00000233639 LINC01158 0,630901287 2,18028E-08 
1571 ENSG00000138411 HECW2 0,629734982 0,017552299 
1572 ENSG00000131873 CHSY1 0,628870881 1,7476E-12 
1573 ENSG00000174206 C12orf66 0,628754956 0,001520124 
1574 ENSG00000047230 CTPS2 0,627793674 1,86651E-07 
1575 ENSG00000161091 MFSD12 0,627779109 1,17281E-11 
1576 ENSG00000105696 TMEM59L 0,627728407 1,78888E-08 
1577 ENSG00000135926 TMBIM1 0,626672264 4,7171E-06 
1578 ENSG00000196236 XPNPEP3 0,626225131 2,5098E-08 
1579 ENSG00000157064 NMNAT2 0,625886955 0,03010122 
1580 ENSG00000229117 RPL41 0,625381957 1,10267E-16 
1581 ENSG00000189157 FAM47E 0,625214024 0,009207402 
1582 ENSG00000105953 OGDH 0,624799434 7,24369E-19 
1583 ENSG00000214455 RCN1P2 0,623777388 4,01827E-05 
1584 ENSG00000160991 ORAI2 0,622635971 2,92215E-13 
1585 ENSG00000025434 NR1H3 0,622494082 0,000386509 
1586 ENSG00000167371 PRRT2 0,621252867 2,15649E-06 
1587 ENSG00000099331 MYO9B 0,621113858 2,56429E-22 
1588 ENSG00000166986 MARS 0,620426657 3,36477E-21 
1589 ENSG00000235552 AP005202.1 0,620209683 1,31374E-11 
1590 ENSG00000163449 TMEM169 0,62008061 2,51403E-09 
1591 ENSG00000135452 TSPAN31 0,619998156 6,3016E-07 
1592 ENSG00000126456 IRF3 0,619129856 1,05598E-09 
1593 ENSG00000234741 GAS5 0,619016127 4,30455E-15 
1594 ENSG00000100211 CBY1 0,618890193 0,000498836 
1595 ENSG00000123600 METTL8 0,61804787 1,92926E-05 
1596 ENSG00000196411 EPHB4 0,617995897 6,81546E-11 
1597 ENSG00000105419 MEIS3 0,617912328 1,63516E-17 
1598 ENSG00000126391 FRMD8 0,617872697 5,244E-18 
1599 ENSG00000196839 ADA 0,617764063 1,78303E-06 
1600 ENSG00000131188 PRR7 0,616762509 5,89063E-05 
1601 ENSG00000229891 LINC01315 0,61674999 0,010960927 
1602 ENSG00000134324 LPIN1 0,616591619 4,10848E-16 
1603 ENSG00000130363 RSPH3 0,616101728 0,000451765 
1604 ENSG00000131408 NR1H2 0,615879209 4,78079E-14 
1605 ENSG00000106333 PCOLCE 0,615640498 0,029971824 
1606 ENSG00000107551 RASSF4 0,615355771 0,001819865 
1607 ENSG00000131015 ULBP2 0,615330692 0,036838424 
1608 ENSG00000182902 SLC25A18 0,61522657 0,020092527 
1609 ENSG00000135931 ARMC9 0,615141533 7,99946E-06 
1610 ENSG00000182154 MRPL41 0,61450482 9,76608E-05 
1611 ENSG00000101986 ABCD1 0,614065147 5,85679E-05 
1612 ENSG00000115183 TANC1 0,61388628 1,92431E-21 
1613 ENSG00000179912 R3HDM2 0,613480048 3,35736E-09 
1614 ENSG00000183150 GPR19 0,613448374 0,000647602 
1615 ENSG00000144791 LIMD1 0,613138594 1,04819E-07 
1616 ENSG00000164088 PPM1M 0,61295811 3,39503E-05 
1617 ENSG00000135414 GDF11 0,612802691 2,21687E-16 
1618 ENSG00000232389 AL583856.1 0,612778826 0,003157117 
1619 ENSG00000127838 PNKD 0,611406482 2,04296E-11 
1620 ENSG00000170581 STAT2 0,611247174 9,35796E-19 
1621 ENSG00000139289 PHLDA1 0,610642842 8,12041E-30 
1622 ENSG00000198920 KIAA0753 0,610329713 1,53147E-07 
1623 ENSG00000130023 ERMARD 0,609781975 0,000139672 
1624 ENSG00000153208 MERTK 0,609423137 3,67305E-06 
1625 ENSG00000235162 C12orf75 0,609216762 3,38163E-08 
1626 ENSG00000157881 PANK4 0,609119825 1,26415E-09 
1627 ENSG00000232533 AC093673.1 0,60908793 0,000585288 




1629 ENSG00000119650 IFT43 0,608908818 0,000259173 
1630 ENSG00000205643 CDPF1 0,607888274 0,000157838 
1631 ENSG00000187815 ZFP69 0,607601572 0,006029625 
1632 ENSG00000121897 LIAS 0,606775945 0,013775979 
1633 ENSG00000104518 GSDMD 0,605751744 0,01974714 
1634 ENSG00000234608 MAPKAPK5-AS1 0,605218785 0,011624842 
1635 ENSG00000204685 STARD7-AS1 0,604955992 0,043926946 
1636 ENSG00000131697 NPHP4 0,604860227 3,79427E-06 
1637 ENSG00000134333 LDHA 0,604271283 1,47974E-24 
1638 ENSG00000145217 SLC26A1 0,604224053 0,020043752 
1639 ENSG00000027697 IFNGR1 0,604211244 8,82248E-08 
1640 ENSG00000087903 RFX2 0,603792708 2,32716E-06 
1641 ENSG00000143324 XPR1 0,603709787 1,18954E-11 
1642 ENSG00000219626 FAM228B 0,603697294 0,005896054 
1643 ENSG00000188010 MORN2 0,603513838 5,29221E-05 
1644 ENSG00000223825 DAZAP2P1 0,60225346 0,02940066 
1645 ENSG00000196656 AC004057.1 0,602010564 0,00017732 
1646 ENSG00000169439 SDC2 0,600632144 1,40526E-12 
1647 ENSG00000123815 COQ8B 0,600612718 2,0154E-14 
1648 ENSG00000136114 THSD1 0,600253813 2,29329E-08 
1649 ENSG00000099290 WASHC2A 0,600246592 0,002417098 





Table 13. List of downregulated gene expression levels (FPKM; >0.6 log2-fold change, FDR<0.01) 
in U3047MG naïve), ciliated GSCs (U3047MG NEK2-KD) cells. 
Sr.No Gene Gene names log2FoldChange  Pvalue 
1 ENSG00000144230 GPR17 -8,039437989 5,9258E-236 
2 ENSG00000078596 ITM2A -7,96985221 4,7233E-180 
3 ENSG00000114279 FGF12 -7,520108233 3,2679E-274 
4 ENSG00000100146 SOX10 -7,481328633 0 
5 ENSG00000146250 PRSS35 -7,251321342 8,0122E-122 
6 ENSG00000148123 PLPPR1 -7,246471645 1,221E-258 
7 ENSG00000175356 SCUBE2 -6,780567363 5,8031E-232 
8 ENSG00000134121 CHL1 -6,760962734 2,6302E-190 
9 ENSG00000158887 MPZ -6,40530121 0 
10 ENSG00000078725 BRINP1 -6,357409534 2,2383E-274 
11 ENSG00000072163 LIMS2 -5,83276228 1,0989E-183 
12 ENSG00000151892 GFRA1 -5,794326359 6,3983E-152 
13 ENSG00000136574 GATA4 -5,766016195 4,4439E-109 
14 ENSG00000163453 IGFBP7 -5,505430534 1,8935E-220 
15 ENSG00000120675 DNAJC15 -5,502092519 2,61697E-85 
16 ENSG00000132329 RAMP1 -5,474184732 0 
17 ENSG00000126861 OMG -5,369447549 0 
18 ENSG00000134184 GSTM1 -5,358941952 9,27724E-82 
19 ENSG00000018236 CNTN1 -5,353850875 0 
20 ENSG00000112280 COL9A1 -5,242521422 0 
21 ENSG00000128242 GAL3ST1 -5,196959503 2,0198E-110 
22 ENSG00000227051 C14orf132 -5,16133079 1,6299E-277 
23 ENSG00000130287 NCAN -5,145009178 0 
24 ENSG00000101203 COL20A1 -5,065865942 0 
25 ENSG00000101695 RNF125 -5,063432816 6,1807E-126 
26 ENSG00000101445 PPP1R16B -5,046959014 3,3882E-139 
27 ENSG00000180787 ZFP3 -5,046714725 3,14294E-97 
28 ENSG00000164176 EDIL3 -5,032304208 0 
29 ENSG00000170011 MYRIP -4,979734623 7,7539E-55 
30 ENSG00000102313 ITIH6 -4,87405976 1,0008E-278 
31 ENSG00000197448 GSTK1 -4,854588382 4,1445E-230 
32 ENSG00000110090 CPT1A -4,839770982 1,84526E-98 
33 ENSG00000197971 MBP -4,824502299 4,40892E-71 
34 ENSG00000122012 SV2C -4,798767138 4,58443E-39 
35 ENSG00000126860 EVI2A -4,787288789 6,07885E-39 
36 ENSG00000101311 FERMT1 -4,768140717 0 
37 ENSG00000196218 RYR1 -4,671503299 8,12621E-50 
38 ENSG00000248184 LINC02283 -4,566857829 9,37288E-89 
39 ENSG00000107807 TLX1 -4,563055892 7,34764E-30 
40 ENSG00000110455 ACCS -4,530826392 1,04738E-41 
41 ENSG00000172349 IL16 -4,525882069 2,89912E-47 
42 ENSG00000157445 CACNA2D3 -4,491087072 7,23341E-34 
43 ENSG00000168309 FAM107A -4,4783084 1,6717E-100 
44 ENSG00000166582 CENPV -4,468670495 0 
45 ENSG00000109220 CHIC2 -4,430498686 0 
46 ENSG00000225127 LINC00237 -4,332391656 7,11028E-24 
47 ENSG00000130762 ARHGEF16 -4,28456177 1,28614E-51 
48 ENSG00000169129 AFAP1L2 -4,232133669 8,9304E-130 
49 ENSG00000003137 CYP26B1 -4,21351088 3,91067E-59 
50 ENSG00000106688 SLC1A1 -4,188323627 0 
51 ENSG00000162670 BRINP3 -4,130973686 1,28565E-94 
52 ENSG00000183715 OPCML -4,125076044 0 
53 ENSG00000187955 COL14A1 -4,111903354 5,41695E-35 
54 ENSG00000261377 PDCD6IPP2 -4,089150458 4,65122E-30 
55 ENSG00000137558 PI15 -4,028665098 4,94074E-27 
56 ENSG00000134864 GGACT -4,026112875 2,22877E-22 
57 ENSG00000156535 CD109 -3,997969818 2,54906E-92 
58 ENSG00000162998 FRZB -3,993243672 1,44022E-40 
59 ENSG00000228203 RNF144A-AS1 -3,956922978 6,60208E-25 
60 ENSG00000112796 ENPP5 -3,954005801 4,18772E-36 
61 ENSG00000171885 AQP4 -3,951673155 0 
62 ENSG00000100441 KHNYN -3,948628567 1,01472E-64 
63 ENSG00000204241 AP000911.1 -3,862532743 2,86878E-25 
64 ENSG00000165757 KIAA1462 -3,814305302 2,2197E-195 
65 ENSG00000167755 KLK6 -3,804063685 1,78517E-26 
66 ENSG00000166897 ELFN2 -3,755315995 0 
67 ENSG00000144668 ITGA9 -3,750649223 2,0864E-190 
68 ENSG00000109610 SOD3 -3,727763894 2,13471E-77 
69 ENSG00000163864 NMNAT3 -3,726838735 3,88943E-40 
70 ENSG00000143458 GABPB2 -3,726373003 8,02551E-30 
71 ENSG00000225614 ZNF469 -3,712103039 1,10545E-62 
72 ENSG00000187720 THSD4 -3,656399494 1,04529E-40 
73 ENSG00000173210 ABLIM3 -3,656370041 4,35282E-52 
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74 ENSG00000187902 SHISA7 -3,650018774 5,60706E-33 
75 ENSG00000116833 NR5A2 -3,647153064 4,352E-24 
76 ENSG00000170091 HMP19 -3,616790489 1,80114E-34 
77 ENSG00000184961 RPL7AP49 -3,616367323 8,57731E-27 
78 ENSG00000103316 CRYM -3,609870107 1,38527E-25 
79 ENSG00000113805 CNTN3 -3,607247578 3,56628E-45 
80 ENSG00000255442 AC109635.5 -3,566458006 1,1088E-25 
81 ENSG00000060718 COL11A1 -3,534235195 0 
82 ENSG00000184785 SMIM10 -3,520421068 2,10994E-16 
83 ENSG00000153902 LGI4 -3,51232754 3,15534E-17 
84 ENSG00000171840 NINJ2 -3,504266385 7,03623E-41 
85 ENSG00000103811 CTSH -3,489508845 5,69629E-62 
86 ENSG00000221946 FXYD7 -3,4807093 5,42584E-18 
87 ENSG00000049540 ELN -3,479404015 0 
88 ENSG00000187398 LUZP2 -3,47747786 1,1191E-112 
89 ENSG00000177570 SAMD12 -3,47563295 3,50821E-14 
90 ENSG00000163235 TGFA -3,469717146 2,0147E-201 
91 ENSG00000186369 LINC00643 -3,463405987 2,98305E-50 
92 ENSG00000077713 SLC25A43 -3,453521637 5,8648E-29 
93 ENSG00000101204 CHRNA4 -3,452433949 4,747E-24 
94 ENSG00000107249 GLIS3 -3,448146504 3,8738E-102 
95 ENSG00000142449 FBN3 -3,436752085 2,74944E-31 
96 ENSG00000117154 IGSF21 -3,424787741 1,93201E-29 
97 ENSG00000204099 NEU4 -3,406767899 1,42759E-71 
98 ENSG00000166091 CMTM5 -3,399186869 9,3634E-176 
99 ENSG00000109107 ALDOC -3,397663819 1,7575E-233 
100 ENSG00000205730 ITPRIPL2 -3,392936404 2,70296E-54 
101 ENSG00000174607 UGT8 -3,388858157 4,7653E-151 
102 ENSG00000152049 KCNE4 -3,323438153 3,22778E-21 
103 ENSG00000151364 KCTD14 -3,315768216 1,47499E-25 
104 ENSG00000151876 FBXO4 -3,313933989 1,44337E-19 
105 ENSG00000082684 SEMA5B -3,296303061 9,7142E-252 
106 ENSG00000197083 ZNF300P1 -3,294065155 2,26565E-14 
107 ENSG00000203805 PLPP4 -3,282412459 4,71634E-65 
108 ENSG00000204291 COL15A1 -3,261996833 0 
109 ENSG00000211445 GPX3 -3,241011427 1,13027E-54 
110 ENSG00000104833 TUBB4A -3,223666104 1,9254E-293 
111 ENSG00000104205 SGK3 -3,223294935 8,05806E-66 
112 ENSG00000168214 RBPJ -3,21327966 0 
113 ENSG00000164932 CTHRC1 -3,174625598 2,4676E-207 
114 ENSG00000181997 AQP7P2 -3,155141307 6,51891E-15 
115 ENSG00000172936 MYD88 -3,140966003 6,82149E-93 
116 ENSG00000254896 OPCML-IT1 -3,135476322 2,13973E-15 
117 ENSG00000181458 TMEM45A -3,12715506 8,26785E-60 
118 ENSG00000115232 ITGA4 -3,120489879 2,62741E-69 
119 ENSG00000178038 ALS2CL -3,10220772 2,18385E-16 
120 ENSG00000272462 U91328.2 -3,090544325 2,45016E-13 
121 ENSG00000170745 KCNS3 -3,070752405 4,90545E-62 
122 ENSG00000186088 GSAP -3,070263056 3,23258E-17 
123 ENSG00000116852 KIF21B -3,059259913 3,5696E-103 
124 ENSG00000158089 GALNT14 -3,055748347 3,56663E-14 
125 ENSG00000145681 HAPLN1 -3,051894425 0 
126 ENSG00000070182 SPTB -3,041465833 9,04188E-44 
127 ENSG00000173705 SUSD5 -3,0385486 1,68157E-46 
128 ENSG00000107518 ATRNL1 -3,011880544 1,6125E-99 
129 ENSG00000198682 PAPSS2 -3,009755411 1,0734E-84 
130 ENSG00000198028 ZNF560 -3,002373748 1,00478E-15 
131 ENSG00000065361 ERBB3 -3,000898729 0 
132 ENSG00000263753 LINC00667 -2,995983633 1,27023E-23 
133 ENSG00000145365 TIFA -2,977322923 8,08491E-13 
134 ENSG00000112559 MDFI -2,975891378 3,38344E-81 
135 ENSG00000197943 PLCG2 -2,971905258 3,95597E-10 
136 ENSG00000262223 AC110285.1 -2,96999267 1,27186E-24 
137 ENSG00000081479 LRP2 -2,967887869 1,20666E-41 
138 ENSG00000174469 CNTNAP2 -2,956436628 2,32802E-36 
139 ENSG00000158008 EXTL1 -2,929240454 1,4451E-104 
140 ENSG00000072182 ASIC4 -2,927041293 4,33488E-46 
141 ENSG00000173482 PTPRM -2,922669511 1,84213E-89 
142 ENSG00000118596 SLC16A7 -2,881642161 3,81087E-11 
143 ENSG00000154856 APCDD1 -2,87786193 1,7391E-274 
144 ENSG00000168542 COL3A1 -2,872472173 1,83144E-21 
145 ENSG00000091490 SEL1L3 -2,853646384 0 
146 ENSG00000231584 FAHD2CP -2,845244478 3,71431E-09 
147 ENSG00000135750 KCNK1 -2,833835105 2,48714E-21 
148 ENSG00000103489 XYLT1 -2,829782321 6,8017E-217 
149 ENSG00000169297 NR0B1 -2,817496117 1,4468E-137 
150 ENSG00000176788 BASP1 -2,805687461 5,87742E-22 
151 ENSG00000169031 COL4A3 -2,788130103 5,19249E-11 
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152 ENSG00000187527 ATP13A5 -2,77615307 2,58589E-11 
153 ENSG00000183960 KCNH8 -2,759741876 4,90578E-35 
154 ENSG00000154764 WNT7A -2,75136343 8,28556E-18 
155 ENSG00000205809 KLRC2 -2,748200139 9,34842E-15 
156 ENSG00000162849 KIF26B -2,746453132 2,43977E-79 
157 ENSG00000169891 REPS2 -2,746075751 4,6043E-135 
158 ENSG00000123243 ITIH5 -2,731733609 1,44115E-26 
159 ENSG00000119673 ACOT2 -2,724595128 3,18627E-18 
160 ENSG00000245060 LINC00847 -2,723045762 6,91699E-10 
161 ENSG00000058866 DGKG -2,718324513 7,56966E-51 
162 ENSG00000241186 TDGF1 -2,710470671 2,41039E-08 
163 ENSG00000001561 ENPP4 -2,706295338 9,21165E-63 
164 ENSG00000226479 TMEM185B -2,686865833 5,34697E-09 
165 ENSG00000164181 ELOVL7 -2,676304226 9,48044E-15 
166 ENSG00000112309 B3GAT2 -2,656519988 4,54246E-16 
167 ENSG00000243902 ELFN2 -2,654502832 2,29357E-09 
168 ENSG00000187837 HIST1H1C -2,652474674 5,0082E-152 
169 ENSG00000106868 SUSD1 -2,632982032 3,34973E-35 
170 ENSG00000198417 MT1F -2,630569348 2,41327E-10 
171 ENSG00000183549 ACSM5 -2,628054183 8,89213E-08 
172 ENSG00000147257 GPC3 -2,622129911 1,17051E-20 
173 ENSG00000171033 PKIA -2,61085775 2,3194E-101 
174 ENSG00000181585 TMIE -2,610246106 2,23713E-23 
175 ENSG00000172348 RCAN2 -2,607007135 3,5027E-16 
176 ENSG00000189058 APOD -2,604236944 0 
177 ENSG00000183508 FAM46C -2,587830673 9,46421E-32 
178 ENSG00000157734 SNX22 -2,579038603 8,3775E-257 
179 ENSG00000138613 APH1B -2,575541455 3,16359E-22 
180 ENSG00000112379 ARFGEF3 -2,574819189 2,7957E-173 
181 ENSG00000255571 MIR9-3HG -2,569654949 4,34276E-33 
182 ENSG00000137809 ITGA11 -2,55530653 2,55243E-41 
183 ENSG00000188452 CERKL -2,547277662 6,89564E-18 
184 ENSG00000120756 PLS1 -2,545494977 1,21725E-29 
185 ENSG00000155974 GRIP1 -2,544286728 1,49288E-12 
186 ENSG00000220785 MTMR9LP -2,53729554 2,85889E-52 
187 ENSG00000246273 SBF2-AS1 -2,53530746 2,35396E-07 
188 ENSG00000081052 COL4A4 -2,531305307 9,80378E-17 
189 ENSG00000154654 NCAM2 -2,523774871 2,1098E-118 
190 ENSG00000130958 SLC35D2 -2,522438191 1,09585E-10 
191 ENSG00000100399 CHADL -2,521352783 9,38359E-51 
192 ENSG00000158258 CLSTN2 -2,518411457 2,10847E-28 
193 ENSG00000187123 LYPD6 -2,511859417 6,13388E-94 
194 ENSG00000180818 HOXC10 -2,501615403 2,54602E-07 
195 ENSG00000162552 WNT4 -2,497343024 2,83342E-09 
196 ENSG00000196132 MYT1 -2,496795052 9,1392E-123 
197 ENSG00000101605 MYOM1 -2,496097632 1,97472E-12 
198 ENSG00000186466 AQP7P1 -2,491554863 5,44795E-36 
199 ENSG00000145824 CXCL14 -2,491281835 1,70763E-26 
200 ENSG00000153132 CLGN -2,490494023 8,3196E-44 
201 ENSG00000134853 PDGFRA -2,486863084 0 
202 ENSG00000123612 ACVR1C -2,482958065 1,19395E-06 
203 ENSG00000204624 DISP3 -2,479922215 3,4784E-58 
204 ENSG00000072133 RPS6KA6 -2,476969781 1,52441E-06 
205 ENSG00000176595 KBTBD11 -2,474426009 1,38464E-54 
206 ENSG00000141639 MAPK4 -2,472603933 2,01497E-95 
207 ENSG00000157766 ACAN -2,472005294 1,0455E-241 
208 ENSG00000136153 LMO7 -2,468909448 7,30961E-59 
209 ENSG00000126005 MMP24-AS1 -2,464672974 4,3375E-19 
210 ENSG00000101638 ST8SIA5 -2,464647895 1,55698E-17 
211 ENSG00000231995 AL590399.4 -2,462814105 2,38905E-21 
212 ENSG00000065609 SNAP91 -2,46063687 1,66581E-13 
213 ENSG00000141431 ASXL3 -2,45043073 1,38742E-12 
214 ENSG00000070214 SLC44A1 -2,444318585 0 
215 ENSG00000255745 AC023796.1 -2,442798115 1,66019E-07 
216 ENSG00000099810 MTAP -2,440239427 2,1234E-53 
217 ENSG00000118322 ATP10B -2,437980045 1,1054E-123 
218 ENSG00000136205 TNS3 -2,424931227 2,7226E-193 
219 ENSG00000116985 BMP8B -2,419904428 7,94246E-36 
220 ENSG00000159871 LYPD5 -2,418480788 1,16989E-12 
221 ENSG00000187135 VSTM2B -2,414193204 1,13244E-37 
222 ENSG00000053900 ANAPC4 -2,409677163 3,6553E-157 
223 ENSG00000248485 PCP4L1 -2,406000669 9,80226E-09 
224 ENSG00000082482 KCNK2 -2,404323754 7,85592E-25 
225 ENSG00000183117 CSMD1 -2,402058726 1,00365E-08 
226 ENSG00000168481 LGI3 -2,397541205 8,08813E-24 
227 ENSG00000187994 RINL -2,396914365 3,44908E-17 
228 ENSG00000103089 FA2H -2,395623171 2,51669E-29 
229 ENSG00000165078 CPA6 -2,393229827 3,49682E-06 
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230 ENSG00000253250 C8orf88 -2,380790003 8,85368E-07 
231 ENSG00000124920 MYRF -2,375582634 4,8573E-156 
232 ENSG00000183196 CHST6 -2,363669971 2,9403E-25 
233 ENSG00000002746 HECW1 -2,362475868 2,5884E-14 
234 ENSG00000244752 CRYBB2 -2,362258021 1,19304E-06 
235 ENSG00000237457 LINC01351 -2,361164937 7,92316E-08 
236 ENSG00000150244 TRIM48 -2,356047829 2,57674E-07 
237 ENSG00000197594 ENPP1 -2,350432443 7,97893E-46 
238 ENSG00000264186 SNRPCP4 -2,348411686 1,96923E-06 
239 ENSG00000184613 NELL2 -2,347103137 8,30228E-13 
240 ENSG00000168675 LDLRAD4 -2,344531036 1,36509E-48 
241 ENSG00000131668 BARX1 -2,335833408 2,0424E-23 
242 ENSG00000077063 CTTNBP2 -2,32845408 2,8166E-111 
243 ENSG00000187546 AGMO -2,327366305 4,16903E-09 
244 ENSG00000165966 PDZRN4 -2,322767878 7,83787E-09 
245 ENSG00000178026 LRRC75B -2,322178069 5,68768E-11 
246 ENSG00000120696 KBTBD7 -2,318234951 1,12284E-31 
247 ENSG00000250317 SMIM20 -2,31624485 3,5471E-151 
248 ENSG00000018625 ATP1A2 -2,311245568 1,76301E-73 
249 ENSG00000178538 CA8 -2,308381171 1,52337E-46 
250 ENSG00000150551 LYPD1 -2,301814574 3,18797E-37 
251 ENSG00000038210 PI4K2B -2,295939698 4,2378E-173 
252 ENSG00000115896 PLCL1 -2,290898413 6,56618E-09 
253 ENSG00000188620 HMX3 -2,281201517 5,72472E-07 
254 ENSG00000188906 LRRK2 -2,276041119 2,5254E-274 
255 ENSG00000249799 SNRPCP13 -2,27498194 1,67144E-05 
256 ENSG00000198331 HYLS1 -2,272227113 1,84717E-06 
257 ENSG00000101542 CDH20 -2,265242722 1,73823E-14 
258 ENSG00000138670 RASGEF1B -2,264647132 4,26798E-18 
259 ENSG00000164659 KIAA1324L -2,262598673 1,97169E-11 
260 ENSG00000169071 ROR2 -2,260816392 1,2196E-09 
261 ENSG00000167034 NKX3-1 -2,252403982 5,88821E-22 
262 ENSG00000119283 TRIM67 -2,251908388 1,10346E-08 
263 ENSG00000128709 HOXD9 -2,247473001 2,6293E-23 
264 ENSG00000126947 ARMCX1 -2,246993452 3,53478E-17 
265 ENSG00000146197 SCUBE3 -2,246766383 5,35507E-85 
266 ENSG00000158373 HIST1H2BD -2,246383855 8,47359E-18 
267 ENSG00000116544 DLGAP3 -2,244984561 2,01423E-14 
268 ENSG00000137968 SLC44A5 -2,242606279 2,56105E-42 
269 ENSG00000125820 NKX2-2 -2,242202164 1,05843E-94 
270 ENSG00000131196 NFATC1 -2,23599072 5,48545E-74 
271 ENSG00000136297 MMD2 -2,226540772 1,6867E-11 
272 ENSG00000177932 ZNF354C -2,219892159 1,23752E-11 
273 ENSG00000153234 NR4A2 -2,218675793 5,57295E-37 
274 ENSG00000151376 ME3 -2,217032538 2,71913E-35 
275 ENSG00000170965 PLAC1 -2,211930654 2,19762E-08 
276 ENSG00000261786 AC006058.1 -2,211574325 1,7215E-122 
277 ENSG00000162755 KLHDC9 -2,20598151 2,21216E-05 
278 ENSG00000168228 ZCCHC4 -2,205570379 7,0499E-66 
279 ENSG00000151692 RNF144A -2,198961472 1,9915E-268 
280 ENSG00000050030 KIAA2022 -2,197742281 3,9896E-34 
281 ENSG00000223749 MIR503HG -2,191073811 1,71457E-75 
282 ENSG00000266709 AC005224.4 -2,188779648 2,74257E-06 
283 ENSG00000164122 ASB5 -2,17081651 2,98807E-05 
284 ENSG00000064787 BCAS1 -2,169857078 3,10409E-06 
285 ENSG00000124657 OR2B6 -2,165487977 2,10915E-05 
286 ENSG00000198597 ZNF536 -2,159128426 5,25832E-05 
287 ENSG00000168453 HR -2,15440813 1,3778E-103 
288 ENSG00000154175 ABI3BP -2,151254814 3,43121E-13 
289 ENSG00000238113 LINC01410 -2,150277063 2,14564E-05 
290 ENSG00000225968 ELFN1 -2,145629498 2,00458E-20 
291 ENSG00000158406 HIST1H4H -2,129255276 3,85016E-11 
292 ENSG00000089041 P2RX7 -2,12739205 2,0153E-242 
293 ENSG00000132199 ENOSF1 -2,125916076 7,56134E-31 
294 ENSG00000134716 CYP2J2 -2,122872981 2,27053E-14 
295 ENSG00000170624 SGCD -2,121261942 7,16552E-81 
296 ENSG00000264515 AC011474.1 -2,116773946 1,5796E-06 
297 ENSG00000183780 SLC35F3 -2,115808523 1,03071E-07 
298 ENSG00000168539 CHRM1 -2,107403907 8,18146E-15 
299 ENSG00000091513 TF -2,104757521 3,02137E-29 
300 ENSG00000164007 CLDN19 -2,103745853 7,77045E-05 
301 ENSG00000169840 GSX1 -2,103455405 6,54775E-15 
302 ENSG00000136237 RAPGEF5 -2,103089442 5,31013E-11 
303 ENSG00000134996 OSTF1 -2,099747743 5,63217E-19 
304 ENSG00000013016 EHD3 -2,094198585 2,597E-148 
305 ENSG00000251350 LINC02475 -2,090389521 6,04657E-05 
306 ENSG00000141655 TNFRSF11A -2,087693427 8,13906E-05 
307 ENSG00000119698 PPP4R4 -2,085831072 5,41073E-07 
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308 ENSG00000164241 C5orf63 -2,075822062 3,30475E-06 
309 ENSG00000169181 GSG1L -2,07031411 1,22089E-10 
310 ENSG00000249577 AC010424.1 -2,068958376 2,02106E-05 
311 ENSG00000152402 GUCY1A2 -2,068848122 4,01952E-30 
312 ENSG00000100628 ASB2 -2,068279131 7,80666E-07 
313 ENSG00000184347 SLIT3 -2,059081067 2,42549E-06 
314 ENSG00000183018 SPNS2 -2,056677421 6,11472E-10 
315 ENSG00000224272 AC131097.3 -2,054337819 2,975E-09 
316 ENSG00000221887 HMSD -2,054328008 4,50983E-08 
317 ENSG00000272079 AC004233.3 -2,052490854 8,41716E-06 
318 ENSG00000261195 AC027130.1 -2,05108171 2,79021E-05 
319 ENSG00000102760 RGCC -2,050926899 3,21455E-21 
320 ENSG00000137801 THBS1 -2,04384977 1,70905E-23 
321 ENSG00000235098 ANKRD65 -2,036601791 3,88222E-12 
322 ENSG00000198732 SMOC1 -2,034991756 1,9915E-268 
323 ENSG00000144339 TMEFF2 -2,034507047 3,54879E-28 
324 ENSG00000169783 LINGO1 -2,033298924 1,1276E-153 
325 ENSG00000114480 GBE1 -2,032887097 4,78954E-36 
326 ENSG00000240005 AC106047.1 -2,018194667 4,45992E-07 
327 ENSG00000148219 ASTN2 -2,008827636 7,34165E-67 
328 ENSG00000187210 GCNT1 -2,004434994 2,24081E-06 
329 ENSG00000186684 CYP27C1 -2,003500648 5,17557E-13 
330 ENSG00000259985 AC017100.1 -1,999963932 3,52542E-16 
331 ENSG00000265194 AL359922.2 -1,996610383 2,61996E-05 
332 ENSG00000184905 TCEAL2 -1,99107011 0,000158639 
333 ENSG00000106733 NMRK1 -1,991043007 3,43487E-13 
334 ENSG00000067798 NAV3 -1,989412433 4,67746E-06 
335 ENSG00000104332 SFRP1 -1,987309168 3,6304E-152 
336 ENSG00000115239 ASB3 -1,978191705 2,13568E-11 
337 ENSG00000160801 PTH1R -1,970374196 6,34104E-10 
338 ENSG00000123388 HOXC11 -1,969374497 4,85391E-06 
339 ENSG00000124635 HIST1H2BJ -1,969175771 2,07585E-07 
340 ENSG00000140332 TLE3 -1,968159499 5,59286E-44 
341 ENSG00000152990 ADGRA3 -1,965738855 6,2783E-195 
342 ENSG00000223812 AC125608.1 -1,963535114 5,16664E-08 
343 ENSG00000109618 SEPSECS -1,963377532 3,50023E-90 
344 ENSG00000123560 PLP1 -1,959538094 7,6875E-261 
345 ENSG00000173406 DAB1 -1,958087448 2,09273E-66 
346 ENSG00000133216 EPHB2 -1,956215961 2,27769E-32 
347 ENSG00000132692 BCAN -1,953955417 0 
348 ENSG00000254139 AC104051.2 -1,951360874 1,03467E-19 
349 ENSG00000116147 TNR -1,950905733 6,1025E-245 
350 ENSG00000197705 KLHL14 -1,949453388 1,414E-07 
351 ENSG00000214999 AC129492.1 -1,943362672 7,70631E-05 
352 ENSG00000232239 RBPJP5 -1,94152415 2,3184E-06 
353 ENSG00000151287 TEX30 -1,936329024 5,88768E-12 
354 ENSG00000140522 RLBP1 -1,9362882 2,5272E-86 
355 ENSG00000166206 GABRB3 -1,930011113 2,34099E-64 
356 ENSG00000272512 AL645608.8 -1,925065749 7,37798E-10 
357 ENSG00000068903 SIRT2 -1,924377565 1,0324E-231 
358 ENSG00000112394 SLC16A10 -1,921232325 1,55852E-07 
359 ENSG00000128710 HOXD10 -1,9183883 2,0373E-45 
360 ENSG00000180596 HIST1H2BC -1,915229008 8,24167E-09 
361 ENSG00000205810 KLRC3 -1,909210965 4,90009E-06 
362 ENSG00000113763 UNC5A -1,900388529 2,10798E-12 
363 ENSG00000175352 NRIP3 -1,891300765 6,78512E-77 
364 ENSG00000167995 BEST1 -1,889283513 2,7907E-35 
365 ENSG00000118160 SLC8A2 -1,882229416 1,54635E-05 
366 ENSG00000128713 HOXD11 -1,880424793 1,88764E-15 
367 ENSG00000181409 AATK -1,877871534 7,82626E-30 
368 ENSG00000145794 MEGF10 -1,871635802 9,75194E-90 
369 ENSG00000158270 COLEC12 -1,861919438 5,76648E-13 
370 ENSG00000170962 PDGFD -1,853327611 0,000627464 
371 ENSG00000101188 NTSR1 -1,852538 0,000493312 
372 ENSG00000134376 CRB1 -1,852379761 6,41037E-32 
373 ENSG00000165443 PHYHIPL -1,851353662 8,75604E-31 
374 ENSG00000153071 DAB2 -1,846805495 6,95397E-07 
375 ENSG00000128594 LRRC4 -1,842893554 3,1468E-43 
376 ENSG00000143867 OSR1 -1,837988299 2,88766E-84 
377 ENSG00000186479 RGS7BP -1,836715243 9,47307E-07 
378 ENSG00000186472 PCLO -1,834865782 1,28326E-06 
379 ENSG00000176641 RNF152 -1,827800376 6,37088E-20 
380 ENSG00000175785 PRIMA1 -1,826742614 6,59128E-06 
381 ENSG00000187773 FAM69C -1,800020556 6,24577E-54 
382 ENSG00000107736 CDH23 -1,798722619 9,75999E-17 
383 ENSG00000260398 AC068700.1 -1,789924906 0,000519386 
384 ENSG00000259417 LINC01314 -1,783023951 8,22262E-27 
385 ENSG00000152192 POU4F1 -1,780366138 4,24041E-13 
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386 ENSG00000188848 BEND4 -1,772740654 0,001220579 
387 ENSG00000104324 CPQ -1,770129518 0,001048912 
388 ENSG00000183542 KLRC4 -1,768557977 0,001265058 
389 ENSG00000197816 CCDC180 -1,768332762 0,000380542 
390 ENSG00000141622 RNF165 -1,767643695 3,25505E-43 
391 ENSG00000115194 SLC30A3 -1,766002348 3,37898E-28 
392 ENSG00000187323 DCC -1,7656766 9,3388E-42 
393 ENSG00000137393 RNF144B -1,761437465 5,14042E-07 
394 ENSG00000171757 LRRC34 -1,760618358 0,00036284 
395 ENSG00000163362 C1orf106 -1,755394374 2,06106E-40 
396 ENSG00000154822 PLCL2 -1,754017089 2,08248E-19 
397 ENSG00000240184 PCDHGC3 -1,753742352 2,64892E-07 
398 ENSG00000133067 LGR6 -1,752046357 0,00086357 
399 ENSG00000143443 C1orf56 -1,747905988 2,94061E-11 
400 ENSG00000160678 S100A1 -1,744589492 1,07592E-09 
401 ENSG00000198598 MMP17 -1,743451778 2,09941E-31 
402 ENSG00000136842 TMOD1 -1,739782601 2,77764E-43 
403 ENSG00000150594 ADRA2A -1,738369623 0,000680292 
404 ENSG00000259218 LINC00928 -1,738144527 8,23108E-05 
405 ENSG00000162614 NEXN -1,737760761 2,41664E-09 
406 ENSG00000198208 RPS6KL1 -1,736025772 2,71035E-24 
407 ENSG00000118276 B4GALT6 -1,732462757 5,49121E-66 
408 ENSG00000205592 MUC19 -1,730761319 0,001733013 
409 ENSG00000114019 AMOTL2 -1,7305732 1,6474E-124 
410 ENSG00000213222 AC093724.1 -1,728569473 7,82488E-12 
411 ENSG00000182022 CHST15 -1,724956122 5,05805E-08 
412 ENSG00000137571 SLCO5A1 -1,720233245 3,55352E-12 
413 ENSG00000090932 DLL3 -1,720148524 1,5026E-146 
414 ENSG00000001626 CFTR -1,718937385 0,000385615 
415 ENSG00000139915 MDGA2 -1,71892529 1,44085E-12 
416 ENSG00000145779 TNFAIP8 -1,718073674 6,88673E-11 
417 ENSG00000164938 TP53INP1 -1,711530574 2,57492E-26 
418 ENSG00000132669 RIN2 -1,707816867 2,66406E-45 
419 ENSG00000197927 C2orf27A -1,704478415 1,02564E-22 
420 ENSG00000163923 RPL39L -1,701520473 6,37312E-20 
421 ENSG00000183873 SCN5A -1,688164246 1,42705E-09 
422 ENSG00000188486 H2AFX -1,6863056 1,3617E-171 
423 ENSG00000235903 CPB2-AS1 -1,683721195 0,000643735 
424 ENSG00000065809 FAM107B -1,68059948 3,17282E-73 
425 ENSG00000182109 AL365277.1 -1,677982487 0,000263852 
426 ENSG00000264575 LINC00526 -1,674467641 0,00185732 
427 ENSG00000259953 AL138756.1 -1,674466163 0,000534664 
428 ENSG00000154975 CA10 -1,671794861 1,6561E-128 
429 ENSG00000136859 ANGPTL2 -1,67173431 2,6093E-146 
430 ENSG00000121440 PDZRN3 -1,671260001 4,67069E-62 
431 ENSG00000071991 CDH19 -1,667896426 0,002728276 
432 ENSG00000185477 GPRIN3 -1,665030455 0,001039624 
433 ENSG00000261478 AC013391.3 -1,661039166 2,6351E-06 
434 ENSG00000127955 GNAI1 -1,660438351 2,50442E-62 
435 ENSG00000013293 SLC7A14 -1,659464393 0,002384919 
436 ENSG00000176438 SYNE3 -1,658966508 4,94449E-06 
437 ENSG00000166342 NETO1 -1,65835722 2,37556E-26 
438 ENSG00000101665 SMAD7 -1,65434049 4,83022E-12 
439 ENSG00000118513 MYB -1,647373926 1,08452E-08 
440 ENSG00000088970 KIZ -1,642621927 6,94185E-72 
441 ENSG00000218739 CEBPZOS -1,642471933 8,13151E-34 
442 ENSG00000168234 TTC39C -1,642046489 5,19737E-57 
443 ENSG00000164398 ACSL6 -1,639659622 9,7943E-23 
444 ENSG00000142611 PRDM16 -1,639296991 0,000125677 
445 ENSG00000148053 NTRK2 -1,638417661 2,6247E-216 
446 ENSG00000012171 SEMA3B -1,638034157 3,32768E-71 
447 ENSG00000037280 FLT4 -1,63196704 0,000100372 
448 ENSG00000197965 MPZL1 -1,629238041 3,0664E-151 
449 ENSG00000162630 B3GALT2 -1,625608189 7,45501E-07 
450 ENSG00000106477 CEP41 -1,622612267 3,35349E-31 
451 ENSG00000226508 LINC01918 -1,622435152 8,78443E-05 
452 ENSG00000187098 MITF -1,622010468 1,5892E-35 
453 ENSG00000246528 AC079089.1 -1,617207777 0,000640832 
454 ENSG00000196421 C20orf204 -1,615192349 0,000933454 
455 ENSG00000161048 NAPEPLD -1,612845634 1,69673E-25 
456 ENSG00000164125 FAM198B -1,607233762 1,93206E-05 
457 ENSG00000116254 CHD5 -1,606037651 2,31691E-06 
458 ENSG00000182010 RTKN2 -1,601767297 8,51797E-38 
459 ENSG00000253159 PCDHGA12 -1,600800851 2,82913E-39 
460 ENSG00000226380 AC016831.1 -1,597968731 0,000111985 
461 ENSG00000073861 TBX21 -1,595296356 1,90719E-06 
462 ENSG00000139364 TMEM132B -1,59495964 4,01077E-54 
463 ENSG00000171714 ANO5 -1,593903809 6,51963E-28 
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464 ENSG00000015568 RGPD5 -1,59355909 2,65102E-06 
465 ENSG00000005513 SOX8 -1,586519492 4,4986E-180 
466 ENSG00000127084 FGD3 -1,585866741 8,19933E-15 
467 ENSG00000137177 KIF13A -1,580514879 3,17078E-97 
468 ENSG00000179477 ALOX12B -1,580012754 0,00389115 
469 ENSG00000144366 GULP1 -1,57709165 7,54511E-05 
470 ENSG00000127152 BCL11B -1,576399435 0,003748708 
471 ENSG00000176746 MAGEB6 -1,575391654 0,004351083 
472 ENSG00000164050 PLXNB1 -1,573138827 5,2753E-155 
473 ENSG00000117791 MARC2 -1,572142335 0,003308242 
474 ENSG00000137877 SPTBN5 -1,571193003 1,31685E-07 
475 ENSG00000171368 TPPP -1,568085183 3,66345E-59 
476 ENSG00000248587 GDNF-AS1 -1,568015164 3,32975E-07 
477 ENSG00000079102 RUNX1T1 -1,56327982 6,04507E-14 
478 ENSG00000089177 KIF16B -1,560946426 3,98708E-08 
479 ENSG00000116132 PRRX1 -1,560841968 7,3962E-106 
480 ENSG00000036565 SLC18A1 -1,559858489 8,52984E-05 
481 ENSG00000156959 LHFPL4 -1,559466528 8,00643E-09 
482 ENSG00000134775 FHOD3 -1,558102361 9,37297E-76 
483 ENSG00000109255 NMU -1,5531869 7,65731E-10 
484 ENSG00000241527 CA15P1 -1,54936418 0,00360088 
485 ENSG00000125845 BMP2 -1,541975721 4,16434E-17 
486 ENSG00000144476 ACKR3 -1,541619495 4,38928E-40 
487 ENSG00000267121 AC008105.3 -1,540866159 0,000139588 
488 ENSG00000064989 CALCRL -1,540637388 4,01204E-30 
489 ENSG00000122971 ACADS -1,539355615 1,30486E-09 
490 ENSG00000101349 PAK5 -1,537296089 0,002010219 
491 ENSG00000205927 OLIG2 -1,534809201 1,0383E-159 
492 ENSG00000164303 ENPP6 -1,531425357 0,00498006 
493 ENSG00000203472 AC009163.1 -1,528932377 0,005882379 
494 ENSG00000085276 MECOM -1,526831 1,32616E-16 
495 ENSG00000136943 CTSV -1,518056305 4,55107E-14 
496 ENSG00000168484 SFTPC -1,517342938 0,002748851 
497 ENSG00000140368 PSTPIP1 -1,516025553 0,006665831 
498 ENSG00000160179 ABCG1 -1,515547716 0,005205002 
499 ENSG00000124406 ATP8A1 -1,515524587 8,59809E-16 
500 ENSG00000164106 SCRG1 -1,514407396 1,12404E-88 
501 ENSG00000273032 DGCR9 -1,509718289 0,000340534 
502 ENSG00000233822 HIST1H2BN -1,508822277 3,00551E-06 
503 ENSG00000203814 HIST2H2BF -1,508524554 0,006067574 
504 ENSG00000250312 ZNF718 -1,508411248 8,41716E-06 
505 ENSG00000197496 SLC2A10 -1,507990881 0,003607449 
506 ENSG00000221716 SNORA11 -1,507192146 6,35233E-05 
507 ENSG00000153162 BMP6 -1,501579551 0,005535406 
508 ENSG00000115159 GPD2 -1,500780883 4,23942E-92 
509 ENSG00000135636 DYSF -1,496931239 4,1235E-18 
510 ENSG00000073910 FRY -1,496319661 1,41003E-32 
511 ENSG00000079819 EPB41L2 -1,49589666 1,0439E-151 
512 ENSG00000197903 HIST1H2BK -1,494702556 1,1973E-26 
513 ENSG00000189221 MAOA -1,493015921 7,79823E-05 
514 ENSG00000167654 ATCAY -1,491846979 2,1887E-124 
515 ENSG00000118515 SGK1 -1,488599991 5,914E-52 
516 ENSG00000185664 PMEL -1,485705916 0,00015503 
517 ENSG00000100311 PDGFB -1,483889407 1,07669E-05 
518 ENSG00000273297 AC009275.1 -1,483741398 0,001043017 
519 ENSG00000080854 IGSF9B -1,483655243 2,20981E-32 
520 ENSG00000176402 GJC3 -1,481447981 0,003165651 
521 ENSG00000250039 AC096719.1 -1,480540806 0,00884405 
522 ENSG00000182247 UBE2E2 -1,479353666 2,50378E-30 
523 ENSG00000260423 LINC02367 -1,479343383 7,46708E-05 
524 ENSG00000206077 ZDHHC11B -1,479271943 6,17742E-21 
525 ENSG00000255864 AC069208.1 -1,475981418 0,000284258 
526 ENSG00000176463 SLCO3A1 -1,475588747 4,57903E-29 
527 ENSG00000092969 TGFB2 -1,475240459 0,002646264 
528 ENSG00000197959 DNM3 -1,475021043 3,14015E-64 
529 ENSG00000105251 SHD -1,474161258 1,34177E-30 
530 ENSG00000171451 DSEL -1,472594441 7,98231E-74 
531 ENSG00000175556 LONRF3 -1,472395369 0,006111522 
532 ENSG00000198133 TMEM229B -1,471657347 2,13419E-42 
533 ENSG00000133878 DUSP26 -1,471437205 0,000118532 
534 ENSG00000124570 SERPINB6 -1,470832235 2,11114E-25 
535 ENSG00000109846 CRYAB -1,468753897 2,45772E-36 
536 ENSG00000196090 PTPRT -1,468479436 7,27974E-33 
537 ENSG00000178031 ADAMTSL1 -1,466963264 8,87722E-07 
538 ENSG00000150625 GPM6A -1,466924974 1,1392E-123 
539 ENSG00000081148 IMPG2 -1,463393284 0,006341105 
540 ENSG00000215612 HMX1 -1,463116858 1,82607E-11 
541 ENSG00000232815 DUX4L50 -1,462646256 0,007552872 
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542 ENSG00000157399 ARSE -1,461984122 2,04405E-12 
543 ENSG00000248690 HAS2-AS1 -1,461256572 2,46135E-05 
544 ENSG00000109680 TBC1D19 -1,457410051 7,55097E-20 
545 ENSG00000179348 GATA2 -1,456551575 6,11792E-07 
546 ENSG00000104327 CALB1 -1,455151224 0,000485544 
547 ENSG00000167900 TK1 -1,455068311 9,92137E-57 
548 ENSG00000064393 HIPK2 -1,454470221 3,8829E-106 
549 ENSG00000237515 SHISA9 -1,451139665 1,29266E-09 
550 ENSG00000184221 OLIG1 -1,448829604 1,456E-141 
551 ENSG00000196787 HIST1H2AG -1,446729569 6,00316E-05 
552 ENSG00000184160 ADRA2C -1,445817549 0,001178151 
553 ENSG00000265579 AC023301.1 -1,444097329 2,76491E-08 
554 ENSG00000105699 LSR -1,441766176 0,00195986 
555 ENSG00000104388 RAB2A -1,440958284 1,4646E-108 
556 ENSG00000197409 HIST1H3D -1,440381961 0,006174882 
557 ENSG00000177103 DSCAML1 -1,440141578 1,0467E-11 
558 ENSG00000117266 CDK18 -1,439609397 6,14133E-10 
559 ENSG00000101417 PXMP4 -1,436010335 6,89235E-11 
560 ENSG00000180573 HIST1H2AC -1,435852389 1,37585E-34 
561 ENSG00000163376 KBTBD8 -1,433593495 6,90438E-08 
562 ENSG00000213785 AKR1B1P3 -1,433444857 0,01157169 
563 ENSG00000256973 AC053513.1 -1,428517568 0,004934465 
564 ENSG00000184564 SLITRK6 -1,428293804 0,011335863 
565 ENSG00000136099 PCDH8 -1,427957505 0,011749634 
566 ENSG00000131773 KHDRBS3 -1,426995205 6,93342E-96 
567 ENSG00000104490 NCALD -1,424038368 6,78728E-66 
568 ENSG00000156475 PPP2R2B -1,420382614 5,85882E-81 
569 ENSG00000145569 FAM105A -1,420256376 9,33548E-07 
570 ENSG00000169184 MN1 -1,415419422 2,66429E-24 
571 ENSG00000069188 SDK2 -1,415103587 1,293E-06 
572 ENSG00000121690 DEPDC7 -1,414754257 2,65657E-08 
573 ENSG00000162836 ACP6 -1,414126729 0,005988542 
574 ENSG00000215417 MIR17HG -1,413826337 0,001052674 
575 ENSG00000184260 HIST2H2AC -1,412499754 0,000456989 
576 ENSG00000173175 ADCY5 -1,411842647 3,26621E-18 
577 ENSG00000126500 FLRT1 -1,410698094 2,29513E-08 
578 ENSG00000109814 UGDH -1,409970181 1,89811E-54 
579 ENSG00000080986 NDC80 -1,40951151 1,44589E-62 
580 ENSG00000163072 NOSTRIN -1,408622765 0,000582918 
581 ENSG00000068615 REEP1 -1,407767781 6,59386E-27 
582 ENSG00000254377 MIR124-2HG -1,407340606 2,31877E-05 
583 ENSG00000163520 FBLN2 -1,406029753 0,000160672 
584 ENSG00000168621 GDNF -1,404728388 0,002428956 
585 ENSG00000227693 GSTM3P1 -1,40425343 8,78216E-11 
586 ENSG00000148120 C9orf3 -1,403010383 4,3684E-24 
587 ENSG00000136869 TLR4 -1,401888205 8,80915E-15 
588 ENSG00000108384 RAD51C -1,401642513 2,97609E-23 
589 ENSG00000176136 MC5R -1,400678067 0,00630708 
590 ENSG00000112414 ADGRG6 -1,400302088 1,41763E-29 
591 ENSG00000172667 ZMAT3 -1,394397456 1,67939E-51 
592 ENSG00000134532 SOX5 -1,394310508 1,27076E-69 
593 ENSG00000154358 OBSCN -1,393552226 7,89771E-05 
594 ENSG00000229151 AC233976.1 -1,391752369 0,014418226 
595 ENSG00000145416 MARCH1 -1,387204036 1,53205E-05 
596 ENSG00000100842 EFS -1,386795037 1,46275E-66 
597 ENSG00000154928 EPHB1 -1,385926944 9,80911E-32 
598 ENSG00000137834 SMAD6 -1,384497826 1,0361E-10 
599 ENSG00000175928 LRRN1 -1,384304113 8,7107E-108 
600 ENSG00000086570 FAT2 -1,379288982 0,000579823 
601 ENSG00000219773 RPSAP45 -1,377515442 0,001073376 
602 ENSG00000154493 C10orf90 -1,376079317 0,00212644 
603 ENSG00000140519 RHCG -1,374039328 0,011624842 
604 ENSG00000170293 CMTM8 -1,374036582 4,22557E-06 
605 ENSG00000141665 FBXO15 -1,371363129 0,00192375 
606 ENSG00000094755 GABRP -1,371246045 0,00845153 
607 ENSG00000132185 FCRLA -1,370905889 1,07378E-41 
608 ENSG00000154316 TDH -1,368852962 0,012887978 
609 ENSG00000005189 REXO5 -1,365116945 2,33963E-31 
610 ENSG00000152661 GJA1 -1,364655411 1,10372E-06 
611 ENSG00000229953 AL590666.2 -1,360798066 3,40835E-06 
612 ENSG00000109686 SH3D19 -1,359626177 3,34137E-65 
613 ENSG00000170162 VGLL2 -1,356503462 0,006416161 
614 ENSG00000101938 CHRDL1 -1,355935559 4,1151E-99 
615 ENSG00000139926 FRMD6 -1,353660841 9,15719E-56 
616 ENSG00000271387 AL445228.2 -1,351052043 0,00750068 
617 ENSG00000134595 SOX3 -1,350926475 1,04797E-05 
618 ENSG00000175445 LPL -1,349962643 1,54105E-68 
619 ENSG00000256616 AP002414.2 -1,346619454 0,00044661 
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620 ENSG00000106078 COBL -1,341350824 1,74553E-77 
621 ENSG00000114757 PEX5L -1,339475545 0,003526494 
622 ENSG00000233846 AL133480.2 -1,338803896 0,000461514 
623 ENSG00000127252 HRASLS -1,337242313 1,64156E-12 
624 ENSG00000169955 ZNF747 -1,333966574 1,22858E-08 
625 ENSG00000119547 ONECUT2 -1,332879404 4,43243E-19 
626 ENSG00000089225 TBX5 -1,332235429 1,65245E-14 
627 ENSG00000007062 PROM1 -1,331457219 2,03899E-16 
628 ENSG00000072952 MRVI1 -1,330507504 0,002009901 
629 ENSG00000150510 FAM124A -1,330337957 5,71093E-06 
630 ENSG00000182255 KCNA4 -1,330204296 0,003477931 
631 ENSG00000189212 DPY19L2P1 -1,328903636 6,11718E-06 
632 ENSG00000204446 C9orf170 -1,325675552 0,015299373 
633 ENSG00000142871 CYR61 -1,325080758 2,75252E-16 
634 ENSG00000254221 PCDHGB1 -1,323724383 1,34326E-05 
635 ENSG00000144407 PTH2R -1,319645668 0,020940651 
636 ENSG00000111199 TRPV4 -1,319546995 0,001040236 
637 ENSG00000169371 SNUPN -1,317185465 6,49573E-11 
638 ENSG00000096433 ITPR3 -1,312926775 3,98838E-37 
639 ENSG00000100033 PRODH -1,311480607 2,62612E-53 
640 ENSG00000130720 FIBCD1 -1,311084586 5,70008E-06 
641 ENSG00000125726 CD70 -1,308585928 1,74294E-36 
642 ENSG00000128652 HOXD3 -1,306118337 8,09288E-07 
643 ENSG00000103381 CPPED1 -1,305771775 6,53923E-09 
644 ENSG00000150627 WDR17 -1,304775949 4,67262E-14 
645 ENSG00000237380 HOXD-AS2 -1,304239219 0,001555097 
646 ENSG00000174171 AC020659.1 -1,303850724 0,000708783 
647 ENSG00000146094 DOK3 -1,303287789 0,003531103 
648 ENSG00000101198 NKAIN4 -1,303235202 1,31508E-08 
649 ENSG00000114541 FRMD4B -1,302845868 6,83551E-28 
650 ENSG00000171766 GATM -1,301960644 0,000174834 
651 ENSG00000167680 SEMA6B -1,301639514 2,05866E-52 
652 ENSG00000101746 NOL4 -1,300670112 1,93828E-10 
653 ENSG00000255399 TBX5-AS1 -1,298530552 2,08489E-06 
654 ENSG00000198944 SOWAHA -1,298356404 0,001931529 
655 ENSG00000198843 SELENOT -1,298053722 5,95669E-80 
656 ENSG00000100276 RASL10A -1,298035535 0,010095017 
657 ENSG00000167588 GPD1 -1,297326516 0,000659986 
658 ENSG00000163082 SGPP2 -1,297166173 0,009361151 
659 ENSG00000198585 NUDT16 -1,296365589 1,23089E-59 
660 ENSG00000131386 GALNT15 -1,295656764 1,55486E-19 
661 ENSG00000162944 RFTN2 -1,293496694 9,62561E-47 
662 ENSG00000224597 SVIL-AS1 -1,29285832 5,41398E-13 
663 ENSG00000125898 FAM110A -1,292680072 2,02682E-14 
664 ENSG00000143816 WNT9A -1,292524763 3,3598E-10 
665 ENSG00000134594 RAB33A -1,291706537 4,64607E-36 
666 ENSG00000253764 AC019257.1 -1,289668965 0,025181505 
667 ENSG00000176244 ACBD7 -1,288966531 4,82967E-13 
668 ENSG00000239268 AC092691.1 -1,288594196 0,009350167 
669 ENSG00000134330 IAH1 -1,286712584 0,010362155 
670 ENSG00000251396 LINC01301 -1,286233292 1,3937E-09 
671 ENSG00000124508 BTN2A2 -1,285085175 7,25193E-26 
672 ENSG00000156298 TSPAN7 -1,2849699 1,02215E-66 
673 ENSG00000180269 GPR139 -1,284563138 0,005496431 
674 ENSG00000007968 E2F2 -1,282234647 2,37804E-27 
675 ENSG00000163697 APBB2 -1,27947771 1,23991E-71 
676 ENSG00000231187 AL356056.2 -1,276564668 0,014223192 
677 ENSG00000225472 AL136366.1 -1,275738357 8,35733E-05 
678 ENSG00000149090 PAMR1 -1,275076935 1,17351E-05 
679 ENSG00000156103 MMP16 -1,274961659 1,73351E-97 
680 ENSG00000206199 ANKUB1 -1,274022123 0,026811836 
681 ENSG00000273492 AP000229.1 -1,272696751 0,00186509 
682 ENSG00000145721 LIX1 -1,272300433 0,000248735 
683 ENSG00000176658 MYO1D -1,27178954 0,004934465 
684 ENSG00000235413 KRT18P63 -1,271713143 0,027630593 
685 ENSG00000138639 ARHGAP24 -1,27090156 0,00903145 
686 ENSG00000151276 MAGI1 -1,269215628 2,32341E-73 
687 ENSG00000196782 MAML3 -1,26910238 2,9205E-05 
688 ENSG00000181218 HIST3H2A -1,26824481 2,93775E-14 
689 ENSG00000130066 SAT1 -1,267731253 2,61028E-91 
690 ENSG00000176771 NCKAP5 -1,267074497 6,88513E-08 
691 ENSG00000198157 HMGN5 -1,266627501 3,63479E-11 




694 ENSG00000204176 SYT15 -1,265630611 0,001071362 
695 ENSG00000226650 KIF4B -1,264974006 1,99203E-05 
696 ENSG00000197122 SRC -1,264726214 2,81587E-17 
697 ENSG00000115112 TFCP2L1 -1,264280933 0,022924474 
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698 ENSG00000170153 RNF150 -1,264166777 1,00879E-16 
699 ENSG00000169515 CCDC8 -1,263003236 0,010355868 
700 ENSG00000229585 AC110792.1 -1,258927135 0,029051828 
701 ENSG00000171791 BCL2 -1,257727948 1,56204E-25 
702 ENSG00000176890 TYMS -1,257421155 8,53796E-68 
703 ENSG00000061938 TNK2 -1,255672155 3,43624E-81 
704 ENSG00000175305 CCNE2 -1,255542613 1,20646E-17 
705 ENSG00000006740 ARHGAP44 -1,255339885 0,002064576 
706 ENSG00000125249 RAP2A -1,255284105 1,16992E-58 
707 ENSG00000110900 TSPAN11 -1,254578676 2,73791E-41 
708 ENSG00000260249 AC007608.3 -1,252821454 0,020914142 
709 ENSG00000103460 TOX3 -1,250810522 1,08295E-22 
710 ENSG00000157017 GHRL -1,245673321 0,028221191 
711 ENSG00000064886 CHI3L2 -1,244101322 0,029998619 
712 ENSG00000229589 ACVR2B-AS1 -1,242412955 1,10531E-05 
713 ENSG00000214776 AC092821.1 -1,238467163 0,000239445 
714 ENSG00000222044 AL031587.1 -1,237154907 0,026275497 
715 ENSG00000257337 AC068888.1 -1,236117499 6,48583E-15 
716 ENSG00000104413 ESRP1 -1,23329679 0,032333812 
717 ENSG00000106537 TSPAN13 -1,233136829 2,47891E-39 
718 ENSG00000159899 NPR2 -1,232840292 0,000290028 
719 ENSG00000231407 AL354732.1 -1,232529042 0,024000393 
720 ENSG00000198429 ZNF69 -1,231118553 7,904E-11 
721 ENSG00000101306 MYLK2 -1,23009253 0,023952804 
722 ENSG00000224243 LINC00403 -1,229528555 0,033611627 
723 ENSG00000070761 CFAP20 -1,229440059 2,09268E-36 
724 ENSG00000224376 AC017104.1 -1,224937263 3,40112E-08 
725 ENSG00000153823 PID1 -1,222127904 7,00767E-33 
726 ENSG00000154040 CABYR -1,221900994 0,034820495 
727 ENSG00000188064 WNT7B -1,218049089 2,5607E-34 
728 ENSG00000145087 STXBP5L -1,217329235 1,28455E-18 
729 ENSG00000125780 TGM3 -1,216627726 0,015148484 
730 ENSG00000185774 KCNIP4 -1,216510924 0,001000321 
731 ENSG00000164188 RANBP3L -1,214921419 0,036884888 
732 ENSG00000171320 ESCO2 -1,214750806 1,912E-34 
733 ENSG00000217275 AL031777.1 -1,214654769 0,033611897 
734 ENSG00000104219 ZDHHC2 -1,211111073 7,32517E-51 
735 ENSG00000188039 NWD1 -1,210177954 0,009631937 
736 ENSG00000151490 PTPRO -1,210038339 3,94436E-24 
737 ENSG00000120742 SERP1 -1,207722235 1,52823E-67 
738 ENSG00000154118 JPH3 -1,206786175 1,04685E-05 
739 ENSG00000172995 ARPP21 -1,206689601 0,000774463 
740 ENSG00000176678 FOXL1 -1,206463722 4,26149E-05 
741 ENSG00000228623 ZNF883 -1,203896565 2,24852E-07 
742 ENSG00000162951 LRRTM1 -1,201433938 0,039951701 
743 ENSG00000112561 TFEB -1,195511206 2,68605E-15 
744 ENSG00000247131 AC025263.1 -1,190864821 0,041662855 
745 ENSG00000198759 EGFL6 -1,189937795 0,037543029 
746 ENSG00000187634 SAMD11 -1,189834433 1,66808E-07 
747 ENSG00000099282 TSPAN15 -1,189174226 3,01801E-32 
748 ENSG00000076826 CAMSAP3 -1,187821987 1,00008E-10 
749 ENSG00000206549 PRSS50 -1,186937497 0,042135047 
750 ENSG00000198093 ZNF649 -1,186593519 6,60221E-30 
751 ENSG00000269416 LINC01224 -1,185681816 8,22399E-14 
752 ENSG00000184481 FOXO4 -1,185295715 3,46016E-21 
753 ENSG00000183346 C10orf107 -1,181896246 0,043629254 
754 ENSG00000049089 COL9A2 -1,181008928 1,46218E-28 
755 ENSG00000128714 HOXD13 -1,179538301 6,51196E-08 
756 ENSG00000164116 GUCY1A3 -1,179472048 0,001166395 
757 ENSG00000095261 PSMD5 -1,17896972 2,37734E-11 
758 ENSG00000272086 AC025181.2 -1,178484035 0,000595682 
759 ENSG00000154655 L3MBTL4 -1,178394757 5,74421E-06 
760 ENSG00000171848 RRM2 -1,176390386 7,28279E-67 
761 ENSG00000117148 ACTL8 -1,174433537 0,045208248 
762 ENSG00000123384 LRP1 -1,173364298 1,11809E-13 
763 ENSG00000223461 AC004471.1 -1,172219581 0,045052095 
764 ENSG00000260139 CSPG4P13 -1,172007901 0,001844606 
765 ENSG00000123892 RAB38 -1,171701975 9,27993E-09 
766 ENSG00000174611 KY -1,170923116 0,04242254 
767 ENSG00000163539 CLASP2 -1,170154562 2,29677E-65 
768 ENSG00000196562 SULF2 -1,169902548 9,62562E-35 
769 ENSG00000124479 NDP -1,168793329 3,14631E-06 
770 ENSG00000076770 MBNL3 -1,168694167 2,62616E-28 
771 ENSG00000255020 AF131216.3 -1,168265889 0,013478287 
772 ENSG00000196345 ZKSCAN7 -1,167142686 3,01071E-05 
773 ENSG00000267500 ZNF887P -1,166375175 0,005763432 
774 ENSG00000204682 CASC10 -1,166278586 0,00014008 
775 ENSG00000213398 LCAT -1,165813011 8,09084E-13 
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776 ENSG00000125637 PSD4 -1,164628572 0,002191477 
777 ENSG00000183248 PRR36 -1,162902842 4,62349E-25 
778 ENSG00000163932 PRKCD -1,160659479 5,11308E-22 
779 ENSG00000259207 ITGB3 -1,160512123 0,003431212 
780 ENSG00000226752 PSMD5-AS1 -1,159190445 3,77196E-10 
781 ENSG00000264278 AC027575.2 -1,158795046 0,02055748 
782 ENSG00000148773 MKI67 -1,157286277 5,17144E-73 
783 ENSG00000177453 NIM1K -1,157130157 2,48789E-08 
784 ENSG00000185565 LSAMP -1,157037895 2,91404E-86 
785 ENSG00000231252 AC099792.1 -1,156801848 0,000398612 
786 ENSG00000106066 CPVL -1,155975432 3,01069E-15 
787 ENSG00000213621 RPSAP54 -1,155105714 0,000143703 
788 ENSG00000164647 STEAP1 -1,153286525 0,034970515 
789 ENSG00000260572 AC069224.1 -1,151864429 0,004360359 
790 ENSG00000157404 KIT -1,151174383 0,023920424 
791 ENSG00000245648 AC022075.1 -1,148455457 0,003560035 
792 ENSG00000092068 SLC7A8 -1,147889817 0,000990025 
793 ENSG00000269486 AC011455.2 -1,14666564 0,010447043 
794 ENSG00000120549 KIAA1217 -1,146488727 1,21059E-11 
795 ENSG00000213186 TRIM59 -1,14405017 0,002223871 
796 ENSG00000111405 ENDOU -1,143951925 0,007418186 
797 ENSG00000148082 SHC3 -1,143681833 3,06647E-45 
798 ENSG00000169122 FAM110B -1,143019054 9,13141E-37 
799 ENSG00000248890 HHIP-AS1 -1,142846049 0,036093117 
800 ENSG00000170891 CYTL1 -1,142706935 1,72028E-05 
801 ENSG00000133863 TEX15 -1,141244735 0,000561814 
802 ENSG00000048740 CELF2 -1,140802357 1,54968E-49 
803 ENSG00000144278 GALNT13 -1,139882274 3,02477E-19 
804 ENSG00000178184 PARD6G -1,138085011 7,94337E-17 
805 ENSG00000196172 ZNF681 -1,137875852 0,000267457 
806 ENSG00000260742 AC009962.1 -1,137684528 0,033439692 
807 ENSG00000142632 ARHGEF19 -1,137474348 0,006029818 
808 ENSG00000136997 MYC -1,137375594 1,828E-56 
809 ENSG00000103260 METRN -1,135427155 4,60307E-80 
810 ENSG00000123570 RAB9B -1,135148875 1,72725E-13 
811 ENSG00000132205 EMILIN2 -1,13496596 5,34768E-35 
812 ENSG00000168874 ATOH8 -1,133877755 1,81333E-16 
813 ENSG00000071282 LMCD1 -1,133677536 6,32462E-12 
814 ENSG00000161082 CELF5 -1,133550261 1,465E-07 
815 ENSG00000149654 CDH22 -1,131998631 0,000186118 
816 ENSG00000224945 AL353150.1 -1,130994453 2,18019E-16 
817 ENSG00000272767 JMJD1C-AS1 -1,129371314 0,010776691 
818 ENSG00000164300 SERINC5 -1,129079738 3,80977E-26 
819 ENSG00000168297 PXK -1,128783295 8,61593E-28 
820 ENSG00000225511 LINC00475 -1,127756579 0,038484169 
821 ENSG00000231607 DLEU2 -1,126273661 2,28434E-06 
822 ENSG00000253457 SMIM18 -1,126199152 0,017034801 
823 ENSG00000198846 TOX -1,125470089 6,97214E-19 
824 ENSG00000183496 MEX3B -1,12531 8,49033E-17 
825 ENSG00000183067 IGSF5 -1,124456104 0,008066898 
826 ENSG00000151612 ZNF827 -1,12379215 1,20168E-32 
827 ENSG00000261770 AC006504.1 -1,123775058 0,000440733 
828 ENSG00000104381 GDAP1 -1,123455737 1,2881E-26 
829 ENSG00000164796 CSMD3 -1,122897573 2,41076E-06 
830 ENSG00000180113 TDRD6 -1,122019692 0,027882937 
831 ENSG00000134508 CABLES1 -1,121366046 0,000556047 
832 ENSG00000149929 HIRIP3 -1,120160788 3,30168E-32 
833 ENSG00000177363 LRRN4CL -1,120001834 0,002696112 
834 ENSG00000230454 U73166.1 -1,117796878 0,009386645 
835 ENSG00000188266 HYKK -1,117471384 0,029763947 
836 ENSG00000261857 MIA -1,114949407 0,009524953 
837 ENSG00000112576 CCND3 -1,114097684 2,82228E-31 
838 ENSG00000106034 CPED1 -1,112588363 0,024561192 
839 ENSG00000188818 ZDHHC11 -1,111145724 2,14169E-07 
840 ENSG00000046604 DSG2 -1,110870059 4,06899E-10 
841 ENSG00000031081 ARHGAP31 -1,110768412 4,14242E-72 
842 ENSG00000064225 ST3GAL6 -1,109499744 1,43621E-32 
843 ENSG00000146147 MLIP -1,108983719 0,003529183 
844 ENSG00000115468 EFHD1 -1,104066343 3,51256E-22 
845 ENSG00000177599 ZNF491 -1,103011581 2,87355E-07 
846 ENSG00000176406 RIMS2 -1,101715804 4,52353E-09 
847 ENSG00000162676 GFI1 -1,10161985 0,023776984 
848 ENSG00000198312 BMS1P9 -1,099846951 0,031633271 
849 ENSG00000118193 KIF14 -1,099462674 6,67988E-37 
850 ENSG00000261829 AC009407.1 -1,098663057 0,003157314 
851 ENSG00000172264 MACROD2 -1,098020051 2,61996E-05 
852 ENSG00000114166 KAT2B -1,096883718 6,78353E-48 
853 ENSG00000127241 MASP1 -1,096419205 1,5702E-52 
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854 ENSG00000123096 SSPN -1,09514327 0,001566436 
855 ENSG00000213638 ADAT3 -1,094541505 9,05647E-06 
856 ENSG00000267041 ZNF850 -1,094181641 3,15153E-14 
857 ENSG00000221955 SLC12A8 -1,090949733 0,012720987 
858 ENSG00000118946 PCDH17 -1,089079785 6,01309E-18 
859 ENSG00000073111 MCM2 -1,087352102 1,11446E-70 
860 ENSG00000152583 SPARCL1 -1,085756422 8,12742E-77 
861 ENSG00000148677 ANKRD1 -1,084737478 0,026912451 
862 ENSG00000164104 HMGB2 -1,082188802 1,20048E-60 
863 ENSG00000140451 PIF1 -1,08074595 6,30983E-23 
864 ENSG00000162878 PKDCC -1,07811601 2,86393E-13 
865 ENSG00000180592 SKIDA1 -1,077998821 0,03031749 
866 ENSG00000169554 ZEB2 -1,077893839 1,20949E-58 
867 ENSG00000131747 TOP2A -1,077403565 7,37914E-89 
868 ENSG00000117724 CENPF -1,076808542 6,5412E-58 
869 ENSG00000163808 KIF15 -1,076046397 4,53785E-41 
870 ENSG00000166432 ZMAT1 -1,074268534 2,65951E-19 
871 ENSG00000179403 VWA1 -1,074123513 4,34276E-33 
872 ENSG00000075945 KIFAP3 -1,070945499 3,81307E-33 
873 ENSG00000184678 HIST2H2BE -1,070812448 5,78582E-31 
874 ENSG00000133131 MORC4 -1,070477864 1,57606E-19 
875 ENSG00000105963 ADAP1 -1,068711432 0,00667825 
876 ENSG00000178999 AURKB -1,068007021 5,14544E-30 
877 ENSG00000254122 PCDHGB7 -1,067938984 1,53651E-45 
878 ENSG00000154188 ANGPT1 -1,066829751 2,65085E-10 
879 ENSG00000227487 NCAM1-AS1 -1,066323745 0,014847434 
880 ENSG00000163935 SFMBT1 -1,065348588 6,64874E-15 
881 ENSG00000111077 TNS2 -1,063771698 1,49908E-51 
882 ENSG00000198947 DMD -1,063689189 1,10329E-12 
883 ENSG00000221990 EXOC3-AS1 -1,06138633 3,92086E-05 
884 ENSG00000175105 ZNF654 -1,060830242 3,14575E-14 
885 ENSG00000124613 ZNF391 -1,060777995 4,52944E-07 
886 ENSG00000175611 LINC00476 -1,060207031 1,00918E-06 
887 ENSG00000118939 UCHL3 -1,059209921 0,028994206 
888 ENSG00000269793 ZIM2-AS1 -1,058990335 1,35036E-07 
889 ENSG00000188290 HES4 -1,058554022 2,62754E-19 
890 ENSG00000198797 BRINP2 -1,056925765 7,86935E-34 
891 ENSG00000115525 ST3GAL5 -1,055840092 3,25428E-45 
892 ENSG00000198131 ZNF544 -1,055596096 2,70882E-06 
893 ENSG00000137812 KNL1 -1,054765619 1,73869E-29 
894 ENSG00000170873 MTSS1 -1,054299683 1,80475E-56 
895 ENSG00000152578 GRIA4 -1,053516751 9,44983E-42 
896 ENSG00000188897 AC099489.1 -1,053335298 0,046056739 
897 ENSG00000080839 RBL1 -1,053334345 2,44607E-20 
898 ENSG00000169964 TMEM42 -1,053272871 0,016607621 
899 ENSG00000102109 PCSK1N -1,052924379 1,2372E-23 
900 ENSG00000233429 HOTAIRM1 -1,05095186 7,54511E-05 
901 ENSG00000164109 MAD2L1 -1,050562038 9,59642E-31 
902 ENSG00000228522 AL845321.1 -1,050335252 0,018104795 
903 ENSG00000136603 SKIL -1,049717105 8,34627E-09 
904 ENSG00000164920 OSR2 -1,049388086 1,68193E-06 
905 ENSG00000112852 PCDHB2 -1,049245121 1,25033E-17 
906 ENSG00000250486 FAM218A -1,047985932 0,005517033 
907 ENSG00000105825 TFPI2 -1,04750729 0,025379245 
908 ENSG00000170961 HAS2 -1,046451784 4,85615E-26 
909 ENSG00000082781 ITGB5 -1,046015404 3,24991E-53 
910 ENSG00000100784 RPS6KA5 -1,045897473 2,67889E-12 
911 ENSG00000076604 TRAF4 -1,043460371 1,0382E-57 
912 ENSG00000087303 NID2 -1,042295098 1,05767E-51 
913 ENSG00000230359 TPI1P2 -1,041226753 0,022069131 
914 ENSG00000168386 FILIP1L -1,041090851 0,027694364 
915 ENSG00000173598 NUDT4 -1,039018764 3,78202E-65 
916 ENSG00000154839 SKA1 -1,035503236 1,19089E-20 
917 ENSG00000245571 AP001258.1 -1,034976094 0,000558051 
918 ENSG00000116299 KIAA1324 -1,03341273 0,024718484 
919 ENSG00000183230 CTNNA3 -1,033118981 0,044464215 
920 ENSG00000001617 SEMA3F -1,032856022 0,0205753 
921 ENSG00000176912 TYMSOS -1,032019308 0,000835237 
922 ENSG00000185442 FAM174B -1,029588957 0,026265639 
923 ENSG00000035499 DEPDC1B -1,028783231 4,30265E-18 
924 ENSG00000137166 FOXP4 -1,027883869 4,79056E-27 
925 ENSG00000119866 BCL11A -1,02771829 0,000429336 
926 ENSG00000170396 ZNF804A -1,027306592 0,029873866 
927 ENSG00000215190 LINC00680 -1,026983539 9,22212E-06 
928 ENSG00000165169 DYNLT3 -1,025239843 2,33031E-21 
929 ENSG00000134758 RNF138 -1,025214519 1,21109E-21 
930 ENSG00000170681 CAVIN4 -1,02503519 0,001613946 
931 ENSG00000271614 ATP2B1-AS1 -1,023745633 0,001470421 
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932 ENSG00000122042 UBL3 -1,02317198 7,71103E-38 
933 ENSG00000149633 KIAA1755 -1,022787724 3,01798E-19 
934 ENSG00000231160 KLF3-AS1 -1,022704748 0,022664167 
935 ENSG00000158234 FAIM -1,02009993 4,98541E-07 
936 ENSG00000101463 SYNDIG1 -1,02003464 2,27534E-08 
937 ENSG00000156395 SORCS3 -1,019381369 3,70406E-14 
938 ENSG00000080503 SMARCA2 -1,019246846 1,8965E-31 
939 ENSG00000165359 INTS6L -1,018575936 8,35595E-09 
940 ENSG00000110092 CCND1 -1,017716106 3,30359E-47 
941 ENSG00000157557 ETS2 -1,0163748 2,55415E-11 
942 ENSG00000088035 ALG6 -1,015783317 2,61712E-17 
943 ENSG00000260633 AC010207.1 -1,015096513 0,044780681 
944 ENSG00000100625 SIX4 -1,01505943 3,96482E-11 
945 ENSG00000111554 MDM1 -1,013122814 5,22381E-08 
946 ENSG00000166851 PLK1 -1,012891876 5,51955E-40 
947 ENSG00000268362 AC092279.1 -1,012700033 3,57358E-05 
948 ENSG00000140534 TICRR -1,012644948 7,12751E-28 
949 ENSG00000140807 NKD1 -1,012281062 1,22797E-06 
950 ENSG00000165795 NDRG2 -1,010650421 4,63421E-48 
951 ENSG00000203819 HIST2H2BC -1,0103519 0,049898102 
952 ENSG00000115350 POLE4 -1,010284471 9,03636E-10 
953 ENSG00000198794 SCAMP5 -1,010261415 2,55291E-27 
954 ENSG00000129810 SGO1 -1,009462293 1,31024E-13 
955 ENSG00000168078 PBK -1,008909205 2,14157E-41 
956 ENSG00000163507 KIAA1524 -1,008560185 2,41613E-27 
957 ENSG00000178878 APOLD1 -1,006613327 5,35411E-16 
958 ENSG00000175548 ALG10B -1,005684784 0,00012887 
959 ENSG00000112290 WASF1 -1,004678902 2,88957E-25 
960 ENSG00000114346 ECT2 -1,00344333 2,16593E-46 
961 ENSG00000145075 CCDC39 -1,003255067 0,000102997 
962 ENSG00000167964 RAB26 -1,003154732 0,000320998 
963 ENSG00000167912 AC090152.1 -1,003090802 1,84082E-06 
964 ENSG00000155970 MICU3 -1,002945469 3,90396E-05 
965 ENSG00000182118 FAM89A -1,002828412 3,16804E-14 
966 ENSG00000256463 SALL3 -1,002024558 5,15305E-37 
967 ENSG00000138160 KIF11 -1,001694832 3,59566E-37 
968 ENSG00000142303 ADAMTS10 -1,001456978 2,90898E-11 
969 ENSG00000213190 MLLT11 -1,000298206 2,22478E-29 
970 ENSG00000109805 NCAPG -0,999802695 2,29589E-28 
971 ENSG00000184661 CDCA2 -0,998933884 4,51945E-24 
972 ENSG00000121211 MND1 -0,998347706 1,54282E-06 
973 ENSG00000112773 FAM46A -0,996934331 4,19063E-08 
974 ENSG00000076706 MCAM -0,995653626 1,00494E-62 
975 ENSG00000007402 CACNA2D2 -0,993325954 2,31228E-06 
976 ENSG00000159023 EPB41 -0,992813163 4,73928E-32 
977 ENSG00000134343 ANO3 -0,992755185 0,019340199 
978 ENSG00000167861 HID1 -0,99259227 4,01076E-12 
979 ENSG00000264364 DYNLL2 -0,992493076 2,0296E-48 
980 ENSG00000170540 ARL6IP1 -0,991965006 6,84025E-67 
981 ENSG00000272817 AL359198.1 -0,989511981 0,030657038 
982 ENSG00000255153 TOLLIP-AS1 -0,989163842 0,033380462 
983 ENSG00000177842 ZNF620 -0,988992086 1,75995E-10 
984 ENSG00000092964 DPYSL2 -0,988482544 2,1416E-63 
985 ENSG00000227124 ZNF717 -0,987523282 0,015138911 
986 ENSG00000186446 ZNF501 -0,986836754 2,3803E-07 
987 ENSG00000187764 SEMA4D -0,985319913 3,65512E-20 
988 ENSG00000189057 FAM111B -0,985091374 1,04811E-19 
989 ENSG00000229676 ZNF492 -0,984594866 0,021826731 
990 ENSG00000197381 ADARB1 -0,984436283 2,08722E-13 
991 ENSG00000173811 CCDC13-AS1 -0,983600705 0,041735331 
992 ENSG00000164574 GALNT10 -0,982757983 1,50863E-48 
993 ENSG00000156398 SFXN2 -0,982093564 4,9536E-07 
994 ENSG00000084628 NKAIN1 -0,980747232 9,97368E-11 
995 ENSG00000182575 NXPH3 -0,98044867 0,000119963 
996 ENSG00000103044 HAS3 -0,980134382 6,0819E-27 
997 ENSG00000110693 SOX6 -0,979337356 2,70518E-55 
998 ENSG00000228630 HOTAIR -0,979169951 0,02671191 
999 ENSG00000101447 FAM83D -0,978690496 8,0276E-23 
1000 ENSG00000263146 LINC01896 -0,977960793 1,418E-18 
1001 ENSG00000166689 PLEKHA7 -0,977901691 6,56618E-09 
1002 ENSG00000144868 TMEM108 -0,976871153 3,74961E-16 
1003 ENSG00000236499 LINC00896 -0,975710035 0,030329363 
1004 ENSG00000100596 SPTLC2 -0,974824024 2,24503E-25 
1005 ENSG00000196081 ZNF724 -0,974729847 1,97579E-07 
1006 ENSG00000117569 PTBP2 -0,97454883 3,43819E-12 
1007 ENSG00000052795 FNIP2 -0,97283337 2,31554E-11 
1008 ENSG00000158352 SHROOM4 -0,972534129 2,2007E-25 
1009 ENSG00000182568 SATB1 -0,97229392 5,13427E-32 
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1010 ENSG00000151883 PARP8 -0,971985817 1,04153E-15 
1011 ENSG00000072134 EPN2 -0,971573541 2,69348E-47 
1012 ENSG00000141298 SSH2 -0,971165696 2,46849E-22 
1013 ENSG00000103037 SETD6 -0,971072695 0,000108954 
1014 ENSG00000214940 NPIPA8 -0,968566925 0,01990221 
1015 ENSG00000171316 CHD7 -0,968064694 7,16031E-50 
1016 ENSG00000137804 NUSAP1 -0,966776255 5,04911E-61 
1017 ENSG00000183856 IQGAP3 -0,966564846 3,30934E-42 
1018 ENSG00000273274 ZBTB8B -0,965840543 7,72797E-08 
1019 ENSG00000130997 POLN -0,965736346 0,003718624 
1020 ENSG00000259877 AC009113.1 -0,965647706 0,000191463 
1021 ENSG00000114993 RTKN -0,964723154 1,82952E-45 
1022 ENSG00000189283 FHIT -0,964237102 0,000177074 
1023 ENSG00000136938 ANP32B -0,96409853 4,46739E-59 
1024 ENSG00000171681 ATF7IP -0,963510308 4,76738E-28 
1025 ENSG00000213988 ZNF90 -0,96320001 1,70268E-05 
1026 ENSG00000183963 SMTN -0,963188062 1,38245E-18 
1027 ENSG00000164093 PITX2 -0,963034691 0,010388506 
1028 ENSG00000173546 CSPG4 -0,962664693 6,72933E-13 
1029 ENSG00000169607 CKAP2L -0,962456777 8,25011E-27 
1030 ENSG00000163083 INHBB -0,962232925 0,000112194 
1031 ENSG00000269821 KCNQ1OT1 -0,961064966 1,55581E-06 
1032 ENSG00000162063 CCNF -0,960874892 1,66072E-18 
1033 ENSG00000169562 GJB1 -0,960577489 5,46538E-09 
1034 ENSG00000066279 ASPM -0,959201966 2,1929E-09 
1035 ENSG00000150275 PCDH15 -0,959077417 6,90889E-37 
1036 ENSG00000196507 TCEAL3 -0,958613228 1,02378E-20 
1037 ENSG00000095203 EPB41L4B -0,957301205 0,000103681 
1038 ENSG00000105767 CADM4 -0,956635499 2,06554E-68 
1039 ENSG00000150907 FOXO1 -0,955011195 1,29192E-13 
1040 ENSG00000260807 AC009041.2 -0,953224142 9,51354E-36 
1041 ENSG00000095383 TBC1D2 -0,953083977 9,1498E-05 
1042 ENSG00000100225 FBXO7 -0,95272056 1,54104E-58 
1043 ENSG00000080573 COL5A3 -0,952685283 1,17355E-21 
1044 ENSG00000109654 TRIM2 -0,952671758 2,18207E-14 
1045 ENSG00000101347 SAMHD1 -0,952643896 2,02199E-16 
1046 ENSG00000186871 ERCC6L -0,950819237 5,16402E-10 
1047 ENSG00000155629 PIK3AP1 -0,950029493 0,019678487 
1048 ENSG00000136824 SMC2 -0,950006716 3,80409E-41 
1049 ENSG00000270964 AC016355.1 -0,948716909 0,047676615 
1050 ENSG00000102221 JADE3 -0,948242872 1,85306E-23 
1051 ENSG00000186193 SAPCD2 -0,948040087 2,81152E-43 
1052 ENSG00000146281 PM20D2 -0,947705804 3,40027E-21 
1053 ENSG00000165424 ZCCHC24 -0,947209213 3,38563E-42 
1054 ENSG00000185614 FAM212A -0,946533928 0,007905656 
1055 ENSG00000079482 OPHN1 -0,943346082 7,89835E-25 
1056 ENSG00000177359 AC024940.1 -0,943011178 1,3324E-05 
1057 ENSG00000120251 GRIA2 -0,942184508 1,05224E-29 
1058 ENSG00000188783 PRELP -0,941762835 9,58792E-10 
1059 ENSG00000169306 IL1RAPL1 -0,941450982 0,010950268 
1060 ENSG00000134779 TPGS2 -0,941416223 1,26005E-47 
1061 ENSG00000272121 AC006058.3 -0,940452741 0,032456384 
1062 ENSG00000172426 RSPH9 -0,937328427 0,02811578 
1063 ENSG00000147364 FBXO25 -0,937173235 7,40354E-09 
1064 ENSG00000138316 ADAMTS14 -0,936564331 0,00042986 
1065 ENSG00000166801 FAM111A -0,935285476 2,23911E-30 
1066 ENSG00000101412 E2F1 -0,933778905 3,83382E-27 
1067 ENSG00000163576 EFHB -0,932164044 0,000549727 
1068 ENSG00000030419 IKZF2 -0,93178689 0,006065442 
1069 ENSG00000237238 BMS1P10 -0,931440901 1,07419E-05 
1070 ENSG00000139344 AMDHD1 -0,931267179 0,046517548 
1071 ENSG00000148541 FAM13C -0,930323453 0,00017352 
1072 ENSG00000011332 DPF1 -0,930243241 5,87502E-16 
1073 ENSG00000180611 MB21D2 -0,929470087 8,32911E-06 
1074 ENSG00000156802 ATAD2 -0,929308255 2,20567E-45 
1075 ENSG00000051341 POLQ -0,92808807 1,98959E-18 
1076 ENSG00000154429 CCSAP -0,92783709 1,84391E-27 
1077 ENSG00000164850 GPER1 -0,926801267 0,001687689 
1078 ENSG00000049192 ADAMTS6 -0,92666256 0,014860022 
1079 ENSG00000184588 PDE4B -0,926438369 2,27955E-46 
1080 ENSG00000096092 TMEM14A -0,92584623 1,19957E-09 
1081 ENSG00000166816 LDHD -0,92534725 0,035526376 
1082 ENSG00000175048 ZDHHC14 -0,925048006 1,70506E-10 
1083 ENSG00000272447 AL135925.1 -0,924823271 0,002410115 
1084 ENSG00000177511 ST8SIA3 -0,922934167 0,004775875 
1085 ENSG00000134030 CTIF -0,922068283 4,42416E-27 
1086 ENSG00000128923 MINDY2 -0,920894966 3,3842E-12 
1087 ENSG00000143476 DTL -0,919404548 7,63297E-28 
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1088 ENSG00000112541 PDE10A -0,91903624 7,30878E-09 
1089 ENSG00000196935 SRGAP1 -0,918396639 2,92271E-21 
1090 ENSG00000158769 F11R -0,91566045 0,003379847 
1091 ENSG00000068078 FGFR3 -0,914495101 9,48434E-35 
1092 ENSG00000067445 TRO -0,913857845 2,19548E-41 
1093 ENSG00000100105 PATZ1 -0,913667231 4,23887E-26 
1094 ENSG00000239445 ST3GAL6-AS1 -0,913354042 0,007022502 
1095 ENSG00000108821 COL1A1 -0,913094951 0,000619283 
1096 ENSG00000167608 TMC4 -0,912781638 0,033586344 
1097 ENSG00000065989 PDE4A -0,912643867 2,96813E-09 
1098 ENSG00000072571 HMMR -0,911295924 4,19619E-16 
1099 ENSG00000178764 ZHX2 -0,910907627 1,21438E-18 
1100 ENSG00000197872 FAM49A -0,910058884 3,04855E-18 
1101 ENSG00000134954 ETS1 -0,909154234 2,6185E-34 
1102 ENSG00000115339 GALNT3 -0,907078758 0,011484218 
1103 ENSG00000157152 SYN2 -0,906054776 5,05734E-05 
1104 ENSG00000196381 ZNF781 -0,905843923 0,003667562 
1105 ENSG00000101439 CST3 -0,905658824 9,81201E-47 
1106 ENSG00000129521 EGLN3 -0,904491944 5,6144E-07 
1107 ENSG00000131831 RAI2 -0,902133495 0,007172101 
1108 ENSG00000137574 TGS1 -0,901780235 1,45844E-14 
1109 ENSG00000137767 SQOR -0,901476322 0,034110412 
1110 ENSG00000104368 PLAT -0,901166058 6,09457E-46 
1111 ENSG00000056736 IL17RB -0,900985233 4,16555E-08 
1112 ENSG00000165480 SKA3 -0,90075986 2,92905E-12 
1113 ENSG00000165478 HEPACAM -0,898105904 1,66125E-19 
1114 ENSG00000233237 LINC00472 -0,897889761 0,005921273 
1115 ENSG00000135916 ITM2C -0,897698902 1,97057E-55 
1116 ENSG00000184602 SNN -0,897492506 1,71645E-28 
1117 ENSG00000256673 AC141557.1 -0,896188367 0,005595849 
1118 ENSG00000109472 CPE -0,896061159 1,81333E-20 
1119 ENSG00000231305 AC112484.2 -0,895254927 0,041744992 
1120 ENSG00000129646 QRICH2 -0,894679432 3,79197E-08 
1121 ENSG00000153310 FAM49B -0,891653948 8,3202E-23 
1122 ENSG00000105088 OLFM2 -0,890611658 4,65882E-33 
1123 ENSG00000122952 ZWINT -0,890256326 4,0604E-22 
1124 ENSG00000170802 FOXN2 -0,890034266 1,80841E-19 
1125 ENSG00000088325 TPX2 -0,890009746 2,38839E-46 
1126 ENSG00000101608 MYL12A -0,889745567 7,34326E-25 
1127 ENSG00000198948 MFAP3L -0,889177303 0,000232682 
1128 ENSG00000177565 TBL1XR1 -0,889165725 1,64504E-34 
1129 ENSG00000135045 C9orf40 -0,888880028 9,47351E-10 
1130 ENSG00000013810 TACC3 -0,888040112 1,29645E-29 
1131 ENSG00000134900 TPP2 -0,88783967 4,99569E-28 
1132 ENSG00000259683 AC243562.2 -0,887591661 0,029234075 
1133 ENSG00000175322 ZNF519 -0,886964593 6,58222E-09 
1134 ENSG00000165813 CCDC186 -0,885060984 3,69737E-05 
1135 ENSG00000112149 CD83 -0,884878714 1,00931E-09 
1136 ENSG00000130675 MNX1 -0,883779214 1,17741E-05 
1137 ENSG00000196724 ZNF418 -0,881883366 8,59525E-05 
1138 ENSG00000171462 DLK2 -0,881785622 0,001110371 
1139 ENSG00000186767 SPIN4 -0,881539876 2,22019E-10 
1140 ENSG00000262246 CORO7 -0,881230501 5,70473E-07 
1141 ENSG00000184349 EFNA5 -0,879870992 0,044396071 
1142 ENSG00000101057 MYBL2 -0,879162352 1,68226E-32 
1143 ENSG00000154914 USP43 -0,878499736 6,72181E-05 
1144 ENSG00000206560 ANKRD28 -0,877601455 4,55769E-30 
1145 ENSG00000118298 CA14 -0,877296182 6,82291E-20 
1146 ENSG00000175130 MARCKSL1 -0,876988963 2,95085E-51 
1147 ENSG00000112759 SLC29A1 -0,87609857 3,17482E-14 
1148 ENSG00000141428 C18orf21 -0,875688205 1,4801E-12 
1149 ENSG00000016391 CHDH -0,875212249 8,25896E-10 
1150 ENSG00000141384 TAF4B -0,874993588 0,000120215 
1151 ENSG00000257167 TMPO-AS1 -0,874705272 0,000115044 
1152 ENSG00000075218 GTSE1 -0,874590725 6,02345E-31 
1153 ENSG00000100167 SEPT3 -0,873808832 5,39419E-43 
1154 ENSG00000167536 DHRS13 -0,872434327 3,85698E-08 
1155 ENSG00000154217 PITPNC1 -0,871856483 2,23493E-09 
1156 ENSG00000163781 TOPBP1 -0,871802466 3,11677E-35 
1157 ENSG00000113368 LMNB1 -0,870500866 4,49573E-45 
1158 ENSG00000109062 SLC9A3R1 -0,870212276 6,15098E-18 
1159 ENSG00000051180 RAD51 -0,869361443 7,13298E-11 
1160 ENSG00000158402 CDC25C -0,869150422 1,23287E-13 
1161 ENSG00000176393 RNPEP -0,869075757 7,60504E-21 
1162 ENSG00000101888 NXT2 -0,867470065 9,15027E-10 
1163 ENSG00000224728 IMPDH1P8 -0,866326335 0,043592665 
1164 ENSG00000175155 YPEL2 -0,866236991 2,93485E-11 
1165 ENSG00000100908 EMC9 -0,866017916 7,85217E-08 
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1166 ENSG00000165152 TMEM246 -0,865731101 8,7586E-22 
1167 ENSG00000142512 SIGLEC10 -0,864055152 0,006128612 
1168 ENSG00000159263 SIM2 -0,863668313 9,71495E-14 
1169 ENSG00000149503 INCENP -0,862922689 5,6036E-28 
1170 ENSG00000226742 HSBP1L1 -0,862846609 0,03657379 
1171 ENSG00000154917 RAB6B -0,861813021 4,60461E-08 
1172 ENSG00000141401 IMPA2 -0,861355623 3,61912E-14 
1173 ENSG00000127564 PKMYT1 -0,861095419 2,12447E-13 
1174 ENSG00000168056 LTBP3 -0,86107602 2,38828E-29 
1175 ENSG00000166974 MAPRE2 -0,860101293 1,17102E-29 
1176 ENSG00000187049 TMEM216 -0,859911278 0,001054817 
1177 ENSG00000150471 ADGRL3 -0,859647796 2,04252E-34 
1178 ENSG00000166803 PCLAF -0,859457521 4,90111E-13 
1179 ENSG00000186868 MAPT -0,859092661 2,03088E-13 
1180 ENSG00000156970 BUB1B -0,854852179 2,82809E-28 
1181 ENSG00000121152 NCAPH -0,853721814 4,34094E-23 
1182 ENSG00000081913 PHLPP1 -0,85274376 2,01467E-38 
1183 ENSG00000183250 LINC01547 -0,8525044 0,005920194 
1184 ENSG00000116016 EPAS1 -0,851938344 2,68056E-19 
1185 ENSG00000131437 KIF3A -0,851919058 6,9829E-16 
1186 ENSG00000140396 NCOA2 -0,851345241 4,26878E-21 
1187 ENSG00000235919 ASH1L-AS1 -0,851106626 0,048949968 
1188 ENSG00000115163 CENPA -0,850936469 1,10612E-11 
1189 ENSG00000147234 FRMPD3 -0,850788869 1,00055E-05 
1190 ENSG00000157150 TIMP4 -0,848520806 6,70455E-29 
1191 ENSG00000104331 IMPAD1 -0,848010201 1,49788E-40 
1192 ENSG00000197622 CDC42SE1 -0,847335091 3,09651E-32 
1193 ENSG00000178966 RMI1 -0,846330417 5,32944E-12 
1194 ENSG00000038382 TRIO -0,845647065 1,59176E-52 
1195 ENSG00000119686 FLVCR2 -0,845176397 0,013771179 
1196 ENSG00000121454 LHX4 -0,844866336 0,001354614 
1197 ENSG00000024526 DEPDC1 -0,844359834 2,13957E-16 
1198 ENSG00000267325 LINC01415 -0,844060666 0,011668539 
1199 ENSG00000104218 CSPP1 -0,842237731 1,31112E-10 
1200 ENSG00000180964 TCEAL8 -0,840678459 5,25363E-17 
1201 ENSG00000129534 MIS18BP1 -0,839879691 7,21572E-16 
1202 ENSG00000010282 HHATL -0,839279965 0,04970852 
1203 ENSG00000261455 LINC01003 -0,83834827 0,002655403 
1204 ENSG00000204128 C2orf72 -0,837799964 5,14079E-19 
1205 ENSG00000177873 ZNF619 -0,836948685 2,36855E-07 
1206 ENSG00000164045 CDC25A -0,836679632 1,19292E-14 
1207 ENSG00000148604 RGR -0,836656405 0,007408533 
1208 ENSG00000196678 ERI2 -0,836262391 3,34837E-11 
1209 ENSG00000125378 BMP4 -0,836211295 0,022587153 
1210 ENSG00000139597 N4BP2L1 -0,834892762 0,003140823 
1211 ENSG00000081154 PCNP -0,833839585 3,18788E-30 
1212 ENSG00000090238 YPEL3 -0,833795809 1,1105E-06 
1213 ENSG00000130962 PRRG1 -0,83280575 0,000247793 
1214 ENSG00000154548 SRSF12 -0,832534564 5,5431E-07 
1215 ENSG00000272933 AL391121.1 -0,83160555 0,013929966 
1216 ENSG00000075340 ADD2 -0,830957035 7,59568E-22 
1217 ENSG00000228801 AC064807.1 -0,829850697 0,019303489 
1218 ENSG00000176597 B3GNT5 -0,829466808 3,20715E-13 
1219 ENSG00000167771 RCOR2 -0,829381881 4,86889E-17 
1220 ENSG00000171817 ZNF540 -0,827969858 0,027462952 
1221 ENSG00000183337 BCOR -0,827902893 7,91843E-18 
1222 ENSG00000077152 UBE2T -0,825490102 1,35687E-18 
1223 ENSG00000163531 NFASC -0,824963495 2,58029E-18 
1224 ENSG00000181467 RAP2B -0,824630951 9,80853E-14 
1225 ENSG00000242539 AC007620.2 -0,824627018 1,68108E-08 
1226 ENSG00000066735 KIF26A -0,824067683 0,049103544 
1227 ENSG00000133138 TBC1D8B -0,823950631 0,000235831 
1228 ENSG00000005249 PRKAR2B -0,823586758 2,55628E-11 
1229 ENSG00000157456 CCNB2 -0,822377096 8,16677E-29 
1230 ENSG00000116990 MYCL -0,822075481 8,85368E-07 
1231 ENSG00000168461 RAB31 -0,822029695 4,60319E-45 
1232 ENSG00000164418 GRIK2 -0,820715819 1,66507E-15 
1233 ENSG00000168952 STXBP6 -0,820118631 0,000288939 
1234 ENSG00000174371 EXO1 -0,819588306 1,33663E-12 
1235 ENSG00000166845 C18orf54 -0,817910051 9,38168E-13 
1236 ENSG00000145386 CCNA2 -0,817743406 1,01302E-19 
1237 ENSG00000081320 STK17B -0,817236769 1,38861E-05 
1238 ENSG00000102316 MAGED2 -0,817174191 3,83736E-53 
1239 ENSG00000182481 KPNA2 -0,81710958 3,38487E-44 
1240 ENSG00000164082 GRM2 -0,815866427 0,039201858 
1241 ENSG00000196517 SLC6A9 -0,814756416 5,74006E-13 
1242 ENSG00000142149 HUNK -0,814591975 2,25528E-14 
1243 ENSG00000206417 H1FX-AS1 -0,814264931 0,003360917 
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1244 ENSG00000100162 CENPM -0,814134837 5,2074E-16 
1245 ENSG00000205704 LINC00634 -0,813156267 0,005841504 
1246 ENSG00000172361 CFAP53 -0,812883763 0,040293359 
1247 ENSG00000034533 ASTE1 -0,812308469 1,14082E-05 
1248 ENSG00000113645 WWC1 -0,812077666 1,42895E-21 
1249 ENSG00000213347 MXD3 -0,812051902 2,51735E-25 
1250 ENSG00000166317 SYNPO2L -0,810548867 0,006494403 
1251 ENSG00000164754 RAD21 -0,810462339 1,74521E-44 
1252 ENSG00000149294 NCAM1 -0,809971915 1,21508E-51 
1253 ENSG00000120802 TMPO -0,808998739 2,86773E-36 
1254 ENSG00000137478 FCHSD2 -0,808750047 7,69137E-20 
1255 ENSG00000205268 PDE7A -0,807993722 2,27811E-10 
1256 ENSG00000109674 NEIL3 -0,805627168 6,39029E-06 
1257 ENSG00000085719 CPNE3 -0,804848614 1,15144E-32 
1258 ENSG00000170312 CDK1 -0,804487784 5,66281E-28 
1259 ENSG00000103145 HCFC1R1 -0,803911121 2,0228E-09 
1260 ENSG00000180834 MAP6D1 -0,802683357 2,61479E-09 
1261 ENSG00000213888 LINC01521 -0,802556243 0,009367796 
1262 ENSG00000139946 PELI2 -0,801262071 1,92393E-08 
1263 ENSG00000117906 RCN2 -0,800595477 5,25185E-32 
1264 ENSG00000114853 ZBTB47 -0,800118696 2,96857E-21 
1265 ENSG00000171408 PDE7B -0,799885927 2,13198E-07 
1266 ENSG00000249859 PVT1 -0,799804371 3,11044E-05 
1267 ENSG00000036448 MYOM2 -0,799023842 0,015104105 
1268 ENSG00000175029 CTBP2 -0,797127685 1,14584E-19 
1269 ENSG00000164506 STXBP5 -0,795467925 0,000735973 
1270 ENSG00000154639 CXADR -0,795293062 2,81938E-26 
1271 ENSG00000239521 GATS -0,794830271 3,97226E-07 
1272 ENSG00000163939 PBRM1 -0,794731355 6,58797E-28 
1273 ENSG00000151725 CENPU -0,794351577 7,13298E-11 
1274 ENSG00000134049 IER3IP1 -0,794074555 8,12321E-11 
1275 ENSG00000247081 BAALC-AS1 -0,793995204 0,006737761 
1276 ENSG00000125871 MGME1 -0,793427837 6,45758E-12 
1277 ENSG00000109458 GAB1 -0,792544424 5,9927E-18 
1278 ENSG00000270504 AL391422.3 -0,792147277 0,000223044 
1279 ENSG00000144647 POMGNT2 -0,791020518 8,45344E-28 
1280 ENSG00000103485 QPRT -0,790985822 1,24776E-06 
1281 ENSG00000173786 CNP -0,790863543 2,19204E-44 
1282 ENSG00000105011 ASF1B -0,790768542 5,15417E-23 
1283 ENSG00000103257 SLC7A5 -0,790374453 7,58017E-16 
1284 ENSG00000121542 SEC22A -0,79029391 1,32104E-06 
1285 ENSG00000244274 DBNDD2 -0,790105479 0,039228752 
1286 ENSG00000031003 FAM13B -0,789401691 7,14324E-11 
1287 ENSG00000073849 ST6GAL1 -0,788956986 7,71892E-20 
1288 ENSG00000185920 PTCH1 -0,788414712 3,75681E-23 
1289 ENSG00000122824 NUDT10 -0,787744668 2,78899E-07 
1290 ENSG00000122547 EEPD1 -0,787348456 4,6124E-08 
1291 ENSG00000105519 CAPS -0,787329341 4,34837E-17 
1292 ENSG00000101856 PGRMC1 -0,787063647 4,088E-31 
1293 ENSG00000166123 GPT2 -0,786850803 2,70688E-30 
1294 ENSG00000088808 PPP1R13B -0,786138942 2,7135E-05 
1295 ENSG00000172014 ANKRD20A4 -0,786136741 0,004123567 
1296 ENSG00000115884 SDC1 -0,785469671 2,06212E-23 
1297 ENSG00000159915 ZNF233 -0,785329788 0,017211914 
1298 ENSG00000092096 SLC22A17 -0,783165675 4,93192E-29 
1299 ENSG00000065154 OAT -0,782732618 8,17314E-21 
1300 ENSG00000178567 EPM2AIP1 -0,782544619 3,79096E-21 
1301 ENSG00000149636 DSN1 -0,782468955 1,0056E-10 
1302 ENSG00000163946 FAM208A -0,7822145 1,11068E-20 
1303 ENSG00000164989 CCDC171 -0,779543264 0,031172719 
1304 ENSG00000188706 ZDHHC9 -0,779055475 2,90603E-21 
1305 ENSG00000114857 NKTR -0,778980102 1,8304E-27 
1306 ENSG00000260018 AC040169.1 -0,77841432 0,035983408 
1307 ENSG00000070413 DGCR2 -0,777529249 3,49655E-39 
1308 ENSG00000146263 MMS22L -0,777229036 1,58845E-08 
1309 ENSG00000173599 PC -0,777074399 1,31004E-17 
1310 ENSG00000102931 ARL2BP -0,776453582 1,17228E-26 
1311 ENSG00000183444 OR7E38P -0,775965869 0,031645184 
1312 ENSG00000139211 AMIGO2 -0,775955172 0,006957032 
1313 ENSG00000146005 PSD2 -0,775609092 0,00274732 
1314 ENSG00000065413 ANKRD44 -0,775370161 5,91239E-09 
1315 ENSG00000166377 ATP9B -0,774892916 1,00991E-16 
1316 ENSG00000136243 NUPL2 -0,774527392 1,61377E-14 
1317 ENSG00000182504 CEP97 -0,774103073 5,90899E-16 
1318 ENSG00000157349 DDX19B -0,774021355 3,02012E-05 
1319 ENSG00000138778 CENPE -0,773822308 2,14353E-15 
1320 ENSG00000203952 CCDC160 -0,773768288 0,042566781 
1321 ENSG00000189319 FAM53B -0,773529283 4,74357E-09 
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1322 ENSG00000170579 DLGAP1 -0,773216844 6,13788E-14 
1323 ENSG00000064300 NGFR -0,773124544 1,67213E-19 
1324 ENSG00000164087 POC1A -0,773118601 3,55995E-15 
1325 ENSG00000160229 ZNF66 -0,771857264 0,021595617 
1326 ENSG00000187391 MAGI2 -0,77148237 3,1574E-11 
1327 ENSG00000154080 CHST9 -0,771358675 0,017912223 
1328 ENSG00000119900 OGFRL1 -0,77129471 3,47281E-09 
1329 ENSG00000198300 PEG3 -0,771090251 9,80138E-18 
1330 ENSG00000156531 PHF6 -0,77071798 1,46765E-27 
1331 ENSG00000113790 EHHADH -0,770128193 0,00439801 
1332 ENSG00000144285 SCN1A -0,769095834 6,56716E-21 
1333 ENSG00000273329 AC078846.1 -0,767956094 0,00179594 
1334 ENSG00000104738 MCM4 -0,767705079 3,444E-36 
1335 ENSG00000159958 TNFRSF13C -0,767644924 0,021846174 
1336 ENSG00000083097 DOPEY1 -0,767334032 7,92097E-11 
1337 ENSG00000162458 FBLIM1 -0,767313586 2,26337E-07 
1338 ENSG00000111206 FOXM1 -0,766560654 1,96913E-26 
1339 ENSG00000106617 PRKAG2 -0,765719278 0,000756461 
1340 ENSG00000164611 PTTG1 -0,765132064 8,42505E-26 
1341 ENSG00000086300 SNX10 -0,765109524 1,82509E-08 
1342 ENSG00000130224 LRCH2 -0,7651059 1,91127E-06 
1343 ENSG00000122545 SEPT7 -0,764968282 1,81171E-39 
1344 ENSG00000271936 AC012073.1 -0,764734406 0,010672266 
1345 ENSG00000131242 RAB11FIP4 -0,764351153 0,000125329 
1346 ENSG00000205413 SAMD9 -0,76375255 9,96337E-07 
1347 ENSG00000173801 JUP -0,763194827 0,001390223 
1348 ENSG00000272870 AC097534.2 -0,76285746 0,036083792 
1349 ENSG00000126778 SIX1 -0,762301684 8,03713E-10 
1350 ENSG00000151466 SCLT1 -0,762153933 0,000167934 
1351 ENSG00000124795 DEK -0,761440813 5,48035E-34 
1352 ENSG00000109832 DDX25 -0,759995531 0,006306709 
1353 ENSG00000204839 MROH6 -0,759863682 0,037150615 
1354 ENSG00000186185 KIF18B -0,759834576 8,25953E-23 
1355 ENSG00000112742 TTK -0,759702577 1,36456E-18 
1356 ENSG00000109046 WSB1 -0,759598082 3,3908E-31 
1357 ENSG00000118200 CAMSAP2 -0,758784553 3,93602E-25 
1358 ENSG00000041515 MYO16 -0,758612222 0,000148238 
1359 ENSG00000197696 NMB -0,758259974 0,02671191 
1360 ENSG00000090097 PCBP4 -0,75730662 3,2959E-36 
1361 ENSG00000100479 POLE2 -0,756911443 0,000760745 
1362 ENSG00000272899 AC025594.3 -0,756559376 0,0481601 
1363 ENSG00000187952 HS6ST1P1 -0,75652167 0,019614379 
1364 ENSG00000183077 AFMID -0,756354687 4,77758E-06 
1365 ENSG00000167088 SNRPD1 -0,75625477 1,15451E-20 
1366 ENSG00000163788 SNRK -0,755255737 8,38685E-13 
1367 ENSG00000103056 SMPD3 -0,755039563 0,006532891 
1368 ENSG00000138311 ZNF365 -0,754372565 9,55456E-06 
1369 ENSG00000170049 KCNAB3 -0,753555326 0,034393232 
1370 ENSG00000196741 LINC01560 -0,75353954 0,031398048 
1371 ENSG00000113810 SMC4 -0,753359602 8,48924E-29 
1372 ENSG00000138468 SENP7 -0,752619414 3,19544E-13 
1373 ENSG00000272758 AC083798.2 -0,752580646 0,021902406 
1374 ENSG00000104369 JPH1 -0,752552154 9,84263E-05 
1375 ENSG00000196693 ZNF33B -0,752458854 0,00025465 
1376 ENSG00000132613 MTSS1L -0,751837133 7,14925E-25 
1377 ENSG00000206561 COLQ -0,751017681 0,024350557 
1378 ENSG00000167363 FN3K -0,750980418 0,037840074 
1379 ENSG00000084070 SMAP2 -0,750750424 4,81164E-16 
1380 ENSG00000140948 ZCCHC14 -0,750737404 2,85948E-16 
1381 ENSG00000141753 IGFBP4 -0,750328086 7,84237E-25 
1382 ENSG00000272686 AC006333.2 -0,750220594 0,000273619 
1383 ENSG00000164402 SEPT8 -0,750051133 6,98836E-36 
1384 ENSG00000182158 CREB3L2 -0,749801028 1,29705E-18 
1385 ENSG00000012983 MAP4K5 -0,749142467 1,79635E-20 
1386 ENSG00000160539 PLPP7 -0,748553197 0,034544297 
1387 ENSG00000179314 WSCD1 -0,748007999 1,94487E-30 
1388 ENSG00000102409 BEX4 -0,747878284 2,89922E-18 
1389 ENSG00000160447 PKN3 -0,747172329 1,5978E-11 
1390 ENSG00000184939 ZFP90 -0,746840965 2,13973E-15 
1391 ENSG00000123473 STIL -0,746817346 3,1114E-11 
1392 ENSG00000142945 KIF2C -0,745776952 6,68556E-23 
1393 ENSG00000101333 PLCB4 -0,745559357 5,25186E-07 
1394 ENSG00000151929 BAG3 -0,744884425 1,65814E-11 
1395 ENSG00000112029 FBXO5 -0,744766358 3,04922E-15 
1396 ENSG00000185269 NOTUM -0,744507345 0,014153691 
1397 ENSG00000214756 METTL12 -0,744457389 0,045291392 
1398 ENSG00000132646 PCNA -0,743755465 2,167E-27 
1399 ENSG00000206579 XKR4 -0,743275481 0,012850913 
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1400 ENSG00000272655 POLR2J4 -0,741932916 0,045305309 
1401 ENSG00000070087 PFN2 -0,740020962 1,56876E-41 
1402 ENSG00000088387 DOCK9 -0,740008194 1,32237E-09 
1403 ENSG00000116667 C1orf21 -0,739980427 6,25659E-34 
1404 ENSG00000145284 SCD5 -0,739689179 1,4678E-37 
1405 ENSG00000140945 CDH13 -0,739685245 6,01949E-28 
1406 ENSG00000114631 PODXL2 -0,739564291 5,20591E-31 
1407 ENSG00000143842 SOX13 -0,739287403 4,05455E-23 
1408 ENSG00000168243 GNG4 -0,738466884 2,01758E-17 
1409 ENSG00000053747 LAMA3 -0,737759245 0,034858662 
1410 ENSG00000267100 ILF3-AS1 -0,737670536 1,93053E-10 
1411 ENSG00000197712 FAM114A1 -0,73764301 1,95763E-06 
1412 ENSG00000164070 HSPA4L -0,737495391 2,6213E-05 
1413 ENSG00000129195 PIMREG -0,737052475 4,2562E-26 
1414 ENSG00000156735 BAG4 -0,736906065 4,78953E-07 
1415 ENSG00000148835 TAF5 -0,736423324 0,001689131 
1416 ENSG00000203880 PCMTD2 -0,735368627 9,08705E-24 
1417 ENSG00000168300 PCMTD1 -0,735296813 9,1134E-07 
1418 ENSG00000214016 RPSAP61 -0,735079483 0,036129459 
1419 ENSG00000106799 TGFBR1 -0,734845547 2,42576E-20 
1420 ENSG00000197563 PIGN -0,734079338 9,2975E-12 




1423 ENSG00000162415 ZSWIM5 -0,732335594 0,000227192 
1424 ENSG00000163535 SGO2 -0,731739242 1,85898E-15 
1425 ENSG00000069712 KIAA1107 -0,731416536 0,021259397 
1426 ENSG00000172602 RND1 -0,731293915 0,007771946 
1427 ENSG00000171067 C11orf24 -0,731161422 3,22378E-16 
1428 ENSG00000089685 BIRC5 -0,73091772 3,52115E-14 
1429 ENSG00000081189 MEF2C -0,730451559 4,94173E-08 
1430 ENSG00000146278 PNRC1 -0,730398796 3,84998E-18 
1431 ENSG00000110047 EHD1 -0,730218012 1,04689E-18 
1432 ENSG00000053524 MCF2L2 -0,729823153 0,022383816 
1433 ENSG00000095209 TMEM38B -0,729126293 3,38284E-09 
1434 ENSG00000070882 OSBPL3 -0,72904691 1,61754E-12 
1435 ENSG00000214530 STARD10 -0,728737394 0,000281407 
1436 ENSG00000145675 PIK3R1 -0,728401357 9,65669E-20 
1437 ENSG00000085274 MYNN -0,727274949 3,29041E-07 
1438 ENSG00000163378 EOGT -0,726616705 0,001327846 
1439 ENSG00000259623 AC125257.1 -0,725701137 1,34729E-05 
1440 ENSG00000235423 AC068768.1 -0,725307146 0,01920025 
1441 ENSG00000108039 XPNPEP1 -0,724816286 4,23669E-19 
1442 ENSG00000186106 ANKRD46 -0,722604079 7,21698E-07 
1443 ENSG00000186907 RTN4RL2 -0,72244167 5,86722E-06 
1444 ENSG00000185697 MYBL1 -0,722431183 4,57055E-13 
1445 ENSG00000141646 SMAD4 -0,721564297 1,55656E-17 
1446 ENSG00000146054 TRIM7 -0,721518317 0,001768544 
1447 ENSG00000131797 CLUHP3 -0,721030574 0,000795616 
1448 ENSG00000091157 WDR7 -0,720486433 1,8335E-10 
1449 ENSG00000144152 FBLN7 -0,720297546 0,041902533 
1450 ENSG00000215018 COL28A1 -0,719512291 0,001265585 
1451 ENSG00000076716 GPC4 -0,719324161 1,69077E-20 
1452 ENSG00000131389 SLC6A6 -0,71911499 1,87104E-13 
1453 ENSG00000104969 SGTA -0,718603549 2,61884E-30 
1454 ENSG00000183778 B3GALT5 -0,718198839 0,000424615 
1455 ENSG00000165238 WNK2 -0,71755518 8,64999E-05 
1456 ENSG00000158560 DYNC1I1 -0,71754635 0,027582356 
1457 ENSG00000133111 RFXAP -0,717175216 0,000507202 
1458 ENSG00000182054 IDH2 -0,716876773 1,67549E-24 
1459 ENSG00000102984 ZNF821 -0,716657009 1,26098E-05 
1460 ENSG00000102384 CENPI -0,716109268 1,7758E-08 
1461 ENSG00000146938 NLGN4X -0,716063426 5,10581E-31 
1462 ENSG00000154845 PPP4R1 -0,715808192 2,20701E-21 
1463 ENSG00000153391 INO80C -0,715469801 7,19756E-05 
1464 ENSG00000161542 PRPSAP1 -0,715135516 2,14034E-22 
1465 ENSG00000128805 ARHGAP22 -0,714658771 1,10489E-05 
1466 ENSG00000134755 DSC2 -0,714396962 0,012316879 
1467 ENSG00000087301 TXNDC16 -0,713986723 8,99287E-10 
1468 ENSG00000121864 ZNF639 -0,713811197 3,20176E-12 
1469 ENSG00000035664 DAPK2 -0,71360453 0,015270375 
1470 ENSG00000119969 HELLS -0,713309797 1,28554E-07 
1471 ENSG00000168899 VAMP5 -0,712827832 0,008705362 
1472 ENSG00000149599 DUSP15 -0,71168316 0,002552417 
1473 ENSG00000165476 REEP3 -0,711600564 2,14941E-13 
1474 ENSG00000105613 MAST1 -0,711185595 2,87679E-09 
1475 ENSG00000124193 SRSF6 -0,710297629 1,30274E-28 
1476 ENSG00000198087 CD2AP -0,709854268 4,47314E-06 
1477 ENSG00000067141 NEO1 -0,709477615 1,03511E-22 
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1478 ENSG00000136492 BRIP1 -0,708772162 2,58981E-10 
1479 ENSG00000082212 ME2 -0,708289555 1,02185E-17 
1480 ENSG00000134690 CDCA8 -0,707619682 8,29387E-14 
1481 ENSG00000132561 MATN2 -0,706959973 1,76238E-38 
1482 ENSG00000079435 LIPE -0,705988582 0,00043224 
1483 ENSG00000169330 KIAA1024 -0,705889948 0,017546535 
1484 ENSG00000162174 ASRGL1 -0,705813463 1,38499E-07 
1485 ENSG00000160957 RECQL4 -0,704966301 7,40736E-18 
1486 ENSG00000240024 LINC00888 -0,704597787 1,55178E-07 
1487 ENSG00000079134 THOC1 -0,703663375 8,35198E-12 
1488 ENSG00000197535 MYO5A -0,703482606 6,65206E-20 
1489 ENSG00000101596 SMCHD1 -0,703383313 3,30145E-20 
1490 ENSG00000176971 FIBIN -0,70332985 1,95771E-29 
1491 ENSG00000003436 TFPI -0,701987718 8,36422E-18 
1492 ENSG00000213853 EMP2 -0,701971596 1,48275E-13 
1493 ENSG00000067177 PHKA1 -0,701961211 1,85461E-05 
1494 ENSG00000158987 RAPGEF6 -0,701569995 0,000688733 
1495 ENSG00000135476 ESPL1 -0,701487062 5,16291E-13 
1496 ENSG00000234420 ZNF37BP -0,701485179 6,60731E-12 
1497 ENSG00000221883 ARIH2OS -0,701037954 0,03956487 
1498 ENSG00000097046 CDC7 -0,700187235 1,48205E-13 
1499 ENSG00000130203 APOE -0,700126505 0,000382941 
1500 ENSG00000136542 GALNT5 -0,700085603 0,028477354 
1501 ENSG00000127589 TUBBP1 -0,699940812 8,81458E-24 
1502 ENSG00000188191 PRKAR1B -0,699901026 1,85825E-07 
1503 ENSG00000059573 ALDH18A1 -0,69983634 2,62754E-19 
1504 ENSG00000176720 BOK -0,699777069 3,24321E-06 
1505 ENSG00000137135 ARHGEF39 -0,699307241 0,011302941 
1506 ENSG00000154832 CXXC1 -0,698962387 5,27642E-17 
1507 ENSG00000047579 DTNBP1 -0,698544682 4,51622E-08 
1508 ENSG00000176170 SPHK1 -0,698431981 5,37125E-17 
1509 ENSG00000182923 CEP63 -0,69823711 2,46448E-13 
1510 ENSG00000171824 EXOSC10 -0,69801235 3,60614E-22 
1511 ENSG00000091622 PITPNM3 -0,69661803 0,000358106 
1512 ENSG00000182195 LDOC1 -0,695696581 5,03568E-13 
1513 ENSG00000167397 VKORC1 -0,695569645 0,00015656 
1514 ENSG00000174672 BRSK2 -0,695194283 1,21713E-14 
1515 ENSG00000143674 MAP3K21 -0,694475166 0,018201367 
1516 ENSG00000112333 NR2E1 -0,694238726 0,020719261 
1517 ENSG00000135766 EGLN1 -0,694137858 1,10902E-13 
1518 ENSG00000166147 FBN1 -0,693994023 2,13973E-15 
1519 ENSG00000187068 C3orf70 -0,693895425 1,69001E-13 
1520 ENSG00000164684 ZNF704 -0,693798779 4,16077E-22 
1521 ENSG00000269834 ZNF528-AS1 -0,693798663 9,57734E-06 
1522 ENSG00000095739 BAMBI -0,693466893 1,38951E-12 
1523 ENSG00000103966 EHD4 -0,693293842 1,02998E-11 
1524 ENSG00000101187 SLCO4A1 -0,693000116 2,7749E-10 
1525 ENSG00000137364 TPMT -0,692600608 1,15273E-07 
1526 ENSG00000146247 PHIP -0,692259971 2,57211E-16 
1527 ENSG00000112144 ICK -0,692090139 4,69286E-13 
1528 ENSG00000157500 APPL1 -0,691998702 6,62622E-18 
1529 ENSG00000163584 RPL22L1 -0,691979407 0,000138698 
1530 ENSG00000145908 ZNF300 -0,691129485 1,19363E-12 
1531 ENSG00000182013 PNMA8A -0,690542689 3,03933E-15 
1532 ENSG00000064666 CNN2 -0,690401346 3,59872E-11 
1533 ENSG00000128283 CDC42EP1 -0,690284978 3,99664E-13 
1534 ENSG00000143942 CHAC2 -0,689991188 0,019448115 
1535 ENSG00000198185 ZNF334 -0,689880533 2,07527E-05 
1536 ENSG00000108055 SMC3 -0,689705451 5,55833E-18 
1537 ENSG00000050344 NFE2L3 -0,688493656 0,003891477 
1538 ENSG00000148143 ZNF462 -0,686744954 6,46173E-17 
1539 ENSG00000185818 NAT8L -0,686343918 2,09208E-17 
1540 ENSG00000266208 AC080112.2 -0,686019412 0,00874556 
1541 ENSG00000158457 TSPAN33 -0,685909169 0,009516289 
1542 ENSG00000118523 CTGF -0,685755127 0,005651607 
1543 ENSG00000082397 EPB41L3 -0,68547765 2,19906E-20 
1544 ENSG00000105750 ZNF85 -0,685475256 1,8737E-06 
1545 ENSG00000149679 CABLES2 -0,684817839 5,49217E-06 
1546 ENSG00000175063 UBE2C -0,684357412 5,66332E-17 
1547 ENSG00000100242 SUN2 -0,684335786 5,17106E-21 
1548 ENSG00000196812 ZSCAN16 -0,683800514 0,002144953 
1549 ENSG00000182372 CLN8 -0,682946041 8,13074E-11 
1550 ENSG00000137124 ALDH1B1 -0,682554383 5,89657E-16 
1551 ENSG00000079337 RAPGEF3 -0,682464197 0,000763222 
1552 ENSG00000226711 FAM66C -0,682358353 0,003848539 
1553 ENSG00000125354 SEPT6 -0,682267889 3,90671E-14 
1554 ENSG00000130830 MPP1 -0,681533374 2,59446E-06 
1555 ENSG00000123130 ACOT9 -0,681526172 5,05753E-09 
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1556 ENSG00000161800 RACGAP1 -0,680684181 2,76669E-23 
1557 ENSG00000120693 SMAD9 -0,680642252 8,55426E-06 
1558 ENSG00000125772 GPCPD1 -0,679277884 3,2898E-07 
1559 ENSG00000171724 VAT1L -0,678573505 0,000649255 
1560 ENSG00000120324 PCDHB10 -0,67848325 7,70986E-05 
1561 ENSG00000164327 RICTOR -0,678399337 8,36319E-09 
1562 ENSG00000188322 SBK1 -0,678117685 2,40605E-11 
1563 ENSG00000176593 AC008969.1 -0,677983136 6,89115E-07 
1564 ENSG00000187257 RSBN1L -0,675639067 3,24312E-09 
1565 ENSG00000165312 OTUD1 -0,674865135 0,013162824 
1566 ENSG00000188312 CENPP -0,673661615 0,000190342 
1567 ENSG00000233369 GTF2IP4 -0,672287596 0,000426075 
1568 ENSG00000108375 RNF43 -0,671651665 0,014693434 
1569 ENSG00000198729 PPP1R14C -0,670648086 2,09208E-17 
1570 ENSG00000152253 SPC25 -0,670315643 1,92393E-08 
1571 ENSG00000162086 ZNF75A -0,670253103 1,18554E-07 
1572 ENSG00000198168 SVIP -0,668374388 1,10805E-09 
1573 ENSG00000092470 WDR76 -0,668271563 8,22982E-10 
1574 ENSG00000235257 ITGA9-AS1 -0,667987547 0,026274982 
1575 ENSG00000241360 PDXP -0,667732242 0,034742517 
1576 ENSG00000001461 NIPAL3 -0,667073677 1,07993E-16 
1577 ENSG00000272143 FGF14-AS2 -0,666801493 0,021653556 
1578 ENSG00000077684 JADE1 -0,666672577 7,65683E-08 
1579 ENSG00000165124 SVEP1 -0,666638749 1,03727E-07 
1580 ENSG00000108312 UBTF -0,665929349 1,77322E-20 
1581 ENSG00000145198 VWA5B2 -0,665682721 0,041306225 
1582 ENSG00000187193 MT1X -0,665618984 0,000496252 
1583 ENSG00000148700 ADD3 -0,665387121 1,66421E-20 
1584 ENSG00000259865 AL390728.6 -0,664912959 0,048832215 
1585 ENSG00000136451 VEZF1 -0,664860338 5,15561E-19 
1586 ENSG00000185219 ZNF445 -0,664859331 1,6418E-14 
1587 ENSG00000001084 GCLC -0,663836054 0,000867682 
1588 ENSG00000136108 CKAP2 -0,663466964 8,06473E-22 
1589 ENSG00000066739 ATG2B -0,663193092 1,26208E-14 
1590 ENSG00000115129 TP53I3 -0,662835528 7,33883E-08 
1591 ENSG00000150867 PIP4K2A -0,662634543 1,51442E-12 
1592 ENSG00000141068 KSR1 -0,662435504 2,58324E-10 
1593 ENSG00000172687 ZNF738 -0,661972237 3,12181E-07 
1594 ENSG00000134901 KDELC1 -0,661960485 5,19953E-05 
1595 ENSG00000188338 SLC38A3 -0,661851592 1,34447E-09 
1596 ENSG00000121904 CSMD2 -0,66175852 8,84713E-13 
1597 ENSG00000138640 FAM13A -0,661721792 5,3862E-05 
1598 ENSG00000100031 GGT1 -0,659869548 0,000175095 
1599 ENSG00000019144 PHLDB1 -0,659002151 5,56548E-27 
1600 ENSG00000145194 ECE2 -0,658619028 0,048394376 
1601 ENSG00000141664 ZCCHC2 -0,658545493 8,34898E-07 
1602 ENSG00000271270 TMCC1-AS1 -0,657923816 6,66178E-05 
1603 ENSG00000142178 SIK1 -0,657866327 0,00091721 
1604 ENSG00000188732 FAM221A -0,656598438 0,001717665 
1605 ENSG00000186814 ZSCAN30 -0,655884346 6,09796E-08 
1606 ENSG00000123975 CKS2 -0,655285822 6,67606E-17 
1607 ENSG00000165113 GKAP1 -0,654912963 8,56235E-05 
1608 ENSG00000167005 NUDT21 -0,654606399 3,76387E-23 
1609 ENSG00000167118 URM1 -0,654352053 8,09666E-21 
1610 ENSG00000117632 STMN1 -0,654019783 5,59726E-34 
1611 ENSG00000080819 CPOX -0,653180633 1,3021E-07 
1612 ENSG00000060656 PTPRU -0,653147965 3,23765E-10 
1613 ENSG00000102383 ZDHHC15 -0,653057015 6,89578E-08 
1614 ENSG00000116191 RALGPS2 -0,652893738 2,86605E-09 
1615 ENSG00000130822 PNCK -0,652397158 0,034344805 
1616 ENSG00000188157 AGRN -0,652307042 9,83145E-26 
1617 ENSG00000122068 FYTTD1 -0,651531033 6,80818E-19 
1618 ENSG00000000460 C1orf112 -0,651360191 2,89084E-06 
1619 ENSG00000006459 KDM7A -0,651265942 0,010471259 
1620 ENSG00000198826 ARHGAP11A -0,650584828 1,76583E-16 
1621 ENSG00000260804 LINC01963 -0,650572716 2,13822E-05 
1622 ENSG00000228716 DHFR -0,650416754 1,64461E-18 
1623 ENSG00000079616 KIF22 -0,650281234 5,1865E-20 
1624 ENSG00000096080 MRPS18A -0,648861091 1,70263E-10 
1625 ENSG00000198960 ARMCX6 -0,648820322 1,37457E-14 
1626 ENSG00000179406 LINC00174 -0,648690658 0,014804407 
1627 ENSG00000177303 CASKIN2 -0,646355379 3,91747E-13 
1628 ENSG00000135245 HILPDA -0,646169391 0,000640615 
1629 ENSG00000163686 ABHD6 -0,645107385 1,58773E-08 
1630 ENSG00000186310 NAP1L3 -0,643229136 0,000130606 
1631 ENSG00000104147 OIP5 -0,643155584 5,71653E-05 
1632 ENSG00000160307 S100B -0,642808767 1,21046E-26 
1633 ENSG00000267544 AC007229.1 -0,642358724 0,040715868 
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1634 ENSG00000152749 GPR180 -0,642276435 0,000323811 
1635 ENSG00000076242 MLH1 -0,641744323 7,01801E-14 
1636 ENSG00000168283 BMI1 -0,64134513 2,5294E-07 
1637 ENSG00000162402 USP24 -0,640554851 1,06345E-17 
1638 ENSG00000090661 CERS4 -0,640112952 3,35326E-13 
1639 ENSG00000214222 TUBBP2 -0,639376651 4,93414E-16 
1640 ENSG00000150477 KIAA1328 -0,639154843 0,005488849 
1641 ENSG00000075336 TIMM21 -0,639073478 6,54303E-09 
1642 ENSG00000099284 H2AFY2 -0,639039678 6,65498E-09 
1643 ENSG00000177602 GSG2 -0,638894183 0,000390697 
1644 ENSG00000144724 PTPRG -0,638545763 7,66262E-16 
1645 ENSG00000134057 CCNB1 -0,63846466 4,32462E-20 
1646 ENSG00000129757 CDKN1C -0,637952514 0,008228096 
1647 ENSG00000139352 ASCL1 -0,637711079 1,81568E-21 
1648 ENSG00000247627 MTND4P12 -0,637704188 4,76001E-16 
1649 ENSG00000052126 PLEKHA5 -0,637448451 0,002152765 
1650 ENSG00000028528 SNX1 -0,636452621 5,06079E-23 
1651 ENSG00000138764 CCNG2 -0,634985969 5,63958E-10 
1652 ENSG00000143409 MINDY1 -0,634814194 1,40885E-05 
1653 ENSG00000126709 IFI6 -0,634215947 6,06848E-06 
1654 ENSG00000145022 TCTA -0,633894257 1,91384E-10 
1655 ENSG00000170017 ALCAM -0,633554083 1,88644E-28 
1656 ENSG00000110841 PPFIBP1 -0,633291959 6,40503E-21 
1657 ENSG00000149548 CCDC15 -0,632981745 0,000497594 
1658 ENSG00000162817 C1orf115 -0,632654155 0,023720358 
1659 ENSG00000114127 XRN1 -0,632558633 2,14689E-10 
1660 ENSG00000273015 AC008124.1 -0,632252555 1,86971E-06 
1661 ENSG00000104472 CHRAC1 -0,632128413 7,62763E-07 
1662 ENSG00000133424 LARGE1 -0,631953787 7,64187E-11 
1663 ENSG00000203760 CENPW -0,631706664 0,000621363 
1664 ENSG00000110042 DTX4 -0,631612101 5,99397E-05 
1665 ENSG00000225733 FGD5-AS1 -0,631564914 1,21029E-26 
1666 ENSG00000130558 OLFM1 -0,630966788 1,99695E-15 
1667 ENSG00000076513 ANKRD13A -0,630965588 1,66494E-10 
1668 ENSG00000177733 HNRNPA0 -0,630894031 1,84644E-24 
1669 ENSG00000256223 ZNF10 -0,630583401 6,84139E-05 
1670 ENSG00000164086 DUSP7 -0,630456378 2,31862E-09 
1671 ENSG00000153395 LPCAT1 -0,630364411 5,73055E-18 
1672 ENSG00000144395 CCDC150 -0,630284256 0,001986655 
1673 ENSG00000182796 TMEM198B -0,630122956 9,1405E-09 
1674 ENSG00000166508 MCM7 -0,629657416 1,21508E-27 
1675 ENSG00000152092 ASTN1 -0,628746791 6,08308E-21 
1676 ENSG00000163320 CGGBP1 -0,627702299 9,85433E-23 
1677 ENSG00000147459 DOCK5 -0,627667711 0,00126014 
1678 ENSG00000083799 CYLD -0,627517459 6,11792E-07 
1679 ENSG00000224189 HAGLR -0,627364545 0,004652709 
1680 ENSG00000152154 TMEM178A -0,626681405 0,014455446 
1681 ENSG00000196220 SRGAP3 -0,626216323 1,17185E-14 
1682 ENSG00000130193 THEM6 -0,626202908 3,32791E-07 
1683 ENSG00000184897 H1FX -0,626055246 7,23724E-21 
1684 ENSG00000100297 MCM5 -0,625389018 1,19053E-21 
1685 ENSG00000225792 AC004540.2 -0,625022866 0,002482765 
1686 ENSG00000181555 SETD2 -0,624648065 4,62164E-17 
1687 ENSG00000165449 SLC16A9 -0,624526744 7,57048E-06 
1688 ENSG00000123358 NR4A1 -0,62418242 2,88913E-11 
1689 ENSG00000176978 DPP7 -0,623736744 0,000274932 
1690 ENSG00000197275 RAD54B -0,623730776 0,007897409 
1691 ENSG00000124374 PAIP2B -0,62350701 0,024561192 
1692 ENSG00000122359 ANXA11 -0,623375092 0,021419759 
1693 ENSG00000184014 DENND5A -0,623316597 4,64656E-26 
1694 ENSG00000184986 TMEM121 -0,621873027 2,79712E-07 
1695 ENSG00000164548 TRA2A -0,621871723 1,79799E-11 
1696 ENSG00000127423 AUNIP -0,621778837 0,004258333 
1697 ENSG00000179455 MKRN3 -0,621545594 0,001470639 
1698 ENSG00000136040 PLXNC1 -0,621537768 0,004371248 
1699 ENSG00000231770 TMEM44-AS1 -0,620907742 0,008785166 
1700 ENSG00000198039 ZNF273 -0,62073173 0,000495457 
1701 ENSG00000163873 GRIK3 -0,620584569 2,2355E-22 
1702 ENSG00000235109 ZSCAN31 -0,619984605 0,021577276 
1703 ENSG00000104356 POP1 -0,619920996 2,30068E-06 
1704 ENSG00000177628 GBA -0,61971002 1,65812E-11 
1705 ENSG00000178700 DHFR2 -0,61956707 5,51901E-05 
1706 ENSG00000172037 LAMB2 -0,619525894 9,46296E-24 
1707 ENSG00000185158 LRRC37B -0,619443321 3,71005E-05 
1708 ENSG00000152240 HAUS1 -0,619091496 8,25896E-10 
1709 ENSG00000154473 BUB3 -0,618602218 1,78051E-18 
1710 ENSG00000152433 ZNF547 -0,618209981 0,015388526 
1711 ENSG00000178917 ZNF852 -0,617181576 0,017351365 
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1712 ENSG00000101558 VAPA -0,617087214 1,13533E-18 
1713 ENSG00000015133 CCDC88C -0,616698329 7,54464E-13 
1714 ENSG00000198901 PRC1 -0,616469218 1,01146E-22 
1715 ENSG00000136754 ABI1 -0,615649652 6,86062E-11 
1716 ENSG00000273270 AC090114.2 -0,615090322 0,035904836 
1717 ENSG00000163659 TIPARP -0,613780799 1,58981E-10 
1718 ENSG00000134444 KIAA1468 -0,613669987 5,36026E-09 
1719 ENSG00000237940 LINC01238 -0,613444787 0,01447202 
1720 ENSG00000142686 C1orf216 -0,613193424 0,015312795 
1721 ENSG00000198890 PRMT6 -0,613093125 2,07047E-07 
1722 ENSG00000182606 TRAK1 -0,612212527 5,98356E-18 
1723 ENSG00000213160 KLHL23 -0,612155058 7,81869E-09 
1724 ENSG00000204899 MZT1 -0,611723462 8,99037E-05 
1725 ENSG00000054654 SYNE2 -0,610952941 8,78555E-13 
1726 ENSG00000198373 WWP2 -0,61075958 1,45335E-14 
1727 ENSG00000069974 RAB27A -0,61051121 0,00134296 
1728 ENSG00000077942 FBLN1 -0,610450087 1,62435E-07 
1729 ENSG00000168496 FEN1 -0,610238096 5,05362E-15 
1730 ENSG00000178585 CTNNBIP1 -0,609780203 2,75055E-11 
1731 ENSG00000170364 SETMAR -0,609195822 1,9339E-05 
1732 ENSG00000129173 E2F8 -0,609184256 0,000589373 
1733 ENSG00000021300 PLEKHB1 -0,606826639 4,98243E-20 
1734 ENSG00000107338 SHB -0,606718676 0,002587718 
1735 ENSG00000114698 PLSCR4 -0,606353174 0,000431687 
1736 ENSG00000181544 FANCB -0,605963831 0,011909396 
1737 ENSG00000140199 SLC12A6 -0,605647819 0,000107169 
1738 ENSG00000108387 SEPT4 -0,605163814 6,51931E-09 
1739 ENSG00000146670 CDCA5 -0,604660985 5,78774E-15 
1740 ENSG00000168374 ARF4 -0,604333074 2,04651E-20 
1741 ENSG00000126970 ZC4H2 -0,603317402 9,8419E-06 
1742 ENSG00000100504 PYGL -0,6020543 8,13617E-14 




1745 ENSG00000152642 GPD1L -0,601958989 4,30498E-15 
1746 ENSG00000101003 GINS1 -0,601616583 3,79639E-11 
1747 ENSG00000138092 CENPO -0,601575357 4,92326E-09 
1748 ENSG00000125675 GRIA3 -0,601508233 2,26245E-10 
1749 ENSG00000128944 KNSTRN -0,601071961 2,19402E-09 
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